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ABSTRACT
Investigation of Mechanisms of Multiple Drug Resistance 
using Polymerase Chain Reaction.
Control of transcription plays a critical role in the multi-step 
process that regulates gene expression. Understanding the regulation of 
gene expression therefore depends, in part, on the ability to accurately 
measure defined mRNA species in cell populations and tissues.
In this study, the presence of a number of mRNAs putatively 
involved in the determination of multiple drug resistance (MDR) was 
investigated, using reverse transcriptase-polymerase chain reaction (RT- 
PCR). This technique was evaluated at a semi-quantitative and a 
quantitative level, giving due consideration to the choice of primers for 
the RT and PCR reactions, controls, reproducibility of the technique, etc. 
mRNA levels were initially studied in sensitive cell lines and their 
corresponding MDR variants. Methods were then developed which enabled 
analysis of intact mRNA from paired normal and tumour biopsies and 
archival tissues (which were embedded in paraffin).
Levels of two proteins (p-glycoprotein and Topoisomerase Ila) known 
to have a role in MDR were studied using Western blotting techniques to 
establish if the mRNA and corresponding protein levels correlated.
MDR 1 expression was induced in cultured cells by short-term 
exposure to a chemotherapeutic drug. This induction corresponded to drug 
concentration and was associated with physiological signs of stress.
A hammer-head ribozyme to MDR 1 was transfected into both a 
resistant cell line and a clonal subpopulation of its sensitive parental 
cell line (as a control). PCR (DNA) and RT-PCR (mRNA) experiments were 
conducted to verify the presence and successful transcription of the 
ribozyme in the cells. Toxicity assays were performed to establish if the 
presence of the ribozyme affected the MDR profile of the cell lines.
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Chapter 1
I n t r o d u c t io n
INTRODUCTION
Failure of chemotherapy is a significant problem in the 
treatment of neoplastic disease. Despite initial sensitivity to 
a particular chemotherapeutic drug, some tumours become 
progressively unresponsive to the same or different anti-tumour 
drugs i.e. they acquire resistance. Combination chemotherapy was 
introduced to alleviate this problem. However, variants can 
arise which are resistant not only to the drugs that have been 
administered, but are cross-resistant to a broad range of other 
compounds. Some tumours appear to be inherently resistant to 
many forms of chemotherapy. The phenomenon described is termed 
multiple drug resistance (MDR) and may be observed in tumour 
cells in vivo and cultured cells in vitro. The emergence of 
multiple drug resistance is the major cause of death in patients 
with many types of cancer, including small cell lung cancer, 
breast cancer, ovarian cancer and acute leukemia (Kaye, 1988). 
Some tumour types e.g. colon carcinoma are inherently resistant, 
rarely responding to chemotherapy. In general, multiple drug 
resistance is characterised by resistance to a defined range of 
structurally and mechanistically unrelated natural product anti­
cancer drugs, including the anthracyclines, vinca alkaloids, 
epipodophyllotoxins, colchicine, actinomycin D and Taxol. 
Sensitivity to alkylating agents (e.g. chlorambucil, 
cyclophosphamide, cisplatin), antimetabolites (e.g. cytosine 
arabinoside, methotrexate, 5-fluorouracil) or platinum compounds 
appears unaltered (Beck and Danks, 1991; Nielsen and Skovsgaard, 
1992; Germann et al., 1993; Clynes et al., 1993; Hill, 1993).
The MDR phenotype was first described in 197 0 by Biedler 
and Riehm, in studies of Chinese hamster lung cells and P388 
leukemia cells. The causes of this phenomenon in vivo have since 
been realised as complex, possibly determined by a combination 
of the tumour characteristics. These include properties of 
resting phase cells, adequacy of blood supply, etc. and specific
1.1 Multiple Drug Resistance
1
cellular mechanisms such as increased drug efflux from cells, 
increased levels of drug detoxification, increased DNA repair, 
failure of activation of anti-tumour agents and alterations in 
the intracellular target of the drug (Judson, 1992).
1.1.1 MDR 1
Multiple drug resistance is associated with a reduction in 
intracellular drug accumulation and increased cellular drug 
efflux. The decreased intracellular drug accumulation in 
multiple drug resistance was first described in 197 6 by Juliano 
and Ling) and has been found to result, at least in part, from 
an increased rate of drug efflux occuring by an energy-dependent 
mechanism (Dano, 1973; Skovsgaard, 1978; Inaba et al. , 1979;
Fojo et al. , 1985; Willingham et al., 1986). This has been
associated with the presence of a 17 0 kDa plasma membrane 
glycoprotein (p-glycoprotein) (Kartner et al., 1983) and 
correlated with specific genes encoding p-glycoprotein (Riordan 
et al., 1985). The MDR gene family consists of two members in 
humans, namely MDR 1 and MDR 3 (sometimes termed MDR 2) (van der 
Bliek et al., 1986; Roninson et al., 1986; Chen et al., 1986; 
1990; Schinkel et al., 1991; Chin et al., 1989) and three in 
rodents (Endicott et al. , 1987; Ng et al., 1989; Gros et al., 
1986a, 1988; Hsu et al., 1989; Croop et al., 1989; Raymond et 
al. , 1990). The human MDR 1 gene encodes a 4.5 - 5.0 Kb mRNA 
(Roninson et al., 1986; Gros et al., 1986 (a; b).
Increased expression of a specific human gene encoding p- 
glycoprotein (the MDR gene) is a common, but not universal, 
phenomenon in multidrug resistant cells (Clynes, 1993). This 
over-expression of the transmembrane efflux pump may be as a 
result of gene amplification (Riordan et al. , 1985; van der
Bliek et al. , 1986, 1988; Scotto et al. 1986; Clynes et al., 
1990; Raymond et al., 1990). Gene amplification, however, is not 
necessary for multiple drug resistance in vitro, suggesting that 
the MDR 1 gene can be transcriptionally or translationally 
regulated ( Benard et al., 1989; Bradley et al., 1989; Biedler,
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1 9 9 2 ) .  Fojo et al. ( 1 9 8 7 )  reported a correlation between the 
level of MDR 1 mRNA and the degree of multiple drug resistance 
in several cell lines and in gene transfer experiments. 
Increased MDR 1 gene expression has been shown to occur prior to 
gene amplification in the development of drug resistance in 
tissue culture (Fojo et al., 1 9 8 7 ;  Bradley et al., 1 9 8 9 ) .
Conflicting ideas exist as to the significance of this. Fojo et 
al. ( 1 9 8 7 )  suggested that analysis of MDR 1 mRNA may prove to be 
useful from a clinical point of view for guiding chemotherapy. 
Harris and Hochhauser ( 1 9 9 2 ) ,  however, warned that measurement 
of MDR 1 mRNA alone may give a misleading impression of the 
amount of functional p-glycoprotein present. This is due to the 
fact that at intermediate drug concentrations, amplification was 
found to be significantly increased; while at high drug levels 
p-glycoprotein levels increased without further changes in mRNA 
or gene copy number, suggesting translational modifications or 
mutations.
Direct proof for the role of MDR 1 in multiple drug 
resistance has been obtained by transfection experiments, where 
expression of a full-length cDNA copy of the human MDR 1 gene in 
a drug sensitive cell, conferred a complete multiple drug 
resistant phenotype (Ueda et al. , 1987 ). However, over­
expression of MDR 1, although generally, is not always 
associated with multiple drug resistance. Harris and Hochhauser 
( 1992 ) reported studies of a cell line, derived from a lymph 
node metastasis of a colon adenocarcinoma, where increased 
expression was not accompanied by increased adriamycin or 
vincristine resistance. Similarly, the multiple drug resistance 
phenomenon is not always associated with MDR 1 over-expression 
(Gervasoni et al., 1991; Coley et al. , 1993). While some drug- 
resistant tumours over-express p-glycoprotein e.g. multiple 
myeloma and lymphoma, other tumours do not e.g. small cell and 
non-small cell lung cancers (Futscher et al., 1994).
The significance of MDR 1 expression in clinical cancer 
must be considered. It has been suggested that p-glycoprotein 
expression may play different roles in multiple drug resistant
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cells selected in vitro and in clinically resistant human 
tumours (Roninson, 1992). Whereas MDR 1 expression may be the 
major, and possibly the only, determinant of the multiple drug 
resistant phenotype in some cultured cells (as they represent 
genetic mutations arising at low frequencies), it may be just 
one of many such mechanisms in a tumour. This may be due to the 
fact that tumours growing in vivo represent a heterogenous 
population of cells in which pleiotropic changes affecting 
various parameters of cell growth are constantly occuring 
(Nicolson, 1984). Consistent high levels of MDR 1 mRNA or p- 
glycoprotein expression have been found mainly in tumours 
derived from normal tissues, which themselves have elevated 
levels of p-glycoprotein i.e. adrenal cancer, renal cancer and 
colon cancer (Kaye et al.r 19 8 8).
MDR 1 expression, in at least some types of tumours, may be 
just one of the traits of a sub-population of tumour cells 
possessing a complex of features, associated with resistance to 
different types of treatment and more aggressive behaviour 
(Roninson, 1992). This is supported by the fact that MDR 1 
expression in human solid tumours is often heterogenous and in 
some tumour types it is preferentially associated with areas of 
apparent invasive growth (Roninson et al. , 1989; Weinstein et
al., 1991). MDR 1 expression has been associated with tumours
that show drug resistance either clinically (Epstein and 
Barlogie, 1989; Ro et al., 1990; Robey-Cafferty et al., 1990; 
Pirker et al., 1991) or in in vitro clonigenic assays (Salmon et 
al., 1989; Kanamaru et al., 1989). However, this expression has 
also been shown to correlate with resistance to combination 
chemotherapy, including drugs that should not affect p- 
glycoprotein (Epstein and Barlogie, 1989; Chan et al., 1990). 
This is consistent with the suggestion that p-glycoprotein 
expression in some tumour types occurs in a population of cells 
that possess multiple changes making them resistant to various 
cytotoxic drugs.
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1.1.2 MDR 3
MDR 3, a second gene in the MDR gene family has been 
identified in humans (termed MDR 2 by some authors) (Lincke et 
al., 1991; Nooter and Herweijer, 1991, Roninson, 1992). Both the 
human MDR 1 and MDR 3 genes are located on the long arm of 
chromosome 7, linked within 230 Kb (Callen et al., 1987). 
Although the MDR 1 and MDR 3 genes encode highly homologous 
proteins, suggesting that the MDR 3 gene product also functions 
as an efflux pump (Herweijer et al., 1990), MDR 3 does not seem 
to be involved in drug resistance. This is shown by the fact 
that insertion of human MDR 3 cDNA into mammalian expression 
vectors does not result in resistance to drugs associated with 
multiple drug resistance. No function of the MDR 3 gene has been 
identified, as yet (van der Bliek et al., 1988; Gros et al., 
1988; Schinkel et al., 1991).
MDR 3 has been reported to be amplified to the same extent 
as MDR 1 in only some cell lines studied. In other cell lines it 
was amplified either to a lesser extent than MDR 1, or not at 
all (undetectable) (Hsu et al. , 1989; Roninson et al., 1991;
Borst and van der Bliek, 1991). This difference was even more 
obvious at the RNA and protein levels. All the multiple drug 
resistant cell lines were found to express MDR 1, which 
correlated with the level of drug resistance in studies 
documented by Roninson (1992). However, the MDR 3 mRNA levels 
were either very low or undectable, even in those cell lines 
where MDR 1 and MDR 3 genes were amplified to the same extent 
(Chin et al. , 1989; Raymond et al. , 1990; Borst and van der
Bliek, 1991; Roninson et al., 1991). Roninson (1992) suggested 
that as MDR 1 and MDR 3 are linked in genomic DNA amplification 
of MDR 3 may result as a chance co-amplification of sequences 
flanking the essential MDR 1 gene. Herweijer et al. (1990), 
however, based on results of their studies suggested that MDR 3 
may contribute to the primary resistance of (B-cell) leukemias.
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1.1.3 MRP
P-glycoprotein, the product of the MDR 1 gene, although 
strongly associated with multiple drug resistance, is not solely 
responsible, or indeed involved, in all forms of multiple drug 
resistance. In addition to p-glycoprotein mediated multiple drug 
resistance ("typical"), at least two other types of multiple 
drug resistance have been described i.e. an "atypical" form due 
to alterations in the level of drug sensitivity of Topoisomerase 
Ila and a "true" form of non-p-glycoprotein (non-p-gp) mediated
multiple drug resistance (Zaman et al., 1993).
Cole et al. ( 1992a) isolated a gene from a non-p-gp 
multiple drug resistant cell line, termed MRP, which has been 
suggested to be a multiple drug resistant gene. This gene, 
mapped to chromosome 16pl3.1, encodes a 190-kDa membrane bound 
protein (Krishnamachary and Center, 1993) which has minor 
sequence homology to p-glycoprotein. The resulting mRNA has been 
estimated to be approximately 7.8 - 8.2 kb (Cole et al., 1992a).
Criteria supporting the involvement of MRP in multiple drug 
resistance include circumstantial evidence i.e. like p- 
glycoprotein, it is a member of the adenosine triphosphate 
(ATP)- binding cassette (ABC) superfamily of transport genes 
(Hyde et al. , 1990; Cole et al. , 1992a). Furthermore, MRP has 
been found to be over-expressed in a number of different non-p- 
gp multiple drug resistant human tumour cell lines selected with 
adriamycin (Cole et al. , 1992a; Slovak et al., 1993; Zaman et
al., 1993; Krishnamachary et al., 1994) with the mRNA transcript 
level correlating well with that of drug resistance (Marquardt 
et al., 1990). More direct evidence has recently been reported 
including the fact that transfection of full-length MRP cDNA 
contained in an expression vector into sensitive cells has been 
shown to result in multiple drug resistant phenotype (Grant et 
al., 1994).
Over-expression of the MRP gene has been shown to occur 
mainly as a result of gene amplification. This is consistent
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with the fact that reversion to drug sensitivity has been 
associated with loss of gene amplification and a significant 
decrease in mRNA expression (Cole et al., 1992a). MRP over­
expression, however, has not been associated multiple drug 
resistance resulting from mitoxantrone selection (Futscher et 
al., 1994) and cannot account for all forms of non-p-gp multiple 
drug resistance (Zaman et al., 1993).
Recent studies of anaplastic carcinoma of the thyroid 
showed high MRP mRNA expression levels in both carcinomas and 
cell lines (Sugawara et al. , 1994). Further analysis of MRP
transcript levels should be performed in human tumour specimens 
to establish the potential clinical relevance of MRP (Futscher 
et al. (1994 ) .
1.1.4 Phase I and Phase II Metabolising Enzymes
Multiple drug resistance may result due to alterations in 
phase I or II metabolising enzymes, resulting in failure of 
activation of anti-tumour agents and / or increased levels of 
drug detoxification. Some of the drugs involved in chemotherapy, 
including mitomycin C, VP-16, cyclophosphamide and a number of 
the anthracyclines, require metabolic activation before they can 
exert their toxic effect (Harris and Hochhauser, 1992; Lewis et 
al., 1992). Certain phase I cytochrome P450 enzymes are involved 
in this role e.g. CYP3A potentiates toxicity of some 
anthracyclines (Lewis et al., 1992). These enzymes are generally 
poorly expressed in most tumour cells in vitro are so there are 
very few reports citing the involvement of such enzymes in 
multiple drug resistant cell line models. However, decreased 
expression of CYPIA1 in adriamycin resistant MCF-7 cell lines 
has been reported (Ivy et al., 1988). It has been suggested that 
CYPIA1 may possibly be involved in the etiology of lung cancer, 
especially that associated with cigarette smoke. This is due to 
the reported elevated levels of its mRNA in lung tissue of 
smokers in comparison to non-smokers (McLemore et al., 1989, 
1990; Kawajiri and Fujii-Kuriyama, 1991). This enzyme is known
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to catalyse the activation of benzo[a]pyrene, a precarcinogen 
found in cigarette smoke, to its tumorigenic form. Such enzymes 
may have an important role to play in vivo in drug resistance.
Glutathione-S-transferases (GSTs) form a family of enzymes 
important in the phase II metabolism of xenobiotics. The three 
major classes of cytosolic GSTs are termed a ,  ¡_i and re. GST
enzymes catalyse the conjugation of reduced glutathione with 
many different electrophilic molecules, resulting in more polar 
and possibly more readily excreted products. The significance of 
GSTs in multiple drug resistance is uncertain. Premature 
detoxification or excretion of the anti-tumour drugs is a 
possibility. Many anti-cancer drugs are substrates for GSTs 
including VP-16, mitomycin C, cyclophosphamide, melphalan, 
chlorambucil, nitrogen mustards, 6-thiopurine, mitoxantrone and 
cisplatin (Clynes, 1993). Conjugation and accelerated 
accumulation of azathioprine and methotrexate, respectively, by 
these enzymes can in some cases enhance toxicity (Wolf et al.,
1987; Hosking et al., 1990).
Different GST isoenzymes show different tissue 
distribution. Overall, GST x is the most prominent form found in
human tumours (Toffoli et al. , 1992), with a 2 to 4 - fold
increase in its mRNA transcript levels in tumours of the colon, 
bladder, ovary and stomach relative to normal tissue (Harris and 
Hochhauser, 1992). Elevated levels of GST jt expression have also
been reported both in adenocarcinomas and squamous cell 
carcinomas, but not in small cell carcinomas of the lung 
(Tsuchida and Sato, 1992). GST x has been implicated in drug
resistance (Moscow et al., 1989; Ali-Osman et al., 1990; Hayes 
et al., 1991; Tidefelt et al., 1992, Peters et al., 1992) and
showed good correlation with smoking history, p-glycoprotein 
over-expression and in vitro sensitivity to adriamycin in non­
small cell lung cancer patients (Volm et al., 1991). Wang et al. 
(1989a), reported a study where cell lines were selected for 
resistance using alkylating agents. Levels of GST x were
elevated in all cell lines, but the cell lines were resistant 
only to their selective agent, and did not express the multiple
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drug resistant phenotype. Furthermore, transfection studies of 
GST jt  cDNA did not suggest a major fundamental role for GST jt  in
multiple drug resistance (Fairchild et al., 1990; Nakagawa et 
al., 1990). Increased protection against adriamycin, although
small, has been consistently found to correlate with GST jt 
(Harris and Hocchauser, 1992). The role which GST jt plays in 
this case may be the conjugation of free radicals, formed as 
part of the cytotoxic effect of adriamycin (Booser and 
Nortobagyi, 1994) enabling cells to survive in the presence of 
this drug.
1.1.5 Topoisomerases
DNA is repeatedly wound and relaxed within a cell cycle. 
Since the coiled state is necessary for recognition by other 
complexes, the role of this unwinding is obviously well 
controlled within the cell (Zhou et al., 1992). The topological 
and conformational changes in DNA molecules which are required 
for DNA replication and transcription are regulated by two 
classes of Topoisomerase enzymes. These enzymes act by binding 
to the substrate DNA, inducing DNA single (Topoisomerase I) and 
double (Topoisomerase II) strand breaks and then binding 
covalently to the 5' of the break. This allows the strands to 
pass through one another, unwinding and relaxing the supercoiled 
DNA (Sander and Hsien, 1983; Liu et al., 1983).
Topoisomerase I is a monomeric protein, encoded by a 4.2 kb 
mRNA transcript resulting from a gene located on chromosome 20 
(Zhou et al., 1992). Two sub-classes of the Topoisomerase II
enzyme have been realised which exist as homodimers, termed 
Topoisomerase Ila and Topoisomerase II|3, respectively (Drake et
al. , 1987), associated with different stages of the cell cycle 
(Drake et al., 1989; Prosperi et al., 1992). These enzymes share 
extensive sequence homology (75 %) within the first two-thirds 
of their transcripts (Chung et al., 1989). Topoisomerase Ila has
been located on chromosome 17q21-22 (Tsai-Pflugfelder et al., 
1988) encoding a 6.2 kb mRNA, resulting in the formation of a
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170 kDa protein. Topoisomerase 11(3 has been mapped to 3p24
(Jenkins et al. , 1992 ; Tan et al., 1992 ). Two forms of 
Topoisomerase 11(3 (11(3-1 and II(i-2) have more recently been
realised and seem to exist as a result of differential splicing 
(Davis et al., 1993).
Topoisomerase enzymes are an important target for a number 
of chemotherapeutic drugs. Camptothecins (Liu, 1989; Kaufmann,
1991) and possibly some anthracyclines (Foglesong et al., 1992) 
effect Topoisomerase I; whereas Topoisomerase II is a target for 
a number of intercalating agents (including adriamycin and 
daunorubicin) and the epipodophyllotoxins, VP-16 and VM-26. 
These drugs seem to act by stabilising a ternary complex that is 
formed between the cleaved DNA and the covalently linked enzyme, 
resulting in permenant cell damage (Liu, 1989).
Cross-resistance to chemically unrelated Topoisomerase II 
inhibitors seems to involve altered (generally reduced) 
Topoisomerase Ila levels or activity, genetic mutations or post-
transcriptional modifications. Reduced levels of Topoisomerase 
II protein, mRNA and activity have been associated with VM-26 
resistance in KB cells (Matsuo et al., 1990). Topoisomerase II 
protein levels and enzyme activity were reduced in adriamycin- 
resistant Chinese hamster ovarian cells, although no changes in 
DNA (Southern blot) or mRNA (Northern blot analysis) were 
realised (Deffie et al. , 1992 ). Alternate splicing of
Topoisomerase II mRNA, resulting in alternative mRNA transcript 
lengths possibly encoding for non-functional proteins, have been 
reported (Deffie et al., 1989(a; b).
Topoisomerase II mediated multiple drug resistance has been 
the only mechanism of resistance identified in some cultured 
cells. As this form of multiple drug resistance does not involve 
efflux pumps it has been termed "atypical" MDR. Alterations in 
Topoisomerase II levels in MDR cell lines, however, generally do 
not occur in isolation. Reduced levels of Topoisomerase II have 
been found to co-exist with alternative mechanisms, including 
over-expression of p-glycoprotein, alterations in levels of
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activity of Topoisomerase I and or GST Jt (Cole et al. , 1991; 
Friche et al., 1991; Lefevre et al., 1991). Modifications in 
Topoisomerase I are generally associated with resistance to a 
range of drugs (most notably, camptothecin and its analogues) 
not included in the typical profile of multiple drug resistance 
associated drugs (Liu, 1989; Pessina, 1993). Topoisomerase I and 
Topoisomerase II frequently seem to be affected in such a way 
that when levels of one is decreased, the other is increased 
(Ferguson et al., 1988; Sugimoto et al., 1990(a, b); Lefevre et 
al., 1991), thereby balancing the physiological state of 
Topoisomerases. Although modification in Topoisomerase II is 
often associated with changes in Topoisomerase I, this is not 
always the case. In studies of VM-26 selected KB cells, Matsuo 
et al. ( 1990) reported a decrease in Topoisomerase II mRNA, 
protein and enzyme activity, by comparison to the sensitive form 
of the cell line. Topoisomerase I, however, was unaffected, 
remaining constant in resistant and sensitive cells. Similarly, 
de Jong et al. (1990) observed a reduction in Topoisomerase II 
in an adriamycin-selected human small cell lung carcinoma cell 
line, with no changes in Topoisomerase I (or p-glycoprotein) 
detected.
In clinical investigations, alterations in Topoisomerase II 
have been found to exist in a large range of tumours. The levels 
of this enzyme seem to be a good indicator of the susceptibility 
of the tumour to chemotherapy. Topoisomerase II levels were 
found to correlate well with clinical responsiveness in studies 
of many cancers including breast cancer, hepatocellular 
carcinomas, liver mestastic breast cancer, gastric cancer, colon 
cancer and oesophageal cancer (Kim et al., 1991, 1992). In
general, Topoisomerase II alterations do not occur solely in 
cancers, but co-exist with other genetic alterations. Increased 
p-glycoprotein and GST jt expression and down-regulation of
Topoisomerase II has been reported from a study of 38 human 
renal cell carcinomas (Volm et al., 1993). Drug resistance in 
human brain tumours has been associated with altered 
Topoisomerase II expression (Mousseau et al., 1993). Decreased 
Topoisomerase II catalytic activity has also been found in
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ovarian tumours which have been subjected to 
platinum/cyclophosphamide chemotherapy (Van der Zee, 1994). 
However, gene amplification resulting in elevated Topoisomerase 
Ila expression has been reported in a study of breast cancer
biopsies (Keith et al., 1993).
1.1.6 Other Possible Mechanisms of Multiple Drug 
Resistance
Many other changes, as well as the previously mentioned, 
have been associated with multiple drug resistance in cultured 
cells and tumours. The existence of membrane proteins of various 
sizes have been putatively associated with this phenomenon. 
These include 24.5 - 34.5 kDa (Mirski and Cole, 1989), 42 kDa 
(Nakagawa et al. , 1992 ), 85 kDa (Sugimoto et al., 1993), 170
kDa, 180 kDa, 300 kDa (Harris and Hochhauser, 1992), 65 kDa
(Kawai et al., 1994), 110 kDa (Scheper et al. , 1993) membrane 
proteins. Altered expression of non-membrane associated proteins 
(36 kDa, 47 kDa and 55 kDa) have also been observed in resistant 
cell lines (Mirski and Cole, 1989). Elevated expression of the 
36 kDa Annexin protein in a human non-p-glycoprotein expressing 
resistant lung cell line has also been reported (Cole et al., 
1992b).
Amplification of other juxtaposed gene classes mapped with 
the p-glycoprotein amplicon on chromosome 7q21-31 (Jongsma et 
al., 1990) have also been detected in multiple drug resistant 
cells, including that of a cytoplasmic calcium binding protein, 
sorcin (Jongsma et al., 1987). No correlation has been found, 
however, with resistance patterns (Harris and Hocchauser, 1992).
Alterations in epidermal growth factor (EGF) receptor 
levels have also been associated with the multiple drug 
phenotype in some cultured cells. However, in studies of human 
lung cell lines, Reeve et al. (1990) reported reduced levels of 
the EGF receptor, whereas Shin et al. (1991) and Meyers et al.
(1993) observed simultaneous amplification of EGF receptor and
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MDR 1. Elevated levels of Nuclear Protein Kinase C has been 
observed in a human drug resistant breast cancer cell line (Lee 
et al., 1992). Higher intracellular pH has also been associated 
with drug resistance in some cell lines (Marquardt and Center,
1992).
One of the most basic criteria for effective cytotoxicity 
to be achieved by anti-cancer drugs is that they enter the cell 
and reach their specific intracellular target. Inefficient drug 
uptake by cells and / or alterations in the intracellular 
distribution of these agents may be responsible, at least in 
part, for drug resistance in some cell types. Alterations in 
intracellular drug accumulation, (i.e. a shift in adriamycin 
location from the nucleus to a cytoplasmic or golgi location, 
have been observed in both "typical" and "atypical" multiple 
drug resistant cell lines (Coley et al. , 1993). Differential
intracellular drug distribution was also reported by Keizer et 
al., 1989; Gervasoni et al., 1991; Schuurhuis et al., 1991 and 
Mulder et al., 1993.
1.2 Importance of mRNA Analysis
Gene expression, leading from DNA to protein, is a complex 
multi-step process, with each portion under regulatory control. 
Such regulation may occur at the level of gene amplification, 
mRNA transcription or protein translation. The phenomenon of 
multiple drug resistance has been associated with both gene 
amplification and increased levels of mRNA transcription. Clynes 
et al. (1992), when studying a multi-drug resistant variant of a 
human lung squamous carcinoma cell line, reported the presence 
of double minute chromosomes with homogenous staining regions, 
both of which are indicative of gene amplification and are a 
common manifestation of multiple drug resistance. Such gene- 
associated cytogenetic abnormalities have also been observed in 
other MDR cell lines (Biedler et al., 1980; Baskin et al., 
1981), both in cell lines selected for vincristine-resistance 
(Meyers et al., 1985; Fojo et al., 1987; Benard et al., 1989)
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and adriamycin-resistance (Fairchild et al. , 1987 ; Slovak et
al. , 1987; Redmond et al., 1990).
In cells with low-level acquired multiple drug resistance, 
however, p-glycoprotein may be over-produced at the mRNA or 
protein level, without concominant gene amplification (Bradley 
et al., 1989 ), suggesting that MDR 1 gene expression may be 
transcriptionally or translationally regulated. Induction of MDR 
1 mRNA by transient exposure to chemotherapeutic drugs (Kohno et 
al., 1989; Chaudhary and Roninson, 1993), heat-shock or arsenite 
(Chin et al., 1990) serum starvation (Tanimura et al., 1992) and 
certain differentiation agents has been documented. This effect 
of chemotherapeutic drugs may be of significance from a clinical 
point of view.
Putative multiple drug resistance-related parameters may, 
therefore, be studied at a DNA, mRNA and protein level. Since 
changes in both gene amplification and transcription are 
reflected in the resulting mRNA levels, understanding the 
regulation of gene expression depends in part on the ability to 
accurately measure mRNA species in defined cell populations. 
Traditionally, levels of individual mRNAs have been analysed by 
procedures such as Northern blot (Alwine et al., 1977; Thomas, 
1980 ), RNA slot/dot blot (Kafatos et al. , 1979 ), RNase
protection assay (Reyes and Wallace, 1987) and in situ 
hybridisation (for details of method see Ausubel et al., 
1991a)).
Expression of eukaryotic mRNAs, in the past, has generally 
been studied using the Northern blot technique (Alwine et al., 
1977; Thomas, 1980). Northern blotting is semi-quantitative and 
does permit mRNA to be sized enabling, for example, the study of 
splicing patterns of mRNA. However, this method is insensitive, 
5-10 pg quantities of purified polyadenylated RNA (poly (A)+ RNA 
is required to produce a signal. It is also cumbersome, 
frequently necessitating the use of specific 32P-labelled probes 
for detection following electrophoresis and transfer of mRNA to 
filters.
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Another method used in the analysis of RNA is the slot/dot 
blot technique described by Kafatos et ai. (1979). Using this 
technique, a semi-quantitative estimation of amounts of 
particular mRNAs present in a sample can be made. However, it is 
limited by its lack of sensitivity (1 - 1 0  jjq of purified poly 
(A)+ RNA is necessary to produce a signal). In addition, the 
method is not dependable for detecting extremely rare sequences 
because of background problems.
RNase protection assays are more sensitive than Northern 
blotting, (100 ng to 1 ^g of poly (A)+ mRNA is required for each 
assay). The main disadvantages of this method is that, like 
Northern blotting, it requires hybridisation with a specific 
probe for each mRNA, as well as the use of radioactive detection 
methods and sequencing gels.
A more sensitive technique for the analysis of mRNA is in 
situ hybridisation (see Ausubel et ai. (1991a) for details of 
method) in which the temporal and spatial expression patterns of 
mRNA can be determined within complex cell populations and 
tissues. Using this method 10 to 100 molecules of mRNA can be 
detected in a single cell and information about transcript 
distribution and cellular localization can be obtained. However, 
in situ hybridisation can be technically difficult and does not 
lend itself well to the processing of a large number of samples. 
In addition, it is not possible to quantify mRNA amounts using 
this method.
It is obvious, therefore, that the above mentioned methods 
are not always sensitive enough to detect mRNA in samples 
limited by either low cell number or low copy number per cell. 
In addition, they permit only crude quantitation of mRNA.
Application of the PCR technique provides another method of 
RNA analysis (Wright and Wynford-Thomas, 1990; Larrick, 1992). 
This PCR based technique has been variously termed RNA-PCR 
(Kawasaki, 1991), RT-PCR (Rappolee et ai. , 1988a), RNA
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phenotyping (Rappolee et al. , 1988b) or message amplification
phenotyping (MAPPing) (Brenner et al., 1989). This technique has 
many advantages over some of the methods mentioned previously. 
Adaptation of PCR to the detection of RNA has increased the 
sensitivity of detection of a particular mRNA species by several 
orders of magnitude (with the exception of in situ 
hybridisation). RT-PCR is 1,000 to 10,000 times more sensitive 
than the traditional RNA blot techniques which are not sensitive 
enough to detect mRNA in samples limited by either low cell 
number or low copy number per cell (Byrne et al., 1988; Wang et 
al. , 1989; Rappolee et al. , 1989; Mocharla et al. , 1990; Singer- 
Sam et al., 1990). It has been claimed that RT-PCR can detect 
actin mRNA from a single cell, or less than 100 mRNA molecules 
(Rappolee et al., 1989). Mocharla et al. (1990) have reported 
that RT-PCR amplified DNA was obtained from as little as 5 pg of 
human pancreatic or parotid total RNA, yet transcripts were not 
detected on Northern blots unless at least 15-30 ng of 
pancreatic total RNA was used.
Improved sensitivity over the RT-PCR method over Northern 
blotting is further supported by reports by Clifford et al.
(1994) where MDR 1 transcripts were detected in 100 % of samples 
analysed compared to < 17 % by Northern blot analysis. Gilliland 
et al. (1990a) reported a study where no signal could be 
detected, after stimulation, using Northern blot analysis of GM- 
CSF mRNA in 106 MLA-144 cells, whereas successful detection with 
good reproducibility was achieved from 200 cells analysed by RT- 
PCR. Small variations in mRNA transcript levels of less than 
two-fold (Clifford et al. , 1994) and less than three-fold
(Rappolee et al., 1989) have been reported. As a result of this 
sensitivity, RT-PCR can be used to analyse RNA of extremely rare 
abundance (Chelly et al., 1988), mRNAs in small numbers of cells 
(1 to 1000 cells (Kawasaki et al., 1988; Rappolee et al., 1989) 
or in small amounts of RNA (as little as 6 pg of total RNA 
(Rappolee et al., 1989; Wang et al. , 1989b; Mocharla et al.,
1990; Kawasaki, 1991).
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RT-PCR can be used for the detection of transcripts that 
display variable expression patterns in tissues and during 
development (Chelly et al., 1988; Rappolee et al., 1988a; Chin 
et al. , 1989 ). The dystrophin gene, defective in patients with 
muscular dystrophy is expressed at very low levels (representing 
only 0.01-0.001% of total muscle mRNA) making it difficult to 
study by conventional methods. RT-PCR was successfully used to 
study levels of dystrophin mRNA in clinical samples (Chelly et 
al. , 1988). More recently, RT-PCR has been used for virology
diagnosis e.g. Hepatitis C virus (Colucci, pers. comm.), 
Hepatitis B virus, HIV, papillomaviruses, enteroviruses (Best, 
pers. comm.).
Expression of multiple mRNAs can be determined 
simultaneously from a single sample of RNA, a difficult task by 
traditional methods. Purification of poly (A)+ mRNA is rarely 
necessary for RT-PCR analysis. RT-PCR should be of particular 
benefit in clinical studies, where biopsy samples may not 
provide enough material for accurate analysis by traditional 
immunological and biochemical analysis.
RT-PCR is generally considered to be a more safe and rapid 
method for RNA studies than Northern Blot analysis. Radio­
labelling (32-p) is frequently used in Northern blotting, 
however, this is not necessary for RT-PCR. Results from this 
technique are also also available more quickly than from 
Northern blot analysis - involving a day instead, possibly, 
days, weeks or months. This means that many more samples and 
many more repeats may be analysed by RT-PCR than Northern 
blotting, in a given time period.
The sensitivity of PCR can be one of the disadvantages of 
the system. As a result of the exponential nature of PCR, even 
trace contamination of reagents, samples and apparatus, with 
cloned or PCR derived sequences, may lead to false positives. 
Unlike the results obtained using Northern blotting, RT-PCR does 
not provide information on the size of the transcripts of 
interest. Although RT-PCR provides an ideal method to survey the
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expression of multiple genes simultaneously in diverse 
populations of cells, subpopulations of cells may provide 
unacceptable background signals. Expression of genes in cells 
should be treated with caution as it may not indicate 
physiological significance e.g. using RT-PCR Chelly et al. 
(1988) detect expression of several tissue specific genes in 
cells not expected to express these genes; this phenomenon has 
been termed "illegitimate" or "leaky" transcription. This leads 
to the question as to whether levels detected by PCR are 
clinically or physiologically relevant and whether in all cases 
functional protein expression results. For example, in the case 
of MDR 1 low level expression may be as a result of leaky 
transcription or possibly may represent subpopulations of p- 
glycoprotein expressing cells within a tumour. A positive result 
may be obtained from an RNA preparation from a tumour which may 
only represent the expression of a gene in a subpopulation of 
tumour cells. These cells would have a growth advantage in the 
course of chemotherapy. Low level expression may be significant 
for some tumour types. Clinical correlative studies are 
necessary to establish whether low levels of MDR 1 expression 
would be prognostically significant for different tumours. 
Recent results by Holzmayer et al. (1992) suggest that such 
correlations may indeed be clinically relevant.
1.2.1 Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR)
Polymerase chain reaction (PCR) is an in vitro technique 
for the selective amplification of defined target DNA sequences. 
This technique was developed by Mullis and co-workers at the 
Cetus Corporation (Mullis and Faloona, 1987). In order to 
amplify a specific target sequence using PCR, some prior DNA 
sequence information about the target DNA locus is normally 
required. This information is needed to design two 
oligonucleotide primers which, when added to denatured DNA, will 
specifically bind to their complementary sequences on opposite 
strands, immediately flanking the desired target i.e. the region
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to be amplified. The primers anneal to opposite strands in such 
a way that the extension reaction directs the synthesis of DNA 
towards each other, both occurring in the 5' to 3' direction 
(see Fig. 1). In the presence of a suitable thermostable DNA 
polymerase enzyme and DNA precursors (the four deoxynucleotide 
triphosphates - dATP, dCTP, dGTP, dTTP), the synthesis of new 
strands of DNA, complementary to the individual primed DNA 
strands, is initiated.
5’  x 3’
^ .............. 3'
31... ;w5’ — — — ............... •>*
3 ’ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - *
5’
Target D N A  
 ______ ^  Prim ers
..........................> -  D irection of Extentionl
\  /
Fig. 1 Primers anneal to their specific sites of recognition on opposite 
strands, flanking the target DNA region to be amplified. The DNA polymerase 
enzyme catalyses the incorporation of the free deoxynucleotide 
triphosphates, resulting in extension of the primers and so the synthesis 
of new complementary strands of DNA.
DNA generally exists as a double stranded molecule. This 
must be denatured to single strands for the primers to recognise 
and bind to their complementary sequences. Denaturation occurs 
at 90-95 °C and the temperature is then lowered to allow the 
primers to anneal. The optimum annealing temperature may range 
from 37 °C to 65 °C; increasing the temperature improves the
19
primer stringency. (The optimum temperature will depend on the A 
+ T and G + C make-up of the primers, as will be discussed 
later). Extension of the annealed primers by the incorporation 
of free deoxynucleotide triphosphates is catalysed by a DNA 
polymerase enzyme at approximately 72 °C.
This completes one cycle of the polymerase chain reaction. 
PCR is a chain reaction because newly synthesized strands from 
one cycle act as templates for further DNA synthesis in 
subsequent cycles (Fig. 2). This cycle is repeated many times 
resulting in an exponential increase in the amount of DNA 
synthesized, until eventually it reaches a plateau.
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Primers anneal
+
Extension
DNA doubles at each cycle
- 20 cycles 7.8xl05 copies
- 25 cycles 2.5x10 copies
- 30 cycles 8.0x108 copies
Continue > 25 Cycles
Fia. 2 Each of the primers is chosen so that it recognises one specific DNA sequence 
and does not bind to any other DNA sequence present in the DNA specimen. Each cycle 
o f the polymerase chain reaction cons ists  of a denaturation step  where 
double-stranded DNA is melted to single strands; an annealing step, where the 
primers bind to their specific recognition sites on the template; and an extension 
step, where new strands of DNA are formed, complementary to the primed single 
strands, by DNA polymerase enzyme extension of the primers. The primers become 
incorporated into the newly synthesised strands of DNA and so become the 
boundaries of the amplified region. New strands of DNA formed at each cycle act as 
template for the next cycle, and so for a finite time DNA strands are synthesised 
exponentially.
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RT-PCR, an adaptation of the basic PCR method enables mRNA 
be studied in a similar way to DNA. This technique was first 
described by Seeburg et al. (1986). The first published results 
using this technique were obtained by Veres et al. in 1987, when 
it was used to study point mutations in the mouse ornithine 
transcarbamylase gene.
mRNA is produced by transcription from DNA and this in turn 
is translated into proteins. More than twenty years ago reverse 
transcriptase (also known as RNA-directed DNA polymerase), an 
animal retro-viral enzyme capable of synthesizing DNA on an RNA 
template was discovered by Termin (1972). Reverse transcriptase 
enzymes have been shown to have three enzymatic activities; they 
can :
(i) copy an RNA molecule to yield double-stranded DNA-RNA, using 
a primer and joining deoxynucleotide triphosphates in a 3'- 5 ’ 
linkage;
(ii) degrade RNA in a DNA-RNA hybrid; and
(iii) copy a primed single strand of DNA to form double-stranded 
DNA (Freifelder, 1983a). The RT-PCR method is based on these 
properties of reverse transcriptase enzymes.
mRNA is extracted from cells, either in isolation or as 
part of a total RNA extraction. However, the extraction of 
undegraded RNA from cells can often prove difficult. This is due 
to both the labile nature of RNA itself and the presence in the 
cells of active ribonuclease (RNase) enzymes. The life-time of 
mRNA is short compared to other types of RNA molecules. This has 
an important regulatory function in the cell. Degradation of 
mRNA (to control the formation of a particular protein) proceeds 
primarily from the 5 1-P terminus by RNase enzyme activity 
(Freifelder, 1983b). Ribonuclease enzymes are formed on 
ribosomes on the cytoplasmic surface of the endoplasmic 
reticulum (ER). They then pass into the internal compartments of 
the ER where they are packaged in secretory granules. This 
causes the synthetic pathways occurring in the cytoplasm to be 
separated from the degradative activity of the RNase enzymes. 
However, the disruption of the cell which occurs when attempting
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to extract RNA liberates RNases and subjects the RNA to 
degradation by these enzymes (Jackson et al., 1991). To 
alleviate this problem, cells are generally lysed in a chemical 
environment containing guanidium thiocyanate.
Guanidium thiocyanate is one of the most effective protein 
dénaturants known. The use of guanidium to lyse cells was 
originally developed to allow purification of RNA from cells 
high in endogenous ribonucleases (Cox, 1968; Ullrich et al., 
1977; Chirgwin et al., 1979). Whereas RNases can recover 
activity after many forms of treatment (such as boiling), they 
are inactivated by 4 M guanidium thiocyanate and reducing agents 
such as (3-mercaptoethanol (Sela et al., 1957).
After disruption of the cells using guanidium thiocyanate, 
p-mercaptoethanol and a mild detergent, RNA can be recovered by
sedimentation through a cesium chloride gradient (or by organic 
extraction and ethanol precipitation). This takes advantage of 
the fact that RNA can be separated from DNA and protein by 
virtue of its density. To achieve this, the cell lysate is 
layered on a cushion of a dense solution of cesium chloride. The 
buoyant density of RNA in cesium chloride (>1.8 g/ml) is much 
greater than that of other cellular components (Glisin et al., 
1974). During centrifugation, RNA forms a pellet on the bottom 
of the tube, DNA is suspended at the interface and protein 
floats in the supernatant solution.
mRNA must be selectively primed for it to act as a template 
on which double-stranded DNA, known as complementary DNA (cDNA), 
can be formed by a reverse transcriptase enzyme. The cDNA area 
of interest, which is a direct copy of the mRNA can then be 
amplified and studied as in a typical PCR. Oligo (dT) primers 
(for eukaryotic RNA), random hexanucleotide primers, or the 3' 
antisense gene-specific primer used in the PCR reaction, may be 
used for this purpose. In choosing the primers for the RT 
reaction the following should be considered:
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Oligo (dT) primers recognise and bind to the poly (A) + tail 
(3') of mRNA allowing it to be copied to cDNA, selectively (see 
Fig.3). (A polyadenylated tail occurs on the 3' end of most, but 
not all, eukaryotic mRNAs (Ausubel et al. , 1991b). The
possibility of having long stretches of cDNA or even full-length 
cDNA made from mRNA have been found to be more likely using 
oligo (dT) primers. Random primers, as their name suggests, bind 
randomly to the mRNA template and, again, the reverse 
transcriptase enzyme catalyses the formation of cDNA strands. 
These primers, rather than oligo (dT), are claimed to minimise 
the effects of mRNA secondary structure and the distance of the 
amplified sequences from the poly (A)+ tail. This is suggested 
to be of particular importance for the analysis of partially 
degraded samples of cellular RNA, such as are commonly isolated 
from tumours and other clinical specimens (Noonan and Roninson,
1991). Because of their random binding, a mixture of short and 
long cDNA stretches may result. The 3' gene-specific 
complementary primer binds selectively to the 3' region flanking 
the mRNA locus of interest. Some advantages of using the 
downstream gene-specific primer include the fact that cDNA 
including the specific area of interest should result. It is 
also convenient as an aliquot of this primer will be used in 
both the RT and the PCR reactions. Alternatively, the advantages 
of using oligo (dT) primers or hexanucleotide primers over gene- 
specific primers for cDNA synthesis is that the products of a 
single RT reaction can be used for amplification of multiple 
mRNA sequences, either in the same PCR reaction, or separately. 
In this way, the cDNA of interest can be amplified 
simultaneously with an internal standard.
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Fia. 3 Oligo (dT) may be used to prime the poly (A)+ tail of mRNA. cDNA is formed on 
this template by reverse transcription. Specific cDNA regions of interest can then be 
amplified by PCR for their analysis.
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1.2.1.1 Criteria to follow when choosing Primers
One of the many advantages of RT-PCR as a method for mRNA 
analysis is its specificity i.e. mRNA sequences which are highly 
homologous can be analysed independently. This specificity is 
determined by the oligonucleotide primer sequences. The success 
of such a study is, therefore, dependent on the correct choice 
of primers for the specific application. The following is a list 
of guidelines for the design of oligonucleotide primers. Due to 
the uniqueness of each situation's requirements it may not be 
possible, or indeed necessary, to conform to all of the 
guidelines listed.
Complementarity to template: The fundamental requirement for a
primer is that it should hybridise efficiently to the sequence 
of interest with negligible hybridisation to other sequences 
present in the sample. (If sufficient amounts of template are 
available, this can be tested by performing oligonucleotide 
hybridisation, Ausubel et al., 1991b).
Target Length: The distance between the primers for which
optimum amplification can be achieved is generally considered to 
between 180 and 500 bp. However, much longer targets may be 
amplified efficiently. Amplifications of sequences up to 10 kbp 
in length are sometimes attempted successfully (Ausubel et al., 
1991b) but long sequences may be difficult to amplify 
consistently. A considerable drop-off in synthesis efficiency 
has been found with distances > 3 kbp (Jeffreys et al., 1988).
The sequence length amplified will obviously be determined 
by the requirements of the study. For the purpose of RFLP 
analysis, for example, it is desirable to have a reasonably 
short distance between primers with the restriction site 
approximately central (Ivinson and Taylor, 1991). Alternatively, 
small distances between primers lessens the ability to obtain 
much sequence information or to re-amplify with nested internal 
oligonucleotides, should that be necessary (Ausubel et al., 
1991b). The fidelity of the DNA polymerase enzyme used in the
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PCR reaction (i.e. the number of errors produced per nucleotide 
synthesized) should be taken into consideration when deciding on 
the target length. Taq DNA polymerase does not have a 3' - 5' 
proofreading exonuclease activity to remove nucleotides that 
have been misinserted during polymerisation. The longer the 
sequence being amplified with Taq DNA polymerase, the more 
mismatches will be present. Other DNA polymerase enzymes e.g. 
the T4 and native T7 DNA polymerases are proofreading-proficient 
and are very accurate with regards to base substitution and one 
base frameshift mutations. The Klenow fragment of E. coli. DNA 
polymerase I also contains 3' - 5' exonuclease, but the
proofreading activity is much weaker than that of T4 or native 
T7 DNA polymerase. However, the T4, native T7 and Klenow DNA 
polymerase are heat labile and operate optimally at 37 °C. Using 
such low temperatures increases the probability of non-specific 
annealing of primers to other regions of the DNA and also the 
likelihood of secondary structure formation being a problem 
(Eckert and Kunkel, 1991).
For many applications, primers are designed to be exactly 
complementary to the regions flanking the target sequence. For 
other purposes, such as engineering of mutations, introducing 
new restriction sites or for efforts to detect or clone gene 
homologs when sequence information is lacking, base-pair 
mismatches will be intentionally or unavoidably created. As far 
as is possible, it is advisable to include these mismatches as a 
"tag" near the 5' end of the primer. This should have no effect 
on the amplification reaction. When incorporating a modification 
at an internal point in the primer, the fewer the number of 
modifications, the better i.e. 1 - 2  changes (Clarkson et al. ,
1991).
Overall, it is best to include any changes as far from the 
3' end of the primer as possible; at least 1 0 - 1 2 bases from the 
3' end of the primer (Clarkson et al., 1991). A mismatch in the 
3' area could prevent extension. When only the protein sequence 
is available, mixed oligonucleotide primers, known as degenerate 
oligonucleotide primers, derived from an amino acid sequence may
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be used. This has had some, but in many cases, limited success 
(Compton, 1990). Again, the less degenerate the 
oligonucleotides, especially at the 3' end, the better (Ausubel 
et al., 1991b). This can be achieved by choosing primers with 
conserved amino acids which have nondegenerate codons (e.g. Trp 
and Met) at the 3' end.
Primer Length: The length of a primer contributes to its
specificity. It is generally considered ideal to choose 
oligonucleotide primers between 18 and 30 bases in length; 
however, shorter and longer primers will work. Low complexity 
DNA e.g. plasmids or previously amplified DNA, can be 
successfully amplified with shorter primers. This is because the 
template itself is more "selective" than, for example, a total 
genomic DNA sample, with a small proportion of the sample 
consisting of the template of interest. For this reason, the 
chances of the primers annealing to and amplifying an unwanted 
template are minimised. Longer primers are often favoured to 
improve specificity. (However, it is unlikely that primers 
longer than 30 bases will help improve specificity significantly 
- Ausubel et al., 1991b). The length of a pair of primers should 
be similar, if not equal.
Annealing Temperature: The annealing temperature of primers is 
determined by their length and base composition. Increasing this 
temperature enhances discrimination against incorrectly 
annealing primers and so reduces the extension of incorrect 
nucleotides at the 3' end of the primer. It is considered 
advisable to choose primers whose melting temperature (Tm) (i.e. 
the temperature at which half of the duplex is dissociated 
(Kimmel, 1987) are between 55 °C and 75 °C (Rappolee, 1990). The 
appropriate PCR annealing temperature may be equal to the 
melting temperature or 5 °C below this temperature (Innis and 
Gelfand, 1990). The Tm for a given primer can be estimated 
using the following equation (Bej et al., 1991):
T m  = 2 °(no. of A+T residues) + 4 °(no. of G+C residues)
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Base Composition: Whenever possible, primers should have a
balanced G/C and A/T concentration. Primers with a random base 
distribution should be selected, avoiding stretches of 
polypurines or polypyrimidines. This, again, is to try to 
prevent non-specific binding e.g. stretches of T's binding to 
poly (A)+ tails, and to inhibit secondary structure formation. A 
pair of primers should not be complementary to each other, 
especially at their 3' end, to avoid the formation of "primer- 
dimers". (This results when the 3' end of one primer anneals to 
the 3' end of the other primer, forming an amplified product 
which will compete with the target of interest in the PCR; as 
well as being, basically, a waste of primers). Individual 
primers should not be self-complementary e.g. they should not 
possess palindromes. This is to avoid secondary structure 
formation.
Location of primers on template:
- Primers should frame a sequence as far 3 1 as possible so 
that cDNA produced by oligo (dT) priming need not be full-length 
to act as template in the PCR (Rappolee, 1990). However, when 
the genomic structure is not known, primers separated by 300 to 
400 bases in the 5' portion of the coding region should be 
chosen. This is because exons larger than 300 bases in this area 
are fairly rare in vertebrates. Avoiding areas which may 
possibly be degraded in mRNA should be a main consideration 
(Hawkins, 1988). For polyadenylated mRNAs, removal of the poly 
(A)+ tail appears to precede mRNA degradation (Carter and 
Maiter, 1991). Avoiding the extreme 3' region in close proximity 
to the poly (A) + may, therefore, increase the chances of 
avoiding areas of degradation. (However, if the poly (A)+ tail 
is degraded, oligo (dT) primers cannot be used successfully in 
the RT reaction and so random or gene specific primers must be 
used).
- Where possible, areas that are likely to present problems 
of secondary structure (as detected by a number of computer 
programs e.g. OLIGO (Rychlik and Rhoads, 1989) should be 
avoided.
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- Primers should flank a sequence that crosses an intron so 
that DNA contamination can be diagnosed.
- Primers should span introns so that primer-DNA annealing 
will not occur.
- Primers should frame a sequence with a diagnostic 
restriction site for validation purposes.
- Primers should frame a sequence that covers a cDNA insert 
possessed by the laboratory, whenever possible, so that the cDNA 
can be used as a positive control (discussed later) and/or for 
validation by Southern blot analysis.
- Primers can be chosen specifically for a single member of 
a gene family by choosing an area that is unique for that 
member. Alternatively, a region conserved by a particular gene 
family may be selected for a more general study of the family. 
Primers can be chosen for regions of interspecies homology so 
that the same set of primers can be used for each species or so 
that primers are sufficiently complementary to hybridise with 
cDNA from a species with unknown sequences of the gene of 
interest. Alternatively, primers unique to a particular species 
may be chosen.
Sequence Banks: Primers should be selected in such a way as to
minimise the possibility of their binding to other templates 
present in the specimen. If one primer binds to an extra 
template this will result in a waste of primers, etc. However, 
if both primers recognise and bind to the extra template, not 
only will reaction components be wasted, but an extra region may 
be amplified unintentionally.
To prevent this happening, the primer sequences can be sent 
to a DNA data-base e.g. EMBL data bank. (See 2.12). At EMBL, the 
submitted sequence is compared to all the stored sequences, and 
the first fifty sequences for which it shows strongest homology 
are listed. For the first thirty of these, the sequences are 
aligned, their percentage homology calculated and the position 
on the template shown.
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It must be remembered, however, that this is not a 
comprehensive list, but only the first fifty sequences of 
common homology. Other templates not listed could possibly share 
enough sequence homology to allow the primers anneal.
1.3 Endogenous Internal Controls
RT-PCR, although renowned for its high sensitivity, 
specificity, ease and speed, can also be a technique of variable 
efficiency between preparations and between RNA species. 
Amplification of replicate samples of plasmid, results in 
product yield which can vary by as much as six-fold (Gilliland 
et al., 1990a). Considerable differences in efficiency of
amplification between tubes was also reported by Wiesner (1992). 
This variability may be due to a number of reasons including the 
fact that the procedure consists of a number of individual 
techniques - extracting RNA; quantifying the RNA 
spectrophotometrically; forming cDNA on the mRNA template; and 
amplifying the region of interest. Taking into account the 
extraction efficiency, the number of very small volume additions 
etc., it is understandable that some amount of variability may 
occur even when extreme care is exercised. For this reason, it 
is important to include an internal control in each RT-PCR.
In general, "house-keeping" gene products including 
transcripts encoding metabolic enzymes, ribosomal proteins or 
translation elongation factors are considered useful as internal 
controls, as these tend to be ubiquitously expressed (Foley et 
al., 1993). Obviously, the level of expression of the endogenous 
control must be the same in each sample to be compared and must 
not change as a result of the experimental treatment. As such 
RNAs are extracted at the same time, by the same procedure, 
using the same solutions, from the same population of cells, 
quantified also as part of the total RNA and included in the 
same RT and PCR reactions as the mRNA to be analysed, the 
products of the two should be directly comparable. The internal 
control PCR product should differ enough in size to be resolved 
from the product of interest, but close enough so as to minimise
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the probability of differences in amplification efficiency. It 
should also be distinguishable in size from artifactual "primer- 
dimers" that may be produced.
The uses of such a control are two-fold. If no signal from 
the sequence of interest is obtained in a given sample, the 
internal control will verify whether this is a true (if internal 
control is present) or false (if both are absent) result. It is 
not uncommon for amplifications to fail, especially since some 
experimental samples contain contaminants that interfere with 
DNA replication (Ausubel et al., 1991b) or inhibitors of Tag DNA 
polymerase. The internal control also allows for quantitation 
since it normalises for several factors including variation in 
the amount of sample RNA; efficiency of the RT reaction; 
efficiency of amplification and the amount loaded on the gel. 
The fact that such a control minimises differences in RNA yields 
between samples is of particular importance when studying small 
tissue samples where the quantities of RNA may be too small to 
measure by UV spectrophotometry.
Chelly et al. ( 1988) were the first group to use this 
approach when they used aldolase A mRNA as an internal standard 
to determine relative levels of dystrophin gene expression in 
different muscle tissues, (3-actin (Horikoshi et al., 1992), P2- 
microglobulin (Noonan et al., 1990; Murphy et al., 1990), S-actin 
(Zaman et al., 1993 ); Esterase D (Cole et al. , 1991),
glyceraldehyde-6-phosphate dehydrogenase (GAPDH) (Dukas et al.,
1993) S14 ribosomal protein (Leonard et al., 1993), 18S rRNA
(Clifford et al., 1994), 28S rRNA (Khan et al., 1992) histone
3.3 (Futscher et al., 1993) are other examples of such 
documented controls. Highly expressed genes such as p-actin and 
p2-niicroglobulin are often chosen, based on the fact that they 
are frequently used to confirm the comparability of RNA loading 
on gels in conventional Northern analysis. GAPDH has also been 
used in this capacity (Murphy et al., 1990; Phillips et al.,
1993). Even these "house-keeping genes", however, are not 
completely invariant in their levels of expression (Mansur et 
al., 1993). The level of the mRNA used as the endogenous control
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must, therefore, be examined to ensure its constancy among all 
of the experimental conditions studied. The ideal control will, 
therefore, depend upon the specific application.
1.4 Quantitative PCR/RT-PCR:
In the last decade, the polymerase chain reaction (PCR) has 
been developed for DNA analysis and has been adapted for the 
study of mRNA (RT-PCR) . It is now being advanced to a 
quantitative level for both DNA and mRNA studies. The aim of 
quantitative PCR is to deduce the initial amount of target 
template from the final amount of PCR product. Quantitative PCR 
can be sub-classed as "semi-quantitative" and "absolutely 
quantitative" or simply "semi-quantitative" and "quantitative", 
respectively. Semi-quantitative PCR enables the relative 
expression of a gene be compared between different samples, 
whereas using absolutely quantitative PCR, the number of 
molecules of target mRNA being expressed can be calculated.
The opinions in published literature seem to vary as to how 
PCR / RT-PCR can be developed to a quantitative level, what 
controls are required, how reliable this quantitation is, etc. 
Further work, therefore, seems necessary to establish if this 
quantitative technique can be made less laborious than has been 
described in some of the previous studies, so that it can be 
used reliably with relative ease for the study of numerous 
samples, simultaneously.
RT-PCR requires two enzymatic steps, synthesis of the cDNA 
template and PCR amplification. Both steps must be considered in 
any attempt to quantitate mRNA, as a linear relationship between 
the quantity of mRNA and PCR product requires both efficient 
conversion to cDNA and exponential amplification (Murphy et al., 
1990) .
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RT R e a c t i o n :
Efficiency of cDNA synthesis (RT reaction) can be monitored 
by the incorporation of radio-labelled dNTPs into TCA 
precipitable material. The efficiency of the RT reaction has 
been reported to vary quite significantly from one research 
group to another (each studying different mRNAs). In studies of 
myosin heavy chain mRNA from rat ventricles, Wiesner (1992) 
found the RT reaction to be 100 % efficient, while only 90 % 
efficiency of this reaction was achieved by Noonan and Roninson 
(1991) in studies of MDR 1 mRNA. Berger et al. (1983) showed
that 50 % of input mRNA was reverse transcribed into full-length 
cDNA. In their calculations, Phillips et al. (1993) made the 
assumption that the efficiency of cDNA production is 50 %. Babu 
et al. (1993) found the efficiency of cDNA synthesis to range 
from 2 3 to 2 7 % in studies of cytokine production by murine T 
cells. One obvious reason for 100 % RT efficiency not being 
achieved would be if the mRNA was in any way degraded. Assuming, 
however, that the mRNA is completely intact, the most likely 
reasons are insufficient RT reaction components (including 
primers, dNTPs and reverse transcriptase enzyme), mRNA substrate 
excess or mRNA secondary structure formation. Results from 
previous studies suggest that insufficient RT reaction 
components may be responsible for this lack of efficiency in 
some cases. Wiesner (1992) reported 100 % RT efficiency when 
using at least a 50, 000 fold excess of primer over template, 
whereas Berger et al. ( 1983) used only a 2 - 3 fold excess of 
primer when 50 % efficiency was realised.
From these results if seems important to consider the 
efficiency of the RT reaction. If this proves inadequate, assays 
should be done to establish the right concentrations of RT 
reaction components to result in 100 % RT efficiency for a 
particular mRNA.
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PCR R e a c t i o n :
PCR amplification is an exponential process and so PCR 
product concentration is proportional to the starting target DNA 
as long as its accumulation remains exponential (Chelly et al., 
1988; Singer-Sam et al., 1990). The number of cycles needed to 
reach the plateau phase varies, depending on the sequence and 
the original amount of the mRNA. Accurate quantitation requires 
working within an exponential range, which varies among samples.
Np
Cycle Number (N )
Fig. 4 Exponential and plateau phases of PCR amplification
The exponential range can be determined by carrying out the PCR 
for a fixed number of cycles on serial dilutions of the RNA 
reverse transcription product or by performing the reaction with 
a varying number of cycles on a fixed quantity of cDNA. Murphy 
et al. (1990) reported similar results using these two 
techniques (however, assays by termination of the reaction at 
sequential cycles requires greater amounts of input RNA). The 
point at which exponential accumulation plateaus can be 
estimated by noting the point at which continued cycles do not 
produce significantly increased product yield. The efficiency 
of PCR decreases at the plateau stage due to depletion of 
reaction components and generation of inhibitors such as
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pyrophosphate, diminished enzymatic activity and accumulation of 
products (Gilliland et a l ., 1990b; "RT-PCR. Methods and
Applications", (Clontech Labs) 1991).
As illustrated in Fig. 4, starting DNA and product 
concentrations are proportional only during the exponential 
amplification phase. After Np cycles, the product yield does not 
increase and, therefore, yield and cycle number are no longer 
quantitatively linked. In the exponential phase, the yield at 
any given cycle number can be measured and the initial 
concentrations can be calculated. Under ideal or theoretical 
conditions, the amount of product doubles during each cycle of 
the PCR reaction, according to the equation:
N = N0 2n
where N = product yield, N0 = initial concentration of cDNA, n = 
cycle number. This suggests that a linear relationship exists 
between the number of amplified target molecules and the initial 
number of target molecules. The efficiency of amplification (E) 
i.e. the fraction of the template replicated during each 
reaction cycle, (ideally E = 1), is determined mainly by the 
sequence of the primers, but may also be influenced by factors 
such as the nucleotide make-up of the sequence being amplified, 
the length of this fragment, etc. Despite careful selection of 
primers (see " Criteria to follow when choosing primers"), all 
PCR reactions are not 100 % efficient i.e. E < 1. The value of E 
has been reported to range from 0.46 to 0.99 for different genes 
(Chelly et al., 1988; Wang et al., 1989b; Choi et al., 1989). 
The value of E also varied, from 0.8 to 0.99, when the same gene 
was amplified in independent tubes under ideal conditions 
(Wiesner, 1992). As this must also be taken into account, the 
following equation results (Siebert, 1993):
N = N0 (1 + E)n
or
Log N = [Log (1 + E)].n + Log N0
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As PCR amplification is an exponential process, small 
variations in amplification efficiency can drastically affect 
the yield of products and in so doing obscure differences in the 
initial amounts of target sequences (Gilliland et al. , 1990b; 
Bloch, 1991). Diviacco et al. (1992) proposed that the 
exponential range is strictly dependent on the abundance of the 
starting material (the more abundant the starting material, the 
shorter the range) and that it is strongly influenced by 
differences in sample preparations, machine performance, 
reaction conditions and the presence of inhibitors. PCR product 
yield, therefore, does not quantitatively reflect the amount of 
initial template DNA after the reaction has reached the plateau. 
To overcome these problems when attempting to quantitate mRNA 
levels by PCR, only products generated during the exponential 
phase of amplification should be analysed and internal controls 
should be used.
1.4.1 Semi-Quantitative PCR / RT-PCR:
Semi-quantitative PCR, the simpler of the two approaches 
for measuring RNA levels by PCR, involves an estimation of the 
relative (but not the actual) initial amounts of cDNA (or target 
mRNA in different samples. An endogenously expressed RNA may be 
used as an internal control template, by which the target gene 
expression can be normalised. This control also acts as a 
control for sample-to-sample variations in RT and PCR reaction 
conditions and monitors the extent of degradation and recovery 
of RNA. The internal control is co-amplified along with the 
target RNA(s) of interest and is also evaluated in the 
exponential range. As these control genes are generally 
expressed at higher levels than most messages under study and so 
plateau quickly, a false appearance of comparable loading would 
occur if care was not taken to study within the exponential 
range of amplification. In their studies, Murphy et al. (1990) 
reported that their internal standard mRNA, (32-microglobulin,
has reached the plateau phase before the target, MDR 1, was even 
detectable. To prevent this problem arising, Khan et al. (1992)
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synthesised cDNA from the control and target mRNAs in separate 
tubes and then mixed dilutions of the control and target cDNAs 
before carrying out the PCR reaction. Kinoshita et al. (1992), 
similarly, overcame this problem by waiting until a later stage 
in the PCR amplification before adding the primers for the 
endogenous standard. An alternative, and possibly simpler 
method, may be to add a lower concentration of the endogenous 
control primers than the target primers when setting up the PCR 
reaction. If the internal standard mRNA is expressed at the same 
level in two samples, the ratio of PCR products generated from 
the target and standard should indicate the relative level of 
expression of the target mRNA in those samples (Horikoshi et 
al. , 1992 ). After normalisation with respect to the internal
control, target RNA levels in separate samples can, in theory, 
be compared directly.
The perceived significance of different amplification 
efficiencies between the control and target DNA seems to differ 
from one research group to another. Foley et al. (1993) 
suggested that as the internal control and target templates are 
amplified by different primer pairs and may differ significantly 
in size, sequence or secondary structure, it may also be 
necessary to control for differences in amplification 
efficiencies. To overcome this, they proposed standardising the 
reaction protocol to a set number of cycles, so that even if the 
RNA concentrations in the two samples are slightly different, 
the ratios between the control and target products can still be 
compared. According to Horikoshi et al. (1992), however, when 
relative gene expression is compared, it is not necessary for 
the target and internal control DNA to be amplified with the 
same efficiency; only that the efficiency of the PCR 
amplification of the same DNA segment remains constant among 
different samples. It is then possible to use the same internal 
standard cDNA for comparison of the relative expression levels 
of any gene whose sequence is known.
When co-amplifying two or more segments, competitive 
effects result even when different primers are used, thus
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limiting the amount of PCR product generated (Horikoshi et al.,
1992). In their studies of low abundance genes in small tumour 
biopsies, Horikoshi et al. (1992) used a simpler form of this 
technique. In these experiments, the relative levels of gene 
expression were determined by comparing the ratio of product 
generated by amplification of target DNA and an endogenous 
internal standard gene in separate reactions. Linear 
amplification regions were determined by serial dilutions of the 
cDNA without the need for quantifying the input RNA. Results 
were calculated from measurements of radio-label incorporation. 
Using this technique, Horikoshi et al. (1992) claimed that less 
than a two-fold difference in gene expression could be 
discriminated. Wiesner (1992) and Gilliland et al. (1990a), 
however, have reported significant differences in efficiencies 
of amplification among duplicate tubes, independent of cycle 
number. If this is so, it seems that the standard and target 
DNAs need to be co-amplified in the same tube in order to 
overcome poor reproducibility of the PCR step.
Semi-quantitative determination of relative target mRNA / 
cDNA in two or more samples can be more accurately achieved 
using either titration or kinetic analysis, when the 
amplification efficiencies are the same for the two samples and 
analysis is limited to the exponential phase of amplification.
Titration analysis is performed by making a dilution 
series, or titration, of mRNA or cDNA, amplifying by PCR and 
quantifying the signal produced. As the amount of target mRNA or 
cDNA is a constant proportion of the total starting material for 
each of the various dilutions in a given sample, the 
amplification efficiencies are the same and the analysis is done 
within the PCR amplification phase, the relative difference in 
initial material can be estimated. This is done by extrapolating 
from a plot of the log of the starting material (e.g. in ¡¿g) 
against the log of the product (cpm or O.D.260 units) for target 
and control (Siebert, 1993).
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An alternative to titration analysis for semi-quantitative 
PCR is comparative kinetic analysis. To perform a kinetic 
analysis, the amount of accumulated product is determined for a 
number of consecutive amplification cycles for each sample under 
study. This can be achieved by either preparing larger PCR 
volumes and removing aliquots after the respective number of 
cycles, or, alternatively, more individual PCR reactions can be 
prepared and whole tubes removed after the required number of 
cycles, respectively. To determine the relative difference in 
target input, using this method, between two co-amplified 
samples, the results are plotted as cycle number (n) v. log N 
(the amount of product accumulated, cpm or O.D.26O units), 
corresponding to each cycle number. A PCR cycle number is then 
chosen from the plot at a point where the two curves are 
parallel (suggesting equal reaction efficiencies) and the amount 
of product is extrapolated from this cycle number for each 
curve. At this point, the difference between the accumulated 
product values is directly proportional to target input 
differences between the samples (Siebert, 1993).
1.4.2 Absolute Quantitative PCR / RT-PCR
Considerable effort has been devoted to designing PCR 
assays for determining absolute RNA concentrations. This 
technique generally involves the use of one of two standards 
i.e. an RNA standard template or an PCR standard template. As 
with endogenous controls, the theory behind the use of 
exogenously added standards is that the amount of amplified 
standard can be quantified after the experiment and the change 
in the amount of standard is proportional to the change in the 
amount of target. However, one advantage of using an exogenously 
added sequence as the control is that the initial amount of 
standard used in the PCR reaction can be precisely measured. 
This makes it possible to calculate the absolute level of target 
mRNA or cDNA present in the original sample.
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The RNA standard is included in the RT reaction, 
simultaneously reverse transcribed with the sample RNA and 
coamplified by PCR with the target cDNA specific primers. In 
this way, the RNA standard serves as an internal standard both 
in the RT and PCR reactions. This approach, using a synthetic 
standard was first reported by Wang et ai. ( 1989b) and 
subsequently by others including Kanangat et al. (1992); Funk 
and Fitzgerald (1991) and Bouaboula et al. ( 1992 ). The PCR 
standard template, on the other hand, is usually DNA not 
normally in the target sample. This is added only to the PCR 
reaction. (The RT step is either assumed to be 100 % efficient 
in this case, or the efficiency, if estimated, is taken into 
account). Quantitative PCR using such an exogenous standard can 
be achieved by either forming a standard curve with the control 
from which the quantity of target can be extrapolated or by 
titrating the standard against the target (or vice versa).
One method of obtaining quantitative results from PCR with 
an exogenous standard involves generating a standard curve from 
the collected data (Wang et al., 1989b). Using this approach, a 
known amount of the RNA standard is mixed with a known quantity 
of the RNA sample (measured spectrophotometrically) and reverse 
transcribed. A series of PCR reactions is then set up with 
dilutions of the cDNA. Similarly, if a DNA control is going to 
be used, known quantities are included at this stage with 
dilutions of the target cDNA. The titration is thus being 
performed on a defined mixture of the target and standard, from 
which two titration curves can be generated - one for the 
standard mRNA / DNA and one for the mRNA. The amount of mRNA in 
the initial sample can then be intrapolated from the standard 
curve of the exogenous standard. Using this method, Wang et al. 
(1989b) realised changes in mRNA levels of three-fold or less.
An important requirement of this experiment is that the 
efficiency of amplification be the same for both the target and 
standard mRNAs. In many cases, this is achieved by designing the 
standard to contain the same primer binding sequences as the 
corresponding target mRNA. Additional requirements for using
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such exogenous standards are that the PCR products be of similar 
size and under 1 Kb (Siebert, 1993).
In many of the reported quantitative PCR studies, radio­
label was incorporated into the PCR product. Radio-labelling is 
sometimes favoured because of its sensitivity, as frequently the 
reaction has started to plateau when PCR products are first 
visualised on a gel stained with ethidium bromide (Siebert and 
Larrick, 1992). Incorporation of radio-label can be achieved by 
either the addition of a radio-labelled dNTP in the mix of 
dNTPs, or an end-labelled primer in the PCR reaction. These can 
then be evaluated by forming an autoradiograph which could be 
scanned by densitometry or by excising the bands of interest and 
performing scintillation counts. The following formula could 
then be used to estimate product formation (Wiesner, 1992):
Nn (moles/^il) = cpm/fil / cpm/mol x y
where, Nn (moles/¿¿I) represents the concentration of 
product accumulation in consecutive cycles; cpm//jl is the 
incorporated radioactivity; cpm/mol, the specific radioactivity 
of the precusor dNTP; and y, the number of this particular dNTP 
which can be incorporated into the newly synthesised stretch of 
product. (The initial concentration of a double-stranded DNA 
template at cycle zero, N0 (moles/^/l) and the efficiency of 
amplification (E), can then be calculated by linear regression 
analysis of the transformed equation describing product 
accumulation in the PCR (Wiesner, 1992):
log Nn = log (1 + E).n + log N0
Competitive PCR, an alternative method of absolute 
quantitative PCR also uses an exogenous template as an internal 
standard and exploits the principle that the two templates 
compete for the same primers and, therefore, for amplification, 
and so preferentially amplify by PCR in proportion to their 
concentrations. This is done by forming a dilution series of the 
target sequence or the standard sequence and adding a constant
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amount of the other component to the reactions. (The standard 
may be an RNA or DNA standard). After amplification, the 
internal standard is distinguished from the product derived from 
the endogenous sequence of interest by either size, restriction 
endonuclease cleavage or specific hybridisation. As the amount 
of template added is known, it is assumed that when the PCR 
products resulting from the standards and the endogenous mRNA 
are equal, the amount of mRNA in the original sample is equal to 
the amount of template added. (This is illustrated in Fig. 5).
Gel Analysis
Target
Standard
J
W hen ratio is 1:1, target + Standard 
Pig. 5 Relationship between target and control products.
When quantifying mRNA or DNA using a competitive internal 
control, the ratio of target intensity (Gilliland et al., 1990a) 
or normalised target intensity (Babu et al., 1993) to that of 
the competitor may be calculated and the log ratios plotted 
against the concentration of competitor used in each tube in a 
log-log scale plot. The amount of target mRNA present in the 
volume of cDNA taken for quantitation can then be determined 
from the plot where the target : competitor ratio is 1 (Fig. 5). 
(When quantifying mRNA, if the RT efficiency has been estimated 
to be less than 100 %, the amount of target mRNA in the total 
cellular RNA can be calculated by correcting to 100 % cDNA 
synthesis). Alternatively, the amount of radioactivity
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(scintillation or Cerenkov counts) associated with each band 
(either target or control) is plotted against the amount of 
cellular (target) or synthetic (control) input templates. By 
interpolation, the amount of target mRNA is calculated from the 
resulting synthetic RNA standard curve (Wang et al., 1989b; 
Futscher et al., 1993).
Using a derivative of this equation, the relative amount of 
the target sequence and endogenous standard (i.e. the ratio Not 
/ Nos) can be determined from the following equation. Values for 
the efficiency of amplification (E) for this target and standard 
are calculated from the slope of a graph of Log N as a function 
of cycle number (n) (Siebert, 1993):
Not / »os - Nt (1 + Es )n / NS (1 + Et )n
where:
Not = Initial number of target molecules;
Nos = Initial number of standard molecules;
Nt = Number of amplified target molecules;
Ns = Number of amplified standard molecules;
Et = Amplification efficiency of target;
Es = Amplification efficiency of standard; 
n = Number of amplified sequences.
When the amplification efficiencies of the target and standard 
are the same, this equation can be simplified to (Siebert,
1992):
Not / N0s = Nt / Ns = At / AS
where:
At = Amount of amplified target (in cpm or O.D. units)
As = Amount of amplified standard (in cpm or O.D. units)
A certain degree of confusion seems to exist as to the 
significance of differing sizes, sequences and amplification
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efficiencies between target and competitive control and whether 
or not quantitation can be achieved beyond the PCR exponential 
phase of amplification. According to Diviacco et al. (1992) the 
most reliable approaches to quantitative PCR seem to be those 
based on the co-amplification of reference templates that share 
the same primer site and near totality of the amplified 
sequence, so that the two templates compete for the same primer 
set and subsequently amplify at the same rate i.e. competitive 
PCR. The target template and competitor should not be very 
different in size as the efficiency of amplification is 
inversely proportional to the size of the amplified fragment. 
Diviacco et al. (1992), however, reported competitive PCR to be 
independent of cycle number, not requiring the exponential phase 
of amplification.
These views are shared by Gilliland et al. ( 1990a) who 
found that using a competitive control with a similar sequence 
to the target of interest, except for the presence of a mutated 
restriction site or a small intron and so with no significant 
difference of amplification efficiency, the ratios of unknown 
product to competitor product remained constant throughout the 
amplification process, irrespective of cycle number. As 
competitive PCR was found not to be cycle dependent using this 
control, amplification could be performed over many cycles so 
that the product could be visualised and quantified by ethidium 
bromide staining. In contrast, a competitor containing a large 
intron or unrelated sequence may have a significantly different 
efficiency of amplification. Pannetier et al. (1993) advised 
that competitive PCR may not provide accurate results when the 
sequences of the target and standard molecules are completely 
different (except for the primer sequences) and analysis is 
performed after the plateau phase of the reaction has been 
reached.
Reports by Murphy et al. (1990) suggest that with either 
endogenous or exogenous controls, the PCR reactions of the 
control and target must both be in the exponential phase of 
amplification, simultaneously, for results to be quantitative.
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The unknown and control should have the same efficiency of 
amplification. (The length or primary sequence differences 
between the two templates could have an effect on relative 
amplification efficiencies). However, results from studies by 
Wang et al. (1989b) and Funk and Fitzgerald (1991) using a 
multi-specific internal control template show that, at least in 
the exponential phase of amplification, no significant 
differences in amplification efficiencies resulted when 
simplifying sequences differing, to some extent, in either length 
or nucleotide make-up. Similarly, Futscher et al. (1993) 
reported PCR amplification of a cellular (401 bp) and a 
synthetic control RNA (487 bp) proceeding with the same 
efficiencies, despite the fact that the control contained an 86 
bp "stuffer" region, so as to enable it be distinguished from 
the cellular target product. Furthermore, according to Cottrez 
et al. (1994), the amount of a specific cDNA, in the total cDNA, 
can be calculated by comparison with the internal standard at 
any cycle number, despite a difference in primary sequence, size 
or initial quantities.
1.4.2.1 Competitive Controls
Competitive controls for quantitative PCR can be formed in 
a number of ways. Controls are formed in such a way that they 
contain the same primer template sequence as the target and so 
compete with the target for primer binding during amplification. 
The remainder of the sequence, however, may be a homologous 
fragment containing an intron or deleted region (yielding a PCR 
product slightly larger or smaller, respectively, than the mRNA 
of interest) or an engineered restriction enzyme site - all of 
which would allow it be distinguished from the target product. 
To form such a control, the genomic DNA form must be available 
so that it can be subcloned. Alternatively, the competitive RNA 
/ DNA fragment may have the same primer template sequence, but a 
completely different (longer or shorter) intervening sequence 
(Becker-Andre and Hahlbrock, 1989; Gilliland et al., 1990a;
Siebert and Larrick, 1992).
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Relatively simple methods for forming competitive controls 
which are homologous to the target, but longer (Diviacco et a l . ,  
1992 ) or shorter (Celi et a l .  , 1993 ) have recently been
described. As illustrated in Fig. 6 , a "nearly-homologous" 
competitor template can be formed by inserting a small "stuffer" 
fragment within the target region using the "overlap extension 
method". This is achieved by selecting four primers - two of 
which span the region to be amplified and are those for which 
the competitor and target will compete (These are the normal 
primers which are used to amplify the target). These are termed 
the out-side primers (indicated as in (1) and (2) in Fig. 6 (a). 
The upper and lower inside primers (numbered (2) and (3) in the 
diagram) are approximately 40 nucleotides long - 20 nucleotides 
of which are identical to non-overlapping inner regions in the 
upper and lower target strands, respectively. The remaining 20 
nucleotides at their 5' ends (blackened boxes in diagram) are 
complementary to each other and are unrelated to the target 
sequence to be amplified. The aim is to include these two 
sequences (which are complementary to each other) in the middle 
region of the final control product. This involves performing a 
total of three PCR reactions.
Using the four primers and some target template (on which 
the competitive control is formed), two separate PCR 
amplifications are carried out using primers (1) and (4) and 
primers (2) and (3), (see fig. 6(b) and 6 (b'), respectively. The 
resulting products are two fragments each with a single 
overlapping region of 20 bp at its end. These two products are 
then combined and re-amplified using the two out-side primers 
(Fig. 6 (c)). The final product is a double-stranded sequence 
(Fig. 6 (d)), homologous to the target, except for an extra 20 
nucleotides internally, which can be amplified with the same 
primers when used as a competitive control (Diviacco et a l . ,
1992) .
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Fig. 6 Formation of an exogenous control, which when co-amplified with the 
cellular target region will result in a product of a pre-selected length 
(longer) than the target product. (The exogenous control and target sequences 
are identical, except for the internal insert).
48
Using a similar method, competitive controls can also be 
formed which are "nearly-homologous" to the target, but when 
amplified with the same primers result in a shorter product. 
Such controls can be formed as shown in Fig. 7. To make such a 
control, two primers are synthesised. One primer, (a), is a 
conventional primer (which is used with primer (c) to amplify 
the normal target region. The second is a composite primer, (be) 
made up of approximately 2 0 nucleotides at the 3' end (segment 
b) complementary to the opposite strand of the target sequence, 
a predetermined distance from (a) (depending on the length of 
the control sequence required) the other half is complementary 
to the target (c) region. The target region (being used as a 
template on which the control is formed) is amplified using the 
primers (a) and (be).
The (c) segment of the (be) primers may also anneal to the 
complementary (c) region of the target (which is where the 
second conventional primer binds). However, extension will not 
occur because the 3' (b) region of this primer is not 
complementary to the sequence proximal to the target (c) region. 
The resulting product, after amplification with the (a) and (be) 
primers, is double stranded except for the (c) segment over­
hang. A second PCR reaction is performed in which the product of 
the first reaction is amplified with the (a) and (c) primers, 
resulting in the required competitive control (Celi et al.,
1993) .
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Fi.q- 7 Formation of an exogenous control, which when co-amplified with 
the cellular target region will result in a product of a pre-selected 
length (shorter) than the target product. (The exogenous control and 
target sequences are identical, except for the lack of the internal 
region).
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Competitive controls with the same primer sequence as the 
target, but with a different intervening sequence can be formed 
as in Fig. 8. This involves amplifying a fragment of 
foreign/neutral DNA using two composite primers. The primers are 
selected in such a way that the sequence of their 5 1 end 
(approximately 20 nucleotides) is that of the primers which 
amplify the target. Their 3' ends (approximately 20 nucleotides) 
are complementary to opposite strands of the neutral DNA, 
respectively (as shown in Fig. 8(a)). Neutral DNA is amplified 
using these primers. This results in the formation of a product 
of the desired length, (selected by the location of the inner 
portions of the primers), with over-hangs complementary to the 
conventional primers used to amplify the target. (The target- 
specific primer sequences are incorporated into the PCR 
product). Using the target-specific primers in a subsequent PCR 
reaction (as in Fig. 8(b)), a product is formed which consists 
of neutral DNA with the primer sequences incorporated onto its 
ends, which can now be amplified with the same primers as the 
target. Competitive control which are longer or shorter than the 
target sequence can be formed in this way, as required.
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Fig. 8 Formation of exogenous control which is amplified with the primers 
selected for the target, but whose intervening sequence if different from 
that of the target. Such a control may be longer or shorter than the target 
region, as desired.
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When deciding which competitive control to create, the 
following should be considered. If the target and control must 
amplify with equal efficiencies, this would seem more likely to 
occur if their sequences were homologous except for a small 
insertion, deletion or restriction enzyme formation; by 
comparison to a foreign DNA sequence. However, Siebert and 
Larrick (1992) reported that unless there are significant 
differences in denaturation or DNA polymerase extension 
characteristics due to high G/C content or secondary structure, 
amplification efficiency is primarily determined by the primer 
sequences. This was also realised by Wang et al. (1989b) who 
reported that the amplification efficiency of an RNA standard 
was the same as that of its corresponding target, even though 
the sequence between the shared primer binding sites was 
completely different. If sufficient care is taken, therefore, 
when selecting the foreign DNA source (to prevent problem 
areas), the latter of the three methods described (fig. 8) may 
be the method of choice. The reasons for this include the fact 
that it is probably the simpler of the three methods to perform. 
Unlike the other methods, each specific DNA target genomic 
sequence is not required to form its corresponding control - 
many sources of foreign DNA will suffice. This DNA, once 
purified, can be used with many different composite primer pairs 
to create any controls required.
If internal RNA standards are required (instead of DNA 
standards), an SP6 or T7 RNA polymerase recognition sequence may 
be incorporated onto the 5 1 end of the primer for subsequent in 
vitro transcription. Alternatively, the PCR product may be 
subcloned into an appropriate vector that contains an RNA 
polymerase recognition sequence (Celi et al., 1993).
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1.4.2.1.1 Endogenous Controls v. Exogenous Controls.
In summary, there are basically two types of controls which 
can be used with PCR - endogenous controls which are selected 
from ubiquitously expressed genes and exogenous controls, sub­
classes as DNA controls and RNA controls. Exactly which type(s) 
of controls should be used can be a difficult descision. Each of 
these controls has slightly different characteristics by 
comparison to the others. The ideal control will, therefore, 
depend upon the specific application.
The use of an endogenous control as a standard has one 
major advantage over any type of exogenous control in so far as 
it controls for any unforseen problems encountered during 
experimental procedures, including possible degradation of RNA 
and variations in the efficiency of cDNA synthesis. Furthermore, 
if care is taken in the selection of an appropriate endogenous 
control it may serve as a very valid base-line by which the 
relative level of expression of a particular target gene between 
different cells or different experimental conditions can be 
compared (Phillips et al. , 1993). Measurement of expression
relative to an endogenous internal reference also avoids the 
need for addition, titration and quantification of an external 
reference standard, or the manipulation of products post­
amplification to distinguish them (Clifford et al., 1994).
Exogenous controls, on the other hand, can be quantified 
very accurately and so absolute values for specific cellular 
mRNA levels can be extrapolated. Unlike endogenous controls, 
which by chance may be degraded or have more complex secondary 
structures than the target, the exogenous control should be pure 
and intact so its efficiency of amplification should be 
predictable. Furthermore, whereas the levels of a so-called 
ubiquitously expressed gene may differ from one cell type to 
another, or even at different stages of the cell cycle in a 
particular cell type, a stock of exogenous control of known 
concentration can be stored for use in many experiments. 
According to Horikoshi et al. (1992), however, competitor DNA is
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often amplified more efficiently than target DNA. This may be 
due to a less complicated tertiary structure of the synthetic 
fragment compared to the target fragment. If this is the case, 
the point where the amplification products are of equal 
intensity on the gel may not actually represent equal 
concentrations of the two competing DNA segments. Errors arising 
from incomplete digestion and heteroduplex formation where 
restriction enzyme digests are used to distinguish the 
competitive standard from the target PCR product can add further 
complications to this procedure.
1 . 4 . 2 . 1 . 2  E x ogenou s  RNA v .  E xogenou s  DNA C o n t r o l s
When forming an exogenous control, the choice of RNA or DNA 
control must also be considered. Again, opinions in the 
published literature seem to conflict in this area. RNA controls 
are more laborious to create, as generally a DNA control is 
formed and this is then used as a template to form cRNA by in 
vitro transcription. According to Foley et al. (1993) however, 
because of the variable efficiency of cDNA synthesis, RNA 
controls are vastly preferable to DNA controls.
Although a competitive RNA control is more reliable than a 
DNA control as it accounts for variation in the RT and PCR 
reactions, care must be taken to ensure that control RNA and 
template mRNA are not in disproportionate concentrations in the 
RT reaction, to avoid competition. To prevent this occuring, 
preliminary simultaneous RT-PCR titration studies with the 
standard RNA and target RNA for each mRNA species in a sample to 
be quantified, should be done. This calibration requires the use 
of more sample RNA and may restrict this approach where 
extensive quantitation with a limiting sample source is needed. 
It has, therefore been suggested that these problems are bests 
overcome by using a DNA control and taking into account the RT 
efficiency (Babu et al., 1993).
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1.5 Ribozymes and their Role in Multiple Drug Resistance
The existence of introns ("int"ervening non-coding 
sequences) in DNA was first reported in 1977 (Berget et al., 
1977 ; Chow et al. , 1977 ). These introns plus exons
("ex"pressing) regions were found to be transcribed to form 
precusor mRNA (pre-mRNA). This pre-mRNA then undergoes specific 
cleavage-ligation reactions, termed RNA splicing, which results 
in the introns being removed and the exons ligated. This process 
occurs after 5' capping and the addition of the 3' poly (A) + 
tail, in the nucleus (Freifelder, 1983b). That splicing and 
ligation reactions may be catalysed by RNA molecules was first 
reported by Cech in 1982 , in studies of the protozoan 
Tetrahymens thermophila. Preceding this discovery, RNA molecules 
were primarily considered as passive carriers of genetic 
information. Such RNA molecules have been termed ribozymes and 
are defined as molecules that undergo intramolecular catalysis 
(e.g. self-splicing or self-cleaving) or that act as enzymes 
(Cech, 1988). Certain ribozymes can cleave substrate RNAs in a 
sequence-specific manner i.e. they behave as an RNA restriction 
endonuclease, although no such enzymes have been found to date. 
In many cases, these essentially RNA-catalysed reactions can be 
further modulated by small nuclear ribonuclear proteins (Cech,
1988).
For an intron to be self-splicing (act as a ribozyme) it 
must meet the following criteria. It must recognise and cut at 
its own beginning, where the preceding exon ends. Similarily, it 
must be able to distinguish its ends from the beginning of the 
following exon and cleave at this point. Following this, the 
intron must join together the ends of the two exons which 
surround it (by "q" ligation) (Maddox, 1989). This is achieved 
by specific recognition sequences in the pre-mRNA.
Following the initial discovery of the existence of 
ribozymes, a number of catalytic RNAs have been identified. 
These are characterised by containing stretches of nucleotides 
that base-pair with a complementary RNA region. The catalytic
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region then cleaves the bound RNA, while the base-pairing holds 
it in position. Based on their variety of three-dimensional 
shapes, these ribozymes have been termed hammer-head, hair-pin 
and axe-head (Barinaga, 1993).
The possibility that ribozymes could be used in bio­
engineering and could be specifically designed to manipulate the 
function of genes or even entire cells was realised (Maddox,
1989). However, reservations existed as to how these ribozymes 
could be transported into cells, their stability in the cells 
and the precision of their actions (Gibbons, 1991). Hammer-head 
ribozymes recognise any GUX (where X can be C, A or U) at the 
target mRNA and so can bind and cleave the target sequence 
(Uhlenbeck, 1987; Haselhoff and Gerlach, 1988; Cameron and 
Jenkins, 1989). The potential role of ribozymes as therapies for 
diseases such as AIDS and chronic hepatitis has been 
illustrated, by the successful application of hammer-head 
ribozymes to cleave human immunodeficiency virus type 1 (HIV-1) 
in cultured cells. This has been achieved by transfecting 
expression plasmids, containing DNA sequences encoding the 
ribozyme framed by other sequences required for the initiation 
and termination of transcription into the cells (Sarver et al., 
1990; Weerasinghe et al., 1991; Dropulic et al., 1992).
The potential of such an approach to gene therapy in 
cancer is also under investigation in vitro. H-ras oncogene is 
thought to be involved in tumorigenesis, invasion and 
metastasis. Ribozyme-mediated reduction of H-ras oncogene 
expression in a cultured human bladder carcinoma cell line (EJ) 
resulted in a reduction in tumour formation and invasion when 
these cells were implanted in nude mice (Kashani-Sabet et al., 
1992). This supports the proposed role of H-ras. Ribozymes 
directed against c-fos, which is thought to mediate its effect 
through transcriptional activation and which is over-expressed 
in multiple drug resistance to a number of anti-cancer drugs 
including cisplatin, 5-fluoruracil and azidothymidine, have been 
transfected into cultured cells. The resulting reduction in c­
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fos gene expression was shown to reverse resistance to a number 
of chemotherapeutic drugs (Scanlon et al., 1991).
P-glycoprotein, encoded by the MDR 1 gene, is associated 
with "typical" multiple drug resistance in many cell types. To 
overcome or reduce the level of multiple drug resistance, the 
activities of p-glycoprotein can theoretically by blocked at the 
DNA, mRNA or protein level. Although MDR 1 gene amplification is 
often associated with p-glycoprotein over-expression, this is 
not a pre-requisite to p-glycoprotein-related resistance in 
human tumour cells. mRNA or protein, therefore, seem to be more 
obvious choices as potential targets for therapy. A hammer-head 
ribozyme directed against MDR 1 mRNA has been engineered and 
transfected into cultured human hepatic carcinoma cells, EPP86- 
181P selected for resistance to daunoblastin (Holm et al., 
1994). Two hammer-head ribozymes which cleave the GUC sequence 
in codon 17 9 and 196 of MDR 1 mRNA were transfected into a human 
acute leukemia cell line resistant to trimetrexate (MOLT- 
3 /TMQ3 0 0) which displayed MDR 1 over-expression (Kobayashi et 
al., 1994). Holm et al. (1994) observed a 75 - 80 % decrease in 
resistance in their studies and Kobayashi et al. (1994), 
approximately 65 %. Kobayashi et al. (1994) reported that the 
level of resistance and the amount of MDR 1 mRNA expressed 
appeared to correlate inversely with the amount of ribozyme 
expression. They proposed that the lack of complete resistance 
reversal may be due to the fact that the amount of ribozyme 
transfected into the cells was not sufficient to cleave the 
constantly over-produced MDR 1 mRNA.
Results from in vitro studies suggest ribozymes to have 
great potential in clinical situations. This form of therapy is 
very soon to undergo clinical trial in HIV-1 infected patients 
(Barinaga, 1993). Unlike the situation with MDR 1 mRNA, HIV-1 
virus RNA is foreign to human cells and does not have a 
physiological role to play. Unfortunately, because of the 
desperation of the situation with HIV-1 positive patients, any 
form of potential therapy may be worth trying despite the fact
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that its side-effects in vivo may not yet have been documented 
completely.
To overcome multiple drug resistance in cancer, further 
work may be required to ensure that the optimal ribozyme is 
created. Kobayashi et al. (1994) reported that their MDR 1 mRNA- 
directed ribozymes had different efficiencies and that the 
transfected cells had various degrees of drug sensitivity. For 
ribozymes to be effective, they must enter the cell, locate and 
cleave the mRNA at their specific target. A hammer-head ribozyme 
directed against HIV-1 RNA has been designed which worked in 
theory, but not in practice, due to the fact that it was not 
reaching its target inside the cell (Barinaga, 1993). If MDR 1 
mRNA directed ribozymes are to seriously be considered as 
potential anti-cancer agents, ways in which their transfection, 
selectively, into tumour cells can be achieved will have to be 
developed. This is because p-glycoprotein is known to be present 
in certain normal tissues and organs and so may be 
indiscriminately destroyed by the actions of the ribozyme. 
Furthermore, all of the cells of the entire tumour must be 
transduced simultaneously if this system is to be successful 
(Kobayashi et al., 1994).
A potential role for ribozymes as therapy in human 
pancreatic carcinomas (Holm et al., 1994) and acute leukemia 
(Kobayashi et al., 1994) has been suggested by in vitro studies 
on appropriate cultured cells. Further work is necessary, 
however, to establish if similar results are produced when 
studying multiple drug resistance (including "typical" multiple 
drug resistance) in cells from other organ tumours.
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1.6 Aims of this Thesis
Multiple drug resistance has been associated with changes 
in expression of a number of genes. In order to accurately 
assess such changes in a range of normal and MDR cell lines, and 
in human tumour tissue samples, a method that could be used 
routinely to assess mRNA transcript levels of a number of genes 
associated with MDR is required. Minimal alterations in
expression of certain genes may have a great influence on the 
physiological state of the cell, so the method of choice must be 
very sensitive. Furthermore, a very specific method of analysis 
is required since, for example, the cDNA sequences of two of the 
gene transcripts under study, MDR 1 and MDR 3, are highly 
homologous. RT-PCR was, therefore, selected as the method to be 
evaluated in this thesis. As RT-PCR analyses of some of the
mRNAs of interest - MDR 1, MDR 3, MRP, GST a, GST it, CYPIA1,
Topoisomerase I, Topoisomerase II, Topoisomerase Ila and
Topoisomerase lip - had not been documented in the literature, 
oligonucleotide sequences had to be selected, using the relevant 
cDNA sequences and following defined criteria, which would act 
as PCR primers. As the analysis was to be performed on normal 
cells, drug sensitive tumour cells and MDR tumour cells, a gene 
that is ubiquitously expressed in each cell type and apparently 
not affected by chemotherapeutic drugs used in this study, had 
to be selected.
mRNA transcript levels of a number of MDR-related genes 
(listed above) were assessed in a number of MDR cell lines, in 
comparison to their parent cell lines, to establish their 
respective mechanisms of MDR. The reproducibility of such 
experiments needed to be assessed from two points of view: 
reproducibility of the RT-PCR reaction using different aliquots 
of the same RNA extract; and reproducibility of the entire 
procedure starting with two different batches of the same cell 
line.
This technique needed to be developed to a quantitative 
level so that the relative levels of gene expression between
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cell lines could be assessed. As PCR product concentration is 
proportional to the starting cDNA only as long as the product 
accumulation remains exponential, the PCR cycle range of 
exponential product accumulation and plateau formation for each 
primer pair had to be established. An "optimum"/suitable cycle 
number specific for amplification with each primer pair was 
selected. Whether or not such an "optimum" cycle number could be 
considered suitable for analysis of the relevant mRNA templates 
extracted from different cell types was also to be assessed. The 
accuracy of the semi-quantitative method, and the way in which 
the results were analysed was assessed. The limitations of the 
technique will be evaluated, and from the results a proposal 
made as to how best this technique can be used for routine 
studies. This technique will also be developed for quantitative 
analysis, to allow absolute levels of gene expression be 
determined. The reproducibility of all RT-PCR techniques will to 
be evaluated.
Control of expression of certain genes may be at the level 
of translation, rather than transcription. Alterations in the 
expression of certain proteins (p-glycoprotein and Topoisomerase 
Ila) associated with MDR were also investigated to establish
whether or not the protein levels reflected the mRNA levels.
The MDR cell lines studied in this thesis developed 
resistance as a result of continuous exposure (up to 18 months) 
to a chemotherapeutic drug (some to adriamycin, others to VP- 
16). The ability of such a drug to induce expression of MDR- 
related genes after short-term exposure (possibly more 
representative of the clinical situation), was assessed.
The possibility of extracting intact RNA from clinical 
specimens and assessing for the presence of MDR-related gene 
transcripts was evaluated, using "fresh" tumour biopsies. A 
method was also developed which would enable intact RNA be 
extracted from paraffin-embedded archival tissue, which would 
allow retrospective studies be performed.
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To assess the significance of the MDR 1 gene product in 
multiple drug resistance, an MDR l*-specific ribozyme was 
transfected into MDR cells and its affect on the MDR 1 gene 
transcript levels was monitored. Possible changes resulting in 
the MDR profiles were also to be assessed by performing toxicity 
assays on the cells.
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Chapter 2
Materials & Methods
MATERIALS AND METHODS
CELL CULTURE
2 . 1  Water
Water used in the preparation of media and solutions was 
purified by passing it through a Millipore Milli-RO Plus system 
with an Elga Elgastat UHP. This involves a pre-treatment which 
utilises activated carbon, pre-filtration and anti-scaling, 
followed by a reverse osmosis step. This was followed by organic 
adsorption, ion exchange, ultra micro-filtration, photo­
oxidation and ultra-filtration. The quality of water was 
monitored on-line. A measure of 18 megaohms/cm reactivity at 25 
°C was considered acceptable.
2 . 2  G la s s w a r e
All glassware and bottle-caps used were soaked, for 1 - 2  
hours, in a 2 % (v/v) solution of RBS (AGB Scientific; RBS-25) 
in warm water. Following this, the bottles were scrubbed 
manually, bottles and bottle-caps were rinsed in warm water and 
machine washed using Neodiser detergent. These were then rinsed 
twice in double-distilled water, once with ultra-pure water and 
autoclaved before use. Glassware containing spent medium from 
cells (see 2.6 for disposal of media containing chemotherapeutic 
drugs) was autoclaved, rinsed with tap water and then treated as 
above.
2 . 3  S t e r i l i s a t i o n
Water, glassware, and solutions containing thermostable 
compounds were sterilised by autoclaving at 120 °C for 20 min., 
at 15 p.s.i. pressure. Temperature labile compounds were
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filtered through a 0.22 jjm sterile filter (Millipore; millex- 
gv).
2 . 4  Medium P r e p a r a t i o n
Growth media for cell culture were prepared as indicated in 
Table 2.1. The pH was adjusted to 7.45 - 7.55, by the addition 
of sterile 1.5 M NaOH, and the volume adjusted to 5 litres. The 
medium was then filtered through a sterile 0.22 jjm bell filter 
(Gelman; G.1423S) into sterile 500 ml bottles. Samples were 
taken from each bottle for sterility checks to be performed as 
follows:
1) 3 ml sample was placed in a sterile universal to check for 
turbidity;
2) 1 ml sample was streaked onto a Columbia (Oxoid; CM331) blood 
agar plate;
3) 1 ml sample was added to 5 ml of sterile Sabauraud (Oxoid; 
CM421) dextrose;
4) 1 ml sample was added to 5 ml of sterile Thioglycollate 
(Oxoid; CM173) broth.
All samples were placed at 37 °C, for 7 days, checking every 24 
hrs. to determine the sterility of the individual media bottles.
The medium containing bottles were labelled, dated and 
stored at 4 °C until required. ATCC medium was prepared by 
mixing Dulbecco's Modified Eagiles medium (DMEM) and Hams F12 
medium in a ratio of 1 : 1. All media were supplemented with 2 
mM L-glutamine (Gibco; 043-05030) and 5 % fetal calf serum (FCS) 
(Seralab; 101024), prior to use. (Throughout the text all 
references to medium will indicate ATCC fully-supplemented 
medium, unless otherwise indicated).
ATCC medium into which tumour biopsies were placed for 
transport from surgery to the laboratory was further 
supplemented with 2 % Penicillin/Streptomycin (Gibco; 5,000 
IU/ml penicillin/5,000 Ug/ml streptomycin).
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Table 2.4.1 Preparation of Growth Media
COMPONENTS DMEM Hams F12
10X Medium 500 ml 10X DMEM 
( G ib c o ;  0 4 2 -0 2 5 0 1 M )
Hams FI2 powder 
( G ib c o ;  0 7 4 -0 1 7 0 0 N )
Ultra-pure H2O 4300 ml 4700 ml
1M Hepes (pH 7.5)* 
(S ig m a ;  H 9136)
100 ml 100 ml
7.5 % NaHC03
(BDH; 3 0 1 5 1 )
45 ml 45 ml
* T h e  w e i g h t  e q u i v a l e n t  o f  1M N -  ( 2 - H y d r o x y e t h y l ) p i p e r a z i n e - N 1 -  ( 2 -  
e t h a n e s u l f o n i c  a c i d )  (H e p e s )  w as d i s s o l v e d  i n  an 80 % v o lu m e  o f  u l t r a - p u r e  
w a t e r  and a u t o c l a v e d .  The pH w as t h e n  a d j u s t e d  t o  7 . 5  w i t h  5 M NaOH.
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2.5 Routine Management of Cells in Culture
Routine maintenance of cultured cells involved feeding, 
sub-culturing, freezing and thawing. All procedures were 
performed aseptically in a down-flow re-circulating laminar flow 
cabinet (Holton or Gelman Cytoguard) which had been swabbed with 
7 0 % IMS (industrial methylated spirits). All articles entering 
the laminar flow were also swabbed with 7 0 % IMS to ensure that 
a sterile atmosphere was maintained. Gloves were worn at all 
times during these procedures.
2 . 5 . 1  C e l l  L i n e s
All cell lines used throughout this thesis are outlined in 
Table 2.5.1.1. These cell lines are all anchorage dependent. 
Cells were grown in 25 cm2 flasks (Costar; 3050) or 75 cm2 
flasks (Costar; 3075). Cells were grown at 37 °C in the presence 
of 5 % CO2 and fed every 2 - 3  days or when a medium pH change 
was observed (as determined by a change in the colour of the 
medium due to the presence of a phenol red indicator) . This 
involved removing waste medium into a sterile waste bottle and 
replacing it with fresh complete medium, as indicated in Table
2.5.1.1 Separate waste and medium-containing bottles were kept 
exclusive to each cell line to prevent cross-contamination.
6 6
Table 2.5.1.1 Cell lines used throughout the course of this Thesis.
CELL LINE GROWTH
MEDIUM
DETAILS OF CELL LINE SOURCE
DLKP ATCC Human Lung Squamous Cell 
Carcinoma
G. Grant 
NCTCC
DLKP-4 ATCC Clone from DLKP S . Me Bride 
NCTCC
DLKP/VP-3 ATCC DLKP adapted to MDR by 
increasing stepwise 
exposure to VP-16*
M.Heenan
NCTCC
DLKP/VP-8 ATCC DLKP adapted to MDR by 
increasing stepwise 
exposure to VP-16*
M.Heenan
NCTCC
DLKPA ATCC DLKP adapted to MDR by 
increasing stepwise 
exposure to Adriamycin''
A . Redmond 
NCTCC
DLKPA-2B ATCC Clone from DLKPA M.Heenan
NCTCC
DLKPA-6B ATCC Clone from DLKPA M .Heenan 
NCTCC
DLKPA-5F ATCC Clone from DLKPA M .Heenan 
NCTCC
OAW42 ATCC Human Ovarian Carcinoma ATCC
OAW42A ATCC OAW42 adapted to MDR by 
increasing stepwise 
exposure to Adriamycin^
A. Redmond 
NCTCC
HEp-2 ATCC Human Epidermoid 
Carcinoma of the Larynx 
(HeLa markers)
ATCC
HEp-2A ATCC HEp-2A adapted to MDR by 
increasing stepwise 
exposure to Adriamycin*
A . Redmond 
NCTCC
T a b le  C o n t in u e d  O ver
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CELL LINE GROWTH
MEDIUM
DETAILS OF CELL LINE SOURCE
SKMES-1 ATCC Human Squamous Lung 
Carcinoma
ATCC
SKMES-1A ATCC SKMES-1 adapted to MDR by- 
increasing stepwise 
exposure to Adriamycin*
A . Redmond 
NCTCC
SKMES-1ADR ATCC SKMES-1 adapted to MDR by- 
increasing stepwise 
exposure to Adriamycin*
I. Cleary 
NCTCC
Note:
~ Adriamycin (Farmatalia)
* VP-16 Bristol Myers Pharmaceuticals
DLKP-4 is a clone from the DLKP cell line. DLKPA-2B, DLKPA-6B and DLKPA-5F 
are clones from the adriamycin-selected cell line, DLKPA. DLKP/VP-3 and 
DLKP/VP- 8 are MDR cell lines selected by continuous exposure to 
concentrations of VP-16, ranging from 0.3 pg/ml to 3.0 /jg/ml in the case of 
DLKP/VP-3, and from 0.3 jjg/ml to 8.0 i^g/ml in the case of DLKP/VP-8 . The 
fold-resistance, with respect to DLKP, of these MDR cell lines to a range 
of chemotherapeutic drugs are shown in Table 4.1. HEp-2A possesses IC50 
values in regard to its toxicity to adriamycin, vincristine, VP-16 and 5- 
fluorouracil which are 87.87-, 14.1, 2.16 and 1.12-fold, respectively
greater than that exhibited by HEp-2. The fold-resistance of SKMES-1ADR to 
adriamycin, vincristine, VP-16 and carboplatin, with respect to SKMES-1 are 
25, 50, 3 and 2.16, respectively.
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2.5.2 Sub-Culture of Cell Lines
The cells used throughout the course of this study grow as 
a monolayer, attached to the bottom of flasks. Upon reaching 
confluency, or when required for experiments, the cells were 
sub-cultured by enzymatic detachment. This involved removing 
waste medium from the flask of cells, rinsing the cells with 2 
ml of trypsin/EDTA (0.25 % trypsin (Gibco; 043-05090), 0.01 % 
EDTA (Sigma; EDS) solution in PBS (Oxoid; BR14a), which had been 
pre-incubated at 37 °C, for 15 mins, and then incubating with a 
further 2 ml of the trypsin/EDTA solution for 7-10 mins., or 
until a single cell suspension had been obtained. An equal 
volume of medium was then added. The cell suspension was 
transferred to a 30 ml sterile universal (Sterilin; 128a) and 
centrifuged at 12 0 g., for 5 mins. The medium was poured from 
the universal into the waste bottle and the cell pellet was 
resuspended in 5 ml medium. A cell count was performed as 
outlined in Section 2.5.3. Approximately 2 X 104 - 105 cells 
were added to 10 ml of medium in a 25 cm2 flask, or 2 0 ml of 
medium in a 7 5 cm2 flask, respectively. These were then 
incubated at 37 °C, in 5 % CO2 .
2 . 5 . 3  C e l l  C o u n t in g
A sample of a single cell suspension was mixed in a ratio 
of 4 : 1 with trypan blue dye (Gibco; 525). This was incubated 
for 2 mins., after which a sample of the cell mixture was 
applied to a haemocytometer, such that it was held in the area 
between the haemocytometer and the cover-slip. Cells in the 16 
squares of the four outer corner grids were counted, and the 
average of the four squares was multiplied by 104, to determine 
the cell number per ml. Cells which stained blue were considered 
non-viable while those unstained were viable.
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2.5.4 Large-Scale Cell Culture
Cells required in large numbers were cultivated in roller 
bottles. Approximately 100 ml of growth medium was allowed to 
equilibrate in a roller bottle at 37 °C, for 30 mins. , after 
which a single cell suspension, of approximately 2 X 107 cells, 
was added. The roller bottle was incubated at 0.25 r.p.m. 
overnight, then the rotor speed was increased to 0.50 r.p.m. The 
cells in the roller bottle were fed as required until they 
reached approximately 80 % confluency, at which stage they were 
ready for use.
2 . 5 . 5  Mycoplasma  D e t e c t i o n
All cell lines used in this study were routinely tested to 
ensure that Mycoplasma contamination had not occurred. These 
procedures were performed in isolation from the routine cell 
culture designated areas (by Cathy Halligan, Una Gilvarry or Dr. 
Roisin Weedle), to avoid possible contamination of clean cell 
stocks. This analysis was done using the Hoechst 33258 indirect 
staining method and Mycoplasma culture methods. The cell lines 
to be tested were grown in a drug-free medium for a minimium of 
three passages following thawing. A 5 ml aliquot of conditioned 
medium i.e. medium which had been exposed to a flask of nearly- 
confluent cells for 2 - 3  days, was then removed and tested for 
the presence of Mycoplasma.
2 . 5 . 5 . 1  H o e c h s t  33258  I n d i r e c t  S t a i n i n g
Indicator cells (NRK) were grown (2 X 103 ) overnight on 
sterile cover-slips in 1 ml DMEM medium supplemented with 5 % 
FCS and 2 mM L-glutamine, in individual 35 mm sterile petri- 
dishes. 1 ml aliquots of the conditioned media (2.5.5), from 
each cell line to be tested, were added to duplicate cover-slips 
of NRK cells and incubated for 5 days (at which stage the NRK 
cells should have reached approximately 50 % confluency). The
70
media was removed from the cover-slips, which were washed twice 
with PBS, once with a 1 : 1 solution of ice-cold PBS : Carnoy's 
fixative (a freshly prepared 1 : 3 solution of glacial acetic 
acid (Sigma; A0808) : methanol (BDH; 101584W) which had been
stored at -20 °C for 30 mins. prior to use), and fixed for 10 
mins. in Carnoy's fixative. Following this, the cover-slips were 
allowed to air dry. Then 2 ml of Hoechst 33258 stain (Sigma; 
B2883) at a concentration of 50 ng/ml in PBS, was added to each 
cover-slip and incubated in darkness for 10 mins. The cover- 
slips were washed with water and mounted on a glass slide, using 
50 % glycerol (BDH; 101184K) in 0.1 M citric acid (Sigma;
C2916), 0.2 M disodium phosphate (Sigma; S9390), pH 5.5 as the 
mounting solution (with the cells between the two surfaces). The 
slides were then examined for Mycoplasma contamination under oil 
immersion using a mercury fluorescent lamp. Hoechst 33258 stains 
nucleic acids. Therefore, the NRK cell nuclei stained brightly. 
Any extra-nuclear staining was an indication of the presence of 
Mycoplasma. Both positive (a sample of medium known to be 
contaminated) and negative (medium not exposed to cells) 
controls were included in this procedure.
2 . 5 . 5 . 2  Mycoplasma  C u l t u r e  Method
The substrate for the Mycoplasma culture method of 
detection consisted of 90 ml of Mycoplasma agar (Oxoid; CM401) 
and Mycoplasma broth (Oxoid; CM403) bases, which were 
supplemented with 16.33 % FCS, 0.002 % DNA (BDH; 42026), 2 ¡uq/ml 
fungizone (Gibco; 05290), 2 X 103 units penicillin (Sigma; Pen- 
3) and 10 ml of a 25 % (w/v) yeast extract solution (which had 
been boiled for 10 mins. and filtered through a 0.2 ^m filter). 
An 0.5 ml aliquot of sample medium from the cell line being 
tested was incubated with 3 ml of the broth for 48 hrs. at 37 °C 
in a CO2 environment. A aliquot of the broth was then streaked 
onto a 10 ml agar plate which was incubated for up to 3 weeks 
at 37 °C in 5 % CO2 , with constant microscopy analysis for
colony formation. The presence of "fried egg" type colonies were 
indicative of Mycoplasma contamination of the cell line.
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2.5.6 Serum Batch Testing
One of the main problems associated with the use of FCS in 
cell culture is its batch to batch variation. In extreme cases, 
this variation may result in a lack of cell growth, whereas in 
more moderate cases, growth may be retarded. It is very 
important to avoid this happening, particularly where cell 
growth is the characteristic being studied in an assay. 
Therefore, a range of FCS batches were screened for growth of 
each cell line. A suitable FCS was then purchased in bulk for a 
block of work, to avoid artifactual variations. Results were 
recorded as a percentage of a control i.e. cells grown in a FCS 
with a known acceptable growth pattern.
Cells were pre-treated, to ensure that all cells were at 
the same stage of growth, by seeding into flasks at low density 
four days prior to assessment. On day 4 the cells were fed with 
complete medium. On day 5 when the cells were approximately 75 % 
confluent, they were seeded from a single cell suspension into a 
96 well plate (Costar; 3599), at a cell density of 103 
cells/well, in 100 /ul medium void of FCS. 100 pi volumes of 
medium containing 2 %, 10 % and 20 % (v/v) of the FCS being
evaluated were added to respective wells on the 96 well plate, 
resulting in final dilutions of the FCS to 1 %, 5 % and 10 %, 
respectively. The first column of each plate was maintained as a 
control where FCS resulting in a known acceptable growth rate 
was used. Plates were placed at 37 °C in a 5 % CO2 environment, 
for 5 days, after which growth was assessed by acid phosphatase 
enzyme activity (Connolly et al. , 1986; Martin and Clynes,
1991). After incubation for the required length of time, medium 
was removed and the assay plates rinsed twice with (100 pi 
volumes/well) PBS. To each well of the 96 well plate, 100 jj  1 of 
10 mM p-nitrophenyl phosphate (Sigma; 104-0) in 0.1 M sodium 
acetate, 0.1 % triton X-100 (Sigma; X100), pH 5.5 was added and 
the plate incubated at 37 °C for 2 hrs., in darkness. Following 
this, the enzyme reaction was stopped by the addition of 50 jul 
of 1.0 M NaOH. The plates were then read in a dual beam plate
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reader at 405 nm (reference wavelength 620 nm) (Titertek; 
Multiskan).
2 . 5 . 7  F r e e z i n g  C e l l s  i n  C u l t u r e
To ensure that adequate stocks of all cell lines were 
maintained and that all studied could be done within a given 
passage number range, stocks of cells were frozen to allow their 
long-term storage.
A single-cell suspension was prepared (Section 2.5.2) from 
a sub-confluent large-scale culture of cells (Section 2.5.4). 
The cell pellet was resuspended in FCS. An equal volume of 10 % 
(v/v) DMSO (Sigma; D5879) in FCS was added drop-wise, with 
constant shaking of the cell suspension, to result in a final 
concentration of 107 (viable) cells/ml. Aliquots of 1.5 ml 
volumes of the resulting cell suspension were then placed in 
cryovials (Greiner; 122 278) (labelled with the cell line, 
passage number, date and operators initials). These were placed 
in the vapour phase of liquid nitrogen (as soon as possible) for
2.5 hrs., and were then stored in the liquid phase until 
required. A vial of cells was thawed 2 - 5  days after freezing 
to determine the sterility and viability of the stock.
2 . 5 . 8  C e l l  Thawing
The required vial of cells was removed from the liquid 
nitrogen storage and thawed in a 37 °C water-bath. The thawed 
cell suspension was quickly transferred to a universal 
containing 5 ml of medium and was centrifuged at 12 0 g. , for 5 
mins. The medium was gently removed and the cell pellet was 
resuspended in a 5 ml volume of medium. This cell suspension was 
then transferred to a 25 cm2 flask containing 5 ml of medium and 
was incubated at 37 °C. Following cell attachment, the cells 
were re-fed with fresh medium.
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2.6 Safe Handling of Cytotoxic Drugs
Because of the potential risks involved in the use of 
cytotoxic drugs, extreme care was exercised in their handling 
and disposal. All work with such drugs was performed in a Gelman 
"Cytoguard" laminar air flow cabinet (CG Series), face masks and 
double gloves were worn when dealing with concentrate stocks and 
all drug waste (pure or diluted in medium) was disposed of as 
recommended by its manufacturer (outlined in Table 2.6.1).
Table 2.6.1 Storage and Disposal of Chemotherapeutic Drugs
CYTOTOXIC DRUG SUPPLIER DISPOSAL STORAGE
Doxorubicin 
(Adriamycin) 
2 mg/ml
Farmatalia Inactivate 
with 1 % 
hyperchlorite
Store at 4°C 
in darkness
Vincristine 
1 mg/ml
David Bull 
Laboratories, Ltd.
Inactivate by 
autoclaving 
and dispose 
with excess 
water
Store at 4°C 
in darkness
VP-16
(Etoposide) 
20 mg/ml
Bristol Myers 
Pharmaceuticals
Incinerate Store at 
room temp. 
Working 
stock at 
-20°C, in 
darkness
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INDUCTION OF GENE EXPRESSION
2 . 7  I n d u c t i o n  o f  MDR 1 mRNA E x p r e s s i o n
Two days prior to induction, all cells (DLKP and OAW42) 
were pre-treated, to ensure that they were healthy and in a 
logarithmic phase of growth. This involved sub-culturing into 75 
cm2 flasks at a density of 2 X 104 cells/flask. The cells were 
allowed to attach overnight. The following day, the cells were 
fed with fresh medium. On the day of experimentation, duplicate 
flasks of each cell line, which were approximately 50 %
confluent, were treated as follows:
1) Cells were fed with 20 ml of medium containing no drug 
(to act as a control);
2) Cells were fed with 20 ml of medium containing 0.1 ^g/ml 
adriamycin;
3) Cells were fed with 20 ml of medium containing 1.0 ^g/ml 
adriamycin.
After 48 h r s . , the cells were re-fed as above. 
Physiological features of the cells were assessed frequently, by 
microscopy, to identify any signs of cell stress. After a total 
of 72 hrs., visible signs of cell stress were apparent in the 
cells treated with drug. RNA was, therefore, extracted at this 
time and the induction of expression of a number of MDR-related 
genes was studied, using RT-PCR techniques (Section 2.10).
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2.8 RIBOZYME TRANSFECTION
2 . 8 . 1  T r a n s f e c t i o n  o f  MDR 1 Ribozyme i n t o  Mammalian 
C e l l s
Plasmid containing the MDR 1 Ribozyme (received as a gift 
from Dr. Kevin Scanlon, City of Hope Medical Center) was 
transfected into DLKPA-5F cells (a cloned population of DLKPA) 
and DLKP-4 cells (cloned population of DLKP) using a calcium 
phosphate transfection technique.
2 . 8 . 1 . 1  P r e - t r e a t m e n t  o f  C e l l s
DLKP-4 and DLKPA-5F cells were pre-treated in a similar way 
to ensure that they were healthy and in a logarithmic phase of 
growth prior to experimentation. This involved sub-culturing the 
cells into a 75 cm2 flask at a density of 2 X 105 cells/flask, 3 
days prior to being required. The cells were allowed to attach 
overnight and the next day the cells were fed with fresh medium. 
The day before transfecting, cells from a sub-confluent 
population were seeded (from a single cell suspension) at 5 X 
105 cells per 10 cm-diameter petri-dish, to ensure that the 
cells were approximately 7 0 % confluent the following day. For 
each plate of cells to be transfected, 10 /jg of plasmid DNA 
(i.e. containing the ribozyme) was diluted with 410 sterile 
ultra-pure H2O in a sterile 3 ml tube and was stored overnight, 
at 4 °C. The following day, 480 ¡il 2 X HBS, pH 7 . 12 (280 mM
NaCl, 1.5 mM Na2HPC>4 , 50 mM HEPES, filtered through a 0.22 /jm 
filter and stored at 4 °C, until required) were placed in a 
sterile tube and left at room temperature. The tubes containing 
the DNA were incubated at 37 °C, for 1 hr. When this incubation 
period was completed, 60 jul of 2 M CaCl2 was added drop-wise 
into these tubes with continual mixing using a vortex. 
Immediately, this DNA-CaCl2 mixture was added to the 2 X HBS 
dropwise, again with continual mixing using a vortex, after 
which this solution was allowed stand at room temperature, for 
30 mins., in a laminar flow cabinet. After 30 mins. this mixture 
was added to the cells, drop by drop, with constant gentle
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aggitation of the universal and swirling of the petri-dish, to 
ensure that an even mixture came in contact with all cells. The 
culture plates were then returned to the incubator for 4 hrs. To 
potentiate the entry of DNA, the cells were glycerol shocked 
after the 4 hr. incubation. This involved removing the DNA-CaCl2 
mixture and adding 5 ml of 10 % sterile glycerol in 1 X HBS. 
This was left on the cells for exactly 3 mins., removed and the 
cells were washed three times with serum free medium. The 
transfected cells were then fed with 20 ml complete medium and 
returned to the incubator.
The plasmid containing the ribozyme sequence also contains 
a gene which confers resistance to geneticin (G418) (Sigma; 
G9516). Geneticin was, therefore, used as a selective agent by 
which transfected cells could be identified i.e. cells which 
grow in the presence of geneticin are resistant and so stable 
transfectants.
2 . 8 . 2  S e l e c t i o n  o f  MDR 1 R ib o z y m e  T r a n s f e c t e d  
C l o n e s
The transfected cells were grown in the presence of 
geneticin, starting with 400 jug/ml of geneticin in medium 48 
hrs. after transfecting, and increasing the concentration of 
geneticin to 1 mg/ml over a three week period. The cells were 
grown with constant monitoring until single cells had formed 
individual colonies of approximately 50 cells. The colonies were 
individually sub-cultured, as follows, using cloning rings 
(stainless steel rings, with an inner diameter of 8 mm) to form 
individual trypsination chambers.
The medium from the petri-dish was removed and the cells 
were washed twice with sterile PBS. The PBS was then removed 
and a sterile cloning ring, with its end dipped in siliconised 
grease, was placed around an individual colony (which had been 
marked when viewed under the microscope), isolating it from 
other cells on the plate and forming a sealed sub-culturing
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chamber. Trypsin/EDTA (100 pil) (Section 2.5.2) was added to the 
colony and the cells incubated at room temperature , for 5 mins. 
The trypsin/EDTA was then gently pipetted up and down ( 4 - 5  
times), using a Gilson micropipette, to ensure that all cells 
had detached (this was checked by viewing under a microscope). 
The cells were transferred to a single well of a 96 well plate 
(Costar; 3599). Medium (100 pil) was added to the well and the 
cells were allowed to attach at 3 7 °C in 5 % CO2 , overnight.
Following attachment, the medium in the well was replaced with 
200 jjI fresh medium. When the cells had reached approximately 90 
% confluency, they were sub-cultured into a single well of a 48 
well plate (Costar; 3548). This was repeated through to a 24 
well plate (Costar; 3424), 6 well plate (Costar; 3406), 25 cm2 
flask (Costar; 3050) and 75 cm2 flask (Costar; 3075). The 10 
transfectants (5 from DLKP-4 and 5 from DLKPA-5F) resulting were 
maintained as individual cell lines, similar to all other cell 
lines used in this study.
To verify that the transfection had been performed 
successfully, that the ribozyme was being transcribed and to 
assess the effect of the ribozyme of the MDR 1 mRNA levels and 
resistance profiles of the cells, a number of studied were 
performed. DNA from the transfectants (and parent lines as 
controls) was amplified by PCR (as in Section 2.10.5) with 
primers specific for the ribozyme DNA, to establish that 
transfection had occurred. RNA isolated from these cells was 
amplified by RT-PCR (Section 2.10.4 & 2.10.5) to i) assess if 
transcription of the transfected ribozyme had occurred, and ii) 
evaluate its effect on the endogenous MDR 1 mRNA levels.
The primers used for ribozyme DNA amplification (221 bp) were as 
follows (Scanlon and co-workers, City of Hope Medical Center):
5' GAC CAG TGT TTG CCT TTT A 3'
5' TCT GGA TCC CTC GAA GC 3'
The primers used for ribozyme RNA analysis (118 bp), which would 
result in an 880 bp product if contaminating DNA was present,
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were as follows (Scanlon and co-workers, City of Hope Medical 
Center):
5 1 AGC ACA GAG CCT CGC CTT T 3'
5' TCT GGA TCC CTC GAA GC 3'
Primers used for MDR 1 mRNA analysis amplify a 157 bp product 
and are documented in Table 3.1
Glyceraldehyde-6-phosphate dehydrogenase (GAPDH) was amplified 
in this studies (380 bp) at both DNA and RNA levels, to act as 
an endogenous control. The primers used for its amplification 
are as follows (Dukas et al., 1993):
5' TCC ATG ACA ACT TTG GCA TCG TGG 3'
5' GTT GCT GTT GAA GTC ACA GGA GAC 3'
The effect or the transfected ribozyme on the drug resistance 
profile of these cell lines was assessed by performing toxicity 
assays with adriamycin, vincristine and VP-16.
2 . 8 . 3  M i n i a t u r i s e d  T o x i c i t y  A s sa y
Two days prior to setting up in a toxicity assay, all cells 
(transfectants and their respective parent cell lines) were pre­
treated, to ensure that they were healthy and in a logarithmic 
phase of growth. This involved sub-culturing into 75 cm2 flasks 
at a density of 2 X 105 cells/flask. The cells were allowed to 
attach overnight. The following day, the cells were fed with 
fresh medium. On the day the assay was set up, the cells were 
sub-cultured and a single cell suspension was obtained (as 
described in Section 2.5.2).
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2.8.3.1 Toxicity Assay
Cells were seeded, from a single cell suspension, into a 96 
well plate (Costar; 3599) at a cell density of 103 cells/well in 
100 pi medium; except for the first column of the plate which 
was used as a control, containing only 100 pil medium. The cells 
were allowed to attach overnight at 3 7 °C, in 5 % CO2 . Drug
concentrations used in each assay ranged from concentrations 
which would result in no kill (i.e. no drug) to approximately 
100 % kill. The required drug dilutions range was prepared (at a 
twice the final concentration to be assayed) and 100 pil of each 
drug dilution was added to each well, in replicas of eight. The 
plates were returned to the incubator and incubated for a 
further 6 days or until control wells (where no drug was added) 
reached 80 % confluency. Drug toxicity was then determined by 
acid phosphatase analysis (Connolly et al., 1986; Martin and 
Clynes , 1991). Medium was removed and the assay plates rinsed 
twice with (100 /j1 volumes/well) PBS. Then 100 pi of 10 mM p- 
nitrophenyl phosphate (Sigma; 104-0) in 0.1 M sodium acetate, 
0.1 % triton X-100 (Sigma; X100), pH 5.5 was then added to each 
well and the plate incubated at 37 °C for 2 hrs., in darkness. 
Following this, the enzyme reaction was stopped by the addition 
of 50 pi of 1.0 M NaOH. The plates were then read in a dual beam 
plate reader at 405 nm (reference wavelength 620 nm) (Titertek; 
Multiskan).
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2.8.3.2 Determination of the ICS0 value.
DLKPA-5F RZ1
V incristine Cone, (fig/ml)
The a b o v e  d ia g r a m  r e p r e s e n t s  t h e  t o x i c i t y  o f  v i n c r i s t i n e  t o  t h e  c e l l  l i n e  
DLKPA-5F R Z 1 . The t o x i c i t y  a s s a y  was p e r f o r m e d  a s  o u t l i n e d  i n  S e c t i o n  2 . 8 . 3 . 1 ,  
and  t h e  l e v e l  o f  a c i d  p h o s p h a t a s e  c o r r e l a t e d  t o  c e l l  s u r v i v a l  i n  t h e  p r e s e n c e  o f  
c h e m o t h e r a p e u t i c  d r u g .  The p o l y n o m i a l  e q u a t i o n  i l l u s t r a t e d  i n  t h e  a b o v e  d ia g r a m ,  
p r e s e n t s  t h e  b e s t  c o r r e l a t i o n  b e t w e e n  c e l l  s u r v i v a l ,  o n  t h e  Y - a x i s  and  t h e  d r u g  
c o n c e n t r a t i o n ,  o n  t h e  X - a x i s .  T h i s  e q u a t i o n  h a s  b e e n  o b t a i n e d  fro m  t h e  g r a p h i c a l  
c u r v e  f i t t i n g  c a r r i e d  o u t  b y  t h e  C r i c k e t  Graph c o m p u te r  s o f t w a r e  p a c k a g e .  The 
c o r r e l a t i o n  c o e f f i c i e n t ,  r ,  c o n v e y s  i n f o r m a t i o n  a b o u t  t h e  s t a t e  o f  t h e  f i t n e s s  
o f  t h e  e q u a t i o n ,  i n  r e l a t i o n  t o  t h e  d a t a  o b t a i n e d  fr o m  t h e  a s s a y .  T h u s ,  t h e  d ru g  
c o n c e n t r a t i o n  c o r r e s p o n d i n g  t o  a n y  p e r c e n t a g e  o f  t h e  c e l l  s u r v i v a l ,  c a n  b e  
c a l c u l a t e d  b y  s o l v i n g  t h e  p o l y n o m i a l  b e s t  f i t  c u r v e .  The d e t e r m i n a t i o n  o f  t h e  
IC50, w h ic h  d e n o t e s  t h e  d r u g  c o n c e n t r a t i o n  c o r r e s p o n d i n g  t o  50% c e l l  s u r v i v a l ,  h a s  
b e e n  c a r r i e d  o u t  b y  t a k i n g  Y = 50 and s o l v i n g  t h e  b e s t  f i t  c u r v e  e q u a t i o n ,  w i t h  
r e s p e c t  t o  Y. The N e w to n -R a p h s o n  m eth o d  f o r  n u m e r i c a l  s o l u t i o n  o f  n t h .  o r d e r  
p o l y n o m i a l  e q u a t i o n s  h a s  b e e n  e m p lo y e d  f o r  t h i s  d e t e r m i n a t i o n .  A c o m p u te r  
p r o g r a m  was d e v e l o p e d  i n - h o u s e ,  b y  D r . Mohamad S a l e h ,  t o  e x e c u t e  and  p e r f o r m  t h e  
c a l c u l a t i o n .  The IC50 v a l u e s ,  fro m  r e p l i c a  a s s a y s ,  w e r e  d e t e r m i n e d  i n  t h i s  manner  
an d  u s e d  t o  a s c e r t a i n  t h e  a v e r a g e  IC» v a l u e  and  t h e  s t a n d a r d  d e v i a t i o n  on  t h e  
a v e r a g e  v a l u e .
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2.9 DNA ANALISIS
DNA for PCR analysis was "extracted" using the following 
procedure as described by Higuchi (1989). A single cell 
suspension was obtained from an approximately 80 % confluent 75 
cm2 flask. These cells were washed twice in PBS, centrifuging 
at 100 g., for 2 - 5  mins. between each wash. The supernatant 
was discarded. The cells were resuspended in a volume of "PCR 
buffer with nonionic detergents and Proteinase K" to result in 6 
X 106 cells per ml. This buffer consisted of 50 mM KC1, 10 mM 
Tris-HCl (pH 8.3), 2.5 mM MgCl2 , 0.1 mg/ml gelatin, 0.45 %
Nonidet P-40 (NP40) (Sigma; N0896), 0.45 % Tween 20 (Sigma;
P1379), which was prepared, autoclaved and stored frozen until 
required. When required, it was thawed and 0.6 p 1 of 10 mg/ml 
Proteinase K (Sigma; P2308) (in water) per 100 pi of solution, 
was added.
This cell suspension was then transferred to an eppendorf 
tube and incubated at 5 0 - 60 °C, for 1 hr. Following this, the 
Proteinase K enzyme was inactivated by incubating at 95 °C, for 
10 mins. DNA quantitation was performed on the cell extracts by 
reading an aliquot of each sample spectrophotometrically at 2 60 
nm and 280 nm. (An optical density of 1 at 260 nm is equivalent 
to 50 mg/ml DNA. A A 260/A280 ratio of 1.8 is indicative of pure 
DNA) . The DNA samples were then stored at -20 °C until required 
for analysis. 1 pg of this crude DNA extract was included in a 
subsequent PCR reaction to establish if transfection of the 
ribozyme had occurred (Section 2.10.5).
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RNA ANALYSIS
A number of special precautions were taken when studying 
RNA due to the labile nature of RNA and the existance of RNase 
enzymes. RNases are ubiquitous in the environment and so care 
was taken to avoid their introduction while extracting RNA.
- General laboratory glassware and plasticware are often 
contaminated by RNases. Glassware was, therefore, treated by 
baking at 180 °C for eight hours, or more. Sterile, disposable 
plasticware is essentially free of RNases and so was used for 
the preparation and storage of RNA without pretreatment. 
Polyallomer ultracentrifuge tubes, eppendorf tubes, pipette 
tips, etc. were all autoclaved prior to use. All spatulas which 
came in contact with any of the solution components were baked 
(as for glassware), chemicals were weighed out onto baked 
aluminium-foil and a stock of chemicals kept separate, for "RNA 
extraction only", from general stocks.
-Solutions that came in contact with the RNA, after lysing 
the cells in guanidium solution, were all prepared in baked 
glassware, made from sterile ultra-pure water and treated with 
0.1% diethyl procarbonate* (DEPC) (Sigma; D5758) before 
autoclaving, with the exception of Tris containing solutions 
(DEPC reacts with amines and so is inactivated by Tris).
- Gloves were worn at all times to protect both the 
operator and the experiment. This, again, prevented the 
introduction of RNases and foreign RNA/DNA into the RT and PCR 
reactions. Gloves were changed frequently.
* DEPC is a strong, but not absolute inhibitor of RNases. Due 
care was taken when using DEPC as it is suspected to be 
carcinogenic.
2.10 Preparation for RNA Extraction
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2.10.1 Total RNA Isolation
2 . 1 0 . 1 . 1  RNA E x t r a c t i o n  from C u l t u r e d  C e l l s
The following procedure was conducted in a laminar flow cabinet 
to maintain sterile conditions and prevent the introduction of 
contaminants. Cells were grown in 135 mm (tissue culture 
treated) diameter petri-dishes, until approximately 80% 
confluent. The medium was removed and the cells rinsed twice 
with PBS. The cells on 5 replica plates were lysed by the 
addition of 5 ml of a 4 M guanidinium thiocyanate (GnSCn) 
solution. The 4 M GnSCn consisted of 50 g of guanidinium 
thiocyanate (Sigma; G6639), 0.5 g of N-lauroyl sarcosine (Sigma; 
L5125) and 5 ml of 1 M sodium citrate (RDH; 32320), pH 7.0. The 
solution was brought up to 100 ml with water which had 
previously been DEPC-treated and autoclaved and was filtered 
through a 0.45 pm filter. This was stored at room temperature, 
in the dark, until required. Immediately before use, 700 pl/100 
ml of p-mercaptoethanol and 330 pi/ 100 ml of antifoam A (Sigma;
A5758) were added.
The pooled cell lysate from the five plates was centrifuged 
at 120 g. , for 5 mins. This was then layered on 5.5 ml of a 5.7 
M cesium chloride cushion in a polyallomer ultracentrifuge tube. 
The 5.7 M cesium chloride solution had been prepared using 95.8 
g of CsCl (Sigma; C3032) and 2.5 ml of 1 M sodium citrate, pH
7.0 per 100 ml of water. The solution was filtered through a 
0.22 pm. filter. DEPC was added (100 pl/100 ml solution) and this 
was then left at room temperature for 2 hrs. before autoclaving.
Taking care on route not to disturb the cesium chloride : 
GnSCn interface, this mixture was spun at 100,000 g. at 15 °C, 
for 2 1 - 2 4  hrs. in a swinging bucket centrifuge. This resulted 
in protein layering on top of the GnSCn, DNA at the GnSCn : 
cesium chloride interface and RNA pelleting at the bottom of the 
tube. Care was taken to prevent disturbing the RNA pellet or 
contaminating the RNA with DNA. The guanidinium thiocyanate and
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"jelly-like" layer below the GnSCn/CsCl interface was removed by 
aspiration, until approximately 1 ml of cesium chloride 
remained. The tube was inverted and the bottom, containing the 
RNA pellet, cut from the rest of the tube using a heated scalpel 
blade. The pellet was rinsed with 95 % ethanol at room
temperature and resuspended in 2 00 pi of DEPC-treated water by 
gently pipetting up and down whilst keeping on ice. The 
resuspended pellet was transferred to an eppendorf tube and the 
suspension remains rinsed into the eppendorf with a further 200 
pi of DEPC-treated water. The RNA was precipitated out of 
solution by the addition of 3 M sodium acetate (to result in a 
final volume of 0.3 M) and 2 volumes of ice-cold absolute 
ethanol, overnight at -80 °C. The RNA was then pelleted by 
spinning at 4 °C, at maximum speed in a microfuge. The pellet 
was washed with 7 0 % ethanol, the supernatant removed and the 
pellet dried briefly*. The pellet was resuspended in 100 jjI of 
DEPC-treated water.
* Care was taken to ensure that the pellet did not dry 
completely as this greatly decreases its solubility. The 
solubility of RNA can be improved by heating to 55 - 60 °C with 
intermittent vortexing or by passing the RNA solution through a 
pipette tip, if necessary.
2 . 1 0 . 1 . 2  RNA E x t r a c t i o n  from Whole T i s s u e
During the course of this research work, RNA was extracted 
from whole tissues using an adaptation of this technique (See
3.9.1).
2 . 1 0 . 1 . 3  RNA E x t r a c t i o n  f r o m  P a r a f f i n - E m b e d d e d  
T i s s u e s
During the course of this thesis, a method was developed 
for the extraction of RNA from paraffin-embedded tissues. Using
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the techniques described RNA was successfully extracted and 
amplified from a number of specimens which had been stored for 
at least ten years (See 3.9.2) .
2 . 1 0 . 2  M i c r o p i p e t t e  A c c u r a c y  T e s t s
Accuracy and precision tests were carried out routinely on 
all micropipettes used in both DNA and RNA analyses by PCR and 
RT-PCR techniques, respectively. The accuracy and precision of
1,000 jil and 100 pi pipettes were determined by standard methods 
involving repeatedly pipetting specific volumes of water, and 
weighing them on an analytical balance. The specifications for 
these tests were supplied by Gilson. The 10 pi pipettes were 
returned to the manafacturer for routine calibration.
2 . 1 0 . 3  RNA Q u a n t i t a t i o n
RNA was quantified spectrophotometrically at 260 nm and 280 
nm. An optical density of 1 at 260 nm is equivalent to 40 mg/ml 
RNA. A A 260/A280 ratio of 2 is indicative of pure RNA. Partially 
solubilised RNA has a ratio <1.6 (Ausubel et al., 1991c). The 
yield of RNA from most lines of cultured cells is 100 - 200 pg 
per 90 mm plate (Sambrook et al., 1989). Similar amounts of RNA 
were retrieved in these studies.
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2.10.4 Typical Reverse Transcriptase (RT) Reaction
cDNA was formed on RNA templates using the following
procedure, which was incubate on ice unless otherwise indicated.
A combination of 1 pi oligo (dT)i2-i8 primers (lpq/pl) (Promega; 
C1101), 1 pi of total RNA (Ipg/pl), and 3 ^1 of water were
placed in an eppendorf, mixed, heated to 70 °C for 10 mins., and 
then chilled on ice. (Heating to 70 °C got rid of any RNA 
secondary structure formations and allow the oligo (dT) primers 
bind to the poly (A)+ tail of the mRNA) . To this, 4 pi of a 5 X 
buffer (consisting of 250 mM Tris-HCl pH 8.3, 375 mM KC1 and 15 
mM MgCl2 ), 2 pi of DTT (100 mM), 1 pi of RNasin (40 U/pl) 
(Promega; N2511), 1 pi of dNTPs (10 mM each of dATP, dCTP, dGTP 
and dTTP), 6 pi of water and 1 pi of Moloney murine leukemia 
virus-reverse transcriptase (MMLV-RT) (40,000 U/pl) (Gibco; 510- 
8025 SA) was added. This mixture was incubated at 3 7 °C for 1 
hr. to allow the MMLV-RT enzyme catalyse the formation of cDNA 
on the mRNA template. The enzyme was then inactivated and the 
RNA and cDNA strands separated by heating to 95 °C, for 2 mins.
Once the cDNA copy had been created using the mRNA
template, the PCR reaction was conducted immediately, as
outlined below. Alternatively, the cDNA was stored at -20 °C, 
until required for analysis.
2 . 1 0 . 4 . 1  R e v e r s e  T r a n s c r i p t i o n  o f  RNA f r o m  
P a r a f f i n - E m b e d d e d  T i s s u e s
cDNA copies of mRNA templated were formed using RNA 
isolated from paraffin-embedded tissues (as detailed in Section
3.9.2).
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RT Reaction Components
5 X Buffer
250 mM Tris-HCl, pH 8.3? 375 mM KC1; 15 mM MgCl2.
The successful use of the PCR buffer instead of the 5 X 
buffer in the reverse transcriptase reaction has been reported 
by Kawasaki (1989). Better results were achieved using the PCR 
buffer, at least when reverse transcribing short RNA sequences. 
This, it is suggested, simplifies the protocol by eliminating 
the possibility of differences in optimal monovalent and 
divalent ionic strengths between the two enzymes.
RNasin
An inhibitor of ribonuclease enzymes was included in the RT 
reaction. This was to prevent degradation of RNA by 
ribonucleases. RNasin is a broad spectrum ribonuclease inhibitor 
which acts by binding noncovalently to ribonuclease enzymes. 
RNasin is unstable at temperatures of 5 0 °C or above. As 
ribonucleases are capable of retaining their degradative 
properties under denaturing conditions, such temperatures were 
avoided for the RT reaction to prevent release of active 
ribonuclease enzymes.
Dithiothreitol (DTT)
The concentration of DTT is critical as RNasin requires 1 
mM DTT to prevent its dissociation from the RNases.
Deoxynucleotide Triphosphates (dNTPs)
The dNTPs (dATP, dCTP, dGTP and dTTP) were aliquoted as a 
mix at a concentration of 10 mM each. These were the precursors 
of the cDNA strand.
Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT)
8 8
MMLV-RT was the reverse transcriptase enzyme used to form 
cDNA on the primed mRNA template. It has been claimed that RT- 
PCR can be simplified by the fact that Tag DNA polymerase also 
exhibits reverse transcriptase activity at 68 °C (Jones and 
Foulkes, 1989). RT-PCR using one enzyme was conducted by Shaffer 
et al. ( 1990) in a study of interleukin-2 mRNA in gibbon T 
cells.
The use of Tag DNA polymerase as the enzyme catalysing the 
RT reaction may have some advantages over MMLV-RT. The RT 
reaction in the presence of reverse transcriptase enzyme 
generally takes approximately an hour. Using Taq DNA polymerase, 
cDNA can be formed in a number of minutes (Shaffer et al., 1990; 
Singer-Sam et al. , 1990). Tag DNA polymerase enzyme is much
more heat-stable than MMLV-RT, which should allow the reaction 
to be conducted at higher temperatures. This should increase the 
primer stringency and help eliminate RNA secondary structure. 
Optimum reverse transcription using Tag DNA polymerase may 
require the addition of magnesium (Bej et al., 1991).
Trouble-Shooting
Rappolee (1990) reported first-strand cDNA synthesis by 
reverse transcription to be a technique of variable efficiency 
between preparations and between RNA species. To overcome 
secondary structure problems in RNA, a number of recommendations 
were made. These include: increasing the RT reaction temperature 
from 37 °C to 55 °C (Tag DNA polymerase seems to be more stable 
at high temperatures than reverse transcriptase enzymes); 
increasing the reverse transcription enzyme concentration from 1 
X to 3 X or more, and using random hexanucleotide primers and/or 
3' antisense oligonucleotide priming. To improve sensitivity, 
the first strand synthesis may be repeated after heat 
denaturation. Reverse transcriptases have some amount of heat 
stability, but it is often advisable to add a fresh aliquot of 
enzyme for greater efficiency if a second cycle of reverse 
transcriptase is included. (This further addition of enzyme may
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not be necessary if Taq DNA polymerase reverse transcriptase 
activity is taken advantage of).
2 . 1 0 . 5  T y p i c a l  P o ly m e r a s e  C hain  R e a c t i o n
The details given here are for a typical PCR reactions, set 
up as 50 pi volumes, using 5 pi of cDNA, and amplifying for 30 
PCR cycles. In many cases, variations to this basic protocol 
were made. Such changes are indicated in the relevant "Results" 
section e.g. when establishing the exponential range of product 
accumulation and the PCR reaction plateau phase, 100 pi PCR 
volumes were prepared by doubling the amount of each of the 
components added and aliquots were removed after 15, 20, 25, 30 
and 35 cycles.
Each PCR reaction tube contained 24.5 pi water, 5 jil 10 X 
buffer (100 mM Tris-HCl, pH 9.0 at 25 °C; 50 mM KC1, 1 % Triton
X-100), 3 pi of 25 mM MgCl2 , 8 pi of dNTPs (1.25 mM each)
(Promega; U1240), 1 pi of first strand target primer (250
nq/pl), 1 pi of second strand target primer (250 nq/pl), 1 pi of 
first strand endogenous control primer (250 nq/pl), 1 pi of 
second strand endogenous control primer (250 nq/pl), 0.5 pi of 
5U/pl Taq DNA polymerase enzyme (Promega; N1862 ) and 5 pi of 
cDNA from the reverse transcriptase reaction. (The cDNA was pre­
heated to 95 °C to separate strands and get rid of any secondary 
structure formations, followed by cooling on ice). A drop of 
mineral oil was added to each reaction tube. The cDNA was then 
amplified by PCR (Techne; PHC-3) using the following program:
- 95 °C for 1.5 mins. (denature ds DNA);
30 cycles: 95 °C for 1.5 mins. (denature);
55 °C for 1 min. (anneal);
72 °C for 3 mins. (extend);
- 72 °C for 7 mins. (extend).
All reaction tubes were then maintained at 4 °C until analysed.
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The products formed were analysed by gel electrophoresis 
and densitometry. A 10 ¡il aliquot of tracking buffer consisting 
of 0.25 % bromophenol blue (Sigma; B5525) and 30 % glycerol in 
water, was added to each tube of amplified cDNA products. 10 pi 1 
of cDNA products from each tube were then separated by 
electrophoresis for 4 hrs. at 100 mV through a 4 % agarose 
(Promega Bioproducts; NuSieve GTG) gel containing ethidium 
bromide (Sigma; E87 51), using TBE (22.5 mM Tris, 22.5 M boric 
acid (Sigma; B7901), 0.5 mM EDTA) as running buffer. Molecular 
weight markers "V" (Boehringer Mannheim; 821 705) or "Phi-X" Hae 
III digested (Promega; G1761) were run, simultaneously, as size 
references.
The resulting product bands were visualised as pink bands 
when the gel was placed on a transilluminator (UVP 
transilluminator), due to the fact that ethidium bromide 
intercalates with the cDNA forming a product that is readily 
visible under ultraviolet transillumination. The gels were 
photographed and the negatives produced were analysed by 
densitometry (Imaging Densitometer. Bio-Rad. Model GS-670).
PCR Components
MgCl2: (25 mM) :
The magnesium chloride concentration has been found to 
greatly influence the PCR result. It is generally advised to 
vary the concentration of magnesium chloride (usual range 1 - 8  
mM) to determine the optimum concentration of this component.
Deoxynucleotide Triphosphates (dNTPs):
The dNTPs for the PCR were aliquoted as a mix (dATP, dCTP, 
dGTP and dTTP) at a final concentration of 1.25 mM each. These 
are the required precursors for the synthesis of new cDNA 
strands.
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Primers: (see Section 1.2.1.1) ) .
A primer pair was included in the PCR which is specific for 
the target cDNA region of interest. A primer pair which results 
in amplification of an ubiquitously occurring cellular component 
was also included. This served as an endogenous control (see
1.3). The majority of primer pairs used were selected as part of
this thesis work (Table 3.1). Other primers used are detailed in 
Section 2.8.2. A set of primers, not previously listed, which 
amplified a putative endogenous control, Esterase D (Cole et 
al. , 1991) were also evaluated during this study. Their
sequences are as follows:
5 1 GGA GCT TCC CCA ACT CAT AAA TGC A 3'
5' GCA TGA TGT CTG ATG TGG TCA GTA A 3'
Note: All oligonucleotide primers used throughout the course of 
this thesis were made to order on an "Applied BioSystems 394 
DNA/RNA Synthesiser" by R & D Systems Ltd., 4-10 The Quadrant, 
Barton Lane, Oxon, England.
Mineral Oil:
The purpose of the mineral oil was to prevent evaporation 
of the reaction components when subjected to the high 
temperatures required for melting the double-stranded DNA to 
single-strands.
2 . 1 0 . 5 . 1  R e s t r i c t i o n .  D i g e s t i o n  o f  RT-PCR P r o d u c t s
Products formed after RT-PCR amplification of MDR 1, MDR 3, 
MRP, GST x, CYPIA1, Topoisomerase I, Topoisomerase II, 
Topoisomerase Ila and Topoisomerase lip were digested with an 
appropriate restriction enzyme (Table 3.1/Table 2.10.5.1.1) as 
follows.
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A 10 pi aliquot of the particular RT-PCR product, 10 units 
of the relevant endonuclease restriction enzyme, 5 ju 1 of 10 X 
buffer (supplied with each restriction enzyme) and the 
appropriate volume of water to result in a total volume of 50 
pi, were mixed in an eppendorf tube and incubated at 37 °C, for 
2 hrs. A 20 pi aliquot of the resulting products was analysed by 
electrophoresis through a 4 % agarose gel (as in 2.10.5).
Table 2.10.5.1.1 R e s t r i c t i o n  E nzym es u s e d  t o  I d e n t i f y  RT-PCR P r o d u c t s
AMPLIFIED RESTRICTION SUPPLIER CATALOGUE
PRODUCT ENZZME NUMBER
MDR 1 Mae 1 Boehringer
Mannheim
822 213
MDR 3 Ssp 1 Boehringer
Mannheim
972 967
MRP Ban II Promeqa R6561
GST jt Sty 1 Promeqa R6481
CYPIA1 Hinc II Promeqa R6031
Topoisomerase I EcoN 1 S.T.S 521 S
Topoisomerase II Hind III Promeqa R6041
Topoisomerase 11a Alu 1 Promeqa R6281
Topoisomerase Ilß Hph 1 S.T.S 158 S
ß-actin Hph 1 S.T.S 158 S
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2.11 Exogenous Control Formation
A non-homologous DNA fragment was constructed (as detailed 
in 1.4.2.1, Fig. 8), by Dr. Carmel Daly, for use as an exogenous 
competitive control to quantify endogenous MDR 1 mRNA levels 
after RT-PCR reactions. The exogenous control was amplified 
during the PCR reaction, using the same primer sequences as 
those for the amplification of MDR 1, resulting in products 
differing by 174 bp in size i.e. MDR 1 product was 157 bp; 
control was 331 bp.
In order to prepare such a competitor fragment for use in 
the quantitation of MDR 1 mRNA, composite primers were chosen. 
These 40 bp composite primers contained 20 bp of MDR 1 specific 
primer as well as 2 0 bp complementary to pGEM4Z. The primers to 
pGEM4Z were chosen so that they would amplify a fragment of 
differing size to the product of the MDR 1 specific primers. The 
MDR 1 specific primers amplify a 157 bp product (Table 3.1) from 
mRNA. The pGEM4Z primers were chosen to produce a fragment of 
291 bp.
Composite primers were used in the first PCR reaction which 
contained 400 ng of pGEM4Z. The PCR reaction was as in Section 
2.10.5, except that only one set of primers was included. The 
second pair was replaced with extra volumes of water. PCR 
amplification resulted in the production of a 291 bp DNA 
fragment incorporating the MDR 1 gene specific primer sequences 
at the extreme ends. Products of the PCR reaction were separated 
on a 2.5 % agarose gel (using buffers etc. as described in 
Section 2.10.5). The portion of the gel containing the 291 bp 
fragment was cut out of the gel and placed in a column (Costar 
spin X - column; 8169). The column containing the agarose was 
frozen at -20 °C, for 1 hr. The DNA was then isolated by 
spinning the column at 13,000 r.p.m., for 10 mins. The resulting 
solution which contained the 291 bp DNA fragment was purified by 
phenol chloroform extraction and ethanol precipitation or using 
a clean up column (Promega wizard DNA clean up system; A7280). A 
400 ng aliquot of this DNA competitor fragment was then PCR
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amplified using MDR 1 specific primers to yield a product of 331 
bp (i.e. combination of pGEM4Z (291 bp) fragment and the two MDR
1 primer lengths ligated onto its ends (20 bp each)). This was
isolated from an agarose gel and purified. This DNA was
quantified spectrophotometrically at 260 nm and 280 nm. (An
optical density of 1 at 260 nm is equivalent to 50 mg/ml DNA. A 
A260/A280 ratio of 1.8 is indicative of pure DNA). This product 
was then stored at -20 °C until required as an exogenous control 
for MDR 1 quantification.
MDR Composite Primers used:
5 1 CCC ATC ATT GCA ATA GCA GGA CGG CCA GTG AAT TGG ATT T 3 '
5' GTT CAA ACT TCT GCT CCT GAT TCC CGA CTC GAA AGC GGG C 3 ’
The first 20 bases (5') of each are MDR 1 specific and the
second 20 (3') are pGEM4Z specific.
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2 . 1 2  U s i n g  cDNA s e q u e n c e  D a t a - B a s e s  t o  c h e c k
U n iq u e n e s s  o f  P r i m e r s .
The most critical element in the choice of primers for PCR 
is obviously that the primers are unique i.e. that they do not
cross-react with sequences likely to be present in the mRNA of
the cells/tissues being studied. This involved choosing primers 
using the criteria described in Section 1.2.1.1, and checking 
via a DNA data-base (e.g. EMBL, GenBank) what similar sequences 
exist. This approach is essential if no references are available 
on RT-PCR of the mRNA in question. Even where references do 
exist, there is need for checking because :
- the cDNA data-base is expanding rapidly and new cross­
reactivity may have been discovered since the choice of primers 
was published;
- occasionally, published primers have not been well chosen 
and cross-reactions have been overlooked; also, occasionally, 
probably due to typographical errors, incorrect primer sequences 
have been published.
Because of the excellent search facilities available, checking 
the sequence uniqueness of primer sequences is a straightforward 
procedure.
EMBL DNA data bases were accessed easily via E-Mail by 
linking to large mainframe computers (e.g. VAX). Using software 
(KERMIT), IBM-PCs were used as VAX terminals for E-Mail. Once E- 
Mail had been accessed on the PC (through use of KERMIT commands 
and the appropriate user number and password), primer sequences 
were sent to be checked to EMBL by the following procedure:
Note:
Italics = prompts received;
Bold = to be typed in;
[R] = "return" key;
???? = type in actual nucleotide sequence;
Accession No. = type in actual accession number;
CTRL/Z = press "control" key and "Z", simultaneously.
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Username : x x x x x x x x  [R] 
Password : yyyyyyyy [R]
$
Mail>
m a i l
s e n d
To: In%"F a s t a @ e m b l - h e i d e l b e r g . d e " [R]
Subj: (not necessary to choose subject) [R]
Enter your message below. Press CTRL/Z when complete or CTRL/C 
to quit:
L i b  e m a i l  [R] (can choose to check a particular library in this 
way)
A l i g n  20 [R] (can choose how many alignments required. Default 
is 30)
S e q  [R]
CCCATCATTGCAATAGCAGG[R] (The example given here is the MDR 1 
primer (a) sequence - see Table 3.1). 
e n d  [R]
CTRL/Z [R]
If you have an accession number e.g. for a cDNA sequence, 
and wish to obtain the cDNA sequence, the address and procedure 
is slightly different:
Mail> s e n d  [R]
To: In%"N e t s e r v @ e m b l - h e i d e l b e r g . d e " [R]
Subj: [R]
Enter your message below. Press CTRL/Z when complete or CTRL/C 
to quit:
GET NUC:X00351 [R] (The example shown here is the EMBL 
accession number of human mRNA for (3-actin).
CTRL/Z
To access returned mail:
Mail> d i r  [R] (will give a list of your directory of returned 
messages)
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Mail>3 [R] (chose the number of any of the listed return 
messages e.g. no. 3)
By pressing [R] you can read through the message or 
Mail> p r i n t  [R]
CTRL/Z (if want message printed).
After use, when have exited by using CTRL/Z command
$ l o  (to exit system).
Depending on the pressure on the EMBL facility at the time, 
a list of related sequences were sent back in minutes or hours.
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2.13 PROTEIN ANALYSIS
Protein levels of p-glycoprotein and Topoisomerase II were 
analysed in a number of cell lines using Western blotting 
techniques.
2 . 1 3 . 1  P - g l y c o p r o t e i n  A n a l y s i s
P-glycoprotein is a membrane-associated protein. Cell 
membranes were, therefore, prepared for its analysis. This 
involved using 2 X 107 cells, during their exponential phase of 
growth. The cells were trypsinised, pelleted and the cell 
pellets were washed three times in PBS. The following procedures 
were performed on ice, except when otherwise indicated. The cell 
pellet was resuspended in 5 ml of ice-cold 10 mM KC1, 1.5 mM 
MgCl2 , 10 mM Tris, pH 7.4, to which 2 mM PMSF was added 
immediately prior to use. The cells were then sonicated until 
lysis was observed in samples viewed under a microscope. The 
lysed cells were centrifuged at 100,000 g., at 4 °C, for 1 hr. 
The resulting pellet was resuspended in 500 pi of lysis buffer. 
This was divided into 100 pi aliquots and lyophilised overnight, 
after removing an aliquot for protein quantitation. The 
lyophilised cell membrane samples were then stored at -80 °C 
until required for Western blot analysis.
2 . 1 3 . 2  N u c l e a r  E x t r a c t i o n  o f  T o p o i s o m e r a s e  I I
The nuclear DNA enzyme, Topoisomerase II, was isolation 
from a large culture (108)(Section 2.5.4) of healthy cells, 
during the logarithmic phase of growth. The protocol used for 
its isolation was an adaption of a method published by Danks et 
ai. (1988). To inhibit proteolytic degradation of Topoisomerase 
II, all solutions used during the isolation procedures contained 
the following freshly prepared cocktail of inhibitors 
phenylmethylsulfonyl fluoride (PMSF)(1 mM), (Sigma; P7626);
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leupeptin (50 jjg/ml),(Sigma; L2884); soyabean trypsin inhibitor 
(1 mg/ml),(Sigma; T9003); pepstatin A (1 ^/g/ml),(Sigma; P6425); 
aprotinin (20 ¡iq/ml)(Sigma; A1153) and benzamidine (1 mM) (Sigma; 
B6506). Unless otherwise indicated, all procedures were 
performed at 4 °C (or on ice).
Cells were trypsinised, pelleted and washed in PBS. The 
resulting cell pellet was permeabilised by resuspending in 1.75 
ml of hypotonic buffer (5 mM KH2PO4 , 2 mM MgCl2 , 4 mM DTT, 0.1 
mM Na2EDTA, pH 7.0) and incubating for approximately 20 mins. 
The viability of samples of the cells were tested as in 2.5.3. 
When approximately 90 % of the cells stained blue (lysed), they 
were centrifuged at 400 g., for 5 mins. The cells were 
resuspended in hypotonic buffer containing 0.25 M sucrose, at a 
cell density of 5 X 108/8 ml of buffer. Each 8 ml aliquot was 
then gently layered over 3 ml of hypotonic buffer containing 0.3 
M sucrose and centrifuged at 2, 000 g., for 20 mins. The
supernatant was removed and the pellet volume estimated. The 
pellet was resuspended in a half volume of lysis buffer (5 mM 
KH2PO4 , 4mM DTT, 1 mM Na2EDTA, pH 7.0) and was incubated for 15
mins. Following this, nuclear Topoisomerase II was extracted by 
adding half the pellet volume of a 1.0 M salt extraction buffer 
(40 mM Tris, 2.0 M NaCl, 4 mM DTT, 20 % glycerol, pH, 7.5). This 
was then vortexed, incubated for 30 mins., and centrifuged at
100,000 g., for 1 hr. The clear supernatant was removed and the 
pellet was re-centrifuged. Both supernatants were pooled and 
were analysed for Topoisomerase II levels. This analysis was 
either performed immediately or the extracts were stored at -17 0 
°C, for up to 3 days.
2 . 1 3 . 3  P r o t e i n  Q u a n t i t a t i o n
To ensure equal quantities of protein were loaded on the 
Western blots, the protein levels in a sample of each extract 
was determined using the Bio-Rad Protein Assay Kit (Bio-Rad; 
500-0006). A range of known concentrations of bovine serum 
albumin (BSA) (Sigma; A9543) were used as standards. A 100 /j 1
1 0 0
volume of the appropriate standards and test samples, were 
placed in clean, dry test-tubes. 5 ml of diluted dye reagent 
(which was provided as a 5-fold concentrate in the kit) was 
added to each tube, and the mixture vortexed. Between 5 - 6 0  
mins. later, the O.D.595 was measured on a spectrophotometer, 
against a reagent blank. A plot of the standard concentrations 
versus their O.D.595 readings was formed, from which the 
concentrations of protein in the test samples were extrapolated.
2 . 1 3 . 4  P o l y a c r y l a m i d e  G el  E l e c t r o p h o r e s i s
The proteins present in the cell extracts were seperated, 
based on size, by electrophoresis through a 7.5 % SDS
polyacrylamide gel. The resolving gel was prepared by mixing 3 .8 
ml of an acrylamide stock (29.1 g acrylamide (Sigma; A8887) and 
0.9 g N,N-methylene bis-acrylamide (Sigma; N7256) made up to 100 
ml with water), 3.0 ml 1 .875 M Tris-HCl, pH 8 . 8  and 8.0 ml 
water. To this solution, 150 pi of 10 % SDS (Sigma; L4509), 50 
pi of 10 % ammonium persulphate (Sigma; A1433) and 7.5 pi of 
TEMED (Sigma; T8133) were added. The gel was immediately poured 
into two clean 10 cm X 8 cm gel cassettes (each consisting of a 
glass and an aliminium plate seperated by two 0.75 cm plastic 
spacers, one on either outer edge). The gels were overlaid with 
saturated butanol and allowed to set. Once set, the saturated 
butanol was poured off and the gel tops washed with water. The 
stacking gels were then poured. The stacking gel was prepared by 
combining 0.8 ml of acrylamide stock, 0.5 ml of 1.25 M Tris-HCl, 
pH 6 . 8 and 3.6 ml of water. To this was added, 50 pi of 10 % 
SDS, 17 pi of 10 % ammonium persulphate and 5 pi of TEMED. This 
solution was poured onto the resolving gels. A comb of the 
appropriate thickness and well size was immediately inserted and 
the gels allowed to set. When the wells had formed, the combs 
were removed and the gels transferred to a mini-electrophoresis 
apparatus. The gels were flooded with running buffer (1.9 M 
glycine (Sigma; G67 61), 0.25 M Tris, 0.1 % SDS. The pH of the 
buffer was 8.3, unadjusted).
1 0 1
Protein samples to be analysed were diluted 1 : 1 with
loading buffer (50 mM Tris-HCl, pH 6 .8 ; 1 % SDS; 5 % (5 —
mercaptoethanol (Sigma; M6250), 5 % glycerol and 0.1 %
bromophenol blue). These were boiled for two minutes. Equal 
quantities of protein from each sample, and appropriate 
molecular weight markers, were then loaded into the wells. The 
gels were run at 250 mV and 45 mA, for 1.5 hrs.
2 . 1 3 . 5  W e ster n  B l o t  P r o c e d u r e
Following electrophoresis, the acrylamide gels were 
equilibrated in transfer buffer (25 mM Tris, 192 mM Glycine, pH 
was between 8.3 - 8.5 without adjusting). Nitrocellulose filter 
(Amersham; Hybond C) onto which the protein was to be 
transferred, was cut to the same size as the gel and was soaked 
in transfer buffer, for 5 mins. Whatman 3 mm filter paper was 
also cut to the same size as the gel, four stacked sheets of 
which were soaked in transfer buffer and placed on the cathode 
plate of a semi-dry blotting apparatus. Trapped air was removed 
from between the filters by rolling a glass pipette over and 
back across them. The nitrocellulose was then placed on the 
wetted filter paper, taking care not to trap air bubbles. The 
acrylamide gel was removed from the transfer buffer and placed 
on the nitrocellulose. The nitrocellulose was marked at the 
locations of the gel lanes and molecular weight markers. A 
further four sheets of Whatman filter paper, which had been 
soaked in transfer buffer were placed on top of the gel (again, 
preventing air bubbles being trapped). The protein was 
transferred from the gel to the nitrocellulose at 0.34 mA/0.15 
V, over a period of 30 mins. The nitrocellulose was then placed 
in blocking buffer (as described in Sections 2.13.5.1 and
2.13.5.2) to prevent non-specific binding of antibody. The 
nitrocellulose was then exposed to a specific primary antibody 
directed against the antigen under analysis. Simultaneously, 
negative control blots were formed where the primary antibody 
was replaced with antibody diluent, or pre-immune serum, if 
available.
1 0 2
2.13.5.1 P-Glycoprotein
Following transfer of protein to nitrocellulose, the 
nitrocellulose was placed in blocking buffer (0.5 % non-fat 
dried milk (Cadbury; Marvel skimmed milk) in TBS (500 mM NaCl, 
2 0 mM Tris, pH 7.5) at room temperature, for 2 hrs. Following 
this, the nitrocellulose was exposed to primary antibody (0.25 
pq/ml C219 (Centicor Diagnostics) in 10 ml TBS containing 0.1 % 
Tween 20) at 4 °C, overnight. The negative control was further 
exposed to antibody diluent for this time. The nitrocellulose 
was washed three times in TBS containing 0.5 % Tween 2 0 to 
remove any unbound primary antibody. The nitrocellulose was then 
exposed to secondary antibody (1/9,500 dilution of rabbit anti­
mouse IgG (Sigma; A1902) in TBS containing 0.1% Tween 20) at 
room temperature, for 1.5 hrs. The nitrocellulose was washed 
three times in TBS containing 0.5 % Tween 20. The blot was 
developed as in Section 2.13.6.
2 . 1 3 . 5 . 2  T o p o i s o m e r a s e  I I
Following transfer of protein to nitrocellulose, the 
nitrocellulose was placed in blocking buffer (10 mM Tris-HCl, pH 
7.4, 140 mM NaCl, 5 % non-fat dried milk, 3 % BSA, 0.2 % Tween 
20) at 4 °C, overnight. The primary antibody, a polyclonal 
rabbit serum raised against Topoisomerase II and pre-immune 
rabbit serum (as a negative control) were each diluted 1/700 in 
blocking solution. (The antibodies were received as gifts from 
Dr. W.T. Beck and documented by Friche et al. (1991)). The 
nitrocellulose was incubated with the primary antibody (or pre- 
immune serum) at 4 °C, for 48 hrs. The nitrocellulose was then 
washed three times in a washing buffer (10 mM Tris, 140 mM NaCl, 
pH 7.4) and was exposed to the secondary antibody (1/13,000 
dilution of goat anti-rabbit IgG (Sigma; A8025) in blocking 
solution) at room temperature, for 2 hrs. The nitrocellulose was 
again washed three time as above. The blot was developed as in 
Section 2.13.6.
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2.13.5.3 Topoisomerase Hot
Following transfer of protein to nitrocellulose, the 
nitrocellulose was placed in blocking buffer (PBS containing 3 % 
BSA) at 4 °C, overnight. The primary monoclonal antibody, 6G2, 
was diluted 1/50 with PBS containing 1 % BSA, at 4 °C,
overnight. (This antibody was received as a gift from Dr. G. 
Astaldi-Ricotti and was described by Negri et al. (1992)). 
Antibody diluent was used in place of 6G2 for the negative 
controls. The nitrocellulose was washed three times with PBS 
containing 0.1 % Tween 20. This was then incubated with the 
secondary antibody (1/9,500 dilution of rabbit anti-mouse IgG 
(Sigma; A1902) in PBS containing 0.1 % BSA and 0.1 % Tween 20) 
at room temperature, for 2 hrs. The nitrocellulose was again 
washed three times with PBS containing 0.1 % Tween 20 and was 
developed as outlined in Section 2.13.6.
2 . 1 3 . 6  D e v e l o p i n g  W e ster n  B l o t s
The blots were developed by incubating in a developing 
substrate until bands and/or background colour appeared. The 
developing substrate consisted of a mixture of 2.5 ml of 
Solution A and 1 ml of Solution B in 22.5 ml of a solution 
consisting of 0.5 M Tris-HCl, pH 8.9 containing 0.1 ml of 1 M 
MgCl2 • Solution A consisted of 0.1 % Nitroblue tetrazolium 
(Sigma; H5514) in 10 ml Tris-HCl, pH 8.9. Solution B consisted 
of 5 mg/ml 5-bromo-4-chloro-indolyphosphate (Sigma; B0274) in 
dimethyl formamide (Sigma; D8654). Once the blots had developed, 
they were washed in water at room temperature, allowed to dry 
and photographed. The blots were stored in darkness to prevent 
fading.
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Chapter 3
Results
RESULTS
3 . 1  D e s ig n  o f  O l i g o n u c l e o t i d e  P r im e r s  f o r  RT-PCR S t u d i e s  
o f  M D R -rela ted  raRNAs
Primer pairs were selected to enable mRNA of multiple drug 
resistant (MDR)-related genes to be analysed by RT-PCR methods 
(Table 3.1). The primers selected were for the study of MDR 3, 
MRP, GST a ,  GST x, CYPIAl, Topoisomerase I, Topoisomerase II, 
Topoisomerase Ila, Topoisomerase lip and p-actin. (The MDR 1 and 
P2-microglobulin primers used throughout the course of this 
study were previously published by other research groups (see
3.1)). All primers were chosen, based on the coding sequence of 
the specific target of interest and the uniqueness of each 
primer was checked via the EMBL DNA data-base (2.12). A number 
of criteria suggested for choosing primers (see 1 .2 .1 .1 ) were 
used as a guide-line and were adhered to as far as possible. It 
was realised, however, that choosing primers representing all of 
the suggested guide-lines was not possible in all situations. 
The primer sequences selected, therefore, represent the best 
attempts to optimise, taking into consideration the conflicting 
requirements of different criteria (see Table 3.1).
3 . 1 . 1  E x a m p le s  o f  P r i m e r  P a i r s  a nd  how t h e y  F i t  
S p e c i f i e d  C r i t e r i a
Topoisomerase II, Topoisomerase Ila and Topoisomerase II/5: 
Primers were chosen which allow amplification of Topoisomerase 
II cDNA, in general, by selecting a region that is common to 
both Topoisomerase Ila and Topoisomerase U p  isozyme. Specific 
primers were also chosen for Topoisomerase Ila and Topoisomerase 
lip so that their transcript levels could be studied 
independently. This allows the levels of Topoisomerase Ila and 
Topoisomerase lip to be analysed individually, the overall 
levels of Topoisomerase II evaluated, and the results compared.
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Topoisomerase IIz When choosing primers for analysis of 
Topoisomerase II, in general, the C-terminus and the extreme N- 
terminal regions were avoided as these are the main areas where 
Topoisomerase Ila and Topoisomerase 11(3 diverge in structure.
The chosen primers are both 100 % homologous to specific regions 
of the Topoisomerase II mRNA template, resulting in a region of 
216 bp being amplified. Digesting with Hind III restriction 
enzyme produced bands of 129 bp and 8 7 bp. The primers are not 
equal in length. This seemed unavoidable, however, when 
attempting to maximise their specificity. Many sequences were 
chosen as potential primers, but the primer pair 1395-1412 and 
1585-1610 (Tsai-Plugfelder et al. , 1988 ) were favoured by
comparison to the others as they are independently homologous to 
fewer other human sequences and they do not share common 
homologies other than Topoisomerase II. The annealing 
temperature for Topoisomerase 11(a) primer is slightly below the 
recommended range; the Topoisomerase 11(b) primer is within this 
range. Neither primer contains palindromes or stretches of 
polypurines or polypyrimidines. Due to the unavailability of the 
Topoisomerase II genomic sequence, it is uncertain whether or 
not these primers span or cross introns.
Topoisomerase Ila (Ila): The C-terminal region which is the 
longest region of divergence between Topoisomerase Ila and 
Topoisomerase 11(3 was considered to be the best area to choose 
specific primers for Topoisomerase Ila and Topoisomerase lip,
respectively. As the region of divergence between Topoisomerase 
Ila and Topoisomerase II{3 is relatively small, primers that span
the longest region possible were favoured. This is so that the 
product and the restriction enzyme digestion products can be 
easily detected on a gel. A number of potential 3' primers were 
not chosen for Topoisomerase Ila as they contained stretches of
polypurines and polypyrimidines. To avoid these and other 
problem areas, primers 4052-4072 and 4165-4190 (Tsai-Plugfelder 
et al., 1988) were chosen. Although the 139 bp region amplified 
is homologous with that of Topoisomerase lip to a small extent 
the primers are specific for Topoisomerase Ila. Digestion with 
Alu 1 restriction enzyme resulted in stretches of 87 bp and 52
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bp being produced. The annealing temperature for the 5' primer 
is within the recommended range, but that for the 3' primer is 
slightly high. Both primers are independently homologous to a 
number of other human sequences, but do not seem to share common 
homologies.
Topoisomerase IJ/S (Ilfi): The Topoisomerase 11(3 primers (4335-
4364 and 4425-4452, Jenkins et al. , 1992; EMBL accession no.
X68060) amplify a 118 bp region unique to Topoisomerase lip.
Digestion with EcoR 1 restriction enzyme produced fragments of 
80 bp and 38 bp; Hph 1 restriction enzyme resulted in 69 bp and 
49 bp products. The primers are quite long - 28 bp and 30 bp, 
respectively, to increase their specificity. They have an 
annealing temperature slightly above the recommended range. 
Neither primer contains palindromes or lengths of polypurines or 
polypyrimidines. Both these primers, too, are independently 
homologous to a number of human sequences, but they apparently 
do not share common human homologies (with the exception of 
IIP).
Glutathione-S-Transferase Jt (GST x)\ The cDNA sequence of GST ;t 
(Moscow et al., 1989) apparently differs from that of human 
myocardial fatty acid ethyl esters-III (FAEE-III) (Bora et al., 
1991) by only six nucleotides. This has been claimed to reflect 
an inherent functional difference between the resulting protein 
products. As primers specific for GST jt could not be found, an
effort was made to find a restriction enzyme recognition site 
that is present in the GST Jt amplified region but not in FAEE-
III, or vice versa (due to the four nucleotide sequence 
difference in this region). However, such a site was not 
identified.
P-Actin: Choosing primers for p-actin amplification was a
difficult task as at least six isoforms of actin are known to 
exist in vertebrates. From the primer sequences published for 
amplification of p-actin it seems to be very difficult to choose 
sequences which are specific for p-actin and do not recognise p- 
actin pseudogene, mutated p-actin, a-actin or y-actin. The p~
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actin primer pair chosen in this thesis were also homologous to 
mutant (3-actin (EMBL accession no. X63432). This was unavoidable
when the other actin forms were avoided and the guide-lines for 
choosing primers were considered, as the normal (EMBL accession 
no. X00351) and the mutant forms differ only by one nucleotide 
in the amplified region.
MDR 1: The primers published by Noonan et al. (1990) are both
100% homologous to the MDR 1 mRNA template, resulting in a 
region of 157 bp being amplified. These primers were also 
assessed in this study to establish how they fit the criteria 
suggested. A diagnostic restriction enzyme recognition site for 
this MDR 1 region was chosen in this laboratory. Digestion with 
Mae 1 results in products of 84 bp and 7 3 bp. The primers are 
equal in length and the annealing temperature for both fit into 
the recommended range of 55 °C to 75 °C. Neither primer contains 
palindromes or stretches of polypurines or polypyrimidines. The 
region amplified by these primers is from position 2596 to 2752 
bp and the poly (A)+ tail commences at position 4223 bp. The 
primers flank a sequence that crosses an intron so that DNA 
contamination can be diagnosed. If the relevant area of DNA was 
amplified, a band of 1,257 bp would result in comparison to a 
band of 157 bp from cDNA. The primers were selected to amplify 
only MDR 1 (avoiding MDR 3). Both primers share homology with a 
number of other human nucleotide sequences. However, their only 
common homologies are MDR 1 mRNA (for which they were selected) 
and MDR 1 gene. By virtue of the fact that the selected region 
has an intron present in the DNA, if contaminating DNA is 
amplified, it should be possible to identify it by its longer 
size in comparison to the amplified region of cDNA.
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Table 3.1: Primers to am plify cDNA formed by reverse transcription on mRNA tem plates of M DR related factors.
Primer A +T: Tm A m p lified D iagnostic Restriction Corresponding Location on
len gth G+C m RNA R.E. product length D N A  length tem p late
(bases) sepuence
length
(bases)
(bases) (bases)
MDR 1 (a) 20 1 0:10 60 157 Mae 1 84 + 73 1,257 2596-2615
(b) 20 11:9 56 (Chen et al., 1990) 2733 - 2752
(Chen et al., 1986 ; 1990)
MDR 3 (a) 24 1 6 :8 64 321 Ssp 1 194 +127 N .K . 2580 - 2603
(b) 24 1 5 :9 66 2877 - 2900
(van der Bliek et al., 1988)
MRP (a) 21 1 3 :8 58 203 B v u l 129 + 74 N .K . 1317-1337
(b) 21 11:10 62 Ban II 
Apa 1
129 + 74 
129 + 74
1499-1519 
(EMBL no. L05628)
TOPO I (a ) 30 17:13 86 180 EcoN 1 115 + 65 2,280 bp 1123-1152
(b) 27 16:11 82 (D ‘Arpa et al., 
1988;
Kunze et al., 1991)
1276- 1302 
(D'Arpa et al., 1988)
TOPO II (a )
(b)
18
26
1 0 :8
1 6:10
52
72
216 H ind III 129 + 87 N .K . 1395-1412
1585-1610
(Tsai-Pflugfelder et al., 
1988)
TOPO Ila (a )
(b)
21
26
11:10
12:14
62
80
139 A lu l 87 + 52 N .K . 4052 - 4072 
4165 - 4190
(Tsai-Pflugfelder et al., 
1988)
TOPO lip (a)
(b)
30
28
19:11
18:10
82
76
118 H ph 1 69 + 49 N .K . 4335 - 4364 
4425 - 4452
(Jenkins et al., 1992) 
(EMBL no. X68060)
Primer A+T: Tm A m p lified D iagnostic Restriction Corresponding Location on
len gth G+C mRNA R.E. product length D N A  length tem p late
(bases) sepuence
length
(bases)
(bases) (bases)
GST 3i (a ) 18 8 :1 0 56 270 Sty 1 171+ 99 749 5 8 -7 5
(b) 24 14:10 68 (EMBLno. X08058) 304 - 327
(Moscow et al., 1989)
G STa (a) 30 1 8:12 84 330 H ind III 206 +124 4,630 235 - 264
(b) 30 14:16 92 H su 1 
M sp l
206 +124 
228 +102
( K lo n e  et al., 1992; 
Tu and Qian, 1986; 
EMBL no.s X65726, 
X65734)
535 - 564
(Tu and Qian, 1986)
CYPIA1 (a) 21 1 2 :9 60 327 H inc II 246 + 81 755 1021-1041
(b) 21 1 4 :7 56 (Ja isw a l  e t a l . ,  1985  
a )
1327-1347
(jaiswal et al., 1985b)
ß-Actin (a ) 29 16:13 84 383 H in f  1 193 +190 590 619 - 647
(b) 22 1 2:10 64 H ph 1 266 +117 (EMBL no. M10277) 980-1001
(EMBL no. X00351, M 10277)
ß2-Micro­ (a ) 20 1 1 :9 58 114 Mse 1 68 + 46 1,974 271 - 290
globulin (b) 20 1 2 :8 56 (G tissow  et al., 
1987)
365 - 384
(Gtissow et al., 1987)
Notes:
* This primer was not selected in our laboratory, but was published by Noonan et al. (1990).
When numbering all primers "A" of the start codon was considered as position "1".
A P2 -microglobulin may be used as an internal control when amplifying this sequence if diagnostic digestion with a restriction enzyme is to be included. This 
is because the region amplified with the primers chosen for p-actin has also a site present for this restriction enzyme, whereas the P2 -microglobuIin region does not.
$ GST a  primers were chosen on the human liver cDNA templates (clone pGTHl and pGTH2) and the human kidney cDN A template (GSTa  12 k), according to the 
sequences published by Klcne and co-workers (1992). GSTa (a) primer is located on exon 4 and primer (b) spans from exon 6 to exon 7 (Klone e t  al., 1992).
N.K. = Not known.
3.1.2 Trial Amplification and Product Restriction for 
all Primer Pairs Selected
To ensure that each primer pair amplified a specific cDNA 
region, producing a single band of the predicted size, PCR 
reactions were set up (as in 2.10.5) including cDNA formed on 
mRNA templates extracted from the sensitive (parent) form of 
each of the cell lines included in this study i.e. DLKP, SKMES- 
1, OAW4 2 and HEp-2. The analysis was performed on two RNA 
extractions from each cell line. All reactions were set up in 
duplicate. An endogenous control was also amplified in all 
reaction tubes; p-actin in the case of MDR 1, MDR 3, MRP, GST it, 
CYPIAl, Topoisomerase I, Topoisomerase II. P2-microglobulin was 
amplified, simultaneously, with the Topoisomerase Ila and 
Topoisomerase lip target regions, respectively. In all cases, 30 
cycles of PCR amplification were performed. An aliquot of each 
amplified product was digested (in duplicate) with an 
appropriate restriction enzyme. An example of these results 
(from the OAW42 cDNA analysis) is illustrated in Fig. 3.1.2.1 
and Fig. 3.1.2.2. Amplification in all cases was successful, 
resulting in a single band of the appropriate size. Digestion 
with a relevant restriction enzyme also produced the predicted 
sized bands. The levels of internal control transcripts, P-actin
remained equal in all reactions (see Table 3.1. for sizes of 
amplified bands and restriction digest products).
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Fig. 3.1.2.1 MDR 1 (157 bp), MDR 3 (321 bp), MRP (203 bp), GST * 
(270 bp), CYPIA1 (327 bp), Topoisomerase I (180 bp), Topoisomerase li 
(216 bp) and Topoisomerase 11« (139 bp) gene transcript analysis by 
RT-PCR, in cDNA derived from 0 A W 4 2  cells. The left-hand lane 
contains the D NA molecular weight marker consisting of 22 fragments 
with the following numbers of base-pairs: 587, 540, 504, 458, 434, 
267, 234, 213, 192, 184, 124, 123, 104, 89, 80, 64, 57, 51, 21, 18, 1 1 
and 8 with which the target products were sized. Two bands were 
produced in all cases. The upper band (in all, except Topoisomerase ilex 
analysis) represents p-actin (383 bp) which acts as an endogenous 
control. p2-microglobulin (114 bp) was amplified as an internal control 
when studying Topoisomerase lla. A band of the expected size was also 
produced in all cases, indicative of the specific target m R N A  under 
analysis. ,, 7
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Fia 3.1.2.2 Restriction digestion of target amplified products (as 
indicated in Fig. 3.1.2.1) with approptriate restriction enzymes: MDR 1 
(Mae 1), MDR 3 (Ssp 1), MRP (Ban II), GST ^ (Sty 1), CYPIA1 (Hinc II), 
Topoisomerase I (EcoN 1), Topoisomerase II (Hind III) and Topoisomerase 
lla (Alu 1). Products of the predicted sizes resulted: MDR 1 (84 + 73), 
MDR 3 (194 + 1 27), MRP (1 29 + 74), GST n (171 + 99), CYPIA1 (246 + 81), 
Topoisomerase I (115 + 65), Topoisomerase II (129 + 87) and 
Topoisomerase lla (87 + 52), when sized against the molecular weight 
marker ran in the left-hand lanes.
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Experiments were done to select, from a range of potential 
endogenous internal controls (see 1.3), one such control which 
could be used routinely to normalise target mRNA transcript 
levels, throughout the course of this study. Such a control 
should not be affected by the experimental conditions. This 
required that the levels of this gene transcript be equal in the 
sensitive and resistant forms of each cell line and that it be 
unaffected during, or following, exposure to the anti-cancer 
drugs - adriamycin, vincristine and VP-16. Based on published 
literature, the endogenous controls considered were (3-actin, P2-
microglobulin, Esterase D and GAPDH. PCR reactions were set up 
to amplify each of these mRNA transcripts from cDNA derived from 
two extracts of DLKP, DLKPA, OAW42, OAW42A, HEp-2, HEp-2A, 
SKMES-1 and SKMES-1A, respectively. All reactions were set up in 
duplicate. As shown for HEp-2 and HEp-2A (Fig. 3.2, Table
3.2.1), the levels of each of the potential endogenous controls 
was fairly consistent in both sensitive and drug resistant cell 
lines, with the exception of Esterase D, which seemed to be 
slightly eleviated in the MDR cell lines by comparison to the 
sensitive cell lines. Similar results were produced when 
studying DLKP, DLKPA, OAW42, OAW42A, SKMES-1 and SKMES-1A. |3-
actin was, therefore, selected as the endogenous control for 
future studies as it produced a sharp, clear band which was 
larger in size than all the other transcripts under analysis. 
P2-microglobulin was chosen for studies of Topoisomerase Ila and 
Topoisomerase I ip when the resulting product was to be digested
by a restriction enzyme as both Alu 1 and Hph 1 restriction 
enzymes which restrict these products, respectively, also cleave 
the (3-actin product.
3.2 Selection of Appropriate Endogenous Internal
Controls
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1 st Analysis 2nd Analysis
HEp-2 HEp-2A C HEp-2 HEp-2A C
(i) 434 m
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434 
267 
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Fig. 3.2 Selecting from a number of putative ubiquitously expressed genes, including (i) 
p-actin (383 bp), (ii) -microglobulin (114 bp), (iii) Esterase D (453 bp) and (iv) 
GAPDH (380 bp), a potential endogenous control for analysis of sensitive and MDR cells. This 
analysis was done, in duplicate, on two independent RNA extracts from HEp -2 and HEp -2A. 
The left-hand lane contains the DNA molecular weight marker. A negative control (C), where 
RNA was replaced by an equal volume of ultra-pure water in the RT reaction, was included 
with each RNA extract analysis (lanes 5 and 10, respectively). The results from each extract 
(lanes 1-4 and 6-8, respectively) were reproducible for all gene products examined. No 
significant differences in any of these transcript levels were realised with MDR, by 
comparison to the drug sensitive cells, with the exception of Esterase D, which was 
apparently increased in MDR lines.
This analysis of HEp -2 and HEp -2A cells is indicative of results obtained in similar 
studies of DLKP, DLKPA, OAW42, 0AW42A, SKMES-1 and SKMES-1A cell lines.
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Endogenous
Control
HEp-2 HEp-2A HEp-2 HEp-2A
P-actin 0.613 0.615 0.609 0.610
p2-m 0.144 0.141 0.164 0.161
Esterase D 0.093 0 . 1 2 1 0.099 0.132
GAPDH 0.518 0.529 0.576 0.581
Table 3.2.1 Analysis, by densitometry, of band intensities 
resulting from RT-PCR amplification of (i) p-actin, (ii) P2- 
microglobulin (P2-m), (iii) Esterase D and (iv) GAPDH (Fig. 3.2) 
when selecting an appropriate endogenous control.
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3.3 Qualitative Analysis of mRNA Transcripts in 
Sensitive v. MDR Cell Lines
Alterations in the expression of genes involved in 
conferring an MDR profile on cells were investigated at the mRNA 
level in a number of MDR cell lines, in comparison to their 
sensitive parent lines. The presence of gene transcripts 
corresponding to MDR 1, MDR 3, MRP, GST a, GST jc, CYPIA1, 
Topoisomerase I, Topoisomerase II, Topoisomerase Ila and 
Topoisomerase lip was investigated in DLKP, DLKPA, OAW42, 
OAW42A, SKMES-1, SKMES-1A, SKMES-1ADR, HEp-2 and HEp-2A. The 
resulting bands were analysed to establish if any differences in 
the resistant and sensitive lines were apparent, which may be 
indicative of MDR. The analysis was performed on two RNA 
extracts from each cell line. Duplicate batches of cDNA were 
generated from each of these RNA sources on which the analysis 
was performed. As always, all reaction tubes were set up in 
duplicate. 30 cycles of PCR amplification of the cDNA of 
interest (and p-actin cDNA) were performed. Successful 
amplification of all gene products, except GST a and CYPIAl was 
achieved; the MDR 3 amplified product was generally quite faint. 
These results are exemplified in Figs. 3.3.1 (DLKP and DLKPA) 
and 3.3.2 (SKMES-1 and SKMES-1A).
MDR 1 transcript levels were increased in the resistant 
variant, by comparison to the sensitive form of each of the cell 
lines studied. This was particularly obvious in DLKP and DLKPA 
(Fig. 3.3.1). A strong band representing the MDR 1 amplified 
product was produced on amplification of DLKPA-derived cDNA; 
DLKP apparently expressed no detectable levels of MDR 1 mRNA. 
Similar results were obtained for SKMES-1 and SKMES-1ADR. 
Although a band resulted after amplification of this region in 
cDNA derived from the SKMES-1 cell line, the intensity of the 
resulting band was significantly weaker than that produced with 
the MDR cell line.
Analysis of mRNA encoding Topoisomerase II revealed the 
presence of this mRNA in all cell lines, with apparent
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reductions (albeit slight) in the resistant variants of the cell 
lines. From the independent studies of Topoisomerase Il a  and 
Topoisomerase lip it seems that the Topoisomerase I la levels 
were slightly reduced and the Topoisomerase 11(3 slightly 
increased, possibly balancing the physiological levels of 
Topoisomerase, overall.
With the exception of the MDR 1 and Topoisomerase II mRNA 
levels, no obvious differences in gene expression were apparent 
from these results. However, as mentioned in 1.4, PCR product 
concentration is proportional to the starting target cDNA only 
as long as the product accumulation remains exponential. As the 
point at which the exponential accumulation plateaus was not 
assessed prior to this analysis, it is possible that other 
differences in mRNAs exist between the resistant and sensitive 
cell lines that had not yet been realised.
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F i g s .  3 . 3 . 1  and 3 . 3 . 2  Gel electrophoresis of the products of 
RT-PCR analysis of MDR 1, MDR 3, MRP, GST Jt, CYPIA1, 
Topoisomerase I, Topoisomerase II, Topoisomerase Ila and 
Topoisomerase lip gene transcripts in MDR cell lines, DLKPA (R) 
and SKMES-1A (R), and their sensitive parent cell line, DLKP (S) 
and SKMES-1 (S), respectively. All reactions were set up in 
duplicate. The analysis was performed after 30 cycles of PCR 
amplification. The left-hand lane contains the DNA molecular 
weight marker consisting of 22 fragments with the following base 
pair numbers: 587, 540, 504, 458, 434, 267, 234, 213, 192, 184, 
124, 123, 104, 89, 80, 64, 57, 51, 21, 18, 11 and 8 with which 
the resulting bands were sized. Two bands were produced in most 
cases; the upper band, by the p-actin primers (acting as an 
endogenous control) and a lower band, the product of 
amplification with specific primers as indicated above each
lane. Amplification with p-actin primers resulted in a single 
band of the appropriate size, verifying that the other products 
formed are the result of amplification with specific target 
primers and not bi-products of p-actin amplification. These
bands also indicate that the levels of p-actin mRNA are not 
significantly different in the sensitive and MDR cell lines.
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MDR1 MDR3 MRP
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EliL.3 .3.1 Increased levels of M DR 1, MDR 3 and reduced levels of 
Topoisomerase II (in general) and Topoisomerase Ilex are apparent in the 
DLKPA cell line (R), when compared to the sensitive parent cell line, 
DLKP (S). Elevated levels of Topoisomerase lip (and possibly MRP) m R N A  
levels were observed. Amplification of the CYPIA1 region seemed to 
produce a faint double band in both DLKP and DLKPA cells, which may be 
indicative of degraded mRNA. No other changes in gene transcript levels 
were observed.
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Fig. 3.3.2 The most significant differences in the gene transcript levels 
studied in SKMES-1 (S) and SKMES-1A (R) cell lines appear to be increased 
expression of MDR 1 and decreased expression of Topoisomerase Hot genes 
in the MDR cell line with respect to the parent cell line. No definate 
changes in MRP, GST k, or Topoisomerase II mRNA, with drug resistance, 
was observed. Increased expression of MDR 3 (although the resulting bands 
are quite faint) and reduced levels of Topoisomerase I m R N A  seemed to 
occur with MDR. No detectable bands were produced on amplification of the 
CYPIA1 region under study, in either SKMES-1 or SKMES-1 A. The results 
from Topoisomerase lip analysis although inconsistent on this gel, were 
generally found to be slightly elevated.
3.4 Establishing PCR Cycle Range where PCR Product 
Accumulation is Exponential
To develop this study to a semi-quantitative level, the PCR 
cycle range of exponential product accumulation and plateau 
formation was established for each primer pair (listed in Table
3.1) when amplifying cDNA formed on mRNA templates extracted 
from the DLKP, DLKPA, OAW42 and OAW42A cell lines (see 2.10.5). 
These were selected as representatives of the cell lines 
included in this study. (Preliminary experiments were performed 
which proved that results were the same whether a range of 50 ^1
PCR volumes were set up and entire tubes were removed at each of 
the cycle time points, or a total volume of 100 ^1 was prepared 
and 10 f^ l volumes were removed at each of these time points - 
15, 20, 25, 30 and 35 cycles (2.10.5). The latter was favoured 
as it prevented any possible tube-to-tube variations. 
Furthermore, it required less cDNA (and so RNA) and all of the 
other PCR components).
The analysis was performed on DLKP and DLKPA RNA extracts a 
total of six times. This involved extracting RNA from three 
independent stocks of each cell line. Duplicate batches of cDNA 
were generated, for analysis, from each of these. As usual, all 
reactions were set up in duplicate. Similarly, OAW42 and OAW42A 
RNA was analysed a total of four times in this way i.e. on 
duplicate stocks of cDNA formed from two independent RNA 
extracts. All results were analysed by densitometry. The level 
of transcripts of interest in each cell line was analysed in 
three different ways, (a) The intensity of the target mRNA was 
normalised to the level of expression of the endogenous control 
mRNA, after correcting for background in both cases, (b) The 
intensity of the target mRNA bands were corrected for background 
reading, without taking into the account the internal control 
and (c) the densitometry readings of intensity for the target 
were analysed without subtracting background or normalising with 
the internal control, p-actin mRNA transcripts were also
studied, independently, in this way. These were also (a) 
corrected for background and (b) analysed in their unadjusted
1 2 2
form. In all cases, the cycle numbers were plotted versus the 
intensity (densitometry reading) and the range of exponential 
accumulation estimated from resulting graphs. Although similar 
plots were achieved in most cases, whether or not they were 
adjusted for background and normalised to p-actin, background
subtraction and normalising with this endogenous control was 
favoured as it allows each sensitive cell line and its resistant 
variant to be compared directly.
Fig. 3.4.1 - 3.4.10 are examples of results (photographs of 
cDNA fragments separated by gel electrophoresis and the 
corresponding plotted data after background subtraction and 
normalising with the ubiquitously expressed internal control) 
for one analysis of cDNA formed on template mRNA from one DLKP 
and DLKPA RNA extract. An estimation of the exponential phase of 
product accumulation, based on these results is presented in 
Table 3.4.1 (Experiment 1). Similar analysis was performed for 
the other five cDNA stocks formed on DLKP and DLKPA mRNA 
templates. These results are shown in Table 3.4.1 also, as 
experiments 2 - 6 .  Corresponding data for OAW42 and OAW42A are 
presented in Table 3.4.2.
MDR 1: The exponential range of amplification for the MDR 1 
primers for all cell lines studied seems to extend, overall, 
from approximately 16 - 33 cycles (see Tables 3.4.1 - 3.4.2). 
However, the range was quite small when amplifing cDNA from 
DLKPA extracts (16 - 23) (see Table 3.4.1). 20 cycles was
considered to be the optimal for MDR1 mRNA studies in this cell 
line as it lies within the exponential range for all extracts of 
DLKPA. No detectable bands were produced with DLKP cDNA, when 
studying this region, even after 35 cyces (Fig. 3.4.1).
The range of exponential increase in product formation with 
these primers was similar for both the OAW42 ( 19 - 33) and 
OAW42A (19 - 29) cell lines (Table 3.4.2). Therefore, although 
20 cycles is, again, within the "acceptable" range for semi- 
quantitative comparisons to be made; approximately 25 cycles
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would possibly be more suitable for amplification of MDR 1 cDNA 
from these particular cell lines.
The amounts of MDR 1 mRNA were significantly greater in the 
DLKPA cells by comparison to the DLKP cells, where no detectable 
bands were realised following gel electrophoresis. A similar 
situation was realised when studying the OAW42 and OAW42A lines 
i.e. the levels of MDR 1 mRNA were apparently greater in the 
resistant, by comparison to the sensitive form of the cell line. 
However, the difference in amounts between the two forms of the 
ovarian cell lines was not as great as that with the lung cell 
lines.
MDR 3: The resulting MDR 3 and |3-actin amplification products 
are 321 bp and 383 bp, respectively. As can be seen in Fig. 
3.4.2, because of the close proximity of these bands on the 
gels, the "smearing" effect below the larger, more intense (3-
actin bands may "mask" the MDR 3 band, making it less obvious. 
The bands produced on amplification of the MDR 3 region, in cDNA 
formed from DLKPA extracted RNA, were quite weak and were not 
visible before approximately 25 cycles of PCR (Fig. 3.4.2). 
Although Fig. 3.4.2.1 suggests cycles 24 - 33 onwards to be on 
the exponential increase line, from the other experiments (Table
3.4.2), it seems as if approximately 2 7 cycles of PCR may be 
required for a detectable product to result. Product 
accumulation remained exponential for most, if not all, of the 
study i.e. 20, 25, 30 (and possibly 35 cycles) all seemed to be 
within the exponential range of amplification.
As indicated in Table 3.4.1 and Fig. 3.4.2, when comparing 
the results of MDR 3 study in DLKP and DLKPA extracts, no 
product seemed to result with DLKP. Similarly, no MDR 3 
amplification product was detected when studying this region in 
the OAW42 and OAW42A extracts.
MRP: The exponential range of product formation when amplifying 
the MRP region of interest seems to be within cycle numbers 2 0 -
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32, for all cell lines studied. 25 cycles was, therefore, chosen 
as the optimum cycle number (Tables 3.4.1 and 3.4.2).
No definite trends were seen between the MRP mRNA amounts 
in the DLKP and the DLKPA cell lines (Fig. 3.4.3), although 
there is apparently a slight increase in level in the resistant 
versus the sensitive cell lines after normalising with |3-actin.
On the other hand, the results from the ovarian lines do not 
suggest any significant changes in MRP mRNA levels in the 
resistant and the sensitive cell lines.
GST n: The overall exponential range of amplification of the 
GST n region appeared to be between cycle numbers 16 - 22 and 16 
- 23, when amplifying cDNA formed on the DLKP and DLKPA mRNA 
extracts, respectively; and between 16 - 24, for both the 0AW42 
and OAW42A cell lines. 20 PCR cycles was, therefore, considered 
as a suitable level of amplification for each of these cell 
lines.
At 20 cycles, the amount of GST n mRNA was found to be 
similar in the DLKP cell line by comparison to the resistant 
form of this line (Fig. 3.4.4). Alternatively, for the ovarian 
cell lines, the GST-rr mRNA levels were apparently slightly 
greater in the resistant form, in comparison to the sensitive 
form of the cell line. This difference was not detected, 
however, in all cases at 25 and 30 cycles. This emphasises the 
importance of working within the exponential range of product 
formation.
CYPIAl: No visible bands were often produced for any of the 
cell lines after amplification with with the CYPIAl primers when 
analysing to establish the exponential and plateau phases of 
amplification, although these primers have previously been shown 
to amplify this region of cDNA when present in a plasmid and 
when analysing cDNA derived from the OAW42 cell line (Fig.
3.1.2.1). This suggests that the primers are suitable and that 
possibly the mRNA levels of this enzyme are undetectable by this 
method; or, at least, the region for which the primers were
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selected. Alternatively, it is possible that because of its 
relative closeness in size to the (3-actin band ((3-actin, 383 bp;
CYPIA1, 327 bp), the bands have not separated sufficiently for 
CYPIAl to be detected. However, this is unlikely as the MDR 3 
band, which is only six base pairs shorter, is often 
distinguishable when amplified with (3-actin.
In a number of experiments conducted, faint bands and 
smears were visible below the {J-actin band, in and below the
region where the CYPIAl band should appear (see Fig. 3.4.5). 
This may possibly be indicative of a CYPIAl mRNA breakdown 
product or amplification of regions with secondary structure 
formations.
Topoisomerase I: The exponential range of amplification of the 
Topoisomerase I cDNA region was estimated to be between cycle 
numbers 21 - 31 for DLKP and DLKPA; and 22 - 28 for OAW42 and 
OAW42A. 25 cycles of PCR amplification was considered to be 
suitable for each of the cell types (see Tables 3.4.1 and
3.4.2).
Generally, no detectable bands were produced for 
Topoisomerase I after 15 cycles of amplification, with faint 
bands often resulting after 20 cycles (Fig. 3.4.6). From the 
results at 25 cycles, it seems that the Topoisomerase I 
transcript levels are slightly reduced in the DLKPA versus DLKP 
cells. All experiments conducted on two sets of RNA extracts 
from these cells (i.e. a total of four) suggest greater amounts 
of this mRNA to be present in the sensitive cell line. However, 
both experiments done on the third extracts suggest the opposite 
i.e. increased levels in the resistant form by comparison to the 
sensitive cells. These differences are not consistent at 30 
cycles suggesting that this is possibly approaching, or within, 
the plateau phase of the reaction.
The level of Topoisomerase I mRNA seemed to be slightly 
decreased in the resistant form of the ovarian cell line
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(OAW42A), in comparison to the parent cell line (OAW42), at all 
PCR time points tested.
Topoisomerase II: The range of exponential amplification of 
the DLKP and DLKPA cDNA with the Topoisomerase II primers was 
generally found to be between 20 - 31 cycles. For OAW42 and 
OAW42A, the exponential range was, apparently, between 16 - 26 
cycles. 24/25 cycles was, therefore, considered to be a suitable 
time point for semi-quantitative comparisons to be made between 
each of these two sets of cell lines, respectively.
When comparing Topoisomerase II mRNA levels between the 
DLKP and DLKPA cell lines (Fig. 3.4.7), in all experiments at 
most time points, the levels seemed to be less in the resistant 
form by comparison to the sensitive form of the cell line. This 
difference is most obvious after 20 and 25 cycles of 
amplification. A similar slight reduction in Topoisomerase II 
transcript levels was also suggested from the results of the 
ovarian cell line studies.
Topoisomerase Ila: The exponential range for Topoisomerase 
Ila amplification of DLKP and DLKPA cDNA was estimated to be 
between 2 1 - 3 0  cycles. Similar results were realised (21 - 31) 
when studying the OAW4 2 and OAW42A cell lines. Approximately 
24/25 cycles of amplification was, therefore, considered 
optimum. In all experiments, the levels of Topoisomerase Ila
were slightly greater in the sensitive (DLKP) by comparison to 
the resistant (DLKPA) cells (Fig. 3.4.8). Similarly, the 
Topoisomerase Ila levels were apparently less in the OAW42A
cells compared to the OAW42 cell line.
T o p o i s o m e r a s e  II/S: Although the results suggest that the
exponential range of amplification of the Topoisomerase 11(3 mRNA 
region under study in the DLKP and DLKPA cells is between 2 6 
35 and 25 - 35 cycles, respectively, it would seem advisable to 
perform at least 26 PCR cycles. This is because the bands are 
quite faint at approximately 2 7 cycles. As the resulting bands 
are not very intense in many cases, at any of the time points
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studied, it seems that approximately 27 - 30 cycles are possibly 
required to increase the chances of any existing product being 
detected. This would also seem to be a suitable PCR cycle number 
for Topoisomerase 11(3 analysis in OAW42 and OAW42A cells, as the
exponential range for these is apparently between 2 6 - 35
cycles.
From these results it seems that the Topoisomerase lip 
levels were apparently slightly greater in the resistant cells 
(DLKPA) by comparison to the sensitive cells (DLKP)(Fig. 3.4.9). 
This was also found to be the case with the OAW42 and OAW42A 
cell lines.
P-actin: The range of PCR amplification during which p-actin 
cDNA product formation is exponential was found to be between 
cycle numbers 16 - 27, for each of the cell lines studied. This 
suggests that p-actin should act appropriately as an endogenous
control as it should not have reached its amplification plateau 
prior to any of the target mRNAs under study. No significant 
difference in p-actin mRNA levels were detected in the DLKP or
OAW42 cell lines, by comparison to their resistant variants.
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Figs. 3.4.1 - 3.4.10 Establishing the PCR cycle range of
exponential product accumulation and plateau formation during 
MDR 1 (157 bp), MDR 3 (321 bp), MRP (203 bp), GST Jt (270 bp), 
CYPIA1 (327 bp), Topoisomerase I (180 bp), Topoisomerase II (216 
bp), Topoisomerase Ila, (139 bp) , Topoisomerase lip (118 bp) and (3- 
actin (383 bp) cDNA amplification, respectively. 100 pi sample 
volumes were set up to amplify the relevant cDNA derived from
DLKP (S) and DLKPA (R) cells, p-actin, which acts as an internal 
positive control and as a means to normalise the intensity of 
the target bands of interest, was also amplified. A band
representing p-actin resulted in all samples, the intensity of 
which increased with cycle numbers, up to 30 cycles. The band 
intensities resulting after 30 and 35 cycles were not visibly
different, in any case. No differences in p-actin band 
intensities were observed after any given PCR cycle number, 
between the sensitive and resistant cells, when co-amplifying 
with any of the target cDNAs. 10 pi volumes were removed at 15, 
20, 25, 30 and 35 cycles. The resulting products were separated 
by electrophoresis through a 4 % gel and identified with respect 
to the molecular weight markers (left-hand lane of each gel), 
consisting of 22 fragments of the following sizes: 587, 540, 
504, 458, 434, 267, 234, 213, 192, 184, 124, 123, 104, 89, 80, 
64, 57, 51, 21, 18, 11 and 8 base pairs. All analysis was
performed in duplicate.
Figs. 3.4.1.1 - 3.4.10.1 Relationship between the PCR cycle
number and intensity of bands produced after analysis by 
densitometry. The densitometry readings represent the results of 
the target gene transcript analysis (Fig. 3.4.1 - 3.4.10), after 
correction i.e. after background subtraction and normalising
with p-actin. From these plots, which generally consist of a log 
and a plateau phase, an estimation can be made of the cycle 
numbers for which PCR products accumulate exponentially, before 
reaching a plateau.
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Fig. 3.4.1 No detectable levels of MDR 1 m R N A  were produced with DLKP 
cDNA. On analysis of DLK.PA, the MDR 1 band (157 bp) apparently 
increased with PCR cycle number up to approximately 25 cycles, after 
which further product yield was not observed. The band intensity 
increased significantly between 1 5 - 20, and again, (possibly to a lesser 
extent), between 20 - 25 cycles. Beyond this, no further increases were 
observed.
130
Cycle Number
Fia. 3.4.1.1 Plot of the PCR cycle numbers versus the densitometry readings 
of the resulting MDR 1 bands amplified from DLKPA-derived cDNA. This 
suggests that the PCR range of exponential product accumulation is between 
16-21 cycles, after which the plateau phase is reached. (Experiment 1, Table 
3.4.1).
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Fig. 3.4.2 Amplification of the MDR 3 target region of DLKP (S) and 
DLKPA (R) cDNA resulted in a visible band (321 bp) being produced after 
25, 30 and 35 PCR cycles (but not at earlier cycle numbers) for DLKPA. 
The intensity of this band apparently increased with increasing PCR 
cycles. No corresponding bands were produced for DLKP.
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Fig. 3.4.2.1 Relationship between PCR cycle numbers and 
corresponding MDR 3 product accumulation with DLKPA cDNA. From this 
plot, it appears that the range of exponential product accumulation is 
between 23/24 - 32/33 cycles. (Experiment 1, Table 3.4.1).
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1 5 CYCLES 20 CYCLES 25 CYCLES
30 CYCLES 35 CYCLES
S S  R R S S  R R
Fig. 3.4.3 Amplified MRP m R N A  (203 bp) was first noted after 20 cycles 
of PCR amplification with both DLKP (S) and DLKPA (R) cDNA. The most 
significant increases in transcript levels were between 20 - 25 cycles 
and, again, between 25 - 30 cycles. No great differences in MRP band 
intensities between 30 and 35 cycles were apparent. MRP band 
intensities were greater for DLKPA (R) than for DLKP (S). This difference 
was most visible after 20 and 25 cycles of amplification, and was 
apparent, although less obviously, after 30 and 35 cycles.
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Fias. 3.4.3.1 and 3.4.3.2 Results from MRP analysis in DLKP and 
DLKPA cell lines, respectively, when presented as PCR cycle numbers 
versus corresponding densitometry reading of MRP band intensities. From 
these plots, product accumulation seems to be exponential between 
approximately cycle numbers 20/21 - 32, when studying cDNA from both 
the sensitive and MDR cell lines. (Experiment 1, Table 3.4.1).
135
1 5 CYCLES 20 CYCLES 25 CYCLES
S S R R S S R R S S R  R
30 CYCLES 35 CYCLES
S S  R R S S R R
Fig. 3.4.4 Bands representing amplified GST it m R N A  (270 bp) were 
visible after 1 5 cycles of PCR amplification when analysis of cDNA 
from both DLKP (S) and DLKPA (R) cells lines was performed. The 
intensities of these bands, which did not seem to differ significantly 
between the sensitive and MDR cell lines, seemed to increase with 
cycle number between 1 5 - 2 0  cycles and 20 - 25 cycles. No changes in 
band intensities were noted for GST x beyond 25 cycles of 
amplification.
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Fias. 3.4.4.1 and 3.4.4.2 The range of exponential accumulation of 
GST n: product seems to be between cycle numbers 1 6 - 22 for DLKP 
(Fig. 3.4.4.1) and 1 6 -23, when analysing DLKPA cDNA (Fig. 3.4.4.2). 
After this a plateau phase occured, suggesting no further product 
formation with extra PCR cycles. (Experiment 1, Table 3.4.1).
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Fig. 3.4.5 No detectable levels of CYPIA1 m R N A  (327 bp) were produced 
by RT-PCR analysis of DLKP (S) or DLKPA (R) cDNA. At higher PCR cycle 
numbers, a "smear" consisting of faint bands occurred below the p-actin 
band, in and below the region where the CYPIA1 amplified product 
should occur. Successful amplification of p-actin cDNA was observed 
(as when amplifying with all the other primer pairs included in this 
study), resulting in bands of similar intensities for both the sensitive 
and MDR cell lines.
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1 5 CYCLES 20 CYCLES 25 CYCLES
S S R R S S R R S S R  R
30 CYCLES 35 CYCLES
S S R R S S R R
Fig. 3.4.6 Products of Topoisomerase I amplification (180 bp) with 
cDNA derived from DLKP (S) and DLKPA (R) cell lines were not visible 
after 1 5 cycles of amplification, but were detected (although quite 
weak) after 20 PCR cycles. The intensities of these bands increased 
significantly between 20 - 25 cycles and, again, between 25 - 30 
cycles. A slight increase between 30 - 35 cycles was apparent.
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Figs. 3.4.6.1 and 3.4.6.2 The plots of PCR cycle numbers versus 
densitometry readings of the resulting Topoisomerase I bands amplified 
from DLKP (Fig. 3.4.6.1) and DLKPA (Fig. 3.4.6.2) cDNA suggest the range 
of exponential product accumulation to be between 21 - 31 PCR cycles, 
for both cell lines. After this, a plateau phase was reached, indicative 
• of no further product formation. (Experiment 1, Table 3.4.1).
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1 5 CYCLES 20 CYCLES 25 CYCLES
S S R R S S R R S S R  R
30 CYCLES 35 CYCLES
S S  R R S S R R
Fig- 3.4.7 No detectable levels of Topoisomerase II m R N A  were 
produced with either DLKP (S) or DLKPA (R) cDNA after 1 5 cycles of 
amplification. Bands were visible, however, after 20 cycles of PCR. The 
band intensities seemed to increase significantly between 20 - 30 
cycles and, to a lesser extent, between 30 - 35 cycles. Topoisomerase I 
m R N A  transcript levels were apparently greater in the sensitive cell 
line, DLKP, compared to the MDR cell line, DLKPA. This difference was 
observed after 20 and 25 cycles of amplification, but was not so obvious 
after 30 and 35 PCR cycles.
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Cycle Number
Cycle Number
Figs. 3.4.7.1 and 3.4.7.2 Results from Topoisomerase II analysis in 
DLKP (Fig. 3.4.7.1) and DLKPA (Fig. 3.4.7.2) cell lines presented as 
numbers of cycles of PCR amplification versus corresponding 
densitometry readings of Topoisomerase II band intensities. These plots 
suggest the exponential range of Topoisomerase II product accumulation 
to be between 2 0 - 3 1  cycles, for both the drug sensitive and resistant 
cell lines. (Experiment 1, Table 3.4.1).
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15 CYCLES 20 CYCLES 25 CYCLES
R R S S R R S S R R S S
30 CYCLES 35 CYCLES
R R  S S R R  S S
Fig. 3.4.8 Topoisomerase lla transcript products were detected after 
20 - 35 cycles of amplification, the levels of which seemed to increase 
significantly up to 30 cycles, but not beyond this. The intensities of the 
bands resulting from Topoisomerase lla amplification were similar, 
although slightly reduced in the MDR cell line, DLKPA (R), compared to 
the sensitive cell line, DLKP (S). This was observed after lower PCR 
cycle numbers (20 and 25), but was not apparent after 30 and 35 cycles 
of amplification.
Note: The order in which the "R" and "S" samples were loaded on the gel 
was not the same as for all of the other gels described in section 3.4.
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Fias. 3.4.8.1 and 3.4.8.2 The range of exponential product 
accumulation when studying Topoisomerase Ilex gene transcripts was 
estimated, from the plots of cycle numbers versus corresponding 
densitometry readings for both DLKP (Fig. 3.4.8.1) and DLKPA (Fig.
3.4.8.2), to be between 21 - 30 PCR cycles of amplification. (Experiment 
1, Table 3.4.1).
144
15 CYCLES 20 CYCLES 25 CYCLES
S S R R S S R R S S R R
30 CYCLES 35 CYCLES
S S  R R S S  R R
Fig. 3.4.9 Detectable levels of Topoisomerase lip m R N A  were not 
produced after 15 or 20 cycles of PCR amplification with either DLKP or 
DLKPA-derived cDNA. Faint bands representing Topoisomerase lip m R N A  
in DLKPA cDNA were realised after 25 cycles and more intense bands 
resulted from amplification of both DLKP (S) and DLKPA (R) cDNA, after 
30 and 35 PCR cycles. The band intensities were apparently greater in 
the MDR cell line in comparison to the sensitive cell line.
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Fias. 3.4.9.1 and 3.4.9.2 Plots of the relationship between PCR cycle 
numbers and densitometry readings of the corresponding Topoisomerase 
lip amplified product intensities suggest that the exponential range of 
product accumulation is between 26 - 35 cycles for DLKP and 2 5 - 3 5  
cycles of PCR for DLKPA. Product accumulation apparently had not 
reached a plateau within the PCR cycle range studied. (Experiment 1, 
Table 3.4.1).
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1 5 CYCLES 20 CYCLES 25 CYCLES
S S R R S S R R S S R  R
30 CYCLES 35 CYCLES
S S  R R S S R R
Fig. 3.4.10 When amplified independently, (3-actin band intensities 
increased, with PCR cycle number, from 1 5 - 3 0  cycles of PCR 
amplification. No changes in band intensities were observed with 
further PCR cycles. After any given cycle number, the band intensities 
were similar in the drug sensitive, DLKP (S), and resistant, DLKPA (R) 
cell lines.
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Fias. 3.4.10.1 and 3.4.10.2 From the plots of PCR number versus 
densitometry readings of the resulting p-actin bands, it can be estimated 
that the PCR range of exponential product accumulation is between 16 - 
27 cycles, when amplifying both DLKP (Fig. 3.4.10.1) and DLKPA (Fig.
3.4.10.2) derived cDNA. After this, product accumulation reached a 
plateau, followed by an apparent slight reduction in product levels. 
(Experiment 1, Table 3.4.1).
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Table 3.4.1: Exponential phase estimated for each mRNA region
of study from DLKP and DLKPA cells.
AiipliEied
Reqion
C e l l
rvpn
Method * E x p t .  1 E x p t . 2 E x p t . 3 E x p t . 4 E xp t . 5 E x p t . 6
TYT.K'P
MDR 1
L*’i-irs.iT
DLKPA (a) 16 _ 2 1 16 2 1 16 _ 23 16 — 24 16 — 2 2 16 _ 2 2
(b) 16 - 2 1 16 - 2 1 16 - 23 16 - 23 16 - 2 2 16 - 2 1
(c) 16 - 2 1 16 - 2 1 16 - 24 16 - 23 16 - 23 16 - 2 2
MDR 3 D T . K PIV.Jj X\ _L
DLKPA (a) 24 _ 33 24 _ 33 26 _ 35 26 _ 35 26 _ 34 26 _ 35
(b) 24 - 34 25 - 30 26 - 34 25 - 34 26 - 35 25 - 35
(C) 25 - 36 25 - 36 25 - 34 25 - 36 25 - 35 25 - 36
MRP DLKP (a) 2 1 - 31 2 1 - 31 2 0 - 29 2 0 - 32 2 2 - 30 2 1 - 30
(b) 2 0 - 29 2 0 - 32 2 1 - 35 19 - 30 2 1 - 29 2 0 - 30
(c) 2 0 - 32 2 0 - 30 2 0 - 30 2 0 - 29 2 1 - 28 2 2 - 30
DLKPA (a) 2 0 - 30 2 0 - 30 2 0 - 30 19 - 32 2 0 - 30 2 0 - 29
(b) 2 0 - 29 2 0 - 30 2 0 - 29 2 2 - 29 2 0 - 29 19 - 31
f ' 19 - 30 2 0 - 32 19 - 29 2 1 - 29 2 0 - 32 19 - 31
GST tz DLKP (a) 16 - 2 2 16 - 2 2 16 - 24 16 - 24 16 - 2 2 16 - 23
(b) 16 - 2 2 16 - 2 2 16 - 24 16 - 24 16 - 24 16 - 23
(c) 16 - 2 1 16 - 24 16 - 24 17 - 24 16 - 24 16 - 24
DLKPA (a) 16 - 23 16 - 23 18 - 26 19 - 26 16 - 24 16 - 23
(b) 16 - 2 0 16 - 26 16 - 26 16 - 26 16 - 26 16 - 26
(c) 16 - 2 2 16 - 26 17 - 24 17 - 24 16 - 25 16 - 26
CYPIA1 T Y T iK PU  X\ IT
T Y T .R P  AL/i-i l \ i r  ¿ \
TOPO I DLKP (a) 23 - 30 23 - 30 2 2 - 29 2 2 - 28 24 - 28 23 - 27
(b) 23 - 30 23 - 27 23 - 29 23 - 28 24 - 28 24 - 29
(c) 2 1 - 29 24 - 28 23 - 28 2 2 - 29 23 - 27 23 - 28
DLKPA (a) 24 - 31 24 - 31 24 - 28 23 - 27 2 2 - 27 2 2 - 27
(b) 25 - 30 24 - 27 23 - 28 2 2 - 27 23 - 29 2 2 - 29
(c) 2 1 - 30 23 - 29 2 2 - 28 2 2 - 28 23 - 29 2 2 - 28
TOPO II DLKP (a) 2 0 - 29 2 0 - 31 2 1 — 31 2 1 - 30 2 0 - 29 2 0 - 28
(b) 2 0 - 31 2 0 - 31 2 2 - 31 2 2 - 31 23 - 31 2 2 - 30
(c) 2 0 - 29 2 1 - 31 2 2 - 31 2 2 - 31 24 - 31 2 2 - 30
DLKPA (a) 2 0 - 29 2 1 - 30 2 2 - 30 2 2 - 29 2 2 - 31 2 1 - 29
(b) 2 1 - 29 2 1 - 31 2 1 - 29 2 1 - 28 24 - 30 24 - 29
(c) 2 1 - 29 2 0 - 30 2 2 - 30 2 2 - 29 24 - 30 23 - 31
TOPO I  l a DLKP (a) 2 1 - 29 2 1 - 30 2 2 - 31 2 2 - 31 23 - 30 2 2 - 29
(b) 23 - 29 2 2 - 29 2 2 - 29 23 - 29 23 - 29 2 2 - 29
(c) 2 1 - 29 23 - 29 2 0 - 28 2 1 - 30 2 2 — 29 2 2 - 30
DLKPA (a) 2 1 - 29 2 1 - 29 2 2 - 31 2 1 - 29 2 1 - 29 2 1 - 29
(b) 24 - 33 23 - 29 23 - 30 23 - 29 2 2 - 29 23 - 30
(C) 2 2 - 29 2 1 - 30 2 1 - 29 2 2 - 29 2 1 - 29 2 2 - 29
TOPO l i p DLKP (a) 26 - 35 26 - 35 25 - 34 24 - 35 27 - 32 27 - 31
(b) 26 - 35 26 - 33 24 - 34 24 - 35 27 - 33 26 - 32
(c) 26 - 32 26 - 32 25 - 35 24 - 37 26 - 33 26 - 31
DLKPA (a) 25 - 35 25 - 35 24 - 33 23 - 35 26 - 32 26 - 33
(b) 25 - 32 25 - 37 23 - 33 23 - 35 26 - 32 25 - 33
(C) 25 - 32 25 - 36 23 - 34 2 2 - 35 24 - 34 24 - 35
P-Actin DLKP (b) 16 - 26 16 - 27 16 - 26 16 - 27 16 - 26 16 - 26
(c) 16 - 26 16 - 26 16 - 26 16 - 26 16 - 27 16 - 25
DLKPA (b) 16 - 26 16 - 27 16 - 27 16 - 26 16 - 26 16 - 26
.V) 16 - 27 16 - 27 16 - 26 16 - 26 16 - 26 16 - 26
N o t e :
  = no bands detected.
Method * = Method of Calculation (see 3.4).
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Table 3.4.2: Exponential phase estimated for each mRNA region
of study from OAW42 and OAW42A cells.
A m plified
Reqion
C e l l
T ype
Method * E x p t . 1 E x p t . 2 E x p t . 3 E x p t . 4
MDR 1 QAW42 (a) 21 - 31 21 - 31 21 - 31 21 - 31
(b) 21 - 30 20 - 30 21 - 30 21 - 30
(c) 20 - 33 20 - 32 20 - 33 20 - 33
QAW42A (a) 19 - 29 20 - 29 20 - 29 20 - 29
(b) 19 - 29 21 - 29 20 - 29 20 - 29
(c) 19 - 29 21 - 29 20 - 29 20 - 29
MDR 3 OAW42
QRW42A
MRP ORW42 (a) 21 - 30 21 - 30 21 - 30 21 - 30
(b) 22 - 29 22 - 30 22 - 30 21 - 29
bfiW42A (c) 22 - 31 22 - 29 22 - 31 22 - 31
(a) 21 - 31 21 - 31 21 - 31 21 - 31
(b) 21 - 29 21 - 29 21 - 29 22 - 30
(c) 21 - 30 22 - 31 21 - 29 22 - 30
GST n OAW42 (a) 16 - 22 16 - 22 16 - 22 16 - 22
(b) 16 - 20 16 - 22 16 - 24 16 - 23
(c) 16 - 21 16 _ 20 16 - 23 16 - 23
ORW42A (a) 16 - 22 16 - 22 16 - 24 16 - 24
(b) 16 - 22 16 - 22 16 - 23 16 - 22
(c) 16 - 24 16 - 21 16 - 23 16 - 21
CYPIA1 QRW42
QRW42A — — — — — —
TOPO I QBW42 (a) 22 - 27 22 - 27 22 - 27 22 - 27
(b) 22 - 27 22 - 28 21 - 28 21 - 27
(c) 22 - 28 21 - 27 21 - 28 21 - 27
QAW42A (a) 22 - 28 22 - 28 22 - 28 22 - 28
(b) 23 - 26 23 - 26 22 - 28 22 - 27
(c) 22 - 28 22 - 28 22 - 28 22 - 28
TOPO I I QAW42 (a) 16 - 25 16 - 25 16 - 25 16 - 25
(b) 16 - 24 16 - 25 16 - 25 17 - 25
(c) 16 - 23 17 - 23 16 - 24 17 - 23
OAW42A (a) 18 - 26 18 - 26 18 - 26 18 - 26
(b) 18 - 26 18 - 25 17 - 25 18 - 26
(c) 18 - 25 17 - 25 17 - 25 17 - 25
TOPO I l a QAW42 (a) 19 - 28 19 - 28 19 - 28 19 - 28
(b) 16 - 32 18 - 31 19 - 30 19 - 30
(c) 21 - 32 20 - 31 20 - 30 19 - 30
QRW42A (a) 16 - 29 19 - 29 19 - 29 19 - 29
(b) 21 - 29 20 - 29 20 - 30 20 - 30
<c ) 21 - 29 19 - 29 20 - 30 20 - 30
TOPO l i p QAK42 (a) 26 - 35 26 _ 35 26 - 35 26 - 35
(b) 26 - 35 26 - 35 26 - 35 26 - 35
(c) 26 - 34 26 - 35 26 - 34 26 - 35
QAW42A (a) 26 - 35 26 - 35 26 - 34 26 - 34
(b) 26 - 35 26 - 36 26 - 34 26 - 35
(c) 26 - 36 26 - 35 26 - 35 26 - 35
P-Actin QAW42 (b) 16 - 27 16 - 27 16 - 27 16 - 27
(c) 16 - 27 16 - 26 16 - 27 16 - 26
QAW42A (b) 16 - 26 16 - 26 16 - 27 16 - 26(c) 16 - 27 16 - 26 16 - 26 16 - 27
N o t e :
  = no bands detected;
Method * = Method of Calculation (see 3.4).
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As these results were fairly reproducible, they can be 
summed up as in Table 3.4.3. Although the ranges when 
amplification of product remains exponential varies to some 
degree from cell line to cell line, and to a lesser extent from 
sensitive to MDR variant; with the exception of MDR 1, the 
"optimum" cycle number can be considered to be the same for each 
of the cell lines studied. (Of course, many other cycle numbers 
within this range could possibly be performed with similar 
success).
With the MDR 1 primers, although 20 and 25 cycles may be 
the time points of choice when amplifying the lung and ovarian 
cell lines, respectively, 20 cycles could, in fact, be performed 
quite successfully for each of the cell types. These results, 
therefore, suggest that the proposed "optimum" numbers of cycles 
may be suitable for studying the relevant transcript levels in a 
range of other cell types. Furthermore, these results support 
the choice of (3-actin as an internal control. The exponential 
range of PCR amplification for p-actin cDNA spans the proposed 
"optimum" cycle numbers for all of the other parameters under 
study. As required (1.4.1), the internal control should not have 
reached a plateau before the target cDNA of interest so that the 
analysis is completed within the PCR exponential phase of 
product accumulation.
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Table 3.4.3
DLKP DLKPA Optim um  
Cycle No.
OAW42 OAW 42A Dptimum
Hycle No.
MDRl 16 - 23 20 19 - 33 19 - 29 25
MDR3 2 4  - 35 27
MRP 20 - 32 2 0  - 32 25 2 0  - 32 2 0  - 32 25
GST jt 16 - 24 16 - 2 6 20 16 - 24 16 - 24 20
CYPIA1
Topo I 21 - 30 21 - 3 0 25 22 - 38 22 - 38 25
T opo II 20  - 31 2 0  - 31 25 16 - 26 16 - 26 25
T opo Ila 21 - 30 21 - 3 0 25 21 - 3 0 21 - 30 25
T opo Ilfi 26  - 35 25 - 35 27 26  - 35 26  - 35 27
p -A ctin 16 - 27 16 - 27 16 - 27 16 - 27
Results from this phase of the experiment emphasise the 
importance of working within the exponential range of 
amplification for each particular pair of primers and RNA type. 
This is supported e.g. when studying Topoisomerase I transcript 
levels in DLKP and DLKPA cell lines. At 25 cycles, differences 
in Topoisomerase I mRNA levels were apparent in the DLKP and 
DLKPA cell lines, in two of the three independent RNA 
transcripts (i.e. four of six experiments), but only in one of 
three (i.e. two of six experiments) at 30 cycles. This also 
emphasises the importance of doing many repeat experiments (as 
with many techniques), to prove the reliability of these 
findings.
When plotted as cycle number versus intensity of band, in 
most cases the resulting graph was indicative of an exponential 
and plateau phase of product accumulation (Figs. 3.4.1.1. -
3.4.10.2). However, in some cases, the plateau did not seem to 
be maintained, but an apparent decreases in product amounts were 
apparent e.g. when studying (3-actin levels (Fig. 3.4.10.1). This
was possibly due to product degradation. Similar results were 
reported by Douglas and Atchison (199 3) who, when amplifing a 
fragment of the apo AI gene set up a number of replicate
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samples, subjecting them to different lengths of the 
denaturation temperature (94 °C).
The most significant overall trend from these results (when 
working within the exponential phase) is a very significant 
increase in MDR 1 mRNA levels in DLKPA, by comparison to DLKP. 
This was seen, also, for OAW42A versus OAW42, but to a lesser 
extent. The results also imply that the levels of Topoisomerase 
II mRNA are reduced in both resistant variants in comparison to 
their sensitive parent cell line. This seems to be due to a 
reduced Topoisomerase Ila transcript level and may be partially 
counter-balanced by a slight increase in Topoisomerase lip 
levels. MRP mRNA levels seem to be slightly increased in the 
resistant variant of the lung cell line, but unchanged in the 
ovarian cell line; whereas GST jt is apparently slightly
increased in OAW42A compared to OAW42, but not obviously 
affected in the multiple drug resistant lung cell line in 
comparison to its parent line. The results from the 
Topoisomerase I study are inconclusive for DLKP and DLKPA. A 
slight decrease in Topoisomerase I transcript level with 
multiple drug resistance was suggested from studies on two RNA 
extracts. This observation was not backed up by studies on a 
third. In all studies of the ovarian cell lines, however, 
Topoisomerase I mRNA levels were reduced with multiple drug 
resistance.
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3.5 S e m i - Q u a nt it at iv e A n a l y s i s  of M D R  1 and 
Topoisomerase II in DLKP and its Resistant Variants.
3.5.1(i) Semi-Quantitative Analysis - within and between 
experiments.
As detailed in 3.4, preliminary studies of gene transcript 
levels of MDR-related factors suggest that the most obvious 
differences between the lung carcinoma cell line, DLKP, and its 
resistant variant, DLKPA, involve MDR 1 and Topoisomerase II 
gene products. Although other differences were noted, they were 
not as consistent or as obvious and so possibly not as 
fundamentally significant. A semi-quantitative study was, 
therefore, attempted to establish the fold-differences of MDR 1, 
Topoisomerase II and the Topoisomerase Ila subunit,
independently, between a number of multiple drug resistant 
variants of the lung carcinoma cell line, DLKP.
DLKPA, an adriamycin selected MDR variant of DLKP, consists 
of a heterogenous population of cells from which a number of 
independent MDR cell lines, representing individual homogenous 
populations with differing toxicity profiles have been cloned. 
The resulting cell lines included in this phase of the study - 
DLKPA-2B, DLKPA-6B and DLKPA-5F were cloned from the 
heterogenous population (by Dr. Mary Heenan). DLKP/VP-3 and 
DLKP/VP-8, two other resistant variants of DLKP selected to 
different concentrations of VP-16 (by Dr. Heenan), which also 
have different MDR profiles, were also included in this 
analysis.
MDR 1 gene transcript levels were studied in the following 
cell lines: DLKPA, DLKPA-2B , DLKPA-6B , DLKPA-5F , DLKP/VP-3 and 
DLKP/VP-8. The sensitive cell line (DLKP) was excluded from this 
analysis as previous experimental results suggested that it 
contains no detectable levels of MDR 1 mRNA. Similar attempts to 
investigate Topoisomerase II and Topoisomerase Ila mRNA levels
in DLKP, DLKPA, DLKP/VP-3 and DLKP/VP- 8 cells were conducted.
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In all cases, analysis was performed on three 
concentrations of RNA extracted from the cell lines of interest
i.e. 0.5 pq/pl, 1.0 pq/pl and 2.0 jjq/pl. RT and PCR reactions 
were carried out as previously described (2.10.4 & 2.10.5), 
using equal volumes of cDNA formed from the three RNA stocks, in 
each PCR reaction. Samples from all MDR 1 amplifying tubes were 
removed at 15, 20, 25 and 30 cycles, and at 20, 25 and 30 cycles 
when amplifying Topoisomerase II or Topoisomerase H a  derived
cDNA, respectively. This analysis was done for MDR 1, 
Topoisomerase II and Topoisomerase I la and each of the relevant
cell lines (mentioned above) a total of four times i.e. on 
duplicate stocks of cDNA formed from two RNA extracts of 
independent cell line stocks. All reaction tubes were set up in 
duplicate.
Results from this analysis are shown in Figs. 3.5.1.1 -
3.5.1.6 for MDR 1 studies of DLKPA, DLKPA-2B, DLKPA-6B , DLKPA- 
5F, DLKP-VP-3 and DLKP-VP/8, respectively. In each Fig., El/Rl 
E1/R2, E2/R1 and E2/R2 represent the two RNA extracts and the 
duplicate analysis of both extracts e.g. El/Rl (RNA extract no. 
1; 1st RT-PCR analysis), etc. The results from the densitometric 
analysis are presented after subtraction of background and 
normalising with p-actin, in tabulated form. In all cases,
densitometry analysis was done on negatives, to prevent the 
inclusion of bias resulting from differential printing. The 
results for each of the four analyses (i.e. two independent 
studies on two independent extracts) were plotted as RNA 
concentration versus densitometrical reading at 20 cycles (as 
this has previously been proposed as a suitable cycle number at 
which to study MDR 1 mRNA levels in DLKP variants (see 3.4)). 
Similarly, the results from the Topoisomerase II and 
Topoisomerase Ila analysis are presented in Figs. 3.5.1.7 -
3.5.1.10 and 3.5.1.11 - 3.5.1.14, respectively. In these cases, 
however, the plotted graphs of RNA concentration versus 
densitometry reading represent the product formed for each of 
the three RNA concentrations at 25 cycles. This cycle number was 
chosen as this has been shown (see 3.4) to be within the 
exponential range of PCR product accumulation when amplifying
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cDNA derived from DLKP variants, with either the Topoisomerase 
II or Topoisomerase Ila primers listed.
With both increasing cycle number (i.e. 15, 20, 25 and 30 
cycles) and increasing cDNA concentration (based on increasing 
concentrations of RNA - 0.5 pq/jjl, 1.0 pq/pl and 2.0 pq/pl - 
from which cDNA was formed), increasing intensities of bands 
were seen for all of the cell lines studied, with few 
exceptions. This indicates that different RNA concentrations are 
reflected in the resulting bands. However, according to the 
tabulated densitometry readings, in all cases, the intensities 
of the bands produced, although linearly related, were not 
proportional to the initial quantities of RNA. Although it is 
difficult to accurately judge this relationship by eye, as each 
band must be normalised with (5-actin, following subtraction of
background, it seemed that in some situations this relationship 
was apparent from the gel photographs. This, however, was not 
reflected in the densitometry readings. Examples of this include 
DLKPA (Fig. 3.5.1.1 (E2/R1)), DLKPA-2B ((Fig. 2.5.1.2 (El/Rl) 
and (E1/R2)), DLKPA-6B (Fig. 3.5.1.3 (El/Rl) and (E2/R1)), 
DLKPA-5F (Fig. 3.5.1.4 (E2/R1) and (E2/R2)), DLKP/VP-3 (Fig.
3.5.1.5 (E1/R2) and (E2/R1)) and DLKP/VP- 8 (Fig. 3.5.1.6 (El/Rl) 
and (E2/R2), when visualised after 20 cyles of PCR. (The bands 
produced on analysis of DLKPA, DLKP/VP-3 and DLKPA-5F are 
relatively strong at 20 cycles and so this can be estimated more 
easily (and possibly more accurately) after 25 cycles of PCR 
amplification. This point is illustrated in Figs. 3.5.1.1,
3.5.1.4 and 3.5.1.5). Results from the densitometry analysis 
suggest that for DLKPA, DLKPA-5F and DLKP/VP-3, the band 
intensities increase from 15 - 25 cycles (as normal), but then 
decrease from 25 - 30 cycles. This is not obvious from the gels 
represented by this data. The fact that this trend was not seen 
with other cell lines studied e.g. DLKPA-2B and DLKPA-6B , may be 
because their product accumulations have not reached a plateau 
to the same extent as DLKPA, DLKPA-5F and DLKP/VP-3, which seem 
to have greater levels of MDR 1 mRNA present. The apparent 
decrease in intensity may be due to product degradation.
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Results from Topoisomerase II (Figs. 3.5.1.7 - 3.5.1.10) 
and Topoisomerase Ila mRNA transcripts (Figs. 3.5.1.11 -
3.5.1.14) similarly suggest a correlation between RNA 
concentrations and resulting densitometry readings. As with the 
MDR 1 studies, however, the densitometry analysis of band 
intensity did not correlate proportionally with the initial RNA 
concentrations, although in many cases, by visual analysis, such 
a correlation could possibly be made. An example of this is Fig.
3.5.1.7 where increasing band intensities were performed in 
proportion to the starting RNA concentrations. This increase was 
most obvious between the three RNA concentrations after 20 
cycles, when fold-differences were apparent. Differences in 
relative band intensities were also observed at 25 cycles, 
whereas at 30 cycles, the differences were very slight.
These results of MDR 1, Topoisomerase II and Topoisomerase 
Ila mRNA studies, in all cell lines included, suggest a
limitation at some stage(s) of the procedure of cDNA formation, 
product amplification by PCR, or analysis of resulting products 
by densitometry. Before proceeding to establish the efficiencies 
of the RT and PCR reactions using a range of concentrations of 
RNA and resulting cDNA, respectively, a series of studies was 
performed to detect any possible limitations of the densitometry 
analysis.
3 . 5 . 1 ( H )  Semi-Quantitative Analysis within an Experiment
The products of MDR 1, Topoisomerase II and Topoisomerase 
Ila mRNA analysis from each cell line studied were ran on
individual agarose gels (3.5(i)) so that attempts to correlate 
differences in band intensities with the initial RNA 
concentrations, after specific PCR cycle numbers, could be made. 
It seemed, however, that although the densitometry readings may 
be relatively accurate within a given gel, data from different 
gels could not be accurately compared. For this reason, it was 
necessary to study further samples from each extract of the cell 
line for comparisons between cell lines be made. 1.0 pg/pl RNA
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from DLKPA, DLKPA-2B, DLKPA-6B , DLKPA-5F, DLKP/VP-3 and DLKP/VP- 
8 were used as template in this analysis and 20 cycles of PCR 
amplification of MDR 1 cDNA were performed. The results are 
shown in Fig. 3.5.1.15 and Table 3.5.1.15.1. Similarly, 1.0 
¡ug/jjl RNA from DLKP, DLKPA, DLKP/VP-3 and DLKP/VP- 8 cDNAs were 
analysed together to establish if significant differences 
existed between their Topoisomerase Ila levels (Fig. 3.5.1.16
and Table 3.5.1.16.1). These studies were performed a total of 
four times for MDR 1 and for Topoisomerase Ila i.e. two repeat
studies on two RNA extracts.
From the results of MDR 1 mRNA studies in adriamycin- 
selected DLKP variants after analysis by densitometry, it seems 
that the levels of this gene transcript in rank order are as 
follows: DLKPA > DLKPA-5F > DLKP/VP-3 > DLKP/VP- 8 > DLKPA-6B > 
DLKPA-2B. The differences in densitometry readings between these 
bands, however, were small. By visual analysis, the MDR 1 
transcript levels were very similar, if not equal, in DLKPA, 
DLKPA-5F, DLKP/VP-3 and DLKP/VP-8 . The rank order appeared to 
be: DLKPA = DLKPA-5F = DLKP/VP-3 = DLKP/VP- 8 > DLKPA-6B > DLKPA- 
2B. In one study (E1/R2), observed both by densitometry and 
visual analysis, the levels in DLKPA-2B were apparently greater 
than in DLKPA-6B . This may possibly be an artifact, resulting 
from inconsistent printing. Differences in band intensities were 
more visible when the bands were not printed very strong. With 
the exception of the gels produced as E1/R2, the band 
intensities seemed to be increased approximately (visually) 1.5- 
fold in DLKPA-6B cells, compared to DLKPA-2B, and approximately 
1.5-fold from DLKPA-6B to DLKPA, DLKPA-5F, DLKP/VP-3 and 
DLKP/VP-8 . Differences of at least 2 - 3  fold were therefore 
visible between the least resistant and most resistant cell 
lines.
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Analysis, by densitometry, of mRNA levels which encode the 
a subunit of Topoisomerase II enzyme suggested that the 
Topoisomerase I la transcript levels were reduced in each of the 
MDR variants, by comparison to DLKP (Fig. 3.5.1.16). The 
densitometry readings, however, did not differ greatly (Table
3.5.1.16.1). No real differences in Topoisomerase Ila levels
between these cell lines were observed by visual analysis.
159
DLKPA-6B , DLKPA-5F, DLKP/VP-3 and DLKP/VP- 8 were studied by 
semi-quantitative PCR analysis using a range of three RNA 
concentrations (0.5 ¡ u q / p l ,  1.0 p q / j j l  and 2.0 ¡ j q / j i l ) .  This was 
done to establish if the resulting MDR 1 bands were indicative 
of the corresponding starting RNA concentrations. 100 ^1 PCR 
sample volumes were set up to amplify MDR 1 cDNA, the target
gene transcript, p-actin, acting as an endogenous control and as 
a means to normalise the intensity of the MDR 1 band, was co­
amplified with the MDR 1 cDNA. 10 j j  1 aliquots were removed after 
15 , 20 , 25 and 30 cycles of amplification. The resulting
products were separated by gel electrophoresis through a 4 % gel 
and were identified with respect to molecular weight markers 
(left-hand lane in each gel) ranging from 587 bp to 8 bp in 
size.
This analysis was performed for each of the cell lines 
(mentioned above) a total of four times i.e. on duplicate stocks 
of cDNA formed from two RNA extracts of independent cell line 
stocks - designated El/Rl, E1/R2, E2/R1 and E2/R2. All reactions 
were performed in duplicate.
Figs. 3.5.1.1 - 3.5.1.6 MDR 1 mRNA levels in DLKPA, DLKPA-2B,
Tables 3.5.1.1.1 - 3.5.1.6.1 MDR 1 band intensities (Figs.
3.5.1.1 - 3.5.1.6, respectively) were analysed by densitometry. 
The resulting data was corrected by subtracting background
readings and normalising with p-actin (the endogenous control).
Figs. 3.5.1.1.2 - 3.5.1.6.2 Relationship between the RNA
concentrations and the corrected densitometry readings of the 
bands resulting after gel electrophoresis of the RT-PCR products 
(Figs. 3.5.1.1 - 3.5.1.6). The data plotted represents the bands 
produced after 20 cycles of PCR amplification, as this was found 
to be within the exponential phase of product accumulation with 
this primer pair and so was suggested as a suitable cycle number 
at which analysis could be performed (see 3.4).
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1 5 C ycles 2 0  C ycles
Q.5 1.0 2.0 0.5 1.0 2.0
El /RI ! !« «
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•• rnm mm
p-Actin
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Fig. 3.5.1.1 Gel electrophoresis of the products of MDR 1 and p-actin 
m R N A  analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 fjg/fj\) extracted from DLKPA cultured cells and removing 
samples after four different PCR cycle time points. This analysis was 
done a total of four times.
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0.5 1.0 2.0 0.5 1.0 2.0
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1 5 Cycles 2 0  Cycles
0.5 1.0 2.0 0.5 1.0 2.0
E2/R2
25 Cycles 3 0  Cycles
0.5 1.0 2.0 0.5 1.0 2.0
Fig. 3.5.1.1. CONTINUED
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M D R  1 
(DLKPA)
RNA Concentration ( fjg / y\ )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15 0.417 0.584 0.600
20 0.592 0.607 0.700
25 0.873 0.915 1.004
30 0.873 0.876 0.946
El / R2 15 0.500 0.585 0.667
20 0.584 0.654 0.727
25 0.785 0.947 0.948
30 0.869 0.838 0.941
E2 / R1 15 0.286 0.400 0.410
20 0.530 0.641 0.671
25 0.798 0.840 0.903
30 0.733 0.786 0.846
E2 / R2 15 0.184 0.215 0.225
20 0.500 0.560 0.631
25 0.757 0.852 0.893
30 0.845 0.877 0.857
Table 3 . 5 .1.1.1 Analysis, by densitometry, of MDR 1 band 
intensities for DLKPA, as in Fig. 3.5.1.1
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0.75-1
0.55-
R N A  Concentration (¿/g/fil)
0.70-
o E1/R1
0.65 -
0.60-
• E1/R2 
o E2/R1 
■ E2/R2
Fia. 3.5.1.1.2 Relationship between R N A  concentrations and 
densitometry readings of resulting band intensities, after 20 cycles of 
amplification of MDR 1 cDNA derived from DLKPA cultured cells.
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1 5 C ycles_________  2 0  C ycles
0.5 1.0 2.0 0.5 1.0 2.0
El /RI
25 Cycles 30  Cycles
El /RI
25  Cycles 30  Cycles
Fi.q. 3.5.1.2 Gel electrophoresis of the products of MDR 1 and p-actin 
m R N A  analysis by RT-PCR, using three template RNA concentrations (0.5, 
1.0, 2.0 /jg//vl) extracted from DLKPA-2B cultured cells and removing 
samples after four different PCR cycle time points. This analysis was 
done a total of four times.
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0.5 1.0 2.0 0.5 1.0 2.0
*  ■» W- I
Fig. 3.5.1.2 CONTINUED
25  Cycles 3 0  Cycles
15
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M D R  1
(DLKPA-2B)
RNA Concentration ( /vg / fj\ )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15 0.000 0.000 0.000
20 0.161 0.181 0.240
25 0.488 0.534 0.549
30 0.561 0.578 0.605
El / R2 15 0.000 0.000 0.000
20 0.143 0.149 0.241
25 0.500 0.636 0.644
30 0.655 0.775 0.787
E2 / R1 15 0.000 0.000 0.000
20 0.087 0.161 0.182
25 0.379 0.456 0.536
30 0.657 0.666 0.781
E2 / R2 15 0.000 0.000 0.000
20 0.085 0.089 0.130
25 0.400 0.414 0.500
30 0.595 0.613 0.658
Table 3 . 5 .1.2 .1 Analysis, by densitometry, of MDR 1 band 
intensities for DLKPA-2B, as in Fig. 3.5.1.2
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RNA Concentration (i/g///l)
Fig. 3.5.1.2.2 Relationship between R N A  concentrations and 
densitometry readings of resulting band intensities, after 20 cycles of 
amplification of MDR 1 cDNA derived from DLKPA-2B cultured cells.
E2/R2
25 Cycles  3 0  Cycles
0.5 1.0 2.0 0.5 1.0 2.0
V 1 1 » » M  1 » i L H  I 1
Fig. 3.5.1.3 Gel electrophoresis of the products of M DR 1 and 
p-actinmRNA analysis by RT-PCR, using three template RNA 
concentrations (0.5, 1.0, 2.0 extracted from DLKPA-6B cultured
cells and removing samples after four different PCR cycle time points. 
This analysis was done a total of four times.
25 Cycles 3 0  Cycles
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Fig. 3.5.1.3 CONTINUED
170
MDR 1
(DLKPA-6B)
RNA Concentration ( pg / f/l )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15 0.000 0.021 0.034
20 0.150 0.227 0.245
25 0.486 0.487 0.499
30 0.513 0.541 0.647
El / R2 15 0.000 0.024 0.052
20 0.211 0.231 0.286
25 0.544 0.624 0.632
30 0.610 0.691 0.711
E2 / R1 15 0.000 0.025 0.050
20 0.141 0.150 0.175
25 0.481 0.542 0.545
30 0.564 0.604 0.852
E2 / R2 15 0.000 0.021 0.039
20 0.144 0.164 0.220
25 0.379 0.390 0.473
30 0.595 0.610 0.619
T a b l e  3 . 5 . 1 . 3  . 1  Analysis, by densitometry, of MDR 1 band 
intensities for DLKPA-6B, as in Fig. 3.5.1.3
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Fig. 3.5.1.3.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 20 cycles of 
amplification of MDR 1 cDNA derived from DLKPA-6B cultured cells.
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Fig. 3.5.1.4 Gel electrophoresis of the products of MDR 1 and p-actin 
mRNA analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 fjg/ij\) extracted from DLKPA-5F cultured cells and 
removing samples after four different PCR cycle time points. This 
analysis was done a total of four times.
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Fig. 3.5.1.4 CONTINUED
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MDR 1
(DLKPA-5F)
RNA Concentration ( y g  /  ¡j \ )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15 0.268 0.281 0.450
20 0.628 0.675 0.791
25 0.741 0.869 0.892
30 0.727 0.737 0.775
E1 / R2 15 0.631 0.646 0.775
20 0.710 0.753 0.810
25 0.788 0.963 1.057
30 0.687 0.800 1.030
E2 / R1 15 0.393 0.437 0.450
20 0.650 0.655 0.730
25 0.885 0.907 0.960
30 0.722 0.789 • 0.853
E2 / R2 15 0.094 0.123 0.293
20 0.534 0.622 0.668
25 0.858 0.859 0.953
30 0.737 0.781 0.784
T a b l e  3 . 5 . 1 . 4  . 1  A n a l y s i s ,  by d e n s i t o m e t r y ,  o f  MDR 1 band  
i n t e n s i t i e s  f o r  DLKPA-5F, as in  F i g .  3 . 5 . 1 . 4
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o E l/R I
• E1/R2
□ E2/R1
E2/R2
RNA Concentration (/yg/^l)
Fia. 3.5.1.4.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 20 cycles of 
amplification of MDR 1 cDNA derived from DLKPA-5F cultured cells.
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Fig- 3-5.1.5 Gel electrophoresis of the products of MDR 1 and (3-actin 
mRNA analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 jL/g//il) extracted from DLKP/VP-3 cultured cells and 
removing samples after four different PCR cycle time points. This 
analysis was done a total of four times.
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Fig. 3.5.1.5 CONTINUED
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MDR 1
(DLKP/VP-3)
RNA Concentration ( / ¡j\ )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15 0.125 0.197 0.200
20 0.389 0.412 0.490
25 0.649 0.680 0.736
30 0.537 0.564 0.666
E1 / R2 15 0.118 0.167 0.167
20 0.282 0.346 0.420
25 0.611 0.690 0.720
30 0.552 0.560 0.618
E2 / R1 15 0.134 0.181 0.241
20 0.515 0.594 0.634
25 0.796 0.796 0.857
30 0.781 0.781 0.793
E2 / R2 15 0.231 0.300 0.332
20 0.553 0.579 0.650
25 0.709 0.893 0.893
30 0.681 0.778 0.822
T a b l e  3 . 5 . 1 .  5 . 1  A n a l y s i s ,  by d e n s i t o m e t r y ,  o f  MDR 1 band  
i n t e n s i t i e s  f o r  DLKP/VP-3, as in  F ig .  3 . 5 . 1 . 5
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Fia. 3.5.1.5.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 20 cycles of 
amplification of MDR 1 cDNA derived from DLKP/VP-3 cultured cells.
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Fig. 3.5.1.6 Gel electrophoresis of the products of MDR 1 and |3-actin 
mRNA analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 jvg//vl) extracted from DLKP/VP-8 cultured cells and 
removing samples after four different PCR cycle time points. This 
analysis was done a total of four times.
181
E2/R1
1 5 Cycles 20 Cycles
0.5 1.0 2.0 0.5 1.0 2.0
-- «*** Âk m» .ÿm Ai §■» tn»
25 Cycles 30 Cycles
. . . . p . . .
E2/R2
1 5 Cycles 20 Cycles
0.5 1.0 2.0 0.5 1.0 2.0
25 Cycles 30 Cycles
0.5 1.0 2.0 0.5 1.0 2.0
Fig. 3.5.1.6 CONTINUED
MDR 1
(DLKP/VP-8)
RNA Concentration ( f/g / pi )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15 0.184 0.222 0.273
20 0.489 0.502 0.581
25 0.659 0.707 0.756
30 0.813 0.837 0.870
El / R2 15 0.167 0.250 0.292
20 0.200 0.387 0.406
25 0.736 0.765 0.778
30 0.869 0.888 0.899
E2 / R1 15 0.118 0.150 0.215
20 0.134 0.211 0.319
25 0.472 0.526 0.612
30 0.534 0.579 0.711
E2 / R2 15 0.118 0.200 0.286
20 0.500 0.500 0.568
25 0.690 0.706 0.758
30 0.783 0.781 0.771
T a b l e  3 . 5  . 1 . 6 . 1  Analysis, by densitometry, of MDR 1 band 
intensities for DLKP/VP-8, as in Fig. 3.5.1.6
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O E l/R I
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RNA Concentration (jyg/jL/l)
Fig. 3.5.1.6.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 20 cycles of 
amplification of MDR 1 cDNA derived from DLKP/VP-8 cultured cells.
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DLKP, DLKPA, DLKP/VP-3 and DLKP/VP-8 were studied by semi- 
quantitative PCR analysis using a range of three RNA 
concentrations (0.5 pg/pl, 1.0 pg/pl and 2.0 pg/pl). This was 
done to establish if the resulting Topoisomerase II bands were 
indicative of the corresponding starting RNA concentrations. 100 
pi PCR sample volumes were set up to amplify Topoisomerase II 
cDNA, the target gene transcript, p-actin, acting as an 
endogenous control and as a means to normalise the intensity of 
the Topoisomerase II bands, was co-amplified with the 
Topoisomerase II cDNA. 10 pi aliquots were removed after 20, 25 
and 30 cycles of amplification. The resulting products were 
separated by gel electrophoresis through a 4 % gel and were 
identified with respect to molecular weight markers (ran on each 
gel) ranging from 587 bp to 8 bp in size.
This analysis was performed for each of the cell lines 
(mentioned above) a total of four times i.e. on duplicate stocks 
of cDNA formed from two RNA extracts of independent cell line 
stocks - designated El/Rl, E1/R2, E2/R1 and E2/R2. All reactions 
were performed in duplicate.
Figs. 3.5.1.7 - 3.5.1.10 Topoisomerase II mRNA levels in
T a b l e s  3 . 5 . 1 . 7 . 1  -  3 . 5 . 1 . 1 0 . 1  Topoisomerase II band
intensities (Figs. 3.5.1.7 - 3.5.1.10, respectively) were
analysed by densitometry. The resulting data was corrected by
subtracting background readings and normalising with p-actin 
(the endogenous control).
F i g s .  3 . 5 . 1 . 7 . 2  -  2 . 5 . 1 . 1 0 . 2  Relationship between the RNA
concentrations and the corrected densitometry readings of the 
bands resulting after gel electrophoresis of the RT-PCR products 
(Figs. 3.5.1.7 - 3.5.1.10). The data plotted represents the 
bands produced after 25 cycles of PCR amplification, as this was 
found to be within the exponential phase of product accumulation 
with this primer pair and was suggested as a suitable cycle 
number at which analysis could be performed (see 3.4).
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Fig. 3.5.1.7 Gel electrophoresis of the products of Topoisomerase II 
mRNA analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 /vg//vl) extracted from DLKP cultured cells and removing 
samples after three different PCR cycle time points. This analysis was 
done a total of four times.
186
Topo II 
(DLKP)
RNA Concentration ( ¿/g / j/1 )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.209 0.268 0.313
25 0.646 0.688 0.732
30 0.732 0.873 1.000
El / R2 15
20 0.111 0.191 0.321
25 0.558 0.619 0.641
30 0.784 0.795 0.811
E2 / R1 15
20 0.134 0.211 0.188
25 0.511 0.562 0.588
30 0.700 0.770 0.795
E2 / R2 15
20 0.167 0.191 0.333
25 0.532 0.586 0.594
30 0.635 0.760 0.775
T a b le  3.5 . 1 . 7 .1 Analysis, by densitometry, of Topoisomerase II 
band intensities for DLKP, as in Fig. 3.5.1.7
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Fig. 3.5.1.7.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase II cDNA derived from DLKP cultured 
cells.
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Fig. 3.5.1.8 Gel electrophoresis of the products of Topoisomerase II 
mRNA analysis by RT-PCR, using three template RNA concentrations (0.5, 
1.0, 2.0 pg/pl) extracted from DLKPA cultured cells and removing 
samples after three different PCR cycle time points. This analysis was 
done a total of four times. 189
Topo II 
(DLKPA)
RNA Concentration ( /vg /  pi )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.000 0.167 0.292
25 0.325 0.390 0.461
30 0.508 0.534 0.591
El / R2 15
20 0.084 0.087 0.100
25 0.091 0.172 0.278
30 0.211 0.266 0.367
E2 / R1 15
20 0.092 0.113 0.118
25 0.248 0.278 0.391
30 0.440 0.500 0.528
E2 / R2 15
20 0.000 0.000 0.137
25 0.193 0.234 0.340
30 0.340 0.515 0.568
T a b le  3.5 . 1 . 8  .1 Analysis, by densitometry, of Topoisomerase II 
band intensities for DLKPA, as in Fig. 3.5.1.8
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Fig. 3.5.1.8.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase II cDNA derived from DLKPA cultured 
cells.
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Fig. 3.5.1.9 Gel electrophoresis of the products of Topoisomerase II 
mRNA analysis by RT-PCR, using three template RNA concentrations (0.5,
1.0, 2.0 pg//vl) extracted from DLKP/VP-3 cultured cells and removing 
samples after three different PCR cycle time points. This analysis was 
done a total of four times.
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Topo II 
(DLKP/VP-3)
RNA Concentration ( p g  / jl/I )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.155 0.155 0.340
25 0.350 0.378 0.478
30 0.535 0.764 0.875
El / R2 15
20 0.129 0.134 0.311
25 0.349 0.382 0.491
30 0.567 0.656 0.720
E2 / R1 15
20 0.125 0.184 0.222
25 0.364 0.393 0.489
30 0.684 0.733 0.694
E2 / R2 15
20 0.125 0.134 0.267
25 0.417 0.459 0.510
30 0.607 0.742 0.775
T a b le  3 . 5 . 1 . 9  . 1  Analysis, by densitometry, of Topoisomerase II 
band intensities for DLKP/VP-3, as in Fig. 3.5.1.9
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Fia. 3.5.1.9.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase II cDNA derived from DLKP/VP-3 
cultured cells.
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Fig. 3.5.1.10 Gel electrophoresis of the products of Topoisomerase II 
mRNA analysis by RT-PCR, using three template RNA concentrations (0.5,
1.0, 2.0 pg/jul) extracted from DLKP/VP-8 cultured cells and removing 
samples after three different PCR cycle time points. This analysis was 
done a total of four times.
19S
Topo II 
(DLKP/VP-8)
RNA Concentration ( pg / jwl )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.146 0.211 0.211
25 0.407 0.427 0.467
30 0.515 0.546 0.563
El / R2 15
20 0.032 0.056 0.200
25 0.250 0.320 0.380
30 0.217 0.343 0.459
E2 / R1 15
20 0.155 0.156 0.284
25 0.343 0.417 0.437
30 0.462 0.568 0.619
E2 / R2 15
20 0.156 0.167 0.211
25 0.311 0.400 0.415
30 0.450 0.554 0.579
T a b l e  3.5.1.10.1 Analysis, by densitometry, of Topoisomerase 
II band intensities for DLKP/VP-8, as in Fig. 3.5.1.10
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o E1/R1
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E2/R2
RNA Concentration (pg//vl)
Fig. 3.5.1.10.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase II cDNA derived from DLKP/VP-8 
cultured cells.
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DLKP, DLKPA, DLKP/VP-3 and DLKP/VP-8 were studied by semi- 
quantitative PCR analysis using a range of three RNA 
concentrations (0.5 jug/pl, 1.0 jjg/pl and 2.0 pg/jjl). This was 
done to establish if the resulting Topoisomerase Ila bands were 
indicative of the corresponding starting RNA concentrations. 100 
pi PCR sample volumes were set up to amplify Topoisomerase Ila
cDNA, the target gene transcript. [3-actin, acting as an 
endogenous control and as a means to normalise the intensity of 
the Topoisomerase Ila bands, was co-amplified with the
Topoisomerase Ila cDNA. 10 jj1 aliquots were removed after 20, 25 
and 30 cycles of amplification. The resulting products were 
separated by gel electrophoresis through a 4 % gel and were 
identified with respect to molecular weight markers (ran on each 
gel) ranging from 587 bp to 8 bp in size.
This analysis was performed for each of the cell lines 
(mentioned above) a total of four times i.e. on duplicate stocks 
of cDNA formed from two RNA extracts of independent cell line 
stocks - designated El/Rl, E1/R2, E2/R1 and E2/R2. All reactions 
were performed in duplicate.
Figs. 3.5.1.11 - 3.5.1.14 Topoisomerase I la mRNA levels in
T a b l e s  3 . 5 . 1 . 1 1 . 1  -  3 . 5 . 1 . 1 4 . 1  Topoisomerase Ila band
intensities (Figs. 3.5.1.11 - 3.5.1.14, respectively) were
analysed by densitometry. The resulting data was corrected by 
subtracting background readings and normalising with p-actin 
(the endogenous control).
F i g s .  3 . 5 . 1 . 1 1 . 2  -  2 . 5 . 1 . 1 4 . 2  Relationship between the RNA
concentrations and the corrected densitometry readings of the 
bands resulting after gel electrophoresis of the RT-PCR products 
(Figs. 3.5.1.11 - 3.5.1.14). The data plotted represents the 
bands produced after 25 cycles of PCR amplification, as this was 
found to be within the exponential phase of product accumulation 
with this primer pair and was suggested as a suitable cycle 
number at which analysis could be performed (see 3.4).
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20 Cycles 25 Cycles 30 Cycles
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E1/R1
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E1/R2
E2/R1
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E2/R2
f  !
Fig. 3.5.1.1 1 Gel electrophoresis of the products of Topoisomerase lla 
mRNA analysis by RT-PCR, using three template RNA concentrations (0.5,
1.0, 2.0 pg/pl) extracted from DLKP cultured cells and removing samples 
after three different PCR cycle time points. This analysis was done a 
total of four times.
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Topo Ila 
(DLKP)
RNA Concentration ( pg / pi )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.084 0.167 0.292
25 0.336 0.363 0.431
30 0.528 0.652 0.789
El / R2 15
20 0.100 0.250 0.417
25 0.333 0.430 0.460
30 0.464 0.500 0.542
E2 / R1 15
20 0.056 0.072 0.117
25 0.287 0.332 0.393
30 0.478 0.519 0.545
E2 / R2 15
20 0.191 0.250 0.371
25 0.366 0.478 0.515
30 0.411 0.508 0.566
T a b l e  3.5.1.11.1 Analysis, by densitometry, of Topoisomerase 
Ila band intensities for DLKP, as in Fig. 3.5.1.11
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Fig. 3.5.1.11.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase Ilex cDNA derived from DLKP cultured 
cells.
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20 Cycles 25 Cycles 30 Cycles
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E1/R1
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E1/R2
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E2/R1
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
E2/R2
Fig. 3.5.1.12 Gel electrophoresis of the products of Topoisomerase lla 
mRNA analysis by RT-PCR, using three template RNA concentrations (0.5, 
1.0, 2.0 jug/pl) extracted from DLKPA cultured cells and removing 
samples after three different PCR cycle time points. This analysis was 
done a total of four times.
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Topo Ila 
(DLKPA)
RNA Concentration ( pg / pi )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.105 0.250 0.304
25 0.225 0.367 0.407
30 0.548 0.652 0.692
El / R2 15
20 0.000 0.000 0.052
25 0.299 0.378 0.409
30 0.405 0.438 0.598
E2 / R1 15
20 0.000 0.000 0.200
25 0.191 0.250 0.345
30 0.356 0.432 0.446
E2 / R2 15
20 0.083 0.149 0.184
25 0.147 0.292 0.361
30 0.349 0.371 0.481
T a b l e  3 . 5 . 1 . 1 2 . 1  Analysis, by densitometry, of Topoisomerase 
Ila band intensities for DLKPA, as in Fig. 3.5.1.12
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Fia. 3.5.1.12.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase lla  cDNA derived from DLKPA cultured 
cells.
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20 Cycles 25 Cycles 30 Cycles
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
Fig. 3.5.1.13 Gel electrophoresis of the products of Topoisomerase Ilex 
mRNA analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 pg/pl) extracted from DLKP/VP-3 cultured cells and 
removing samples after three different PCR cycle time points. This 
analysis was done a total of four times.
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Topo Ila 
(DLKP/VP-3)
RNA Concentration ( pg / pi )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.238 0.268 0.422
25 0.494 0.502 0.589
30 0.555 0.664 0.698
El / R2 15
20 0 .00 0 0.101 0.223
25 0.385 0.407 0.481
30 0.519 0.533 0.640
E2 / R1 15
20 0.101 0.175 0.282
25 0.429 0.484 0.519
30 0.533 0.649 0.677
E2 / R2 15
20 0.118 0.141 0.273
25 0.308 0.417 0.440
30 0.342 0.471 0.500
T a b l e  3 ♦ 5 . 1 . 1 3  . 1  Analysis, by densitometry, of Topoisomerase 
Ila band intensities for DLKP/VP-3, as in Fig. 3.5.1.13
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Fia. 3.5.1.13.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase lla cDNA derived from DLKP/VP-3 
cultured cells.
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20 Cycles 25 Cycles 30 Cycles
• #*• *'* •“
Fig. 3.5.1.14 Gel electrophoresis of the products of Topoisomerase Ilct 
mRNA analysis by RT-PCR, using three template RNA concentrations 
(0.5, 1.0, 2.0 /jg/pl) extracted from DLKP/VP-8 cultured cells and 
removing samples after three different PCR cycle time points. This 
analysis was done a total of four times.
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Topo Ila 
(DLKP/VP-8)
RNA Concentration ( pg / pi )
Extraction/Run Cycles 0.5 1.0 2.0
El / R1 15
20 0.150 0.250 0.332
25 0.228 0.404 0.436
30 0.542 0.615 0.654
El / R2 15
20 0.046 0.083 0.119
25 0.177 0.313 0.345
30 0.412 0.475 0.475
E2 / R1 15
20 0.111 0.150 0.191
25 0.149 0.217 0.323
30 0.528 0.556 0.565
E2 / R2 15
20 0.087 0.116 0.143
25 0.227 0.333 0.400
30 0.543 0.572 0.572
T a b l e  3.5.1.14.1 Analysis, by densitometry, of Topoisomerase 
Ila band intensities for DLKP/VP-8, as in Fig. 3.5.1.14
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Fig. 3.5.1.14.2 Relationship between RNA concentrations and 
densitometry readings of resulting band intensities, after 25 cycles of 
amplification of Topoisomerase Ilex cDNA derived from DLKP/VP-8 
cultured cells.
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Fig. 3.5.1.15 MDR 1 mRNA levels in DLKPA, DLKPA-2B, DLKPA-6B, DLKPA-5F, DLKP/VP-3 and 
DLKP/VP-8 cells were studied, simultaneously, using 1.0 pg/p\ RNA as template in the RT reaction and 
performing 20 cycles of PCR amplification. The p-actin (383 bp) and MDR 1 (157 bp) amplification 
products were separated by electrophoresis through a 4 % agarose gel. Their sizes were verified by 
comparison to molecular weight markers, ranging from 587 bp to 8 bp (left-hand lane). The analysis 
was performed for each of the cell lines (mentioned above) a total of four times i.e. on duplicate stocks of 
cDNA formed from two RNA extracts of independent cell line stocks. These were designated El /R1, El /R2, 
E2/R1 and E2/R2. All reactions were performed in duplicate. The results were analysed by densitometry 
(Table 3.5.1.15.1). 211
Fig. 3.5.1.16 Topoisomerase 11« mRNA levels in DLKP, DLKPA, DLKP/VP-3 and DLKP/VP-8 
cells were studied, simultaneously, using 1.0 pg/p\ RNA as template in the RT reaction and 
performing 25 cycles of PCR amplification. The p-actin (383 bp) and Topoisomerase lla (139 
bp) amplicons were separated by electrophoresis through a 4 % agarose gel. Their sizes were 
verified by comparison to molecular weight markers, ranging from 587 bp to 8 bp (left-hand 
lane). The analysis was performed for each of the cell lines (mentioned above) a total of four 
times i.e. on duplicate stocks of cDNA formed from two RNA extracts of independent cell line 
stocks. These were designated E1/R1, E1/R2, E2/R1 and E2/R2. All reactions were performed in 
duplicate. The results were analysed by densitometry (Table 3.5.1.1 6.1).
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Cell
Line/Clone
El/Rl E1/R2 E2/R1 E2/R2
DLKPA 0.600 0.610 0.494 0.488
DLKPA-2B 0.420 0.497 0.338 0.310
DLKPA-6B 0.486 0.490 0.318 0.362
DLKPA-5F 0.610 0.608 0.492 0.487
DLKP/VP-3 0.604 0.606 0.490 0.485
DLKP/VP-8 0.600 0.603 0.487 0.484
T a b l e  3 . 5 . 1 . 1 5 . 1  Densitometry analsyis (after background 
subtraction and normalising with P-actin) of MDR 1 mRNA levels
in MDR variants of DLKP, after 20 cycles of PCR amplification.
Cell
Line/Clone
El/Rl E1/R2 E2/R1 E2/R1
DLKP 0.646 0.648 0.678 0.666
DLKPA 0.640 0.644 0.670 0.662
DLKP/VP-3 0.642 0.645 0.672 0.658
DLKP/VP-8 0.642 0.641 0.669 0.657
T a b l e  3 . 5 . 1 . 1 6 . 1  Densitometry analsyis (after background 
subtraction and normalising with p-actin) of Topoisomerase Ila
mRNA levels in DLKP and its MDR variants, after 25 cycles of PCR 
amplification.
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Assessing the variations between products from different RT-PCR 
analyses from the same batch of RNA e.g. El/Rl and E1/R2 and 
between different batches of RNA i.e. El and E2 from the same 
cell line was quite difficult, for two reasons. Firstly, 
inconsistant printing may cause bias in the photographs which 
would hinder visual analysis (negatives were favoured for 
densitometry analysis). Secondly, it seemed that although the 
relative values obtained by densitometry analysis were 
consistent, the actual values differed greatly, even on repeat 
analysis of the same gel). This implies that readings cannot by 
directly compared from one gel (negative) to another. Since 
inconsistent printing from one photograph to another affects the 
|3-actin bands as well as the MDR 1 bands, some visual assessment
of the reproducibility was made.
By visual analysis of MDR 1, Topoisomerase II and 
Topoisomerase Ila mRNA levels, the reproducibility of the these
studies was generally found to be quite consistent between RNA 
extracts (El and E2), and between different RT-PCR analyses (R1 
and R2). An example of this is Fig. 3.5.1.2. In some cases, 
e.g. Fig. 3.5.1.3, good reproducibility between studies on a 
given extract was found, but not from one extract to another. 
The lower levels of RNA apparently in one extract by comparison 
to another were generally found with both (3-actin and MDR 1. As
all measurements of RNA concentration were performed in the same 
way (by spectrophotometry), it is unlikely that this difference 
is due to different RNA concentrations being included in 
respective RT reactions. This suggested either slight 
degradation of the RNA prior to analysis, or inconsistent 
printing of the resulting negatives were responsible for this 
difference. (Differences in printing were generally also 
observed with the molecular weight marker). Overall, these, 
generally consistent results, suggest that both the RT and PCR 
reactions are reproducible.
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3.5.2 Analysis of Densitometry Efficiency
From many of the preceding results, although the 
densitometry readings often were linearly related to the 
intensities of the bands they represented, the relationship, 
according to these readings was not proportional to the starting 
RNA concentrations. This suggested that possibly the data 
produced by the densitometer was not completely accurate.
In an attempt to check the accuracy of the densitometer for 
the analysis of products differing by approximately two-fold, 
serial dilutions of DNA of which the actual concentrations were 
known (Lambda DNA and molecular weight marker V) were 
electrophoresed on agarose gels, photographed and analysed. The 
DNA concentrations were plotted with the corresponding 
densitometry data. Each DNA concentration was electrophoresised 
and analysed in duplicate. This study was repeated four times 
for lambda and twice for molecular weight marker V. Photographs 
of the resulting gels after lambda DNA electrophoresis are shown 
in Fig. 3.5.2.1. Although approximately two-fold concentration 
differences are visible on the gel, this was not reflected in 
the densitometry readings, as illustrated in Fig. 3.5.2.2. A 
plot of similar shape resulted from both analysis of the 
molecular weight marker V DNA (Fig. 3.5.1.3).
Results from this study suggest that the analysis by 
densitometry, and not the RT or PCR efficiencies, was the 
limiting factor when studying MDR 1, Topoisomerase II and 
Topoisomerase Ila transcript levels, as described in 3.5. The
plotted results can be used, therefore, as a standard curve from 
which the relative concentrations of an unknown RNA can be 
estimated, if it is within the range of these plots. Due to 
another limitation of the densitometer, however, if a certain 
gel is analysed repeatedly, although the same trend of values 
may result (i.e. the same relative values), the absolute values 
may vary. Therefore, if an unknown sample is to be estimated 
from such a standard curve, it should be electrophoresed and 
analysed by densitometry with the "standards".
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Fig. 3-5-2.1 Gel electrophoresis of lambda DNA serial dilutions. Four 
independent serial dilutions (i)-(iv), ranging from 1 pg to 15.63 ng of 
DNA (1 yg, 0.5 pg, 0.25 pg, 0.125 pg, 62.5 ng, 31.25 ng and 15.63 ng) 
were made and were ran out on a 1 %  agarose gel, in duplicate.
Lambda (pg)
Lambda (pg)
Fig. 3.5.2.2 Relationship between the lambda DNA concentration and 
intensity of the resulting bands represented by the densitometry 
readings (after background subtraction). The values plotted are the 
means for each of the duplicate readings. Graphs (i), (ii), (iii) and (iv) 
correspond to gels (i), (ii), (iii) and (iv) in Fig. 3.5.2.1, respectively.
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Fig. 3.5.2.2 CONTINUED
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Fig. 3.5.2.3 Serial dilutions of a molecular weight marker (V, 
Boehringer Mannheim), ranging from 1 pg to 15.63 ng (1 pg, 0.5 pg, 0.25 
pg, 0.125 ¡jq , 62.5 ng, 31.25 ng and 15.63 ng) were analysed by 
densitometry after electrophoresis through a 1 %  agarose gel. The 
values plotted are the DNA (molecular weight marker) concentrations 
versus the means of the corresponding densitometry readings, after 
background subtraction.
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3 . 5 . 3  S e m i - Q u a n t i t a t i v e  A n a l y s i s  o f  MDR 1 mRNA u s i n g  a 
r a n g e  o f  RNA c o n c e n t r a t i o n s  and cDNA amounts
In order to verify that the densitometer, and not the 
efficiency of the RT and/or PCR reactions, was the major 
limiting factor in this semi-quantitative analysis, a range of 
RNA concentrations and resulting cDNA amounts were analysed. If 
similar shaped graphs were produced from this analysis as were 
produced when testing out the densitometer (as in 3.5.2), and 
yet the bands were visually as expected, this would strongly 
suggest that the densitometer is the "limiting factor" in these 
studies, and not either the RT or PCR reactions.
DLKPA-2B and DLKPA-5F were the two cell lines included in 
this study of MDR 1 mRNA, as they seemed (based on the 
preliminary data presented above) to possess relatively low and 
high levels of this gene transcript, respectively. 20 cycles of 
PCR amplification were performed throughout this phase of the 
study. In all cases, the densitometry readings plotted were the 
result of background subtraction and normalising with (3-actin 
(Gel (i), in each figure). Amplifications of the MDR 1 and (5- 
actin transcripts, independently, were also done in most cases 
(Gels (ii) and (iii), respectively) to ensure, by comparison to 
the gels resulting after co-amplification of these transcripts, 
that neither amplified product was limited due to the presence 
of the other (Gel (i)).
The initial run for DLKPA-2B (El/Rl i.e. extract no. 1; RT- 
PCR analysis no. 1) was performed on only two RNA concentrations 
(0.5 pg/pl and 2.0 pg/pl) to establish if a difference in band 
intensities was apparent (Fig. 3.5.3.1). As indicated in Fig.
3.5.3.1.1, the results after densitometry analysis were 
indicative of a linear relationship between RNA concentrations 
and between cDNA amounts, but not proportionally. However, by 
visual analysis of the MDR 1 bands, in particular, this 
relationship between the bands frequently seemed to be 
proportional to the starting RNA and cDNA concentrations. Using 
similar RNA concentrations (0.5 pg/pl, 1.0 pg/pl and 2.0 pg/pl
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and the three different amounts of cDNA), a similar trend was 
noted for DLKPA-5F at the lowest cDNA concentrations. However, 
because this cell line expressed relatively high levels of MDR 1 
compared to DLKPA-2B, the resulting band intensities were much 
stronger with this cell line, and so not as easily analysed. The 
results from this are shown in Figs. 3.5.3.2 and 3.5.3.2.1. 
Probably due to the greater intensities of the MDR 1 bands 
formed on analysis of the DLKPA-5F RNA, the relationship between 
RNA concentration and densitometry readings was even less 
obvious (both by densitometry and visual analysis). When 
plotted, the curves resulting from the three RNA concentrations 
using 5 ¡ul cDNA reached a plateau almost immediately. A range- 
finding experiment was therefore performed for this cell line, 
after which it was realised that lower concentrations of RNA 
template were more suitable for its semi-quantitative study. 
In the following experiments, 0.125 juq/pl, 0.25 ]uq/pl and 0.5 
]jq/H± of RNA extracted from the DLKPA-5F cell line were 
analysed. The higher RNA concentrations, 0.5 pq/pl, 1.0 pq/pl 
and 2.0 pq/pl were used throughout, when studying the DLKPA-2B 
cell line.
In the resulting experiments on the DLKPA-2B cell line, 
Figs. 3.5.3.3 - 3.5.3.5.1, a linear relationship between both 
RNA concentration and densitometry reading, and cDNA amount and 
densitometry reading, was observed, although not proportionally. 
Again, by visual analysis a proportional relationship frequently 
did seem to exist. This was seen for example in Fig. 3.5.3.3 
where fold-differences were apparent with both different RNA and 
cDNA concentrations. (Similar results were produced for DLKPA- 
5F). Although the bands produced on the gel were weaker for the 
two studies on the second RNA extracts, compared to the first, 
after normlising with p-actin, similar curves resulted. This
suggests that the MDR 1 mRNA is expressed at the same levels in 
both cell lines, as is the p-actin gene transcript. The reduced
levels of both in the second RNA extracts may be indicative of 
partial degradation. The importance of including an endogenous 
control, such as p-actin, is emphasised by the fact that 
normalising the MDR 1 band with the corresponding p-actin in
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both extracts, gave similar results. The results from studies 
using 2.5 jj 1 cDNA and 5.0 pi cDNA are almost parallel in all 
cases and seem to represent the actual gel bands more 
accurately, by comparison to those resulting from 1 j j  1 cDNA. 
This suggests that the bands produced by the latter are possibly 
too weak to be detected by the densitometer.
As with the DLKPA-2B cell line, the bands produced on 
analysis of the DLKPA-5F second RNA extract (Figs. 3.5.3.8.1 and 
3.5.3.9.1), were weaker, although relatively the same as those 
from the first extract (Figs. 3.5.3.6.1 and 3.5.3.7.1). As in 
most of the DLKPA-2B studies, the curves resulting when plotting 
DLKPA-5F RNA concentration versus densitometry readings are 
parallel. This, again, supports the idea that the RT and PCR 
reactions are equally efficient with each RNA concentration and 
cDNA amount, and that it is the densitometry analysis that is 
preventing the proportional relationship be identified.
From these studies, the levels of MDR 1 mRNA seemed to be 
more than four-fold that in the DLKPA-2B cells. This is because 
the initial concentration of RNA analysed for DLKPA-2(3 was four
times that for DLKPA-5F, and yet slightly stronger bands seemed 
to be produced for DLKPA-5F. However, as these products were not 
run out on a gel together no definite statement about the 
relationship between their RNA levels can be made.
222
F i g s .  3 . 5 . 3 . 1  -  3 . 5 . 3 . 8  MDR 1 mRNA levels in DLKPA-2B and
DLKPA-5F were studied by semi-quantitative PCR analysis using a 
range of three RNA concentrations (except for DLKPA-2B, Fig.
3.5.3.1, where two RNA concentrations were analysed) and three 
amounts of resulting cDNA (equivalent to 1 pi, 2.5 ^1 and 5.0 
pi), formed during the RT reaction in each case. This was done 
to establish if the MDR 1 bands, resulting after RT-PCR, were 
indicative of the corresponding starting RNA concentrations and 
cDNA amounts. After preliminary analyses were performed (Fig. 
3.5. 3.1 for DLKPA-2B, and Fig. 3. 5. 3.2 for DLKPA-5F), RNA from 
each of the cell lines was studied a total of four times i.e. 
duplicate stocks of cDNA were formed from two RNA extracts of 
independent cell line stocks - designated El/Rl, E1/R2, E2/R1 
and E2/R2. The RNA template concentration for DLKPA-2B cells 
were 0.5 pg/pl, 1.0 pq/pl and 2.0 pq/pl. For DLKPA-5F, the RNA 
concentrations were 0.125 pq/pl, 0.25 pq/pl and 0.5 pq/pl.This
study involved (i) co-amplifying (5-actin (383 bp) and MDR 1 cDNA
(157 bp), and individually amplifying (ii) MDR 1 and (iii) (3- 
actin cDNA, respectively. 10 pi aliquots of the products 
resulting after 20 cycles of PCR amplification were separated by 
gel electrophoresis through a 4 % agarose gel. Bands were
identified with respect to molecular weight markers (left-hand 
lane in each gel) ranging from 587 to 8 base pairs in size. All 
reactions were performed in duplicate.
F i g s .  3 . 5.3 . 1 . 1  - 3 , 5 . 3 . 9 . 1  Relationship between template
RNA concentrations and densitometry readings after correction 
(by background subtraction and normalising with (5-actin) of the 
bands resulting from RT-PCR analysis of MDR 1 mRNA, for each of 
the cDNA dilutions (as illustrated in Figs. 3 . 5 . 3 . 1  -  3 . 5 . 3 . 8 ) .
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1 .Ojul cDNA 2.5fvl cDNA 5.0 /jI cDNA
0.5 2.0 0.5 2.0 0.5 2.0
E1/R1
(0
(Ü)
(m)
Fig. 3.5.3.1 Gel electrophoresis of products resulting from RT-PCR 
amplification of (3-actin (383 bp) and MDR 1 (157 bp) cDNA formed on 
RNA templates extracted from DLKPA-2B cultured cells, ((i) is 
co-amplification of p-actin and MDR 1; (ii) and (iii) are independant 
amplifications of MDR 1 and p-actin, respectively). The amounts of 
cDNA (1 pi, 2.5 pi and 5.0 pi) formed on RNA templates at two 
concentrations (0.5 pg/pl and 2.0 pg/pl) were analysed (E1/R1).
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Fig. 3.5.3.1.1 Analysis, by densitometry, of MDR 1 band intensities 
for DLKPA-2B, as in Fig. 3.5.3.1.
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1 u\ cDNA 2.5 u\ cDNA 5.0 uI cDNA 
0.5 1.0 2.0 0.5 1.0 2.0 1.0 0.5 2.0 (pg/pl RNA)
Fig. 3-5.3-2 Gel electrophoresis of products resulting from RT-PCR 
co-amplification of p-actin (383 bp) and MDR 1 (157 bp) cDNA formed on 
RNA templates extracted from DLKPA-5F cultured cells. Amounts of 
cDNA <1 pi, 2.5 pi and 5.0 pi) formed on RNA templates at three 
concentrations (0.5 pg/pl, 1.0 pg/pl and 2.0 pg/pl) were analysed. 
Increasing band intensities with increasing RNA concentrations and 
cDNA amounts, were noted. This was most obvious at lower RNA and 
cDNA concentrations.
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Fig. 3.5.3.2.1 Analysis, by densitometry, of MDR 1 band intensities 
for DLKPA-5F, as in Fig. 3.5.3.2.
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Fig. 3.5.3.3 Gel electrophoresis of products resulting from RT-PCR 
amplification of p-actin (383 bp) and MDR 1 (157 bp) cDNA formed on 
RNA templates extracted from DLKPA-2B cultured cells, ( ( i)  is 
co-amplification of p-actin and MDR 1; (ii) and (iii) are independant 
amplifications of MDR 1 and p-actin, respectively). The amounts of 
cDNA (1.0 pi, 2.5 pi and 5.0 pi) formed on RNA templates at two 
concentrations (0.5 pg/pl, 1.0 pg/pl and 2.0 pg/pl) were analysed 
(E1/R2).
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Fia. 3.5.3.3.1 Analysis, by densitometry, of MDR 1 band intensities 
for DLKPA-2B (E1/R2), as in Fig. 3.5.3.3.
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Fig. 3.5.3.4 Gel electrophoresis of products resulting from RT-PCR 
amplification of p-actin (383 bp) and MDR 1 (157 bp) cDNA formed on 
RNA templates extracted from DLKPA-2B cultured cells, ( ( i)  is 
co-amplification of p-actin and MDR 1; (ii) and (iii) are independant 
amplifications of MDR 1 and p-actin, respectively). The amounts of 
cDNA (1.0 pi, 2.5 pi and 5.0 pi) formed on RNA templates at two 
concentrations (0.5 pg/pl, 1.0 pg/pl and 2.0 pg/pl) were analysed 
(E2/R1).
n
230
RNA Concentration (pg/pl)
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o 2.5 ij\ cDNA
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Fig. 3.5.3.4.1 Analysis, by densitometry, of MDR 1 band intensities
for DLKPA-2B (E2/R1), as in Fig. 3.5.3.4.
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Fig. 3.5.3.5.1 Analysis, by densitometry, of MDR 1 band intensities
for DLKPA-2B (E2/R2).
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Fig. 3 .5 .3 .6  Gel electrophoresis of products resulting from RT-PCR 
amplification of p-actin (383 bp) and MDR 1 (1 57 bp) cDNA formed on 
RNA templates extracted from DLKPA-5F cultured cells, ( ( i )  is 
co-amplification of p-actin and MDR 1; (ii) and (iii) are independant 
amplifications of MDR 1 and p-actin, respectively). The amounts of 
cDNA (1 .0  pi, 2.5 pi and 5.0 pi) formed on RNA templates at two 
concentrations (0.125 pi, 0.25 pi and 0.5 pi) were analysed (E1 /R1).
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Fia. 3.5.3.6.1 Analysis, by densitometry, of MDR 1 band intensities
for DLKPA-5F (E1/R1), as in Fig. 3.5.3.6.
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Fig. 3 .5 .3 .7  Gel electrophoresis of products resulting from RT-PCR 
amplification of p-actin (383 bp) and MDR 1 (1 57 bp) cDNA formed on 
RNA templates extracted from DLKPA-5F cultured cells, ( ( i )  is 
co-amplification of p-actin and MDR 1; (ii) and (iii) are independant 
amplifications of MDR 1 and p-actin, respectively). The amounts of 
cDNA (1 .0  pi, 2.5 pi and 5.0 pi) formed on RNA templates at two 
concentrations (0.125 pi, 0.25 pi and 0.5 pi) were analysed (E1/R2).
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Fia. 3.5.3.7.1 Analysis, by densitometry, of MDR 1 band intensities
for DLKPA-5F (E1/R2), as in Fig. 3.5.3.7.
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Fig. 3 .5.3.8  Gel electrophoresis of products resulting from RT-PCR 
amplification of p-actin (383 bp) and MDR 1 (157 bp) cDNA formed on 
RNA templates extracted from DLKPA-5F cultured cells, ( ( i )  is 
co-amplification of p-actin and MDR 1; (ii) and (iii) are independant 
amplifications of MDR 1 and p-actin, respectively). The amounts of 
cDNA (1 .0 pI, 2.5 pI and 5.0 pi) formed on RNA templates at two 
concentrations (0.1 25 pi, 0.25 pi and 0.5 pi) were analysed (E2/R1).
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Fig. 3.5.3.8.1 Analysis, by densitometry, of MDR 1 band intensities
for DLKPA-5F (E2/R1), as in Fig. 3.S.3.8.
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Fia. 3.5.3.9.1 Analysis, by densitometry, of MDR 1 band intensities
for DLKPA-5F (E2/R2).
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3.6 Quantitative RT-PCR
Q u a n t i t a t i v e  a n a l y s i s  o f  MDR 1 mRNA t r a n s c r i p t  l e v e l s  w e r e  
a t t e m p t e d ,  u s i n g  a n  e x o g e n o u s  c o n t r o l / s t a n d a r d  ( c o n s t r u c t e d  b y  
D r .  C a r m e l  D a l y ,  a s  d e s c r i b e d  i n  2 . 1 1 ) .  T h i s  c o n t r o l ,  w h i c h  i s  
a m p l i f i e d  d u r i n g  t h e  PCR r e a c t i o n  w i t h  t h e  s a m e  p r i m e r s  ( T a b l e
3 . 1 )  a s  cDNA f o r m e d  o n  t h e  e n d o g e n o u s  MDR 1 mRNA t e m p l a t e  ( b u t  
w i t h  a  d i f f e r e n t  i n t e r v e n i n g  s e q u e n c e  b e t w e e n  t h e  p r i m e r s ,  
r e s u l t s  i n  t h e  f o r m a t i o n  o f  a  3 3 1  b p  p r o d u c t .  T h i s  p r o d u c t  i s  
e a s i l y  d i s t i n g u i s h e d  f r o m  t h e  e n d o g e n o u s  1 57  b p  a m p l i f i e d  
p r o d u c t ,  w h e n  s e p a r a t e d  b y  g e l  e l e c t r o p h o r e s i s  t h r o u g h  a  4 % 
a g a r o s e  g e l .
T h e  a i m  o f  u s i n g  s u c h  a n  e x o g e n o u s  c o m p e t i t i v e  c o n t r o l  i s  
t o  c a l c u l a t e  t h e  a b s o l u t e  l e v e l s  o f  t h e  t a r g e t  mRNA. T h i s  w a s  
d o n e  b y  t i t r a t i n g  a  ( c o n s t a n t )  u n k n o w n  a m o u n t  o f  cDNA t e m p l a t e  
t o  b e  q u a n t i f i e d  a g a i n s t  a  d i l u t i o n  s e r i e s  o f  k n o w n  
c o n c e n t r a t i o n s  o f  e x o g e n o u s  c o n t r o l .  S i n c e  t h e  a m o u n t  o f  c o n t r o l  
i s  k n o w n ,  i t  m a y  b e  a s s u m e d  t h a t  w h e n  t h e  PCR p r o d u c t s  r e s u l t i n g  
f r o m  t h e  e n d o g e n o u s  mRNA a n d  c o n t r o l  a r e  e q u a l ,  t h e  a m o u n t  o f  
t h e  s p e c i f i c  mRNA u n d e r  a n a l y s i s  i n  t h e  o r i g i n a l  s a m p l e  i s  e q u a l  
t o  t h e  a m o u n t  o f  t e m p l a t e  a d d e d .  F r o m  t h i s ,  t h e  n u m b e r  o f  
m o l e c u l e s  o f  t a r g e t  mRNA i s ,  t h e o r e t i c a l l y ,  d e d u c i b l e  u s i n g  
s i m p l e  m a t h e m a t i c s .
T h e  a m o u n t  o f  e x o g e n o u s  c o n t r o l  i n  g r a m s  i s  k n o w n .  G r a m s  
a r e  c o n v e r t e d  t o  m o l e s  u s i n g  t h e  c o n s t a n t  3 0 9 ,  w h i c h  i s  t h e  
a v e r a g e  m o l e c u l a r  w e i g h t  o f  t h e  A, T ,  C a n d  G b a s e s  ( m o l e c u l a r  
w e i g h t  o f  b a s e s :  A = 3 1 2 . 2 ;  C = 2 8 8 . 2 ;  G = 3 2 8 . 2 ;  T = 3 0 3 . 2 ) .  
M o l e c u l e s  o f  c o n t r o l  p e r  m l  i s  t h e n  c a l c u l a t e d ,  u s i n g  t h e  
f o l l o w i n g  f o r m u l a  ( P h a r m a c i a  G e n Q u a n t  S y s t e m ) :
M o l e c u l e s / m l  = Cone.  ( j i g /m l ) X 6 . 0 2 3  X 1023 /  
M o l e c u l a r  W eight  X 106
(A s  a n  a d d i t i o n a l  r e f i n e m e n t ,  t h i s  f o r m u l a  c a n  b e  f u r t h e r  
m o d i f i e d  b y  a c c o u n t i n g  f o r  i t s  p h o s p h o r y l a t e d  o r  p h o s p h o r y l a t e d
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s t a t e  o f  t h e  s e q u e n c e .  I f  p r e c i s e  c a l c u l a t i o n s  a r e  r e q u i r e d ,  
t h e  i n d i v i d u a l  b a s e  m o l e c u l a r  w e i g h t s  a n d  t h e  m o l e c u l a r  w e i g h t  
o f  U r a c i l  ( 2 8 9 . 2 )  i n  t h e  mRNA b e i n g  q u a n t i f i e d ,  c a n  b e  t a k e n  
i n t o  a c c o u n t ) .
A p r e l i m i n a r y  e x p e r i m e n t ,  u s i n g  t h i s  e x o g e n o u s  c o n t r o l  t o  
a n a l y s e  t h e  a m o u n t s  o f  t h e  MDR 1 t r a n s c r i p t  i n  RNA e x t r a c t e d  
( 0 . 2 5  v q / y l  RNA; 2 . 5  p i  cDNA) f r o m  DLKPA-5F c e l l s  i s  i l l u s t r a t e d  
i n  F i g .  3 . 6 . 1 .  T h e  a m o u n t s  o f  e x o g e n o u s  c o n t r o l  i n c l u d e d  w e r e  2 
n g / ^ 1 ,  1 n g / / j l ,  0 . 5  n g / ^ 1 ,  0 . 2 5  n q / p l ,  0 . 1 2 5  n g / p l ,  0 . 0 6 3  n q / p l  
a n d  0 . 0 3 1  n q / p l .  E a c h  PCR r e a c t i o n  w a s  s e t  u p  i n  d u p l i c a t e .  As 
i n d i c a t e d  i n  F i g .  3 . 6 . 1 . 1 ( i ) ,  b o t h  t h e  e x o g e n o u s  c o n t r o l  a n d  MDR 
1 cDNA d e n s i t o m e t r y  r e a d i n g s ,  a n d  t h o s e  o f  t h e  e x o g e n o u s  c o n t r o l  
w h e n  a m p l i f i e d  s e p a r a t e l y  ( F i g .  3 . 6 . 1 . 1 . ( i i  ) )  , w h e n  p l o t t e d ,  
p r o d u c e  c u r v e s  s i m i l a r  i n  f o r m  t o  t h a t  o f  t h e  DNA c o n t r o l s  u s e d  
t o  a n a l y s e  t h e  e f f i c i e n c y  o f  t h e  d e n s i t o m e t e r  ( s e e  S e c t i o n
3 . 5 . 2 ) .  T h i s ,  a g a i n ,  s u g g e s t s  t h a t  t h e  d e n s i t o m e t e r  a n a l y s i s  i s  
n o t  c o m p l e t e l y  a c c u r a t e  a n d  t h a t  t h e  g e l  p h o t o g r a p h s  s h o u l d  a l s o  
b e  a n a l y s e d  v i s u a l l y .  F r o m  t h i s  e x p e r i m e n t ,  h o w e v e r ,  i t  s e e m s  
t h a t  t h e  i n t e r n a l  c o n t r o l  r a n g e  o f  c o n c e n t r a t i o n s  c h o s e n  w a s  t o o  
g r e a t ,  a n d  t h a t  a  l o w e r  c o n c e n t r a t i o n  r a n g e  i s  r e q u i r e d  t o  
q u a n t i f y  t h e  MDR 1 mRNA l e v e l s  i n  t h i s  DLKPA-5F e x t r a c t .
I n  s u b s e q u e n t  PCR r e a c t i o n s , t h e  r a n g e  o f  e x o g e n o u s  c o n t r o l  
c o n c e n t r a t i o n s  w a s  r e d u c e d  t o  b e t w e e n  0 . 2 5  n q / p l  -  0 . 0 0 2  n q / p i l .  
T h e  e x o g e n o u s  c o n t r o l  c o n c e n t r a t i o n s  w e r e  t i t r a t e d  a g a i n s t  cDNA 
f o r m e d  o n  mRNA t e m p l a t e s  e x t r a c t e d  f r o m  DLKPA-2B a n d  DLKPA-5F 
c e l l  l i n e s .  To a c t  a s  a n  e n d o g e n o u s  c o n t r o l  f o r  t h e  cDNA, P 2 -
m i c r o g l o b u l i n  w a s  a l s o  a m p l i f i e d .  T h i s  c o n t r o l  w a s  f a v o u r e d  o v e r  
( 3 - a c t i n  i n  t h e s e  e x p e r i m e n t s  a s  i t  i s  m o r e  e a s y  d i s t i n g u i s h e d
f r o m  t h e  c o n t r o l  d u e  t o  t h e i r  s i z e  d i f f e r e n c e s  ( e x o g e n o u s  
c o n t r o l  = 3 31  b p ;  ( 3 - a c t i n  = 383  b p ;  f 3 2 - n i i c r o g l o b u l i n  = 114  b p )  .
T h i s  a n a l y s i s  w a s  p e r f o r m e d  o n  a  n u m b e r  o f  RNA a n d  cDNA 
c o n c e n t r a t i o n s .
By v i s u a l  a n a l y s i s ,  t h e  a m o u n t  o f  MDR 1 mRNA i n  t h i s  
c o n c e n t r a t i o n  o f  DLKPA-2B t o t a l  RNA i s  a p p r o x i m a t e l y  e q u i v a l e n t  
t o  0 . 0 1 6  n q / p l  e x o g e n o u s  c o n t r o l ,  a n d  t h a t  o f  D L K P A - 5 F ,
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a p p r o x i m a t e l y  e q u i v a l e n t  t o  0 . 0 3 1  n g / p l  e x o g e n o u s  c o n t r o l .  F rom  
t h i s ,  t h e  a m o u n t  o f  MDR 1 mRNA i n  t h e  D LK PA -5F  c e l l s  i s  
t h e r e f o r e  e s t i m a t e d  t o  b e  a p p r o x i m a t e l y  t w i c e  t h a t  i n  t h e  DLKPA- 
2B c e l l s .  H o w e v e r ,  i t  m u s t  a l s o  b e  t a k e n  i n t o  a c c o u n t  t h a t  t h e  
c o n c e n t r a t i o n  o f  i n i t i a l  DLKPA-5F t e m p l a t e  w a s  i s  4 t i m e s  t h a t  
o f  t h e  DLKPA-2B c e l l s .  O v e r a l l ,  t h e  MDR 1 mRNA l e v e l s  i n  DLKPA- 
5F c e l l s  i s  e s t i m a t e d  t o  b e  a l m o s t  8 t i m e s  t h a t  i n  t h e  DLKPA-2B 
c e l l s .
D e n s i t o m e t r y  a n a l y s i s  w a s  a l s o  p e r f o r m e d  o n  t h e s e  b a n d s  s o  
t h a t  a n  e x o g e n o u s  c o n t r o l  s t a n d a r d  c u r v e  c o u l d  b e  d r a w n ,  a g a i n s t  
w h i c h  t h e  MDR 1 mRNA l e v e l s  i n  t h e  DLK PA -2B a n d  DLKPA-5F 
e x t r a c t s  c o u l d  b e  e x t r a p o l a t e d  i . e .  t h e  a m o u n t  o f  e x o g e n o u s  
c o n t r o l  w h i c h  p r o d u c e s  t h e  s a m e  d e n s i t o m e t r y  r e a d i n g  d e t e r m i n e d  
b y  t h e  p o i n t  o f  i n t e r s e c t i o n  o f  t h e  c o r r e s p o n d i n g  l i n e s  o n  t h e  
g r a p h .  T h i s  ( o f  c o u r s e  a s s u m i n g  a c c u r a t e  r e a d i n g s  b y  t h e  
d e n s i t o m e t e r )  w a s  d o n e  t o  g i v e  a n  i n d i c a t i o n  o f  t h e  r e s u l t s  
o b t a i n a b l e .  T h e  r e s u l t s  f r o m  t h i s  a n a l y s i s  a r e  s h o w n  i n  F i g .  
3 . 6 . 2 . 1 .
T h e  c o n c e n t r a t i o n  o f  t h e  e x o g e n o u s  c o n t r o l  a t  t h e  p o i n t  
w h e r e  t h e  c u r v e s  i n t e r s e c t  w a s ,  t h e r e f o r e ,  c a l c u l a t e d  u s i n g  t h e  
a s s u m p t i o n  t h a t  a t  t h e  p o i n t  o f  i n t e r s e c t i o n  t h e  e q u a t i o n  o f  
b o t h  c u r v e s  a r e  e q u a l .
DLKPA-2B:
E x o g e n o u s  C o n t r o l  C u r v e  E q n . : y  = 2 3 . 3 7  + 5 . 5  l o g ( X )
MDR 1 C u r v e  E q n . :  y  = 5 . 1 9  -  4 . 0  l o g ( X )
( w h e r e  y  = D e n s i t o m e t r y  r e a d i n g  a n d  x  = E x o g e n o u s  C o n t r o l  
c o n c e n t r a t i o n )
A t  t h e  p o i n t  o f  i n t e r s e c t i o n  -
2 3 . 3 7  + 5 . 5  l o g ( x )  = 5 . 1 9  + 4 . 0  l o g ( x )  
l o g ( x )  = -  1 . 9 1  
x  = 0 . 0 1 2
i . e .  E x o g e n o u s  C o n t r o l  C o n e .  = 0 . 0 1 2  n g / ^ 1
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DLKPA-5F:
E x o g e n o u s  C o n t r o l  C u r v e  E q n . : y  = 2 3 . 7 8  + 7 . 2 5  l o g ( X )
MDR 1 C u r v e  E q n . :  y  = 8 . 5 8  -  1 . 8 5  l o g ( X )
( w h e r e  y  = D e n s i t o m e t r y  r e a d i n g  a n d  x  = E x o g e n o u s  C o n t r o l
c o n c e n t r a t i o n )
A t  t h e  p o i n t  o f  i n t e r s e c t i o n  -
2 3 . 7 8  + 7 . 2 5  l o g ( x )  = 8 . 5 8  + 1 . 8 5  l o g ( x )  
l o g ( x )  = -  1 . 6  
x  = 0 . 0 2 5
i . e .  E x o g e n o u s  C o n t r o l  C o n e .  = 0 . 0 2 5  n g / j u l
T h e  r e l a t i o n s h i p  b e t w e e n  t h e  MDR 1 mRNA c o n c e n t r a t i o n  i n  t h e
DLKPA-2B ( u s i n g  1 . 0  p g / p l  i n i t i a l  RNA t e m p l a t e )  a n d  DLKPA-5F 
c e l l s  ( u s i n g  0 . 2 5  pg/pil i n i t i a l  RNA t e m p l a t e )  i s  s i m i l a r  t o  t h a t  
o b s e r v e d  f r o m  t h e s e  g e l s  b y  v i s u a l  a n a l y s i s ,  a l t h o u g h  b y  
d e n s i t o m e t r y  a n a l y s i s  t h e  o v e r a l l  MDR 1 mRNA l e v e l s  i n  t h e  
DLKPA-5F c e l l s  i s ,  a p p a r e n t l y ,  s l i g h t l y  m o r e  t h a n  8 t i m e s  t h a t  
i n  t h e  DLKPA-2B c e l l s .
U s i n g  t h e  f o r m u l a :
M o l e c u l e s / m l  = Cone,  (¿¿g/ml) X 6 .0 2 3  X 102 3 /
M o le c u la r  W eight X 106
t h e  n u m b e r  o f  e x o g e n o u s  c o n t r o l  m o l e c u l e s  a t  t h i s  p o i n t  c a n  b e  
c a l c u l a t e d .
DLKPA-2B:
m o l e c u l e s / m l  = 0 . 0 1 2  X 6 . 0 2 3 X 1 0 23 /  1 . 0 2  X 1 0 5 X 106 = 7 . 0 9  X I Q 10 
DLKPA-5F:
m o l e c u l e s / m l  = 0 . 0 2 5  X 6 . 0 2 3 X 1 0 23 /  1 . 0 2  X 1 0 5 X106 = 1 . 4 7  X 1 0 11
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F i g s .  3 . 6 . 1  a n d  3 . 6 . 2  G e l  e l e c t r o p h o r e s i s  o f  p r o d u c t s  f o r m e d  
a f t e r  c o - a m p l i f i c a t i o n  o f  a n  MDR 1 e x o g e n o u s  c o m p e t i t i v e  c o n t r o l  
( 3 3 1  b p )  w i t h  MDR 1 ( 1 5 7  b p )  a n d  P 2 - m i c r o g l o b u l i n  cDNA f o r m e d  o n  
e n d o g e n o u s  mRNA t e m p l a t e s  e x t r a c t e d  f r o m  ( i )  DLKPA-2B a n d  ( i i )  
DLKPA c e l l  l i n e s .  E n d o g e n o u s  MDR 1 mRNA i s  t h e  t a r g e t  t o  b e  
q u a n t i f i e d  a n d  f ^ - n i i c r o g l o b u l i n ,  t h e  e n d o g e n o u s  p o s i t i v e  
c o n t r o l .  S e r i a l  d i l u t i o n s  o f  e x o g e n o u s  c o n t r o l  w e r e  a m p l i f i e d  
w i t h  a  c o n s t a n t  a m o u n t s  o f  t h e  t a r g e t  cDNA t o  b e  q u a n t i f i e d .  T h e  
l e f t - h a n d  l a n e  o f  e a c h  g e l  c o n t a i n s  t h e  DNA m o l e c u l a r  w e i g h t  
m a r k e r  c o n s i s t i n g  o f  22 f r a g m e n t s  o f  t h e  f o l l o w i n g  b a s e - p a i r  
s i z e s :  5 8 7 ,  5 4 0 ,  5 0 4 ,  4 5 8 ,  4 3 4 ,  2 6 7 ,  2 3 4 ,  2 1 3 ,  1 9 2 ,  1 8 4 ,  1 2 4 ,  
1 2 3 ,  1 0 4 ,  8 9 ,  8 0 ,  6 4 ,  5 7 ,  5 1 ,  2 1 ,  1 8 ,  11 a n d  8 b a s e  p a i r s ,  b y  
w h i c h  t h e  a m p l i c o n s  c o u l d  b e  i d e n t i f i e d .
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(i) Exogenous 
Control 
MDR 1
Fig. 3 .6.1 ( i )  Gel electrophoresis of products  formed after
co-amplification of an MDR 1 exogenous competitive control (331 bp) 
with cDNA formed on endogenous MDR 1 mRNA templates ( 157  bp), 
extracted from DLKPA-5F cells using 2.5 pi of cDNA formed on a 0.25 
pg/pl RNA template. Serial dilutions of exogenous control, ranging from 
2 ng/pl to 0.031 ng/pl were amplified, in duplicate, with a constant 
concentration of the target MDR 1 cDNA to be quantified. From this 
preliminary analysis, it seems that the concentrations of exogenous 
control are too great for estimating the endogenous MDR 1 concentration. 
A range of lower concentrations should apparently be used.
(ii) The same range of concentrations of exogenous competitive control 
(2 ng/pl to 0.031 ng/pl) were amplified independently, to establish if 
co-amplification with the endogenous MDR 1 gene product limited its 
amplification in any way. 7A!-
Internal Control (ng/pl)
Internal Control (ng)
Fig. 3.6.1.1 (i) Relationship between concentrations of exogenous 
control and densitometry readings (after background subtraction) of the 
intensities of the resulting bands. The densitometry readings of the 
corresponding bands resulting from target MDR 1 cDNA amplification in 
each sample, were also plotted on this graph ( i . e .  analysis of Fig. 
3.6.1(i)).
(ii) Plot of exogenous control concentrations versus corresponding 
densitometry readings, after background subtraction (as illustrated in 
Fig. 3.6.1 (ii)).
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Fig. 3.6.2 2.5 pi of cDNA formed on a 1.0 /vg/^l RNA template, in the 
case of (i) DLKPA-2B and on a 0.25 pg/pl RNA template extracted from 
(ii) DLKPA-5F cells were co-amplified, respectively, with the exogenous 
competitive control.
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DLKPA - 2B
Exogenous Control (ng/pl)
DLKPA - 5F
Exogenous Control (ng//vl)
Fig. 3.6.2.1 Densitometry analysis of results illustrated in Fig 3.6.1 
when titrating a range of known concentrations in exogenous control 
(MDR 1) against a constant amount of cDNA (2.5 pi) formed on 1.0 pg/pl 
RNA template in the case of DLKPA-2B, and 0.25 pg/pl in the case of 
DLKPA-5 F.
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3.7 Protein Analysis using Western Blotting Techniques.
A l t e r a t i o n s  i n  t h e  e x p r e s s i o n  o f  c e r t a i n  p r o t e i n s  
a s s o c i a t e d  w i t h  m u l t i p l e  d r u g  r e s i s t a n c e  w e r e  i n v e s t i g a t e d  b y  
w e s t e r n  b l o t  a n a l y s i s ,  t o  e s t a b l i s h  i f  c h a n g e s  n o t e d  a t  t h e  g e n e  
t r a n s c r i p t  l e v e l  w e r e  i n d i c a t i v e  o f  t h e  c o r r e s p o n d i n g  p r o t e i n  
l e v e l s .  L e v e l s  o f  p - g l y c o p r o t e i n  w e r e  s t u d i e d  i n  DLKP, i t s  
m u l t i p l e  d r u g  r e s i s t a n t  v a r i a n t  DLKPA, c l o n e s  i s o l a t e d  f r o m  
DLKPA, i n c l u d i n g  D L K P A -2B , D L K PS -6B  a n d  D LK PA -5F  a n d  V P - 1 6 -  
s e l e c t e d  MDR v a r i a n t s ,  D L K P /V P -3  a n d  D L K P / V P - 8 .  A l t e r a t i o n s  i n  
T o p o i s o m e r a s e  I I  p r o t e i n  l e v e l s ,  a n d  t h a t  o f  i t s  a  s u b u n i t  w e r e
a n a l y s e d  i n  DLKP, DLKPA, D L K P/V P -3  a n d  D L K P /V P -8 .
3 . 7 . 1  W estern  B l o t  A n a l y s i s  o f  P - g l y c o p r o t e i n  L e v e l s
W e s t e r n  b l o t  a n a l y s i s  o f  p - g l y c o p r o t e i n  w a s  p e r f o r m e d  o n  
c e l l u l a r  m e m b r a n e  p r e p a r a t i o n s  u s i n g  t h e  a n t i - p - g l y c o p r o t e i n  
a n t i b o d y ,  C 2 1 9 ,  t o  d e t e c t  t h i s  170  kD a  p r o t e i n .  T h e  r e s u l t s  
( F i g .  3 . 7 . 1 ;  T a b l e  3 . 7 . 1 . 1 )  s u g g e s t  t h a t  t h i s  p r o t e i n  i s  o v e r ­
e x p r e s s e d  i n  a l l  MDR c e l l  l i n e s  s t u d i e d ,  t o  a  g r e a t e r  o r  l e s s e r  
e x t e n t .  P - g l y c o p r o t e i n  w a s  n o t  d e t e c t e d  i n  t h e  s e n s i t i v e  f o r m  o f  
t h e  c e l l  l i n e ,  DLKP.
CELL LINE /  CLONE P - q p  LEVEL
DLKP/VP- 3 0 . 1 4
DLKP/VP- 8 0 . 0 7
DLKP 0 . 0 0
DLKPA 0 . 0 3
DLKPA-2B 0 . 0 9
DLKPA-6B 0 . 0 4
DLKPA-5F 0 . 0 1
Table 3.7.1.1: Densitometry analysis of p-glycoprotein levels detected 
by western blotting
T h e  m o s t  s i g n i f i c a n t  i n c r e a s e s  i n  p - g l y c o p r o t e i n  l e v e l s  
w i t h  m u l t i p l e  d r u g  r e s i s t a n c e  w e r e  d e t e c t e d  i n  t h e  V P - 1 6
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s e l e c t e d  c e l l  l i n e s .  D L K P / V P - 3 ,  t h e  l e s s e r  r e s i s t a n t  v a r i a n t  
e x p r e s s e d  h i g h e r  l e v e l s  o f  t h i s  p r o t e i n  t h a n  t h e  m o r e  r e s i s t a n t  
c e l l  l i n e ,  D L K P / V P - 8 .  E l e v a t e d  l e v e l s  o f  p - g l y c o p r o t e i n  
e x p r e s s i o n  i n  t h e  a d r i a m y c i n - s e l e c t e d  c e l l  l i n e  a n d  i t s  c l o n e d  
p o p u l a t i o n s  w e r e  a p p a r e n t ,  b u t  t o  a  l e s s e r  e x t e n t  t h a n  i n  t h e  
V P - 1 6  s e l e c t e d  c e l l  l i n e s .  As w i t h  t h e  V P - 1 6  s e l e c t e d  c e l l  
l i n e s , t h e  l e v e l s  o f  p - g l y c o p r o t e i n  d i d  n o t  c o r r e l a t e  w i t h  t h e i r  
m u l t i p l e  d r u g  r e s i s t a n t  r a n k i n g  o r d e r .  D L K P A - 5 F ,  t h e  m o s t  
r e s i s t a n t  c l o n e  s e e m e d  t o  e x p r e s s  l o w e s t  l e v e l s  o f  
i m m u n o d e t e c t a b l e  p - g l y c o p r o t e i n ,  f o l l o w e d  b y  DLKPA, t h e  
h e t e r o g e n o u s  p o p u l a t i o n  o f  t h e  r e s i s t a n t  v a r i a n t s .  T h e  g r e a t e s t  
i n c r e a s e s  i n  p - g l y c o p r o t e i n  i n  t h e  DLKPA v a r i a n t s  w a s  f o u n d  t o  
b e  f o r  DLKPA-2B, t h e  l e a s t  r e s i s t a n t  c l o n e .
3 . 7 . 2  W e stern  B l o t  A n a l y s i s  o f  T o p o is o m e r a se  I I  l e v e l s .
L e v e l s  o f  t h e  n u c l e a r  e n z y m e  T o p o i s o m e r a s e  I I  a n d  i t s  a  
s u b u n i t  w e r e  a n a l y s e d  i n  n u c l e a r  e x t r a c t s  f r o m  v a r i a n t s  o f  t h e  
DLKP c e l l  l i n e .  T h i s  a n a l y s i s  w a s  d o n e  u s i n g  a  p o l y c l o n a l  
a n t i b o d y  r a i s e d  a g a i n s t  T o p o i s o m e r a s e  I I  w h i c h  d e t e c t s  b o t h  t h e  
170  k D a  ( T o p o i s o m e r a s e  I l a )  a n d  1 8 0  k D a  ( T o p o i s o m e r a s e  I I P )
i s o f o r m s  o f  t h e  e n z y m e  a n d  a  m o n o c l o n a l  a n t i b o d y  s p e c i f i c  f o r  
t h e  a  s u b u n i t ,  r e s p e c t i v e l y .  As i l l u s t r a t e d  i n  F i g .  3 . 7 . 2 ( i ) .
R e s u l t s  f r o m  a n a l y s i s  w i t h  t h e  p o l y c l o n a l  a n t i b o d y  s h o w e d  t h a t  
a l l  c e l l  l i n e s  s t u d i e d  p o s s e s s e d  i m m u n o l o g i c a l l y  r e a c t i v e  
T o p o i s o m e r a s e  I I ,  w i t h  r e d u c e d  l e v e l s  p r e s e n t  i n  t h e  m u l t i p l e  
d r u g  r e s i s t a n t  v a r i a n t s ,  DLKPA a n d  D L K P / V P - 3 ,  i n  c o m p a r i s o n  t o  
t h e  s e n s i t i v e  c e l l  l i n e  ( T a b l e  3 . 7 . 2 . 1 ) .  A s l i g h t  i n c r e a s e  i n  
t h e  l e v e l  o f  t h i s  p r o t e i n  w a s  a p p a r e n t  i n  D L K P/V P -8  n u c l e a r  
e x t r a c t s .  H o w e v e r ,  t h e  d i f f e r e n c e s  d e t e c t e d  a r e  v e r y  s l i g h t ,  
e x c e p t  i n  t h e  c a s e  o f  DLKPA.
I t  i s  n o t  p o s s i b l e  t o  d e t e r m i n e  f r o m  t h i s  w e s t e r n  b l o t  
( F i g .  3 . 7 . 2 . 1 )  w h i c h  T o p o i s o m e r a s e  I I  i s o f o r m  i s  a l t e r e d  w i t h  
t h e  MDR p h e n o m e n o n ,  a s  t h e  i s o f o r m s  a r e  n o t  c l e a r l y  
d i s t i n g u i s h a b l e .  H o w e v e r ,  f r o m  t h e  a n a l y s i s  o f  T o p o i s o m e r a s e  
I l a ,  s p e c i f i c a l l y ,  u s i n g  t h e  m o n o c l o n a l  a n t i b o d y  d i r e c t e d
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a g a i n s t  t h e  a  s u b u n i t  o f  T o p o i s o m e r a s e  I I * ,  r e d u c e d  l e v e l s  o f  
t h i s  s u b - u n i t  w e r e  d e t e c t e d  i n  t h e  r e s i s t a n t  v a r i a n t s ,  i n  
c o m p a r i s o n  t o  DLKP ( F i g .  3 . 7 . 2 ( H ) ;  T a b l e  3 . 7 . 2 . 1 ) .  T h i s ,  a g a i n ,  
w a s  m o s t  o b v i o u s  i n  t h e  DLKPA c e l l  l i n e .  A s i g n i f i c a n t  d e c r e a s e  
i n  T o p o i s o m e r a s e  I l a  p r o t e i n  l e v e l s  w a s  a l s o  a p p a r e n t  i n  t h e
m o s t  r e s i s t a n t  V P - 1 6  s e l e c t e d  v a r i a n t ,  D L K P / V P - 8 .  L e v e l s  o f  
T o p o i s o m e r a s e  I l a  s e e m e d  t o  b e  o n l y  s l i g h t l y  a l t e r e d  i n  t h e
DLK P/VP-3  c e l l  l i n e .
C e l l  L i n e T o p o  I I T o p o  I I  a
DLKPA 0 . 7 6 0 . 1 6
DLKP 0 . 9 0 0 . 5 2
DLKP/VP- 3 0 . 8 2 0 . 4 4
DLKP/VP-8 0 . 9 9 0 . 3 7
Table 3.7.2.1: Densitometry analysis of Topoisomerase II and
Topoisomerase Ila detection by Western blotting.
* An e x t r a  b a n d  w a s  o b s e r v e d  n e a r  t h e  e n d  o f  t h e  T o p o i s o m e r a s e  
I l a  W e s t e r n  b l o t .  T h i s  e x t r a  b a n d  w a s  a l s o  d e t e c t e d  i n  t h e
n e g a t i v e  c o n t r o l ,  s u g g e s t i n g  t h a t  i t  i s  t h e  r e s u l t  o f  n o n ­
s p e c i f i c  b i n d i n g  o f  t h e  s e c o n d a r y  a n t i b o d y .
251
COI CO1 CO CO 11CL CL C\J ID LO>N >N < <
<
<
t
<CL CL Cl CL CL 0L CL
_1 _l _J _l
o o O o o Q Q
(i)
180 KDa _
GO
180 KDa
Fia. 3.7.1 Western blot detection of p-glycoprotein in cell membrane 
preparations from DLKP variants, using C219 antibody. In both (i) the 
positive blot and (ii) the negative blot, 10 f j g  of protein was loaded per 
lane (as indicated for the positive blot). The blotting procedures for both
(i) and (ii) were identical, except that the positive blot was incubated 
with a monoclonal antibody, C219, directed against p-glycoprotein, 
whilst for the negative blot, the primary antibody was replaced with an 
equal volume of antibody diluent. The size of the detected protein (170 
kDa) was verified using the molecular weight markers (ran in the 
left-hand lane on the positive blot and the right-hand lane on the 
negative blot).
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F ig . 3 . 7 . 2  ( i )  Weste rn  b lo t  d e te c t io n  o f  Topo isomerase  II p ro te in  in nuc lear e x t ra c ts ,
iso la ted  f rom  DLKP va r ian ts . For bo th  the  pos i t iv e  ( le f t -h a n d )  and nega t ive  ( r ig h t -h and )  
b lo ts , 35 pg o f p ro te in  was loaded per lane. The procedures fo r  bo th  b lo ts  were identica l,  
excep t th a t  the  pos i t ive  b lo t was incuba ted  w i th  a po lyc lona l an t ibody  d irec ted  against  
Topo isomerase II, w h i ls t th e  nega tive  b lo t was incuba ted w ith  pre- immune serum. Molecular 
we igh t markers were ran in the le f t-hand lane o f the pos it ive  b lo t and the  r igh t-hand lane o f  
the negative blot.
( i i )  W este rn b lo t d e te c t io n  o f  Topo isomerase lla in nuclear e x t ra c ts  from  DLKP va r ian ts ,  
using a monoc lona l a n t ib o d y  d i re c te d  aga in s t th is  p ro te in .  For the  nega t ive  co n t ro l  
( r ig f j t -h a nd  b lo t ) ,  the > pr imary an t ibody  was replaced w ith  an equal vo lume o f pre- immune  
serum , w i th  the rema inder o f  the b lo t t in g  p rocedure  pe r fo rm ed  as fo r  the  pos i t iv e  b lo t  
( le f t - h a n d  b lo t ) .  In all cases, 35 /jg o f  p ro te in  was loaded per lane. Molecu lar we igh t  
markers were ran in the  le f t -hand  lane o f the pos it ive  b lo t and the  r igh t-hand lane o f the  
negative blot.
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3.8 Induction of MDRl Gene Expression.
P o s s i b l e  i n d u c t i o n  o f  MDR 1 g e n e  e x p r e s s i o n  b y  e x p o s i n g  
c u l t u r e d  c e l l s  t o  a  c h e m o t h e r a p e u t i c  d r u g ,  f o r  a  r e l a t i v e l y  
s h o r t  p e r i o d  o f  t i m e ,  w a s  a t t e m p t e d .  T h i s  s t u d y  i n v o l v e d  
e x p o s i n g  p o p u l a t i o n s  o f  DLKP c e l l s  a n d  OAW42 c e l l s  t o  t w o  
c o n c e n t r a t i o n s  o f  a d r i a m y c i n  ( 0 . 1  p g / p l  a n d  1 . 0  p g / j j l )  u n t i l  
o b v i o u s  s i g n s  o f  s t r e s s  w e r e  a p p a r e n t ,  a s  d e s c r i b e d  b y  C h a u d b a r y  
a n d  R o n i n s o n  ( 1 9 9 3 ) ,  f o r  72 h o u r s .  P o s s i b l e  a l t e r a t i o n s  i n  MDR 
1 ,  T o p o i s o m e r a s e  I I ,  MRP o r  GST jt t r a n s c r i p t  l e v e l s  w e r e
a n a l y s e d  b y  " i n  s i t u"  RT-PCR u s i n g  m u l t i p l e x  p r i m e r s .
As i l l u s t r a t e d  i n  F i g .  3 . 8 . 1 ,  e x p o s u r e  o f  DLKP c u l t u r e d  
c e l l s  t o  a d r i a m y c i n  r e s u l t e d  i n  i n c r e a s e d  c y t o p l a s m i c  
g r a n u l a r i t y  a n d  v a c u o l a r  s p a c e s . T h e  c e l l s  l o s t  t h e i r  r o u n d e d  
s h a p e ,  s t r e t c h i n g  i n t o  l o n g ,  t h i n  c e l l s  w i t h  e x t e n d e d  p r o c e s s e s  
c o n t a c t i n g  n e i g h b o u r i n g  c e l l s .  T h e s e  c h a r a c t e r i s t i c s  w e r e  m o s t  
p r o n o u n c e d  a t  t h e  h i g h e r  d r u g  c o n c e n t r a t i o n s .  S i m i l a r l y ,  t h e  
p r e s e n c e  o f  t h e s e  c o n c e n t r a t i o n s  o f  a d r i a m y c i n  h a d  s i g n i f i c a n t  
e f f e c t s  o n  t h e  OAW42 c e l l  l i n e  ( F i g .  3 . 8 . 2 ) .  I n  a r e a s  o f  t h e  
f l a s k  w h e r e  t h e  c e l l s  h a d  r e a c h e d  n e a r - c o n f l u e n c y , t h e  p r e s e n c e  
o f  l a r g e  v a c u o l e s  i n  t h e  c y t o p l a s m i c  r e g i o n s  w e r e  n o t e d .  I n  l e s s  
d e n s e l y  p o p u l a t e d  a r e a s ,  t h e  c e l l s  w e r e  o u t - s t r e t c h e d  w i t h  s m a l l  
p r o t r u s i o n s  a c t i n g  a s  c o n t a c t s  b e t w e e n  c e l l s .
As i n d i c a t e d  i n  F i g .  3 . 8 . 3 ( i ) ,  n o  s i g n i f i c a n t  c h a n g e s  i n  
t h e  mRNA l e v e l s  s t u d i e d  w e r e  n o t e d  w i t h  t h e  l u n g  c e l l  l i n e ,  
f o l l o w i n g  e x p o s u r e  t o  e i t h e r  c o n c e n t r a t i o n  o f  d r u g ,  w h e n  
c o m p a r e d  t o  t h e  u n t r e a t e d  c e l l s .  H o w e v e r ,  i n d u c t i o n  o f  t h e  MDR 1 
mRNA l e v e l s  b y  a d r i a m y c i n  w a s  a p p a r e n t  i n  t h e  o v a r i a n  c e l l  l i n e ,  
f o l l o w i n g  e x p o s u r e  o f  t w o  i n d e p e n d e n t  s t o c k s  o f  t h i s  c e l l  l i n e .  
T h e  r e s u l t s  s e e m e d  t o  c o r r e l a t e  w i t h  t h e  c o n c e n t r a t i o n s  o f  d r u g  
a d d e d  ( F i g .  3 . 8 . 3 ( i i )  a n d  F i g .  3 . 8 . 3 ( i i i ) )  i . e .  a  s l i g h t  
i n c r e a s e  i n  MDR 1 t r a n s c r i p t  l e v e l s  o c c u r r e d  w i t h  t h e  p r e s e n c e  
o f  0 . 1  n g / y l  a d r i a m y c i n ,  w i t h  a  m o r e  p r o n o u n c e d  e f f e c t  o b s e r v e d  
f o l l o w i n g  e x p o s u r e  t o  t h e  h i g h e r  d r u g  c o n c e n t r a t i o n .  mRNA l e v e l s  
o f  T o p o i s o m e r a s e  I I ,  MRP, GST ut, o r  i n d e e d  p - a c t i n ,  w e r e  n o t
a p p a r e n t l y  a f f e c t e d  i n  t h i s  w a y .
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0,1 /jg/rvs!
1 ,0/i*g/rn!
Fig. 3 .8.1 Effects of short-term exposure of the drug sensitive lung 
ceil line, DLKP, to increasing concentrations of adriamycin.
2 5 5
Parent
0.1/jg/m!
ADR
1 .Opg/ml 
ADR
Fig. 3.8.2 Effects of short-term exposure of the drug sensitive ovarian 
cell line, OAW42, to increasing concentrations of adriamydn.
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l-lTOPO II 
—  MRP
OAW42
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Fig. 3.8.3 Gel electrophoresis of products resulting from i n  s i t u  RT-PCR 
analysis using multiplex primers to amplify p-actin (383 bp), GST  ^
(270 bp), Topoisomerase II (216 bp), MRP (203 bp) and MDR 1 (157 bp), in 
cDNA derived from cells following short-term exposure to adriamycin. 
Sensitive parent cell lines were also analysed as a control, (i) No 
obvious changes in gene transcript levels were observed in DLKP cells 
after exposure to adriamycin. (ii) Induction of MDR 1 expression in 
OAW42 cells seemed to occur. This observation was verified in a repeat 
experiment (iii) on an independent stock of OAW42 cells.
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3.9 Clinical Studies of MDR-Related Factors.
A n a l y s i s  o f  t r a n s c r i p t  l e v e l s  o f  M D R - r e l a t e d  f a c t o r s  i n  
c l i n i c a l  s i t u a t i o n s  ( a s  w e l l  a s  c u l t u r e d  c e l l s )  w a s  e v a l u a t e d  
w i t h  a l l  o f  t h e  p r i m e r  p a i r s  l i s t e d  i n  T a b l e  3 . 1
3 . 9 . 1  A n a l y s i s  o f  mRNA T r a n s c r i p t s  i n  "Fresh" T i s s u e s .
A m p l i f i c a t i o n  o f  cDNA r e p r e s e n t i n g  mRNA r e g i o n s  o f  MDR 1 ,  
MRP, GST Jt, T o p o i s o m e r a s e  I ,  T o p o i s o m e r a s e  I I ,  T o p o i s o m e r a s e  I l a  
a n d  T o p o i s o m e r a s e  11(3 a n d  | 3 - a c t i n  w a s  a t t e m p t e d  w i t h  RNA 
e x t r a c t e d  f r o m  b o t h  n o r m a l  a n d  t u m o u r  l u n g  b i o p s i e s .  T h i s  h a s  
b e e n  d o n e  s u c c e s s f u l l y ,  i n  t h i s  s t u d y ,  f o r  8 / 8  p a i r e d  l u n g  
n o r m a l  a n d  t u m o u r  b i o p s i e s  ( f o u r  o f  w h i c h  a r e  i l l u s t r a t e d  a s  
e x a m p l e s  i n  F i g s .  3 . 9 . 1  -  3 . 9 . 4 ) .
B i o p s i e s  t a k e n  a t  s u r g e r y  w e r e  p l a c e d  i n  ATCC c o m p l e t e  
m e d i u m  c o n t a i n i n g  a n t i b i o t i c  ( a s  d e s c r i b e d  i n  S e c t i o n  2 . 4 )  a n d  
w e r e  t h e n  t r a n s p o r t e d  t o  t h e  l a b o r a t o r y  w h e r e  t h e  RNA e x t r a c t i o n  
p r o c e d u r e  w a s  p e r f o r m e d  i n  a  l a m i n a r  f l o w  c a b i n e t ,  a s  f a r  a s  
p o s s i b l e .  A r e a s  o f  n e c r o s i s  w e r e  r e m o v e d  f r o m  t h e  b i o p s i e s ,  
w h i c h  w e r e  t h e n  r i n s e d  t w i c e  i n  D E P C - t r e a t e d  w a t e r .  F o l l o w i n g  
t h i s ,  t h e  t i s s u e  w a s  w r a p p e d  i n  t i n - f o i l  w h i c h  h a d  b e e n  b a k e d  a t  
1 8 0  °C f o r  a t  l e a s t  e i g h t  h o u r s .  T h i s  w a s  t h e n  i m m e r s e d  i n  
l i q u i d  n i t r o g e n  t o  " s n a p "  f r e e z e  t h e  t i s s u e ,  w h i c h  w a s  t h e n  
p u l v e r i s e d  b y  " s m a s h i n g "  t h e  f r o z e n - s o l i d  m a s s .  T h e  p r o c e d u r e  
f o r  e x t r a c t i n g  RNA f r o m  c u l t u r e d  c e l l s  w a s  t h e n  f o l l o w e d  ( s e e  
F i g .  2 . 1 0 . 1 . 1 ) .
T h e  MDR 1 ,  MRP, GST x ,  T o p o i s o m e r a s e  I ,  T o p o i s o m e r a s e  I I  
a n d  i t s  T o p o i s o m e r a s e  I l a  a n d  T o p o i s o m e r a s e  I I | 3  s u b u n i t  g e n e  
t r a n s c r i p t s  w e r e  r e v e r s e  t r a n s c r i b e d  a n d  a m p l i f i e d  s u c c e s s f u l l y  
i n  e a c h  o f  t h e  n o r m a l  a n d  t u m o u r  l u n g  b i o p s i e s  i n c l u d e d  i n  t h i s  
a n a l y s i s  ( F i g s .  3 . 9 . 1  -  3 . 9 . 4 ) .  As i n  t h e  c u l t u r e d  c e l l  s t u d i e s ,  
a m p l i f i c a t i o n  o f  t h e  CYPIA1 r e g i o n  d i d  n o t  o c c u r .  I n  t w o  o f  t h e  
e i g h t  c a s e s  s t u d i e d ,  MDR 1 mRNA r e g i o n s  w e r e  a p p a r e n t l y  o v e r ­
e x p r e s s e d  i n  t u m o u r s ,  c o m p a r e d  t o  n o r m a l  t i s s u e  ( e . g .  F i g .
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3 . 9 . 3 ) .  I n  a  f u r t h e r  t h r e e  c a s e s  ( e . g .  F i g s .  3 . 9 . 1  a n d  3 . 9 . 4 ) ,  
t h e  l e v e l s  o f  t h i s  g e n e  t r a n s c r i p t  s e e m e d  t o  b e  g r e a t e r  i n  
n o r m a l  l u n g  t h a n  i n  t u m o u r  t i s s u e .  No a m p l i f i c a t i o n  o f  t h i s  
r e g i o n  o c c u r r e d  i n  t h e  r e m a i n i n g  t h r e e  n o r m a l  o r  t u m o u r  RNA 
e x t r a c t s .  W h e t h e r  t h e  l a c k  o f  a m p l i f i c a t i o n  o f  t h i s  MDR 1 cDNA 
r e g i o n  i s  a  t r u e  i n d i c a t i o n  o f  t h e  l e v e l s  o f  t h i s  g e n e  
t r a n s c r i p t  i n  s o m e  n o r m a l  a n d  t u m o u r  l u n g  t i s s u e s  i s  n o t  
c e r t a i n .  I t  i s  p o s s i b l e  t h a t  t h i s  l a c k  o f  p r o d u c t  f o r m a t i o n  i s  
d u e  t o  d e g r a d a t i o n  o f  t h e  MDR 1 mRNA ( o r  a t  l e a s t ,  i t s  s p e c i f i c  
r e g i o n  u n d e r  s t u d y ) . Why t h i s  g e n e  t r a n s c r i p t  s h o u l d  b e  a f f e c t e d  
i n  t h i s  w a y  s o o n e r  t h a n  MRP, GST jt e t c .  h a s  n o t  y e t  b e e n
e s t a b l i s h e d .
A l t h o u g h  t h e  r e s u l t s  f r o m  t h i s  s t u d y  a r e  n o t  q u a n t i t a t i v e  
( a s  t h e  PCR r e a c t i o n  w a s  p e r f o r m e d  f o r  30 c y c l e s  i n  a l l  c a s e s ,  
a n d  s o  w a s  n o t  w i t h i n  t h e  e x p o n e n t i a l  p h a s e  o f  PCR p r o d u c t  
a c c u m u l a t i o n ) ,  i t  i s  c l e a r  t h a t  i s o l a t i o n  o f  i n t a c t  RNA a n d  
a n a l y s i s  o f  m a n y  g e n e  t r a n s c r i p t  l e v e l s  c a n  b e  s u c c e s s f u l l y  
a c h i e v e d  w i t h  b o t h  n o r m a l  a n d  t u m o u r  t i s s u e s  r e m o v e d  a t  l e a s t  
1 . 5  -  4 . 0  h o u r s  b e f o r e  p r o c e s s i n g .  M o r e  c a u t i o n  m u s t  b e
e x e r c i s e d ,  h o w e v e r ,  w h e n  a n a l y s i n g  s u c h  r e s u l t s ,  i n  c o m p a r i s o n  
t o  t h o s e  f r o m  c u l t u r e d  c e l l s .  T h i s  i s  b e c a u s e  c e r t a i n  mRNAs i n  
c l i n i c a l  b i o p i e s  may  b e  d e g r a d e d  i n  t h i s  t i m e  p e r i o d .  I n  t h e  
c a s e  o f  c u l t u r e d  c e l l s ,  t h e  mRNA i s  g e n e r a l l y  e x t r a c t e d  u n d e r  
i d e a l  c o n d i t i o n s  i . e .  f r o m  c e l l s  w h i c h  w e r e  i n  t h e i r  l o g  p h a s e  
o f  g r o w t h  i m m e d i a t e l y  p r i o r  t o  t h e i r  e x t r a c t i o n  a n d  s o  t h e  t u r n ­
o v e r  o f  mRNA m a y  b e  g r e a t e r .  F o r  e x a m p l e ,  i t  s h o u l d  b e  
c o n s i d e r e d  t h a t  t h e  l e s s  i n t e n s e  b a n d  r e p r e s e n t i n g  mRNA ( e . g .  
F i g s .  3 . 9 . 1  a n d  3 . 9 . 4 )  i n  t h e  t u m o u r  b i o p s i e s  i n  c o m p a r i s o n  t o  
n o r m a l  l u n g  t i s s u e  may b e  d u e  t o  mRNA d e g r a d a t i o n  o r  d e c r e a s e d  
g e n e  e x p r e s s i o n .
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o f  MDR 1 ,  MDR 3 ,  MRP, GST tz , C Y P I A 1 ,  T o p o i s o m e r a s e  I ,  
T o p o i s o m e r a s e  I I ,  T o p o i s o m e r a s e  I l a  a n d  T o p o i s o m e r a s e  I I |3  
a n a l y s i s ,  b y  RT-PCR,  o f  RNA e x t r a c t e d  f r o m  " f r e s h "  n o r m a l  (N) a n d  
t u m o u r  ( T )  l u n g  b i o p s i e s .  A l l  r e a c t i o n s  w e r e  s e t  u p  i n  
d u p l i c a t e .  30 c y c l e s  o f  PCR a m p l i f i c a t i o n  w e r e  p e r f o r m e d .  T h e  
l e f t - h a n d  l a n e  c o n t a i n e d  e i t h e r  t h e  DNA m o l e c u l a r  w e i g h t  m a r k e r  
"V" c o n s i s t i n g  o f  22 f r a g m e n t s  o f  t h e  f o l l o w i n g  b a s e  p a i r  s i z e s :  
5 8 7 ,  5 4 0 ,  5 0 4 ,  4 5 8 ,  4 3 4 ,  2 6 7 ,  2 3 4 ,  2 1 3 ,  1 9 2 ,  1 8 4 ,  1 2 4 ,  1 2 3 ,  1 0 4 ,  
8 9 ,  8 0 ,  6 4 ,  5 7 ,  5 1 ,  2 1 ,  1 8 ,  11 a n d  8 ,  o r  a l t e r n a t i v e l y ,  " P h i  X" 
m a r k e r  d i g e s t e d  w i t h  H ae  I I I  r e s t r i c t i o n  e n z y m e ,  r e s u l t i n g  i n  11 
f r a g m e n t s  o f  t h e  f o l l o w i n g  s i z e s :  1 , 3 5 3 ,  1 , 0 7 8 ,  8 7 2 ,  6 0 3 ,  3 1 0 ,  
2 8 1 ,  2 7 1 ,  2 3 4 ,  1 9 4 ,  118  a n d  72 b a s e  p a i r s ,  w i t h  w h i c h  t h e
t a r g e t  p r o d u c t s  w e r e  s i z e d .  T h e  f o u r  r i g h t - h a n d  l a n e s  o n  g e l s  
( i i i )  c o n t a i n e d  n e g a t i v e  c o n t r o l s * ,  w h e r e  cDNA w a s  r e p l a c e d  i n  
t h e  RT r e a c t i o n  b y  a n  e q u a l  v o l u m e  o f  u l t r a - p u r e  w a t e r .
* T h e  f o u r  n e g a t i v e  c o n t r o l s  s h o w n  w e r e  t h e  r e s u l t s  o f  MDR 1 ,
MRP, GST j t a n d  T o p o i s o m e r a s e  I I  a n a l y s i s .  N e g a t i v e  c o n t r o l s  f o r  
a l l  o t h e r  p r i m e r s  w e r e  a l s o  p e r f o r m e d ,  b u t  a r e  n o t  s h o w n  d u e  t o  
a  l a c k  o f  s p a c e .  As f o r  t h e  n e g a t i v e  c o n t r o l s  i n c l u d e d ,  n o  b a n d s  
r e s u l t e d .
Figs. 3.9.1.1 - 3.9.1.4 Gel electrophoresis of the. products
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Fig. 3.9.1.1 Gel electrophoresis of products of RT-PCR analysis of 
mRNA extracted from normal (N) and tumour (T) lung biopsies from a 
62 year old female (Hospital No. 7059428). Tissues were processed for 
RNA extraction within 3.5 hrs of their removal.
CYPIA1 TOPO I TOPO II
N T N T N T
Fig. 3.9.1.2 Gel electrophoresis of products of RT-PCR analysis of 
mRNA extracted from normal (N) and tumour (T) lung biopsies from a 68 
year old male (Hospital No. 2004610). Tissues were processed for RNA 
extraction within 2 hrs of their removal.
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Fig. 3.9.1.3 Gel electrophoresis of products of RT-PCR analysis of 
mRNA extracted from normal (N) and tumour (T) lung biopsies from a 
57 year old male (Hospital No. 39761 1). Tissues were processed for 
RNA extraction within 1 hr. 32 min of their removal.
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Fig. 3.9.1.4 Gel electrophoresis of products of RT-PCR analysis of 
mRNA extracted from normal (N) and tumour (T) lung biopsies from a 
52 year old male (Hospital No. 405435). Tissues were processed for 
RNA extraction 4 hrs after tftejr remG&fef.^
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3 . 9 . 2  A n a l y s i s  o f  mRNA T r a n s c r i p t s  i n  P a r a f f in - E m b e d d e d  
T i s s u e s .
D ue t o  t h e  s e n s i t i v i t y  o f  t h e  PCR r e a c t i o n ,  r e t r o s p e c t i v e  
s t u d i e s  o f  a  w i d e  r a n g e  o f  p a t h o l o g i c a l  a r c h i v a l  t i s s u e  m ay  b e  
p o s s i b l e .  W h e t h e r  RNA c o u l d  b e  e x t r a c t e d  r o u t i n e l y ,  h o w e v e r ,  
f r o m  s u c h  a r c h i v a l  m a t e r i a l  w a s  u n c e r t a i n .  J a c k s o n  e t  a l .  ( 1 9 9 1 )  
r e p o r t e d  a  5 - d a y  p r o t e i n a s e  K i n c u b a t i o n  f o r  DNA e x t r a c t i o n  f r o m  
p a r a f f i n - e m b e d d e d  t i s s u e  w h i c h  a l s o  p r o d u c e d  s i g n i f i c a n t  a m o u n t s  
o f  RNA.  A l t h o u g h  t h i s  w a s  a t t e m p t e d ,  o n l y  s u c c e s s f u l  
a m p l i f i c a t i o n  o f  p - a c t i n  cDNA f r o m  p a r a f f i n - e m b e d d e d  b r e a s t  o r
o v a r i a n  t i s s u e  w a s  a c h i e v e d  ( F i g .  3 . 9 . 2 ) .  T h e  f o l l o w i n g  
p r o c e d u r e  w a s ,  t h e r e f o r e ,  d e v e l o p e d  i n  a n  a t t e m p t  t o  o v e r c o m e  
t h i s  p r o b l e m .  ( S t r i n g e n t  c o n d i t i o n s  f o r  RNA h a n d l i n g  w e r e  
a d h e r e d  t o  a s  o u t l i n e d  i n  2 . 1 0 ) .
S e c t i o n s  o f  t i s s u e  ( 1 0  jum t h i c k )  w e r e  c u t  f r o m  t h e  
p a r a f f i n  b l o c k  a n d  p l a c e d  i n  a n  a u t o c l a v e d  e p p e n d o r f .  200  p i  o f  
o c t a n e  w a s  a d d e d  t o  t h i s  a n d  p l a c e d  i n  a  60 °C w a t e r - b a t h ,  f o r  
1 0 .  m i n s ,  t o  r e m o v e  t h e  p a r a f f i n .  T h e  c o n t e n t s  o f  t h e  e p p e n d o r f  
w e r e  s p u n  f o r  10 m i n s . ,  a t  maxim um s p e e d  i n  a  b i o f u g e , a t  4 °C 
r e s u l t i n g  i n  t h e  t i s s u e  p e l l e t i n g  a t  t h e  b o t t o m  o f  t h e  t u b e  a n d  
t h e  p a r a f f i n  f o r m i n g  a  w a x  l a y e r  a t  t h e  t o p .  T h e  w ax  w a s  r e m o v e d  
u s i n g  a  p a s t e u r  p i p e t t e  a n d  t h e  r e m a i n i n g  t i s s u e  p e l l e t  w a s  
w a s h e d  w i t h  7 0 % e t h a n o l .  A f t e r  r e - c e n t r i f u g i n g  a t  maximum s p e e d  
i n  a  b i o f u g e  ( 1 3 , 0 0 0  g ) ,  a t  4 °C a n d  r e m o v i n g  t h e  e t h a n o l ,  t h e  
t i s s u e  p e l l e t  w a s  r e s u s p e n d e d  i n  2 0 0  p i  ° f  d i g e s t i o n  b u f f e r  
c o n s i s t i n g  o f  25  mM EDTA, 100 mM N a C l ,  0 . 5  % SDS,  10 mM T r i s -  
HCL, pH 8 . 0 ,  t o  w h i c h  p r o t e i n a s e  K w a s  a d d e d  t o ,  t o  r e s u l t  i n  a  
c o n c e n t r a t i o n  o f  0 . 1  m g / m l ,  i m m e d i a t e l y  p r i o r  t o  i t s  u s e .  T h e  
t u b e  w a s  t h e n  w r a p p e d  i n  p a r a f i l m  a n d  i n c u b a t e d  a t  5 2 °C w i t h  
c o n s t a n t  a g i t a t i o n ,  t o  b r e a k  dow n p r o t e i n s .  A f t e r  18 h o u r s ,  a  
p h e n o l / c h l o r o f o r m / i s o a m y l  a l c o h o l  ( 2 5 : 2 4 : 1 )  e x t r a c t i o n ,  f o l l o w e d  
b y  c h l o r o f o r m / i s o a m y l  a l c o h o l  ( 2 4 : 1 )  e x t r a c t i o n  w a s  p e r f o r m e d  t o  
g e t  r i d  o f  p r o t e i n  p r o d u c t s .  T h e  RNA ( a n d  DNA) w e r e  p r e c i p i t a t e d  
o u t  o f  s o l u t i o n  u s i n g  t w o  v o l u m e s  o f  c o l d  a b s o l u t e  e t h a n o l  a n d  a  
1 / 1 0  v o l u m e  o f  3 M s o d i u m  a c e t a t e  (pH 5 . 2 ) ,  a t  -  80  °C f o r  a  
p e r i o d  o f  30 m i n s .  T h e  RNA a n d  DNA w e r e  p e l l e t e d  b y  c e n t r i f u g i n g
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a n d  t h e  s u p e r n a t a n t  d i s c a r d e d .  To  g e t  r i d  o f  t h e  DNA, t h e  p e l l e t
w a s  t r e a t e d  w i t h  a n  R N a s e  f r e e - D N a s e  I  e n z y m e  a t  37 ° C , f o r  30
m i n s . RNA w a s  p h e n o l / c h l o r o f o r m / i s o a m y l  a l c o h o l  e x t r a c t e d  a n d  
p r e c i p i t a t e d  o u t  o f  s o l u t i o n ,  u s i n g  e t h a n o l  a n d  s o d i u m  a c e t a t e ,  
a s  a b o v e .  A f t e r  c e n t r i f u g i n g  a t  4 ° C ,  t h e  p e l l e t  w a s  r e s u s p e n d e d  
i n  DEPC-H2 O a n d  q u a n t i f i e d  s p e c t r o p h o t o m e t r i c a l l y  ( a s  d e s c r i b e d  
i n  2 . 1 0 . 3 ) .
I n i t i a l  a t t e m p t s  t o  e x t r a c t  RNA a n d  a m p l i f y  t h e  r e s u l t i n g  
cDNA f o r m e d  u s i n g  o l i g o  ( d T )  p r i m e r s  i n  t h e  R T - r e a c t i o n  ( a s  i n  
2 . 1 0 . 4 )  r e s u l t e d  i n  a m p l i f i c a t i o n  o f  p - a c t i n  cDNA o n l y  ( i n  m a n y ,
b u t  n o t  a l l  c a s e s ) .  U s i n g  r a n d o m  p r i m e r s  i n d e p e n d e n t l y ,  a  b a n d
w a s  f r e q u e n t l y  p r o d u c e d  f o r  p - a c t i n ,  p l u s  a  l o t  o f  n o n - s p e c i f i c
b a n d s  ( F i g . 3 . 9 . 3 ) .  S i m i l a r  r e s u l t s  w e r e  a c h i e v e d  w h e n  u s i n g  
g e n e - s p e c i f i c  p r i m e r s  a n d  r a n d o m  p r i m e r s ,  i n d e p e n d e n t l y .  V a r i o u s  
c o m b i n a t i o n s  o f  t h e s e  t h r e e  p r i m e r  t y p e s  w e r e  u s e d ;  t h e  m o s t  
s u c c e s s f u l  c o m b i n a t i o n  b e i n g  a  1 : 1 r a t i o  o f  o l i g o  ( d T )  p r i m e r s  
: r a n d o m  p r i m e r s .  R e s u l t s  o f  t h i s  a n a l y s i s  a r e  e x e m p l i f i e d  i n  
F i g s .  3 . 9 . 4  -  3 . 9 . 6 .  S u c c e s s f u l  a m p l i f i c a t i o n  o f  t h e  i n t e r n a l  
c o n t r o l ,  p - a c t i n ,  a n d  m a n y  o f  t h e  o t h e r  mRNA t r a n s c r i p t s
s t u d i e d ,  t o  a  g r e a t e r  o r  l e s s e r  e x t e n t ,  ( w i t h  t h e  e x c e p t i o n  o f  
C Y PIA 1)  w a s  a c h i e v e d .  A " s m e a r i n g "  e f f e c t  w a s  s e e n  i n  m o s t  
l a n e s . T h i s  w a s  p r o b a b l y  d u e  t o  RNA d e g r a d a t i o n  p r o d u c t s .
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Fig- 3.9.2 (i) Gel electrophoresis of products of RT-PCR analysis using multiplex primers to 
amplify p-actin (383 bp), GST n (270 bp), Topoisomerase II (216 bp), MRP (203 bp) and MDR 1 
(1 57 bp) from cDNA formed on mRNA templates, extracted from four paraffin-embedded breast 
tumour biopsies. An RNA extraction procedure, detailed by Jackson et al. (1991), was used. cDNA 
was formed during the RT reaction, using oligo dT primers. Successful amplification of p-actin, 
only, (in 2/4 cases) was achieved. (Left-hand lane contains "Phi X" molecular weight marker).
(ii) Attempts to individually amplify MDR 1, GST n, CYPIA1, Topoisomerase I, Topoisomerase II, 
Topoisomerase 11« and p-actin (endogenous control) cDNA formed on RNA templates extracted from 
paraffin-embedded ovarian biopsy, resulted in amplification, only, of p-actin. The RNA extraction 
and RT procedures were as for (i) above. (Left-hand lane contains molecular weight marker "V").
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Fig. 3.9,3 Gel electrophoresis of products formed after RT-PCR analysis 
of mRNA extracted from two paraffin-embedded breast tumour biopsies, 
designated specimens (1) and (2). RNA was extracted as detailed in 
Section 3.9.2 and cDNA was formed using Oligo dT primers in the RT 
reaction. All reactions were performed in duplicate. A band representing 
p-actin was produced in many cases. No p-actin band was detected, 
however, after co-amplification with MDR 1, MDR 3, MRP or CYPIA1 
primers. "Non-specific" bands resulted in many samples.
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F i g s . 3 . 9 . 4  -  3 . 9 . 6  G e l  e l e c t r o p h o r e s i s  o f  p r o d u c t s  r e s u l t i n g  
f r o m  RT-PCR a n a l y s i s  o f  RNA e x t r a c t e d  f r o m  s i x  p a r a f f i n - e m b e d d e d  
b r e a s t  t u m o u r  b i o p s i e s .  RNA w a s  e x t r a c t e d  a s  d e t a i l e d  i n  3 . 9 . 2 .  
cDNA w a s  f o r m e d  o n  t h e  r e s u l t i n g  mRNA t e m p l a t e s  u s i n g  a  1 : 1 
r a t i o  o f  o l i g o  dT : r a n d o m  p r i m e r s ,  i n  t h e  RT r e a c t i o n .  C o ­
a m p l i f i c a t i o n  o f  MDR 1 ( 1 5 7  b p ) ,  MRP ( 2 0 3  b p ) ,  GST x  (270 b p ) ,
CYPIA1 ( 3 2 7  b p ) ,  T o p o i s o m e r a s e  I  ( 1 8 0  b p ) ,  T o p o i s o m e r a s e  I I  ( 2 1 6  
b p )  T o p o i s o m e r a s e  I l a  (139 bp)  a n d  T o p o i s o m e r a s e  11 (3 (118 b p )  cDNA, 
r e s p e c t i v e l y ,  w i t h  p - a c t i n  ( e n d o g e n o u s  c o n t r o l ) ,  w a s  a t t e m p t e d .  
T h e  r e s u l t i n g  b a n d s  w e r e  s i z e d  b y  c o m p a r i s o n  t o  t h e  m o l e c u l a r  
w e i g h t  m a r k e r s  i n  t h e  l e f t - h a n d  ( a n d  s o m e t i m e s ,  r i g h t - h a n d )
l a n e s  o f  e a c h  g e l .  B a n d s  r e p r e s e n t i n g  P - a c t i n  r e s u l t e d  i n  a l l  
c a s e s  w h e r e  p - a c t i n  p r i m e r s  w e r e  i n c l u d e d .  A n u m b e r  o f  t h e  
t a r g e t  g e n e  p r o d u c t s  a l s o  a m p l i f i e d  s u c c e s s f u l l y .  A r r o w s  
i n d i c a t e  t h e  p o s i t i o n s  w h e r e  b a n d s  w e r e  e x p e c t e d ,  b u t  s u c c e s s f u l  
a m p l i f i c a t i o n  a p p a r e n t l y  d i d  n o t  o c c u r .
269
cm
Q
, ^ 0 0 0  o ^ o. a a  a ft >: o o o oC3 (J |_ |—  (_ K
r- _  3 CO.
(i)
434
267
184
124
(ii)
Fia 3.9.4. Gel electrophoresis of products of RT-PCR analysis of mRNA 
extracted from two paraffin-embedded breast tumour biopsies, 
designated (i) (Hospital No. 1721 1/89) and (ii) (Hospital No. 14536/85). 
These specimens had been stored for 5 yrs. and 9 yrs. respectively, 
before this analysis was performed. (Arrows indicate the position 
where bands were expected, but amplification did not occur).
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Fia 3.9.5. Gel electrophoresis of products of RT-PCR analysis of mRNA 
extracted from two paraffin-embedded breast tumour biopsies, 
designated (i) (Hospital No. 8538/92) and (ii) (Hospital No. 13535/87). 
These specimens had been stored for 2 yrs. and 7 yrs. respectively, 
before this analysis was performed. (Arrows indicate the position 
where bands were expected, but amplification did not occur).
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Fig 3.9.6. Gel electrophoresis of products of RT-PCR analysis of mRNA 
extracted from two paraffin-embedded breast tumour biopsies, 
designated (i) (Hospital No. 17998/86) and (ii) (Hospital No. 16897/89). 
These specimens had been stored for 8 yrs. and 5 yrs. respectively, 
before this analysis was performed. (Arrows indicate the position 
where bands were expected, but amplification did not occur).
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3 . 1 0  MDR 1 Ribozyme T r a n s f e c t i o n  and A s s e s s m e n t  o f  i t s  
E x p r e s s i o n .
An MDR 1 - s p e c i f i c  r i b o z y m e  w a s  t r a n s f e c t e d  i n t o ,  DLKPA-5F,  
t h e  m o s t  r e s i s t a n t  c l o n e  o f  DLKPA. T h e  r i b o z y m e  w a s  a l s o  
t r a n s f e c t e d  i n t o  a  c l o n e  o f  t h e  p a r e n t  c e l l  l i n e ,  DLKP-4 ( c l o n e d  
o u t  o f  a  h e t e r o g e n o u s  p o p u l a t i o n  b y  S h i r l e y  Me B r i d e ) ,  a s  a  
n e g a t i v e  c o n t r o l .  T h e  t r a n s f e c t i o n  t e c h n i q u e  ( S e c t i o n  2 . 8 )  
i n v o l v e d  c a l c i u m - p h o s p h a t e  p r e c i p i t a t i o n  o f  t h e  r i b o z y m e  o n t o  
t h e  c e l l  m o n o l a y e r  o f  t h e  c u l t u r e d  c e l l s ,  f o l l o w e d  b y  g l y c e r o l  
s h o c k i n g  t h e  c e l l s  t o  i n c r e a s e  t h e  e f f i c i e n c y  o f  r i b o z y m e  
u p t a k e .  F i v e  c o l o n i e s  o f  e a c h  c e l l  l i n e ,  a r i s i n g  f r o m  s i n g l e ,  
w e l l - d i s p e r s e d  c e l l s ,  a n d  k n o w n  t o  c o n t a i n  t h e  r i b o z y m e  d u e  t o  
t h e i r  a b i l i t y  t o  g r o w  i n  t h e  s e l e c t i v e  a g e n t ,  g e n e t i c i n ,  w e r e  
c l o n e d  o u t  a n d  m a i n t a i n e d  a s  i n d i v i d u a l  c e l l  l i n e s .  T h e s e  w e r e  
d e s i g n a t e d  D L K P 4 -R Z 1 ,  D L K P 4 -R Z 2 , D L K P 4 - R Z 3 , D L K P 4 - R Z 4 , DLKP4- 
R Z 5 , DLKPA5F-RZ1 ,  D LK PA 5F-RZ2 , DLKPA5F-RZ3 ,  DLKPA5F-RZ4 a n d  
DLKPA5F-RZ5.
3 . 1 0 . 1  Ribozyme DNA A n a l y s i s  by PCR.
S u c c e s s f u l  t r a n s f e c t i o n  o f  t h e  MDR 1 r i b o z y m e  i n t o  b o t h  
DLKP-4 a n d  DLKPA-5F c e l l s  w a s  c o n f i r m e d  b y  p e r f o r m i n g  2 0 c y c l e s  
o f  PCR a m p l i f i c a t i o n  o n  DNA e x t r a c t e d  f r o m  e a c h  c e l l  l i n e  ( a n d  
c o m p a r i n g  i t  t o  t h a t  f r o m  c e l l s  n o t  t r a n s f e c t e d )  ( F i g .  3 . 1 0 . 1 ) .  
T h e  PCR p r i m e r s ,  o n e  s p e c i f i c  f o r  a  s e q u e n c e  u p s t r e a m  o f  t h e  
p o l y l i n k e r  i n  t h e  p l a s m i d  a c t i n g  a s  v e c t o r  a n d  t h e  o t h e r  f o r  t h e  
r i b o z y m e  DNA, a m p l i f i e d  a  2 2 1  b p  p r o d u c t .  T h i s  w a s  c l e a r l y  
d i s t i n g u i s h a b l e  f r o m  t h e  3 8 0  b p  GAPDH p r o d u c t  ( a m p l i f i e d  a s  a  
c o n t r o l ) .  D e n s i t o m e t r y  a n a l y s i s  o f  t h e  b a n d s  r e s u l t i n g  f r o m  PCR 
a m p l i f i c a t i o n  o f  t h e  r i b o z y m e  DNA ( T a b l e  3 . 1 0 . 1 . 1 )  a f t e r  
b a c k g r o u n d  s u b t r a c t i o n  a n d  n o r m a l i s i n g  w i t h  GAPDH s u g g e s t  t h a t  
t h e  l e v e l s  o f  r i b o z y m e  s u c c e s s f u l l y  t r a n s f e c t e d  i n t o  b o t h  t h e  
s e n s i t i v e  a n d  MDR c e l l  l i n e s  w a s  s i m i l a r  i n  e a c h  o f  t h e  
r e s u l t i n g  t r a n s f e c t a n t s .
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3.10.2 Ribozyme RNA Analysis by RT-PCR.
E x p r e s s i o n  o f  t h e  r i b o z y m e  mRNA i n  a l l  c e l l  l i n e s  i n t o  
w h i c h  t h e  r i b o z y m e  w a s  t r a n s f e c t e d  w a s  r e a l i s e d  b y  p e r f o r m i n g  20 
c y c l e s  o f  PCR a m p l i f i c a t i o n  o n  RNA e x t r a c t e d  f r o m  t h e s e  c e l l  
l i n e s  ( i n  c o m p a r i s o n  t o  DLKP-4 a n d  DLKPA-5F u n t r e a t e d  c e l l s ) .  As 
f o r  t h e  PCR a n a l y s i s  o f  t h e  r i b o z y m e  DNA, t h e  p r i m e r s  f o r  t h e  
RT-PCR s t u d y  w e r e  s e l e c t e d  s o  t h a t  t h e y  d i d  n o t  a m p l i f y  a n y  
e n d o g e n o u s  c e l l u l a r  mRNA p r o d u c t s  ( S c a n l o n  a n d  c o - w o r k e r s ,  C i t y  
o f  H ope  M e d i c a l  C e n t e r ) .  As i n d i c a t e d  i n  F i g .  3 . 1 0 . 2 ,  s u c c e s s f u l  
t r a n s c r i p t i o n  o f  t h e  r i b o z y m e  o c c u r r e d  i n  b o t h  t h e  s e n s i t i v e  a n d  
m u l t i p l e  d r u g  r e s i s t a n t  t r a n s f e c t e d  v a r i a n t s ,  r e s u l t i n g  i n  a  118 
b p  p r o d u c t .  I n  b o t h  t h e  DLKP-4  a n d  DLKPA-5F n o n - t r a n s f e c t e d  
c e l l s ,  o n l y  t h e  GAPDH p r i m e r s  p r o d u c e d  a  b a n d .  T h i s  c o n f i r m s  
t h a t  t h e  118 b p  p r o d u c t  i s  a  r e s u l t  o f  t h e  t r a n s f e c t i o n ,  a n d  n o t  
a n  i n h e r e n t  c e l l u l a r  c o m p o n e n t .  C o n t a m i n a t i o n  o f  t h e  e x t r a c t e d  
RNA b y  DNA w o u l d  h a v e  r e s u l t e d  i n  a n  e x t r a  b a n d  o f  8 8 0  b p .  T h e  
f a c t  t h a t  t h e  RNA i s  f r e e  f r o m  a n y  s u c h  DNA i s  v e r i f i e d  b y  t h e  
l a c k  o f  s u c h  a n  e x t r a  b a n d  ( F i g .  3 . 1 0 . 2 ) .
T h e  l e v e l s  o f  e x p r e s s i o n  o f  t h e  r i b o z y m e  a p p e a r e d  t o  b e  
s i m i l a r  i n  b o t h  t h e  DLKP-4 a n d  DLKPA-5F t r a n s f e c t a n t s , w h e n  t h e  
i n t e n s i t y  o f  t h e  c o r r e s p o n d i n g  GAPDH b a n d  w a s  t a k e n  i n t o  
c o n s i d e r a t i o n ,  b y  v i s i b l e  a n a l y s i s .  T h i s  w a s  c o n f i r m e d  b y  
d e n s i t o m e t r y  a n a l y s i s  ( T a b l e  3 . 1 0 . 1 . 1 ) .
3 . 1 0 . 3  MDR 1 mRNA A n a l y s i s  i n  T r a n s f e c t a n t s , by RT-PCR.
To e s t a b l i s h  i f  t h e  r i b o z y m e  t r a n s f e c t e d  i n t o  t h e  c e l l s  h a d  
a n  e f f e c t  o n  t h e  MDR 1 mRNA l e v e l s ,  RT-PCR a n a l y s i s  o f  a  157 b p  
MDR 1 mRNA r e g i o n  w a s  p e r f o r m e d  u s i n g  MDR 1 p r i m e r s  d e t a i l e d  i n  
T a b l e  3 . 1 ,  w h i c h  f l a n k  t h e  MDR 1 mRNA r e g i o n  t o  w h i c h  t h e  
r i b o z y m e  w a s  t a r g e t e d .  T h e  r e s u l t s  f r o m  t h i s  s u g g e s t  t h a t  t h e  
DLKP c l o n e ,  D L K P -4 ,  d o e s  n o t  e x p r e s s  t h i s  g e n e  t r a n s c r i p t .  As 
e x p e c t e d ,  t h e r e f o r e ,  MDR 1 mRNA e x p r e s s i o n  w a s  n o t  o b s e r v e d  i n  
t h e  DLKP-4  t r a n s f e c t e d  c e l l  l i n e s .  I t  h a s  p r e v i o u s l y  b e e n  
e s t a b l i s h e d  i n  t h i s  s t u d y  ( s e e  3 . 5 )  t h a t  DLKPA-5F c e l l s  e x p r e s s
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MDR 1 mRNA. T h i s  w a s  c o n f i r m e d  i n  t h i s  a n a l y s i s .  L i k e w i s e ,  t h e  
p r e s e n c e  o f  MDR 1 g e n e  t r a n s c r i p t s  w e r e  a l s o  r e a l i s e d  i n  a l l  o f  
t h e  DLKPA-5F t r a n s f e c t e d  c e l l  l i n e s  ( F i g .  3 . 1 0 . 3 ) .
A l t h o u g h  t h e  r i b o z y m e  h a s  b e e n  s u c c e s s f u l l y  t r a n s f e c t e d  
i n t o  DLKPA-5F c l o n e s  ( F i g .  3 . 1 0 . 1 )  a n d  i s  b e i n g  e x p r e s s e d  i n  
t h e s e  c e l l  l i n e s  ( F i g .  3 . 1 0 . 2 ) ,  MDR 1 mRNA l e v e l s  i n  t h e  
t r a n s f e c t a n t s  a p p e a r e d  t o  b e  u n a l t e r e d ,  w h e n  c o m p a r e d  t o  t h e  
t r a n s c r i p t  l e v e l s  i n  DLKPA-5F , t h e  u n t r a n s f e c t e d  c e l l  l i n e .  T h i s  
w a s  c o n f i r m e d  b y  d e n s i t o m e t r y  a n a l y s i s  ( T a b l e  3 . 1 0 . 1 . 1 ) .  T h e s e  
r e s u l t s  s u g g e s t  t h a t  e i t h e r  t h e  r i b o z y m e  i s  n o t  m e e t i n g  a n d  
c l e a v i n g  i t s  t a r g e t  MDR 1 mRNA, o r  t h a t  t h e  e f f e c t  i s  s o  s m a l l  
t h a t  i t  i s  n o t  o b v i o u s  w h e n  a n a l y s i n g  t h e  MDR 1 mRNA l e v e l s .
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Fig. 3.10.1 Gel electrophoresis of PCR products resulting from 
amplification of DNA extracted from ribozyme transfectants - 
DLKP-4/RZ1 - RZ5 and DLKPA-5F/RZ1 - RZ5, and their respective 
untransfected cell lines. All reactions were performed in duplicate. Two 
bands were produced in all cases with DNA extracted from the ribozyme 
transfectants. The upper band (380 bp) was produced by the GAPDH 
primers, and the lower band (221 bp) by the primers selected for 
ribozyme DNA amplification, verifying successful transfection of the 
ribozyme into the cells. Only GAPDH bands were produced for the parent 
cell lines.
Note: The first few GAPDH bands on the DLKP-4 gel appeared faint due to inconsistant 
staining of the agarose gel in this region. An average densitometry reading for GAPDH bands in 
the remaining lanes was used when normalising their corresponding DNA bands.
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Fig. 3.10.2 Gel electrophoresis of RT-PCR products resulting from
analysis of RNA extracted from ribozyme transfectants - DLKP-4/RZ1 - 
RZ5 and DLKPA-5F/RZ1 - RZ5, and their respective untransfected cell 
lines. All reactions were performed in duplicate. Two bands were 
produced in all cases with RNA extracted from the ribozyme
transfectants. The upper band (380 bp) was produced by the GAPDH
primers, and the lower band (118 bp) by the primers selected for
ribozyme RNA analysis, verifying successful expression of the ribozyme 
in the transfectants. Only GAPDH bands were produced for the parent cell
IQ.
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Fig. 3.10.3 Gel electrophoresis of RT-PCR products resulting from amplification of MDR 
1 mRNA extracted from ribozyme transfectants - DLKP-4/RZ1 - RZ5 and DLKPA-5F/RZ1 
- RZ5, and their respective untransfected cell lines. All reactions were performed in 
duplicate. One band was produced after amplification of cDNA derived from DLKP-4 and 
its transfected variants, representing the endogenous control, GAPDH. No detectable 
MDR 1 mRNA levels were apparent in these cell lines. Two bands, indicative of GAPDH 
(upper 380 bp band) and MDR 1 (lower 1 57 bp band) mRNA resulted, on analysis of 
mRNA extracted from DLKPA-5F and its five transfectants.
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C e l l
L i n e / C l o n e
R i b o z y m e  DNA 
( F i g . 3 . 1 0 . 1 )
R i b o z y m e  RNA 
( F ic j .  3 . 1 0 . 2 )
MDR 1 mRNA 
( F i q .  3 . 1 0 . 3
DLKP-4 0 . 0 0 0 * 0 . 0 0 0 0 . 0 0 0
DLKP-4/RZ1 0 . 5 0 9 * 0 . 4 6 0 0 . 0 0 0
D L K P-4 /R Z 2 0 . 4 9 3 * 0 . 4 5 1 0 . 0 0 0
D L K P-4 /R Z 3 0 . 5 0 0 0 . 4 5 7 0 . 0 0 0
D LK P-4 /R Z4 0 . 4 9 6 0 . 4 6 1 0 . 0 0 0
D LK P-4 /R Z5 0 . 5 0 0 0 . 4 6 5 0 . 0 0 0
DLKPA-5F 0 . 0 0 0 0 . 0 0 0 0 . 6 1 0
DLKPA-5F/RZ1 0 . 4 9 9 0 . 4 5 2 0 . 6 0 0
DLKPA-5F/RZ2 0 . 5 0 2 0 . 4 5 0 0 . 5 9 5
DLKPA-5F/RZ3 0 . 5 0 7 0 . 4 5 6 0 . 6 0 8
DLKPA-5F/RZ4 0 . 5 0 0 0 . 4 5 9 0 . 6 0 9
DLKPA-5F/ RZ 5 0 . 4 9 6 0 . 4 4 8 0 . 5 9 6
T a b l e  3 . 1 0 . 1 . 1  A n a l y s i s ,  b y  d e n s i t o m e t r y ,  o f  b a n d s  r e s u l t i n g  
a f t e r  PCR a n a l y s i s  o f  ( i )  t r a n s f e c t e d  r i b o z y m e  DNA, a n d  RT-PCR 
a n a l y s i s  o f  ( i i )  RNA r e s u l t i n g  f r o m  r i b o z y m e  e x p r e s s i o n  a n d  
( i i i )  MDR 1 mRNA l e v e l s ,  c o r r e s p o n d i n g  t o  F i g s .  3 . 1 0 . 1 ,  3 . 1 0 . 2  
a n d  3 . 1 0 . 3 ,  r e s p e c t i v e l y .  ( T h e  d a t a  p r e s e n t e d  i s  t h e  m e a n  o f  
e a c h  o f  t h e  d u p l i c a t e  r e s u l t s  a f t e r  c o r r e c t i o n  b y  b a c k g r o u n d  
s u b t r a c t i o n  a n d  n o r m a l i s i n g  w i t h  GAPDH).
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3 . 1 0 . 4  M u l t i p l e  D r u g  R e s i s t a n c e  P r o f i l e  o f  
T r a n s f e c t a n t s .
To d e t e r m i n e  i f  e x p r e s s i o n  o f  t h e  MDR 1 r i b o z y m e  h a d  a n  
e f f e c t  o n  t h e  c r o s s - r e s i s t a n c e  p r o f i l e  o f  t h e  DLKPA-5F c e l l s ,  
t o x i c i t y  a s s a y s  w e r e  p e r f o r m e d  i n  w h i c h  t h e  s e n s i t i v i t i e s  o f  a l l  
t h e  r i b o z y m e - t r a n s f e c t e d  c e l l  l i n e s  ( a n d  t h e  DLKP-4 a n d  DLKPA-5F 
c e l l  l i n e s )  t o  a  r a n g e  o f  c h e m o t h e r a p e u t i c  d r u g s ,  w e r e  a s s e s s e d .  
T h e  c o m p o u n d s  t e s t e d  i n c l u d e d  a d r i a m y c i n ,  v i n c r i s t i n e  a n d  V P - 1 6  
a s  t h e s e  a r e  t h e  c h e m o t h e r a p e u t i c  c o m p o u n d s  t o  w h i c h  DLKPA-5F 
h a s  p r e v i o u s l y  b e e n  f o u n d  t o  b e  h i g h l y  r e s i s t a n t  ( b y  D r .  M a r y  
H e e n a n ) .  T h e  s e n s i t i v i t i e s  o f  a l l  t h e  c e l l  l i n e s  t o  t h e
d i f f e r e n t  c h e m o t h e r a p e u t i c  a g e n t s  w a s  t e s t e d  a  m in im u m  o f  t h r e e  
t i m e s ,  w i t h  e i g h t  r e p l i c a s  p e r f o r m e d  i n  e a c h  a s s a y .  T h e  r e s u l t s  
a r e  p r e s e n t e d  i n  T a b l e  3 . 1 0 . 4 . 1 .
No s i g n i f i c a n t  i n c r e a s e s  ( o r  d e c r e a s e s )  i n  s e n s i t i v i t y  t o  
a n y  o f  t h e  t h r e e  d r u g s  i n  t h e  DLKP-4 v a r i a n t s ,  b y  c o m p a r e d  t o  
t h e i r  s e n s i t i v e  p a r e n t  c e l l  w a s  o b s e r v e d .  T h i s  i s  a s  e x p e c t e d  a s  
n o  MDR 1 mRNA h a s  b e e n  d e t e c t e d  i n  t h i s  c e l l  l i n e .
R e s u l t s  f r o m  a n a l y s i s  o f  t h e  D L K P A -5 F  t r a n s f e c t a n t s
s u g g e s t e d  a  s l i g h t  i n c r e a s e  i n  d r u g  s e n s i t i v i t y  t o  a d r i a m y c i n ,  
v i n c r i s t i n e  i n  t h e  DLK PA -5F/RZ2 t r a n s f e c t a n t s , b y  c o m p a r i s o n  t o  
DLK PA -5F .  R e d u c e d  l e v e l s  o f  r e s i s t a n c e  t o  a d r i a m y c i n  a n d  V P -16  
w e r e  n o t e d  i n  D L K P A -5 F /R Z 5 . No c h a n g e s  i n  s e n s i t i v i t y  t o  VCR w a s
o b s e r v e d  w i t h  t h i s  t r a n s f e c t e d  c e l l  l i n e .  R e d u c e d  l e v e l s  o f  d r u g
r e s i s t a n c e  w e r e  n o t  o b s e r v e d  i n  a n y  o f  t h e  o t h e r  DLKPA-5F 
t r a n s f e c t a n t s .
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DLKPA-5F
IC50 value
(yM)
Parent RZ1 RZ2 RZ3 RZ4 RZ5
Adriamycin 1 14.988 9 .215 11.177 8 .873 17.363 8 .751
2 14 .504 8 . 998 14.904 5 . 027
3 10.924 14 .420 6 .278 10.018 7 . 773 10.092
X 12.958 
(2.872)
12 .519 
(2 .869)
8 .820 
(2.452)
9 .447 
(0.812)
13 .347 
(4.982)
7 . 958 
(2 .625)
Vincristine 1 1.608 1.504 1.256 1.589 2.804 1.375
2 1.869 2 . 084 4 .321 5.114 1.864
3 3 .327 
2 .483
1.876 
3 .106
2 . 089 
1.588
3 . 060 
3 .024
3 .482 3.193
2.199
X 2 .472 
(0.859)
2.089
(0.700)
1.754
(0.406)
2.999
(1.115)
3 .800 
(1.188)
2.109
(0.768)
VP -16 1 13.575 3 .840 4 .759 9.162 10.141 8 .755
2 5.369 5.260 16 .281 10 . 737 7 .543 
4.490
3
X
4 .273 5 .292 9.570 9.676 11.582
13.575 4 .494 
(0.788)
5.104
(0.299)
11.672 
(3.998)
10.185 
(0.532)
8 . 092 
(2.937)
DIjKP-4
IC50 value 
(tiM)
Parent RZ1 RZ2 RZ3 RZ4 RZ5
Adriamycin 1 16.311 35 .862 15.880 14.052
2 18 .621 25 .862 25.862 16.156 19.655 17.087
X 17 .414 
(1.552)
30.862
(7.069)
25.862 16.017 
(3 .145)
19.655 15.568
(2.069)
Vincristine 1 1.809
1.896
2.026 1.690
1.603
1.972 
1. 744
1.972
2.037
2 2.015 2 .167 1.560 1.831
X 1.852
(0.108)
2.015
(0.006)
2 .167 1.749
(0.108)
1.852
(0.108)
2.005
(0.108)
VP -16 1 168 .026 169 .725 181.787 180.088
139.314
2 161.570 227.659 280.326 181.787
X 164 .798 
(10.703)
198.777 
(40.775)
280.326 181.787 166 .497 
(23.785)
Table 3.10.4.1 : The toxicity of adriamycin, vincristine and VP-16 to DLKP-4
and DLKPA-5F cell lines and to their ribozyme-transfected sublines (RZ1, RZ2, 
RZ3, RZ4 and RZ5) . The toxicities of the chemotherapeutic drugs are 
represented by the IC50 values for each drug (in /jM and r^ M quantities for DLKPA- 
5F and DLKP-4 cell lines, respectively), as determined by 96-well plate assays 
and with cellular acid phosphatase levels as an indication of cell growth. 
Numbers 1-3 refer to repeat assays. X is the mean IC^ , value, as determined from 
these assays and the value in brackets are the standard deviations on the mean 
values.
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Chapter 4
Discussion
DISCUSSION
T h e  p h e n o m e n o n  o f  m u l t i p l e  d r u g  r e s i s t a n c e  w a s  f i r s t  
d i s c o v e r e d  a  q u a r t e r  o f  a  c e n t u r y  a g o .  B e c a u s e  o f  i t s  c o m p l e x  
n a t u r e ,  i n v o l v i n g  m a n y  m e c h a n i s m s  ( s o m e  o f  w h i c h  y e t  r e m a i n  t o  
b e  d i s c o v e r e d ,  t h i s  m a j o r  o b s t a c l e  i n  t h e  p a t h w a y  o f  c a n c e r  
t r e a t m e n t  h a s  y e t  t o  b e  o v e r c o m e .  To a i d  i n  t h e  r e s e a r c h  o n  MDR, 
a  m e t h o d  f o r  r o u t i n e  a n a l y s i s  o f  s p e c i f i c  g e n e  t r a n s c r i p t s  i n  
c u l t u r e d  MDR c e l l s  a n d  e s p e c i a l l y  i n  t u m o u r s ,  w h e r e  v e r y  l i m i t e d  
a m o u n t s  o f  t i s s u e  a r e  a v a i l a b l e ,  i s  n e e d e d .  T h i s  m e t h o d  c o u l d  
t h e n ,  i d e a l l y ,  b e  u s e d  t o  m e a s u r e  d e t e r m i n a n t s  o f  r e s p o n s e  t o  
a n t i - c a n c e r  d r u g s  i n  t u m o u r  b i o p s i e s  f r o m  i n d i v i d u a l  p a t i e n t s .
4 . 1  mRNA A n a l y s i s  i n  MDR
A n u m b e r  o f  e s t a b l i s h e d  m e t h o d s  f o r  mRNA a n a l y s i s  h a v e  b e e n  
d o c u m e n t e d  t o  d a t e .  As m e n t i o n e d  i n  S e c t i o n  1 . 2 ,  e a c h  o f  t h e s e  
m e t h o d s  h a s  i t s  a d v a n t a g e s  a n d  d i s a d v a n t a g e s .  T h e  m a i n  
d i s a d v a n t a g e s  o f  m a n y  o f  t h e s e  t e c h n i q u e s  a r e  t h e i r  l a c k  o f  
s e n s i t i v i t y  ( w h i c h  w o u l d  p r e v e n t  t h e m  b e i n g  d e v e l o p e d  a s  
q u a n t i t a t i v e  t e c h n i q u e s ) ,  t h e i r  f r e q u e n t  r e q u i r e m e n t  o f  
r a d i o a c t i v e  l a b e l s  a s  a  d e t e c t i o n  m e t h o d ,  a n d  t h e  f a c t  t h a t  m any  
o f  t h e s e  t e c h n i q u e s  a r e  l a b o r i o u s  a n d  t i m e - c o n s u m i n g ,  h e n c e  
l i m i t i n g  t h e  n u m b e r  o f  s a m p l e s  t h a t  c a n  b e  s t u d i e d  i n  a  g i v e n  
p e r i o d  o f  t i m e .
I t  h a s  b e e n  l o n g  e s t a b l i s h e d  t h a t  e v e n  v e r y  l o w  l e v e l s  o f  
MDR 1 g e n e  e x p r e s s i o n  c a n  c o n f e r  a s e v e r a l - f o l d  i n c r e a s e  i n  t h e  
l e v e l  o f  d r u g  r e s i s t a n c e  w h i c h  m ay  b e  c l i n i c a l l y  s i g n i f i c a n t  
( S h e n  e t  a l . ,  1 9 8 6 a ;  C h i n  e t  al., 1 9 8 9 ) .  MDR 1 e x p r e s s i o n  h a s  
b e e n  a n a l y s e d  b y  c o n v e n t i o n a l  RNA s l o t / d o t  b l o t t i n g  t e c h n i q u e s  
( G o l d s t e i n  e t  a l . ,  1 9 8 9 ;  F o j o  e t  a l .  , 1 9 8 7 ;  B o u r h i s  e t  a l . ,
1 9 8 9 )  a n d  N o r t h e r n  b l o t s  ( S h e n  e t  a l . ,  1 9 8 6 b ;  R o n i n s o n  e t  a l . ,  
1 9 8 6 ;  F o j o  e t  a l . , 1 9 8 7 ;  K r a m e r  e t  a l . , 1 9 9 3 ) .  H o w e v e r ,  i n  c e l l s  
w i t h  a  s e v e r a l  f o l d  i n c r e a s e  i n  c e l l u l a r  d r u g  r e s i s t a n c e ,  MDR 1 
e x p r e s s i o n  l e v e l s  a r e  c l o s e  t o  t h e  l i m i t s  o f  s e n s i t i v i t y  o f
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c o n v e n t i o n a l  m e t h o d s  e v e n  w h e n  l a r g e  a m o u n t s  o f  RNA a r e  u s e d  f o r  
t h e  a s s a y  ( S h e n  e t  a l . ,  1 9 8 6 b ;  F o j o  e t  a l . ,  1 9 8 7 ;  N o o n a n  e t  a l . ,  
1 9 9 0 ) .  RNA b l o t t i n g  t e c h n i q u e s  m ay  n o t  b e  s e n s i t i v e  e n o u g h  t o  
d e t e c t  l o w  l e v e l s  o f  MDR 1 g e n e  e x p r e s s i o n  w h i c h  m ay  b e  
s u f f i c i e n t  f o r  c l i n i c a l l y  r e l e v a n t  m u l t i p l e  d r u g  r e s i s t a n c e  
( S h e n  e t  a l . ,  1 9 8 6 b ;  N o o n a n  e t  a l . ,  1 9 9 0 ;  N o o n a n  a n d  R o n i n s o n  
1 9 9 1 ;  H o l z m a y e r  e t  a l . ,  1 9 9 2 ) .
T h e r e  a r e  a  n u m b e r  o f  a d d i t i o n a l  p r o b l e m s  i n  t h e  s t u d y  o f  
g e n e  e x p r e s s i o n  i n  m u l t i d r u g  r e s i s t a n c e  i n  c l i n i c a l  s a m p l e s .  T h e  
a m o u n t  o f  a v a i l a b l e  t i s s u e  i s  o f t e n  l i m i t e d ;  a n a l y s i s  o f  RNA 
f r o m  t h e s e  s a m p l e s  i s  o f t e n  p r o b l e m a t i c  b e c a u s e  RNA m ay h a v e  
s u f f e r e d  s i g n i f i c a n t  d e g r a d a t i o n .  D e t e c t i o n  o f  MDR 1 i s  o f t e n  
c o m p l i c a t e d  b y  t h e  e x i s t e n c e  o f  a  h o m o l o g o u s  g e n e ,  MDR 3 ,  w h i c h  
i s  a p p a r e n t l y  n o t  a s s o c i a t e d  w i t h  r e s i s t a n c e  t o  c h e m o t h e r a p e u t i c  
d r u g s ;  MDR 3 mRNA s h o w s  c r o s s  r e a c t i v i t y  w i t h  s o m e  MDR 1 n u c l e i c  
a c i d  p r o b e s .  W hen  u s i n g  MDR 1 a n d  MDR 3 DNA p r o b e s  h i g h  
s t r i n g e n c y  h y b r i d i s a t i o n  c o n d i t i o n s  a r e  r e q u i r e d  t o  a v o i d  c r o s s  
h y b r i d i s a t i o n  o f  MDR 3 p r o b e s  w i t h  MDR 1 mRNA. T h i s  l i m i t s  t h e  
s e n s i t i v i t y  o f  t h e  a s s a y  a n d  a s  a  r e s u l t ,  c e l l s  w i t h  a  l o w  
d e g r e e  o f  r e s i s t a n c e  m ay  e s c a p e  n o t i c e .  MDR e x p r e s s i o n  i n  
t u m o u r s  i s  o f t e n  h e t e r o g e n e o u s  w i t h  o n l y  a  s u b p o p u l a t i o n  o f  
t u m o u r  c e l l s  e x p r e s s i n g  t h e  g e n e  ( W e i n s t e i n  e t  a l . ,  1 9 9 0 ) .  E v e n  
i f  s o m e  c e l l s  i n  t h e  t u m o u r  e x p r e s s  t h e  g e n e  a t  a  r e l a t i v e l y  
h i g h  l e v e l ,  h e t e r o g e n e i t y  m ay  l e a d  t o  a  v e r y  l o w  s i g n a l  w hen  
t o t a l  RNA e x t r a c t e d  f r o m  t h e  t u m o u r  i s  a n a l y s e d .  S u b p o p u l a t i o n s  
o f  p - g l y c o p r o t e i n  e x p r e s s i n g  c e l l s  w i t h i n  t h e  t u m o u r  m ay  h a v e  a  
g r o w t h  a d v a n t a g e  i n  t h e  c o u r s e  o f  c h e m o t h e r a p y  ( N o o n a n  e t  a l . ,
1 9 9 0 ) .  T h e s e  p r o b l e m s  w e r e  a l l  f a c e d  w h e n  s e l e c t i n g  a  m e t h o d  o f  
g e n e  t r a n s c r i p t  a n a l y s i s  f o r  MDR 1 a n d  a  n u m b e r  o f  o t h e r  d r u g  
r e l a t e d  g e n e s .
T h e  d e v e l o p m e n t  o f  P C R - b a s e d  t e c h n o l o g y  h a s  p r o v i d e d  a  
s e n s i t i v e ,  s p e c i f i c  a n d  q u a n t i t a t i v e  p r o t o c o l  f o r  m e a s u r i n g  t h e  
l e v e l s  o f  MDR 1 mRNA i n  c l i n i c a l  s a m p l e s  w h i c h  o v e r c o m e s  m any  o f  
t h e s e  d r a w b a c k s .  PCR m e t h o d s  r e q u i r e  m u c h  l e s s  t i s s u e  t h a n  
t r a d i t i o n a l  m e t h o d s  a n d  s o  a r e  a p p l i c a b l e  t o  t h e  d e t e c t i o n  o f  
MDR 1 i n  c l i n i c a l  s a m p l e s ,  e v e n  f r o m  a  h e t e r o g e n e o u s  p o p u l a t i o n
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o f  c e l l s .  I n  a d d i t i o n ,  b y  c a r e f u l  c h o i c e  o f  s e q u e n c e  s p e c i f i c  
p r i m e r s ,  i t  i s  p o s s i b l e  t o  a m p l i f y  s e l e c t i v e l y  e v e n  s u c h  h i g h l y  
r e l a t e d  s e q u e n c e s  a s  MDR 1 a n d  MDR 3 .  T h e r e f o r e ,  a l t h o u g h  t h e  
RT-PCR m e t h o d  h a s  o n e  m a i n  d i s a d v a n t a g e  ( i . e .  i t  d o e s  n o t  r e n d e r  
i n f o r m a t i o n  o n  t r a n s c r i p t  s i z e ) ,  t h i s  m e t h o d  w a s  c h o s e n  f o r  t h e  
w o r k  i n  t h i s  t h e s i s  d u e  t o  i t s  s e n s i t i v i t y ,  s p e c i f i c i t y ,  s p e e d  
a n d  e a s e .
4 . 2  S e l e c t i o n  o f  an Endogenous C o n t r o l  t o  u s e  in
r o u t i n e  RT-PCR A n a l y s i s
T h e  c o m p a r i s o n  o f  b i o c h e m i c a l  q u a n t i t i e s  r e q u i r e s  
n o r m a l i s a t i o n  s o  t h a t  t h e  d a t a  c a n  b e  c o m p a r e d  t o  a common 
d e n o m i n a t o r .  A l t h o u g h  w h e n  s t u d y i n g  c u l t u r e d  c e l l s  t h i s  may b e  
b a s e d  o n  c e l l  n u m b e r ,  t h e  n u m b e r  o f  c e l l s  t h a t  a r e  p r e s e n t  i n  a  
t i s s u e  s p e c i m e n  c a n n o t  u s u a l l y  b e  e s t a b l i s h e d  w i t h  c e r t a i n t y .  
One m a i n  a d v a n t a g e  o f  u s i n g  t h e  e x p r e s s i o n  o f  a n  e n d o g e n o u s  g e n e  
i n  t h i s  c a p a c i t y  a s  a n  i n t e r n a l  s t a n d a r d  i s  t h a t  t h e  r e f e r e n c e  
mRNA a n d  t a r g e t  s h a r e  t h e  s a m e  c i r c u m s t a n c e s  t h r o u g h o u t  
p r e p a r a t i o n  o f  t h e  s a m p l e  ( e . g .  f i x a t i o n  a n d  e m b e d d i n g  o f  
t i s s u e )  a n d  mRNA i s o l a t i o n  a n d  s t o r a g e .
C o n s i d e r a b l e  d i f f e r e n c e s  i n  e f f i c i e n c i e s  o f  PCR 
a m p l i f i c a t i o n  b e t w e e n  t u b e s  h a s  b e e n  r e p o r t e d  ( G i l l i l a n d  e t  a l . ,  
1 9 9 0 a , b ;  W i e s n e r ,  1 9 9 2 ) ,  r e a s o n s  f o r  w h i c h  a r e  s u g g e s t e d  i n  
S e c t i o n  1 . 3 .  B e c a u s e  t h i s  s t u d y  i n v o l v e d  a n a l y s i s ,  b y  RT-PCR, o f  
m any  g e n e  t r a n s c r i p t s  i n  m a n y  c e l l  l i n e s  a n d  b i o p s i e s ,  a n  e f f o r t  
w a s  m a d e  t o  s e l e c t  a n  e n d o g e n o u s  c o n t r o l  ( o r  c o n t r o l s )  t h a t  
c o u l d  b e  u s e d  r o u t i n e l y .  Some o f  t h e  m a i n  c o n s i d e r a t i o n s  w h e n  
c h o o s i n g  s u c h  a n  e n d o g e n o u s  c o n t r o l  w e r e  t h a t  i t s  l e v e l s  o f  
e x p r e s s i o n  s h o u l d  b e  t h e  s a m e  i n  e a c h  o f  t h e  s a m p l e s  t o  b e  
c o m p a r e d ,  n o t  v a r y i n g  a p p r e c i a b l y  d u r i n g  t h e  c e l l  c y c l e  o r  among 
d i f f e r e n t  t i s s u e s ,  a n d  n o t  a f f e c t e d  b y  e x p e r i m e n t a l  c o n d i t i o n s .  
T h e  p r o d u c t s  r e s u l t i n g  f r o m  i t s  a m p l i f i c a t i o n  h a d  t o  b e  e a s i l y  
d i s t i n g u i s h e d  f r o m  t h e  r e s u l t i n g  t a r g e t  p r o d u c t s  a n d  t h e  p r i m e r s  
c h o s e n  f o r  i t s  s t u d y  s h o u l d  n o t  c r o s s - r e a c t  w i t h  p r i m e r s  
a m p l i f y i n g  a n y  o f  t h e  t a r g e t  cD N A s . F ro m  a  l i s t  o f  a t  l e a s t  n i n e
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p o t e n t i a l  e n d o g e n o u s  c o n t r o l s  d o c u m e n t e d  i n  t h e  l i t e r a t u r e  ( s e e  
S e c t i o n  1 . 3 ) ,  ( 3 - a c t i n ,  P 2 - m i c r o g l o b u l i n , E s t e r a s e  D a n d
G l y c e r a l d e h y d e - 6 - p h o s p h a t e  d e h y d r o g e n a s e  (GAPDH) w e r e  c o n s i d e r e d  
f o r  t h i s  r o l e .  P r e v i o u s l y  p u b l i s h e d  p r i m e r s  f o r  t h e  
a m p l i f i c a t i o n  o f  P 2 - m i c r o g l o b u l i n ,  E s t e r a s e  D a n d  GAPDH w e r e
c o n s i d e r e d ,  a f t e r  a s s e s s i n g  how  t h e y  m e t  w i t h  t h e  c r i t e r i a  
s u g g e s t e d  f o r  c h o o s i n g  p r i m e r s  a n d  c h e c k i n g  t h a t  t h e y  d i d  n o t  
c r o s s - r e a c t  w i t h  a n y  o f  t h e  o t h e r  p r i m e r  p a i r s  i n c l u d e d  i n  t h i s  
s t u d y ,  w i t h  w h i c h  t h e y  w o u l d  p o t e n t i a l l y  b e  u s e d .
P-actin: S u i t a b l e  p r i m e r s  f o r  p - a c t i n  cDNA a m p l i f i c a t i o n  w e r e  
v e r y  d i f f i c u l t  t o  s e l e c t .  A c t i n  i s  t h e  m o s t  a b u n d a n t  s t r u c t u r a l  
p r o t e i n  i n  e u k a r y o t i c  c e l l s  ( N a k a j i m a - I i j i m a  e t  a l . ,  1 9 8 5 ;
P o l l a c k ,  1 9 8 0 ;  F i r t e l , 1 9 8 1 ;  F u l t o n ,  1 9 8 1 )  w i t h  a t  l e a s t  s i x  
i s o f o r m s  i n  v e r t e b r a t e s .  p - a c t i n ,  a  c y t o p l a s m i c  a c t i n ,  c o ­
e x i s t s  w i t h  Y- a c t ; >-n  i-n  m a n y  c e l l  t y p e s  a n d  i s  i n v o l v e d  i n  a  
v a r i e t y  o f  f u n c t i o n s .  M u l t i p l e  g e n e  c o p i e s  r e l a t e d  t o  t h e  
c y t o p l a s m i c  a c t i n s  h a v e  b e e n  f o u n d  t o  e x i s t ,  m o s t  o f  w h i c h  s e e m  
t o  b e  p s e u d o g e n e s  ( E n g e l  e t  a l . ,  1 9 8 1 ;  Moos  a n d  G a l l w i t z ,  1 9 8 2 ;  
M oos  a n d  G a l l w i t z ,  1 9 8 3 ;  P o n t e  e t  a l . ,  1 9 8 3 ) .  F u r t h e r m o r e ,  
o v e r - e x p r e s s i o n  o f  c y t o p l a s m i c  a c t i n  h a s  b e e n  f o u n d  t o  b e  
a s s o c i a t e d  w i t h  n e o p l a s t i c  t r a n s f o r m a t i o n  o f  h u m a n  f i b r o b l a s t s  
( L e a v i t t  a n d  B u s h a r ,  1 9 9 2 ;  N a k a j i m a - I i j i m a  e t  a l . ,  1 9 8 5 ) .  (5-
a c t i n ,  h o w e v e r ,  i s  g e n e r a l l y  f a v o u r e d  a s  a  s t a n d a r d  b y  m a n y  
r e s e a r c h e r s  i n c l u d i n g  H o r i k o s h i  e t  a l . ( 1 9 9 2 ) ,  A v r a h a m  e t  a l .
( 1 9 9 2 )  a n d  L o n n  e t  a l .  ( 1 9 9 2 ) .
T h e  p r i m e r s  s e l e c t e d  f o r  p - a c t i n  ( T a b l e  3 . 1 )  i n  t h i s  t h e s i s  
s u c c e s s f u l l y  a m p l i f i e d  a  r e g i o n  o f  383  b p  ( a n d  5 9 0  b p  h a d  t h e r e  
b e e n  a n y  c o n t a m i n a t i n g  DNA p r e s e n t ) .  C a r e  w a s  t a k e n  t o  e n s u r e  
t h a t  n e i t h e r  o f  t h e s e  p r i m e r s  w o u l d  c r o s s - r e a c t  w i t h  a n y  o f  t h e  
o t h e r  p r i m e r  p a i r s  s e l e c t e d  t o  e i t h e r  a m p l i f y  a n o t h e r  cDNA 
r e g i o n  o r  f o r m  " p r i m e r - d i m e r s " .  E x a m p l e s  o f  t h e  b a n d s  r e s u l t i n g  
a f t e r  a m p l i f i c a t i o n  w i t h  t h e s e  p r i m e r s  c a n  b e  s e e n  i n  m a n y  o f  
t h e  f i g u r e s  i n c l u d e d  i n  t h e  r e s u l t s  ( S e c t i o n  3 . 2 ) .  When l e v e l s  
o f  p - a c t i n  w e r e  e v a l u a t e d  i n  d r u g  r e s i s t a n t  a n d  s e n s i t i v e  c e l l
l i n e s ,  e q u a l  l e v e l s  o f  t h i s  mRNA w e r e  f o u n d  t o  e x i s t ,  p r o v i n g  
t h a t  t h e  e x p e r i m e n t a l  c o n d i t i o n s  d i d  n o t  e f f e c t  i t s  e x p r e s s i o n .
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T h i s  i s  e x e m p l i f i e d  b y  r e s u l t s  f r o m  a n a l y s i s  o f  H E p -2  a n d  HEp-2A 
( F i g .  3 . 2 ( i ) ,  T a b l e  3 . 2 . 1 ) .
P2 - M i c r o g l o b u l i n : P 2 - m i c r o g l o b u l i n  h a s  a l s o  b e e n  u s e d  a s  a n
i n t e r n a l  c o n t r o l  ( N o o n a n  e t  a l . ,  1 9 9 0 ) .  P 2 - m i c r o g l o b u l i n  i s  a  
s m a l l  ( 1 2  kD a)  p o l y p e p t i d e  f o u n d  i n  s e r u m  a n d  a s s o c i a t e d  w i t h  
t h e  m a j o r  h i s t o c o m p a t i b i l i t y  c o m p l e x  c l a s s  1 h e a v y  c h a i n  o n  t h e  
s u r f a c e  o f  n e a r l y  a l l  c e l l s  (G i i s s o w  e t  a l . ,  1 9 8 7  ) .  I t  h a s  b e e n  
c l a i m e d  b y  o t h e r s  a s  a  g e n e  t h a t  i s  u b i q u i t o u s l y  e x p r e s s e d  a n d  
i t s  e x p r e s s i o n  c o r r e l a t e s  w i t h  t h e  c e l l  s u r f a c e  a r e a  i n  m o s t  
c e l l  t y p e s  ( N o o n a n  e t  a l . ,  1 9 9 0 ) .  N o o n a n  e t  a l .  , ( 1 9 9 0 )
s u g g e s t e d  t h a t  a s  t h e  a m o u n t  o f  P 2-m i c r o g l ° t)Ul i r i i s  n o t  c o n s t a n t
i n  d i f f e r e n t  c e l l  t y p e s ,  b u t  i s  p r o p o r t i o n a l  t o  t h e  c e l l  s u r f a c e  
a r e a ,  i t  m a y  n o t  b e  t h e  b e s t  c o n t r o l  f o r  g e n e s  e n c o d i n g  f o r  
i n t r a c e l l u l a r  p r o t e i n s .
I n  t u m o u r  t y p e s ,  i n c l u d i n g  s m a l l  c e l l  l u n g  c a n c e r ,  t h e  
a m o u n t  o f  P2-m i c r o g i ° b u l i n  anc* a n o t h e r  H L A - r e l a t e d  g e n e  may b e
d e c r e a s e d  o r  e l i m i n a t e d  ( D o y l e  e t  a l . ,  1 9 8 5 ) .  H o r i k o s h i  e t  a l .  
( 1 9 9 2 )  s t u d i e d  t h e  r a t i o s  o f  P 2 - n i i c r o g l o t > u l i n  : f i - a c t i n  a n d
f o u n d  a  c o n s i d e r a b l e  v a r i a t i o n  a m o n g  t h e  t i s s u e s  t e s t e d .  T h i s  
s u g g e s t e d  t h a t  e i t h e r  o n e  o r  b o t h  a r e  n o t  e x p r e s s e d  a t  s i m i l a r  
l e v e l s  am ong  d i f f e r e n t  t i s s u e s ,  p - a c t i n  w a s  f o u n d  t o  b e  m o r e
c o n s t a n t l y  e x p r e s s e d  a n d  s o  w a s  f a v o u r e d  b y  t h e m  a s  t h e  i n t e r n a l  
s t a n d a r d .  I n  t h e i r  s t u d i e s  o f  b l a d d e r  c a n c e r ,  C l i f f o r d  e t  a l .  
( 1 9 9 4 )  o b s e r v e d  a  1 4 0 - f o l d  v a r i a t i o n  i n  P 2 - m i c r o g l o b u l i n  l e v e l s
b e t w e e n  i n d i v i d u a l  t u m o u r s ,  r e n d e r i n g  i t  u n a c c e p t a b l e  a s  a  
c o n t r o l .  N o o n a n  e t  a l .  ( 1 9 9 0 ) ,  h o w e v e r ,  c o n s i d e r e d  t h i s  a s  a n  
a c c e p t a b l e  c o n t r o l  f o r  t h e i r  s t u d i e s  o f  MDR 1 e x p r e s s i o n  i n  a  
r a n g e  o f  c e l l  l i n e s  a n d  h u m a n  n o r m a l  a n d  t u m o u r  t i s s u e s .
A l t h o u g h  t h e  l e v e l s  o f  P 2 - m i c r o g l o b u l i n  w e r e  g e n e r a l l y  
s l i g h t l y  r e d u c e d  ( a s  a s s e s s e d  b y  d e n s i t o m e t r y  a n a l y s i s )  i n  t h e  
MDR c e l l  l i n e s  i n c l u d e d  i n  t h i s  s t u d y  ( F i g .  3 . 2 ( i i ) ,  T a b l e
3 . 2 . 1 ) ,  t h e  l e v e l s  o f  t r a n s c r i p t  r e d u c t i o n  w e r e  p r o b a b l y  
i n s i g n i f i c a n t .
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E s t e r a s e  D: E s t e r a s e  D h a s  a l s o  b e e n  c h o s e n  a s  a n  i n t e r n a l  
c o n t r o l  b y  C o l e  e t  a l .  , ( 1 9 9 1 )  w h o  c l a i m e d  i t  t o  b e  l e s s
d e p e n d e n t  o n  c e l l  c y c l e  t h a n  o t h e r  g e n e s  e . g .  (3 a n d  y a c t i n s .
B e c a u s e  o f  t h e  n a t u r e  o f  t h e i r  s t u d y  t h e y  f a v o u r e d  E s t e r a s e  D 
o v e r  ( 3 2 - m i c r o g l o b u l i n  a s  t h e y  b e l i e v e d  P 2 - m i c r o g l o b u l i n  t o  b e
o f t e n  u n d e t e c t e d  i n  s m a l l  c e l l  l u n g  c a n c e r .  H o w e v e r ,  t h e  
p o l y m o r p h i c  e n z y m e  E s t e r a s e  D ( 1 3 q l 4 )  h a s  b e e n  u s e d  a s  a  m a r k e r  
f o r  l o s s  o f  h e t e r o z y g o s i t y  i n  l i n k a g e  a n a l y s i s  s t u d i e s  o f  t h e  
r e t i n o b l a s t o m a  g e n e  ( R B I ) .  M u t a t i o n s  o f  t h e  RBI g e n e  h a v e  b e e n  
f o u n d  i n  m a n y  t u m o u r  t y p e s  a n d  i n  p a r t i c u l a r ,  i n  s m a l l  c e l l  l u n g  
c a n c e r .  I n  77% o f  s m a l l  c e l l  l u n g  c a n c e r s  s t u d i e d ,  a b s e n c e  o r  
t r a c e  l e v e l s  o f  RBI mRNA h a v e  b e e n  r e p o r t e d  ( M a c d o n a l d  a n d  F o r d ,
1 9 9 1 ) .  I t  i s  p o s s i b l e  t h e r e f o r e  t h a t  E s t e r a s e  D m ay  a l s o  b e  
a f f e c t e d  i n  t h i s  w a y .  T h i s  w o u l d  m a k e  i t  a n  u n r e l i a b l e  c o n t r o l  
i f  i t s  p r e s e n c e  i n  a l l  t u m o u r  t y p e s  s t u d i e d  w a s  u n c e r t a i n .
I n  t h i s  s t u d y ,  l e v e l s  o f  E s t e r a s e  D w e r e  f r e q u e n t l y  f o u n d  
t o  b e  s l i g h t l y  i n c r e a s e d  i n  MDR c e l l s ,  b y  c o m p a r i s o n  t o  t h e i r  
c o r r e s p o n d i n g  s e n s i t i v e  c e l l  l i n e s .  An e x a m p l e  o f  t h i s  i s  s e e n  
i n  d u p l i c a t e  s t u d i e s  o f  H E p -2  a n d  H E p-2A  ( F i g .  3 . 2 ( i i i ) ,  T a b l e
3 . 2 . 1 ) .  B a s e d  o n  t h e s e  s t u d i e s ,  E s t e r a s e  D w a s  n o t  c o n s i d e r e d  a s  
a n  a p p r o p r i a t e  c o n t r o l  f o r  f u r t h e r  s t u d i e s .
6APDH: GAPDH, l i k e  p - a c t i n ,  i s  f r e q u e n t l y  u s e d  a s  a n  e n d o g e n o u s  
c o n t r o l  i n  N o r t h e r n  b l o t  a n a l y s i s  ( N a k a j i m a  e t  a l . , 1 9 9 3 ) .  I n  
t h e i r  e v a l u a t i o n  o f  a  n u m b e r  o f  " h o u s e - k e e p i n g "  g e n e s  a s  
p o t e n t i a l  e n d o g e n o u s  c o n t r o l s ,  D u k a s  e t  a l .  ( 1 9 9 3 )  s u g g e s t e d  
GAPDH t o  b e  a  v e r y  r e l i a b l e  e n d o g e n o u s  c o n t r o l  f o r  s t u d i e s  o f  
g e n e  e x p r e s s i o n .  B a s e d  o n  t h i s ,  GAPDH l e v e l s  w e r e  a s s e s s e d  i n  
t h i s  s t u d y ,  b u t  w e r e  g e n e r a l l y  f o u n d  t o  b e  s l i g h t l y  i n c r e a s e d  
w i t h  MDR ( F i g .  3 . 2 ( i v ) ,  T a b l e  3 . 2 . 1 ) .
A l t h o u g h  p - a c t i n ,  P 2 - m i c r o g l o b u l i n  a n d  GAPDH m a y  b e  
a c c e p t a b l e  a s  e n d o g e n o u s  c o n t r o l s ,  p - a c t i n  w a s  f a v o u r e d  f o r  
s e v e r a l  r e a s o n s .  T h e  m a i n  r e a s o n  f o r  t h e  c h o i c e  o f  p - a c t i n  a s  
c o n t r o l  f o r  r o u t i n e  RT-PCR a n a l y s i s  w a s  t h a t  t h e  l e v e l s  o f  t h i s  
g e n e  p r o d u c t  a p p e a r e d  t o  b e  p r a c t i c a l l y  t h e  s a m e  i n  a l l  o f  t h e  
c e l l  l i n e s  s t u d i e d ,  w h e n  c o m p a r e d  t o  t h e i r  p a r e n t  c e l l  l i n e s .
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T h e  b a n d s  r e s u l t i n g  f r o m  a m p l i f i c a t i o n  w i t h  t h e s e  p r i m e r s  w a s  
g e n e r a l l y  s t r o n g  a n d  s o  e a s i l y  d e t e c t e d  ( c o m p a r e d ,  f o r  e x a m p l e ,  
w i t h  t h a t  p r o d u c e d  w h e n  a n a l y s i n g  E s t e r a s e  D ) .  T h i s  p r o d u c t  
l e n g t h  w a s  s l i g h t l y  g r e a t e r  t h a n  a l l  o f  t h e  o t h e r  t a r g e t  
p r o d u c t s  a s s e s s e d  i n  t h i s  s t u d y .  T h e r e f o r e ,  i f  RNA d e g r a d a t i o n  
o c c u r r e d ,  b a s e d  o n  t h e  s i z e  o f  t h e  a m p l i f i e d  r e g i o n s ,  p - a c t i n
w o u l d  p r o b a b l y  b e  a t  l e a s t  a s  l i k e l y  t o  b e  a f f e c t e d  a s  a n y  o f  
t h e  t a r g e t  a m p l i f i e d  p r o d u c t s .  I n  a  f e w  c a s e s  t h r o u g h o u t  t h i s  
t h e s i s ,  h o w e v e r ,  p - a c t i n  w a s  n o t  s u i t a b l e  a n d  s o  a n o t h e r
e n d o g e n o u s  c o n t r o l  w a s  a m p l i f i e d .
F o r  e x a m p l e ,  w h e n  a m p l i f i e d  p r o d u c t s  o f  T o p o i s o m e r a s e  I l a  
o r  T o p o i s o m e r a s e  11(3 w e r e  t o  b e  d i g e s t e d  w i t h  a  r e s t r i c t i o n  
e n z y m e  t o  c o n f i r m  a m p l i f i c a t i o n  o f  t h e  e x p e c t e d  r e g i o n ,  P 2 -  
m i c r o g l o b u l i n  w a s  u s e d  a s  a  c o n t r o l  i n s t e a d  o f  p - a c t i n .  T h i s  i s  
b e c a u s e  t h e  r e g i o n  a m p l i f i e d  w i t h  t h e  p r i m e r s  c h o s e n  f o r  p - a c t i n
a l s o  c o n t a i n  a  r e c o g n i t i o n  s i t e  f o r  t h e  r e s t r i c t i o n  e n z y m e s  u s e d  
t o  c l e a v e  T o p o i s o m e r a s e  I l a  ( A l u  1)  a n d  T o p o i s o m e r a s e  l i p  (Hph 1)
p r o d u c t s .  I t  t h e r e f o r e  s i m p l i f i e d  m a t t e r s  t o  u s e  a  c o n t r o l  
r e g i o n  n o t  a f f e c t e d  i n  t h i s  w a y .
P 2 - m i c r o g l o b u l i n  ( 1 1 4  b p )  w a s  a l s o  c h o s e n  a s  e n d o g e n o u s  
c o n t r o l  i n  q u a n t i t a t i v e  PCR s t u d i e s  ( S e c t i o n  3 . 6 )  w h e r e  t h e  MDR 
1 e x o g e n o u s  c o n t r o l  w a s  u s e d .  T h e  r e a s o n  f o r  t h i s  i s  t h a t  t h e  
e x o g e n o u s  c o n t r o l  a m p l i f i e d  p r o d u c t s  i s  3 3 1  b p  i n  l e n g t h ,  a n d  
t h o s e  o f  p - a c t i n  a n d  GAPDH a r e  383  b p  a n d  3 80  b p ,  r e s p e c t i v e l y .
B e c a u s e  o f  t h e  r e l a t i v e l y  c l o s e  p r o x i m i t y  o f  t h e  e x o g e n o u s  
c o n t r o l  a n d  p - a c t i n  b a n d s  o n  t h e  r e s u l t i n g  a g a r o s e  g e l s ,  t h e
r e s u l t s  w e r e  m o r e  c l e a r  a n d  m o r e  e a s i l y  ( a n d  s o  p o s s i b l y  m o r e  
a c c u r a t e l y )  e v a l u a t e d  b y  d e n s i t o m e t r y  i f  t h e y  w e r e  w e l l  
s e p a r a t e d .
GAPDH w a s  f a v o u r e d  a s  c o n t r o l  w h e n  a n a l y s i s  o f  t h e  r i b o z y m e  
t r a n s f e c t a n t s  w a s  p e r f o r m e d .  T h i s  i s  b e c a u s e  t h e  v e c t o r  w h i c h  
c o n t a i n s  t h e  r i b o z y m e  DNA a t  i t s  p o l y l i n k e r  s i t e  a n d  w h i c h  i s  
t r a n s f e c t e d  i n t o  t h e  c e l l s ,  a l s o  c o n t a i n s  p - a c t i n  s e q u e n c e s
u p s t r e a m  f r o m  t h i s  r e g i o n  ( w h i c h  a r e  u s e d  f o r  o t h e r  p u r p o s e s  i n  
o t h e r  s t u d i e s ) .  To  p r e v e n t  t h e  p o s s i b i l i t y  o f  t h e  p r i m e r s
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s e l e c t e d  f o r  p - a c t i n  b i n d i n g  t o  t h i s  s e q u e n c e  a n d  p o s s i b l y  
r e s u l t i n g  i n  a m p l i f i c a t i o n  o f  " n o n - s p e c i f i c "  b a n d s ,  p - a c t i n  
p r i m e r s  w e r e  n o t  u s e d .
4 . 3  P r im e r s  u s e d  i n  RT-PCR A n a l y s i s .
T h e  p r i m e r s  u s e d  i n  t h i s  R T -P C R  a n a l y s i s  o f  M D R - r e l a t e d  
g e n e  t r a n s c r i p t s  w e r e  d e s i g n e d  a n d  s e l e c t e d  a s  p a r t  o f  t h i s  
t h e s i s ,  w i t h  t h e  e x c e p t i o n  o f  MDR 1 a n d  P 2 - m i c r o g l o b u l i n
p r i m e r s ,  w h i c h  h a d  p r e v i o u s l y  b e e n  p u b l i s h e d  b y  N o o n a n  e t  a l .  
( 1 9 9 0 ) .  H o w e v e r ,  a s  w i t h  a l l  t h e  o t h e r  p r i m e r  p a i r s  t h e  a b i l i t y  
o f  t h e s e  MDR 1 a n d  P2 - m i c r o g l o b u l i n  p r i m e r s  t o  f i t  t h e  p r e ­
d e t e r m i n e d  c r i t e r i a  f o r  p r i m e r  s e l e c t i o n  w a s  a s s e s s e d .  As 
d e t a i l e d  i n  S e c t i o n  3 . 1 ,  i t  w a s  n o t  p o s s i b l e  t o  c o n f o r m  t o  a l l  
t h e  g u i d e - l i n e s  w h e n  c h o o s i n g  p r i m e r s ,  s o  c o m p r o m i s e s  h a d  t o  b e  
m a d e  b e t w e e n  d i f f e r i n g  r e q u i r e m e n t s .  I t  w a s  e n s u r e d ,  h o w e v e r ,  
t h a t  " p r i m e r - d i m e r s " w o u l d  n o t  o c c u r  b e t w e e n  a n y  o f  t h e  s e l e c t e d  
p r i m e r  p a i r s  a n d  t h o s e  c h o s e n  t o  a m p l i f y  t h e  e n d o g e n o u s  
c o n t r o l s .  T h e  p r i m e r s  w e r e  a l s o  d e s i g n e d  i n  s u c h  a  w a y  t h a t  
c r o s s - r e a c t i v i t y  w o u l d  n o t  o c c u r  b e t w e e n  a n y  o f  t h e  p r i m e r s  
c h o s e n  t o  a m p l i f y  t h e  t a r g e t  cDNA r e g i o n s ,  s o  t h a t  m a n y  o f  t h e s e  
p r i m e r  c o u l d  b e  u s e d  s i m u l t a n e o u s l y  a s  m u l t i p l e x  p r i m e r s .  To  
c o n f i r m  a m p l i f i c a t i o n  o f  t h e  e x p e c t e d  m o l e c u l e s ,  c l e a v a g e  w i t h  a  
r e s t r i c t i o n  e n d o n u c l e a s e  e n z y m e  w h o s e  s i t e  o f  r e c o g n i t i o n  i n  t h e  
a m p l i f i e d  r e g i o n  i s  k n o w n ,  w a s  i n c l u d e d .
T h e  s u c c e s s f u l  c h o i c e  o f  a l l  p r i m e r s  w a s ,  t h e r e f o r e ,  
v e r i f i e d  b y  b a n d s  o f  t h e  p r e d i c t e d  s i z e  b e i n g  p r o d u c e d  f o l l o w i n g  
a m p l i f i c a t i o n  w i t h  e a c h  p r i m e r  p a i r  ( F i g .  3 . 1 . 2 . 1 )  a n d ,  a g a i n ,  
f o l l o w i n g  r e s t r i c t i o n  o f  t h e  r e s u l t i n g  p r o d u c t s  ( F i g .  3 . 1 . 2 . 2 )  
w i t h  a p p r o p r i a t e  r e s t r i c t i o n  e n z y m e s  ( T a b l e  3 . 1 ) .  T h e  p r e d i c t e d  
l e n g t h s  o f  b a n d s  t h a t  w o u l d  r e s u l t  f r o m  DNA a m p l i f i c a t i o n  w i t h  
t h e s e  p r i m e r s  a r e  a l s o  d e t a i l e d  i n  T a b l e  3 . 1 ,  w h e n  e v e r  t h e  g e n e  
s e q u e n c e  i n f o r m a t i o n  w a s  a v a i l a b l e .  S u c c e s s f u l  i s o l a t i o n  o f  RNA, 
f r e e  o f  c o n t a m i n a t i n g  DNA w a s  s h o w n  b y  l a c k  o f  a m p l i f i e d  b a n d s ,  
c o r r e s p o n d i n g  t o  DNA. I n f o r m a t i o n  o n  t h e  c o r r e s p o n d i n g  DNA 
s e q u e n c e s  i s  n o t  a v a i l a b l e  f o r  a l l  g e n e  p r o d u c t s  s t u d i e d .
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H o w e v e r ,  a s  a n a l y s i s  o f  a l l  g e n e  t r a n s c r i p t s  w a s  p e r f o r m e d  o n  
t h e  s a m e  s t o c k s  o f  cDNA f r o m  e a c h  RNA e x t r a c t  ( w h i c h  w a s  s h o w n  
t o  c o n t a i n  n o  c o n t a m i n a t i n g  DNA w h e n  a m p l i f i e d  w i t h  o t h e r  t a r g e t  
r e g i o n s )  i t  c a n  b e  a s s u m e d  t h a t  t h e  b a n d s  r e s u l t i n g  i n  a l l  c a s e s  
a r e  r e p r e s e n t a t i v e  o f  c e l l u l a r  RNA.
4 . 4  P r e c a u t i o n s  t a k e n  when A n a l y s i n g  RNA L e v e l s
by RT-PCR
As w i t h  a l l  PCR s t u d i e s ,  g e n e r a l  p r e c a u t i o n s  w e r e  t a k e n  a n d  
g o o d  l a b o r a t o r y  p r o c e d u r e s  e x e r c i s e d .  T h e s e  i n c l u d e d  p r e -  
a l i q u o t i n g  a l l  s o l u t i o n s  i n  s m a l l  a m o u n t s  a n d  d i s c a r d i n g  t h e  
r e m a i n s  a f t e r  e a c h  u s e ;  p h y s i c a l l y  s e p a r a t i n g  t h e  r e a c t i o n  
p r e p a r a t i o n  f r o m  t h e  a m p l i f i e d  p r o d u c t s ;  u s i n g  s e p a r a t e  p i p e t t e s  
e t c .  f o r  s e t t i n g - u p  t h e  r e a c t i o n  a n d  a n a l y s i n g  t h e  p r o d u c t ;  a n d  
o p t i m i s i n g  t h e  c o n d i t i o n s  f o r  e a c h  s e t  o f  t e m p l a t e s  a n d  p r i m e r s .
M o re  o b v i o u s  p r e c a u t i o n s  i n c l u d e d  a u t o c l a v i n g  a l l  n e c e s s a r y  
s o l u t i o n s ,  e p p e n d o r f s ,  p i p e t t e  t i p s  e t c .  a n d  w e a r i n g  g l o v e s .  
E x t r a  p r e c a u t i o n  w e r e  t a k e n  e . g .  b a k i n g  g l a s s w a r e ,  D E P C - t r e a t i n g  
s o l u t i o n s  e t c .  b e c a u s e  o f  t h e  l a b i l e  n a t u r e  o f  t h e  RNA u n d e r  
s t u d y .  A l t h o u g h  g r e a t  c a r e  w a s  t a k e n  w h e n  e x t r a c t i n g  RNA a f t e r  
s e d i m e n t i n g  t h r o u g h  t h e  c e s i u m  c h l o r i d e  c u s h i o n ,  t h e  p o s s i b i l i t y  
o f  DNA c o n t a m i n a t i o n  ( f r o m  t h e  c e s i u m  c h l o r i d e  : g u a n i d i u m
t h i o c y a n a t e  i n t e r f a c e )  c o u l d  n o t  b e  r u l e d  o u t .  T h e r e f o r e ,  
b e c a u s e  i t  m u s t  b e  p o s s i b l e  t o  d i s c r i m i n a t e  b e t w e e n  t h e  RNA 
p r o d u c t  a n d  t h a t  o f  c o n t a m i n a t i n g  DNA, p r i m e r s  f r o m  d i f f e r e n t  
e x o n s  w e r e  u s e d  w h e n e v e r  p o s s i b l e .  D i f f e r e n t  p r o d u c t  s i z e s  w o u l d  
t h e n  r e s u l t  i f  mRNA o r  DNA w e r e  u s e d  a s  t h e  t e m p l a t e .  R e a c t i o n  
c o m p o n e n t s  w e r e  a d d e d  o n  i c e  a n d  t h e  a c c u r a c y  o f  t h e  p i p e t t e s  
w a s  m o n i t o r e d  r e g u l a r l y .  T h i s  l a s t  p o i n t ,  a l t h o u g h  s o m e w h a t  
o b v i o u s ,  i s  e x t r e m e l y  i m p o r t a n t  f o r  t h e s e  p r o c e d u r e s  a s  t h e  
v o l u m e s  i n v o l v e d  a r e  q u i t e  s m a l l .  Due  t o  t h e  s e n s i t i v i t y  o f  t h i s  
t e c h n i q u e  a  v e r y  s m a l l  i n a c c u r a c y  i n  s e t t i n g  u p  t h e  r e a c t i o n  
c o m p o n e n t s  c o u l d  r e s u l t  i n  a  v e r y  l a r g e  i n a c c u r a c y  i n  t h e  f i n a l  
p r o d u c t .
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Good experimental design was considered very important. 
This involved including negative controls to detect 
contamination and positive controls, whenever possible, to 
ensure the reaction was conducted successfully. All reactions 
were set up at least in duplicate. To standardise the procedure, 
it was generally considered better to prepare a master-mix of 
all the ingredients including the enzyme and aliquoting (on ice) 
just prior to the template addition. The minimum number of PCR 
cycles required were performed in order to minimize the chances 
of a rare contaminating template being amplified.
4.5 Method of Analysis of RT-PCR Products
Products of RT-PCR may be detected in a number of ways. For 
quantitative studies, incorporation of a radio-label during PCR 
amplification is generally the method of choice (Rappolee et 
al. , 1989; Wang et al.r 1989b; Gilliland et al., 1990a,b; Murphy 
et al. , 1990; Noonan et al. , 1990; Diviacco et al., 1992; 
Horikoshi et al. , 1992; Siebert and Larrick, 1992; Wiesner,
1992; Futscher et al., 1993; Phillips et al., 1993; Clifford et 
al. , 1994). This generally involves the use of either end-
labelled primers or the inclusion of a radio-labelled 
deoxynucleotide in the deoxynucleotide mix to be incorporated 
into the newly synthesised strands of DNA. The resulting radio­
labelled products are then quantified by either excising bands 
from the gel, indicated by ethidium bromide staining and 
subsequently performing scintillation counts, or scanning the 
bands after autoradiography. The use of fluorescent-labelled 
primers, followed by analysis using a fluorescent automated DNA 
analyser, has also been reported (Cottrez et al., 1994).
The method of product analysis chosen in this study was the 
more simple method of densitometry scanning ethidium bromide 
stained gels (Nakayama et al., 1992; Babu et al., 1993; Deng et 
al., 1993; Dukas et al. , 1993). Although it has been claimed
that at larger cycle numbers there may be variability in the 
strength of the ethidium bromide signal for individual samples
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and so incorporation of a radio-label into the PCR generated 
fragments may be the preferred method for quantitative analysis 
(Rappolee et al. , 1989), rapid saturation of radioactivity
incorporated into amplified products has also been claimed 
(Phillips et al. 1993). This suggests that one method is 
possibly as valid as the other. The method of densitometry 
scanning ethidium bromide-stained gels was favoured, therefore, 
because of its speed and ease, which subsequently meant that 
many more samples could be analysed and many more repeat 
experiments performed.
Using this procedure it was realised, however, that the 
densitometry readings did not always correspond proportionally 
with (visibly) obvious differing band intensities. There are 
many examples of this seen generally throughout the results, 
including Fig. 3.5.1.1, El/Rl. For each respective initial RNA 
concentration, the resulting bands seem, by eye, to be at least 
double in intensity between 15 and 20 cycles of PCR 
amplification. However, according to the densitometry data, the 
greatest increase between 15 and 20 cycles was when analysing 
the 0.5 jjq/jul RNA samples, where only a 1.4-fold increase was 
detected. The differences according to the densitometry data for 
the 1.0 pq/pil and 2.0 pq/pl RNA concentrations between 15 and 2 0 
cycles was even less than this (Fig. 3.5.1.1, Table 3.5.1.1.1). 
This effect was more pronounced when the band intensities were 
relatively weak or relatively strong, suggesting that the 
densitometer is not sensitive enough to detect faint bands and 
that the range of linearity of the machine is quite limited. To 
establish if this was so, or if differences suggested by visible 
analysis were not real, serial dilutions of DNAs of known 
concentrations were ran on an agarose gel and analysed by 
densitometry (Fig. 3.5.2.1). Although the two-fold differences 
in intensities of subsequent bands were clearly visible by eye 
after ethidium bromide staining, this was not apparent from the 
densitometry data. For this reason, the limitations of the 
densitometer had to be taken into consideration when analysing 
all results.
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4.6 Analysis of MDR 1 Gene Products:
MDR 1 mRNA and P-glycoprotein.
MDR 1 mediated multiple drug resistance is an important and 
often acquired mechanism of drug resistance in many tumours, 
identified by an over-expression of the MDR 1 gene at the mRNA 
and protein levels (p-glycoprotein) (Bradley et al., 1989; Reeve 
et al., 1989; Baas et al., 1990). Over-expression of the MDR 1 
gene transcripts (determined by RT-PCR) were observed in all of 
the cell lines included in this study i.e. DLKPA (Figs. 3.3.1 
and 3.5.1.15) and its cloned variants (DLKPA-2B, DLKPA-6B and 
DLKPA-5F (Fig. 3.5.1.15)), DLKP/VP-3 and DLKP/VP - 8 (Fig. 
3.5.1.15), 0AW42A, HEp-2A, SKMES-1A (Fig. 3.3.2) and SKMES-1ADR, 
when compared to their common parent, DLKP. It is known, 
however, that cells can modulate gene expression, even after 
transcription and RNA processing has occurred, by controlling 
mRNA transport from the nucleus to the cytoplasm, cytoplasmic 
mRNA accumulation and degradation, translation, protein 
processing and localisation (Carter and Malter, 1991). The 
levels of p-glycoprotein (the product of the MDR 1 gene) was 
also analysed, therefore, to establish if the levels of this 
protein reflect the MDR 1 mRNA levels.
Overexpression of p-glycoprotein, when analysed in the DLKP 
MDR variants, was observed (by Western blot analysis using C219 
antibody). However, neither the levels of mRNA nor protein 
detected in the DLKP variants correlated precisely with the 
resistance profiles of these cells, as detailed in Table 4.1. 
Simplifying the details from this Table, DLKP/VP-8, DLKPA-5F and 
DLKPA seem to be the most resistant cell lines, overall; 
followed by DLKP/VP-3, DLKPA-6B and then, DLKPA-2B. Analysis of 
mRNA levels by RT-PCR, during exponential product accumulation, 
suggests that the MDR 1 mRNA levels in the DLKPA and its cloned 
variants could generally be correlated with their respective 
drug resistance profiles (Fig. 3.5.1.15, Table 3.5.1.15.1) i.e. 
with greatest levels of MDR 1 mRNA observed in DLKPA and DLKPA- 
5F. Greater levels of MDR 1 gene transcripts were detected in
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DLKPA-6B compared to DLKPA-2B, which is the least resistant 
variant (with the exception of E1/R2). The apparent increased 
levels in DLKPA-2B cells in this case, may be due to 
inconsistent printing of the photograph (Fig. 3.5.1.15, Table
3.5.1.15.1).
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FOLD
RESISTANCE
Adriamycin Cisplatin Vincristine VP-16 5-Fluorouracil
DLKPA 2 5 4 . 1 4  + / -  1 1 9 . 4 3 1 . 4 6  + / -  0 . 4 2 1 5 0 4 . 2 6  + / -  7 0 7 . 3 6 6 0 . 6 7  + / -  8 . 0 0 1 . 7 5  + / -  0 . 7 4
DLKPA-2B 3 6 . 8  + / -  1 5 . 9 7 0 . 5 7  + / -  0 . 0 7 2 2 8 . 3 2  + / -  7 0 . 7 4 1 8 . 1 7  + / -  8 . 3 3 1 . 2 8  + / -  0 . 7 7
DLKPA-6B 9 4 . 5 9  + / -  3 2 . 6 4 0 . 7 1  + / -  0 . 0 8 3 6 7 . 1 1  + / -  1 6 3 . 8 6 2 9 . 7 7  + / -  1 2 . 7 1 0 . 7 7  + / -  0 . 3 3
DLKPA-5F 3 3 0 . 5 9  + / -  6 8 . 5 3 1 . 3 9  + / -  0 . 0 3 1 2 7 5 . 0 4  + / -  6 2 4 . 9 8 5 0 . 6 0  + / -  8 . 0 7 0 . 9 8  + / -  0 . 4 7
DLKP/VP-3 9 0 . 1 0  + / -  1 3 . 2 4 0 . 3 2  + / -  0 . 1 7 1 0 8 8 . 9 8  + / -  1 6 1 . 0 8 5 8 . 2 3  + / -  2 . 3 1 0 . 4 7  + / -  0 . 3 8
DLKP/VP-8 2 7 2 . 4 2  +/- 3 8 . 0 7 0 . 2 2  + / -  0 . 0 6 1 7 3 7 . 4 2  + / -  3 4 7 . 6 0 1 0 1 . 2 4  + / -  6 . 5 4 0 . 9 0  + / -  0 . 4 3
Table 4.1 Fold increase in resistance of DLKP MDR variants to chemotherapeutic drugs, 
with respect to DLKP. (This analysis was performed by Dr. Mary Heenan).
The results from p-glycoprotein analysis by Western 
blotting indicate that the VP-16 MDR cell lines express 
significantly higher levels of this protein, by comparison with 
the adriamycin-selected cell lines (Fig. 3.7.1, Table 3.7.1.1). 
In these cell lines, greatest levels of p-glycoprotein 
expression seemed to correlate with the least resistant cell 
line (DLKP/VP-3) , with slightly lower levels apparently 
occurring in the DLKP/VP- 8 cells. This correlated with slight 
differences in MDR 1 mRNA levels in DLKP/VP-3 and DLKP/VP- 8  
cells, as detected by densitometry. However, no visible 
difference in mRNA levels was apparent (Fig. 3.5.1.15).
Although the levels of p-glycoprotein appeared greater in 
DLKP/VP-3 by comparison to DLKP/VP-8, by visual analysis of the 
Western blots, a two-fold difference, as suggested by 
densitometry (Table 3.7.1.1), was not apparent. These overall 
analyses of the VP-16-selected cell lines seemed to correlate, 
inversely, with the levels of adriamycin accumulation (as 
determined by fluorescence spectrophotometry, by Dr. Mary 
Heenan). DLKP/VP-3, the least resistant variant, expressed 
higher levels of MDR 1 mRNA and p-glycoprotein, and accumulated 
less adriamycin than DLKP/VP-8, the more resistant cell line, 
which apparently expressed lower levels of both MDR 1 mRNA and 
its product, p-glycoprotein. Discrepancies between the suggested 
p-glycoprotein levels (as determined by mRNA analysis) and the 
detected p-glycoprotein levels (as determined by Western blot 
analysis) may be as a result of inadequate protein translation 
due to mRNA instability. It is known that mRNAs coding for 
certain proteins, including transport molecules, tend to be 
rapidly degraded with half-times from 10 to 60 minutes (Carter 
and Malter, 1991). Alternatively, they may be the result of 
post-translational modifications, alterations in the location of 
the protein and/or partial protein degradation.
From the analysis of MDR 1 mRNA, p-glycoprotein expression 
and MDR fold-resistance it seems that, although the over­
expression of this gene may contribute greatly to the phenomenon
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of MDR in DLKPA and its cloned variants, other mechanisms of 
resistance are also involved.
4.7 Ribozyme Transfectants
Due to the ability of tumour cells to develop multiple drug 
resistance, the use of chemotherapy as a treatment is very 
limited in certain tumour types. The potential role of ribozymes 
in the treatment of cancer is, at present, undergoing 
investigation in vitro in many laboratories. For a ribozyme to 
be effective as an anti-cancer agent, it must enter specific 
cells and then locate and cleave its specific target mRNA.
Increased expression of the MDR 1 gene has been associated 
with MDR in many cancer types (Clynes et al., 1993). Ribozymes 
specific for this mRNA have recently been formed and transfected 
into human tumour cells (Holm et al., 1994; Kobayashi et al., 
1994). To date, however, the numbers of studies done with MDR 1 
ribozymes have been limited to only a few MDR cell line types.
Non-small cell lung carcinoma (NSCLC) is generally 
considered to be an intrinsically resistant tumour type, 
unresponsive to chemotherapy. Although certain studies have 
indicated that at least some NSCLCs may show response to 
chemotherapy (Volm et al., 1992; Wilbur et al., 1992), this form 
of treatment alone is not adequate for routine treatments of 
NSCLCs.
The ability of an MDR-directed ribozyme to enter, be 
expressed and function in DLKPA-5F, an MDR variant of a human 
lung squamous cell carcinoma, DLKP, which has been shown in this 
thesis (Section 3.5) to significantly overexpress MDR 1 mRNA, 
was assessed in this study. Simultaneously, the MDR 1 ribozyme 
was also transfected into a cloned variant (DLKP-4) of the 
sensitive parent cell line which does not express detectable 
levels of MDR 1 mRNA. This was done as a control i.e. if the
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ribozyme had any adverse toxic effects on the cell, this should 
occur with DLKP-4 cells, as well as the DLKPA-5F cells.
Successful transfection of the ribozyme into both cell 
lines was achieved and, in turn, the ribozyme was successfully 
expressed. This was verified by PCR (Fig. 3.10.1, Table
3.10.1.1) and RT-PCR analysis (Fig. 3.10.2, Table 3.10.1.1) of 
DNA and RNA extracted from all the transfectants. However, no 
significant effects were apparent in any of the MDR variants 
studied i.e. the MDR 1 mRNA levels were not notably reduced when 
analysed by RT-PCR using primers which amplify the region to 
which the ribozyme was targeted (Fig. 3.10.3, Table 3.10.1.1). 
The drug resistance profiles of the transfectants were analysed 
by performing toxicity assays with chemotherapeutic drugs to 
which DLKPA-5F cells have previously been found to be highly 
resistant, including adriamycin, VP-16 and vincristine. No 
significant alterations in the drug resistance levels of any of 
these transfectants, compared to DLKPA-5F, were noted.
A number of possible explanations for this lack of effect 
may be that, although the ribozyme entered the cell and was 
transcribed, the transcript was unable to reach its target mRNA. 
Results of this nature have been referenced by Barinaga (1993) 
in which a hammer-head ribozyme to target HIV RNA was 
successfully transfected into cells, but was ineffective against 
the HIV RNA. This was suggested to result from "traffic-control" 
within the cell, preventing the ribozyme mRNA from getting close 
to its target. Alternatively, because of the relatively high 
levels of MDR 1 mRNA expression in these cells, the effect of 
the ribozyme may be insignificant to the overall MDR 1 
transcript levels. This suggestion is supported by studies by 
Holm et al. (1994) and Kobayashi et al. (1994) who transfected 
MDR 1 ribozyme into drug resistant human hepatic carcinoma and 
acute leukemia cultured cell lines, respectively. Although 
significant reductions in MDR 1 mRNA levels were reported in 
both these studies, complete resistance reversal was not 
achieved. This was suggested to result from insufficient
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accumulation of ribozyme to cleave the constantly over-produced 
MDR 1 mRNA.
Although further studies may be necessary to establish why 
the expressed ribozyme did not exert its effects on MDR 1 mRNA 
in this lung cell line, it must be considered that the levels of 
MDR 1 expression in this cell line are possibly not clinically 
relevant to lung tumours, where generally only low levels of MDR 
1 mRNA, when detected, have been reported (Lai et al. , 1989; 
Holzmayer et al., 1992). Transfection of this ribozyme into cell 
lines e.g. DLKPA-2B and DLKPA-6B which are less resistant and 
which possess lower levels of MDR 1 mRNA, may be of more 
significance now that it has been established that successful 
transfection and expression of this ribozyme in DLKPA variants 
can be achieved.
4.8 MDR 1 Gene Induction
Transcriptional control mechanisms have been suggested to 
play a significant role in the regulation of MDR 1 mRNA levels 
(Goldstein et al., 1989; Zastawny et al., 1993). Induction of 
MDR 1 expression in a number of subpopulations of leukemia cell 
lines, following transient (12 hrs. - 4.5 days) exposure to a 
range of p-glycoprotein substrates including adriamycin, 
daunorubicin, vinblastine and VP-16 and non-p-glycoprotein 
transported drugs including cisplatin, methotrexate, 
fluorouracil and hydroxyurea, was reported by Chaudhary and 
Roninson (1993). Activators of protein kinase C were also shown 
to increase MDR 1 gene expression, which was blocked by protein 
kinase C inhibitors. Such increases in MDR 1 levels after short­
term exposure to such agents, which may be due to mRNA 
stabilisation or increased transcription, have also been 
associated with exposure to heat shock, arsenite (Chin et al., 
1990; Kioka et al. , 1992) and certain differentiation agents
(Mickley et al., 1989; Bates et al., 1989). In experiments where 
the MDR 1 promoter has been isolated and used to drive the CAT 
gene, DNA Topoisomerase I (Camptothecin) and Topoisomerase II
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(VP-16 and VM-26) inhibitors have been found to induce CAT 
activity, by activation of the MDR 1 promoter. Similar effects 
have been observed with the mutant form of p5 3, whilst the wild- 
type represses p-glycoprotein promoter activity. Although this 
is apparently associated with the natural physiological role of 
p-glycoprotein as a protector of the cell against foreign 
stimuli, this may also be of major significance in the
development of MDR in cancer cells.
To establish if such a phenomenon would occur with tumour
cell lines from other origins, DLKP and OAW42 (lung and ovarian
drug sensitive cell lines, respectively), were exposed to
adriamycin for 72 hours i.e. until physical signs of cell 
distress were seen, after which transcript levels of a number of 
MDR-related genes including MDR 1, MRP, GST jt and Topoisomerase 
II were evaluated. (3-actin mRNA levels were also analysed. 
Exposure to adriamycin caused a number of visible signs 
characteristic of cell damage including increased granularity, 
the development of extensions forming contacts between cells, 
cell swelling, altered cell shape and growth inhibition in both 
DLKP (Fig. 3.8.1) and OAW42 (Fig. 3.8.2) cell lines. Induction 
of only MDR 1 gene expression was observed only in the ovarian 
cell line (Fig. 3.8.3). No changes in MRP, GST x, Topoisomerase 
II or (3-actin levels were observed.
The short-term drug exposure involved in this induction 
study may be more closely related to clinical MDR than other in 
vitro MDR models where cells are selected following continuous 
(up to 18 months) exposure to drug. Damage-induced activation in 
tumour cells may occur during chemotherapy treatment and 
account, at least in part, for the increased incidence of MDR 1 
expression in drug-treated human tumours (Chaudbary and 
Roninson, 1993).
Why induction of MDR 1 occurred in the ovarian and not the 
lung cell line is unclear as adriamycin has been used in the 
treatment, although not generally the primary treatment, of both 
tumour types. Over-expression of the MDR 1 gene with no DNA
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amplification has been associated with MDR in both types of 
tumour cell lines. Furthermore, the presence of MDR 1-expressing 
tumour cells has been suggested as a useful predictive marker 
for clinical resistance to combination chemotherapy in ovarian 
and small cell lung carcinoma (Holzmayer et al. , 1992). The
differential MDR 1 gene induction in these cell lines may, in 
some way, be related to the fact that because of their location 
and physiological role, lung cells are routinely exposed to 
foreign particles in the environment, including cigarette smoke, 
smog, chemical waste, etc., whereas ovarian cells are in a much 
more protected environment. Therefore, the response by ovarian 
cells may be much more rapid and extreme than in lung cells, 
which are more accustomed to insult by foreign matter.
4.9 Topoisomerase II mRNA and Protein Levels.
"Atypical" MDR in cells may occur due to alterations in the 
nuclear enzyme DNA Topoisomerase II. The cytotoxicity of most 
chemotherapeutic Topoisomerase II poisons is directly related to 
the number of active Topoisomerase II molecules. Therefore, a 
reduction in this number - generally involving the a subunit of
Topoisomerase II - may lead to drug resistance (Per et al., 
1987 ; de Jong et al. , 1990; Mirski et al., 1993). Slight
reductions in Topoisomerase II mRNA expression were observed in 
each of the adriamycin-selected MDR cell lines included in this 
study i.e. DLKPA (Fig. 3.3.1), OAW42A, HEp-2A, SKMES-1A (Fig.
3.3.2) and SKMES-1ADR, when compared to their respective parent 
cell lines. This trend was also seen when Topoisomerase Ila 
transcripts were studied independently. Topoisomerase lip 
levels, on the other hand, seemed to be slightly increased. 
However, these initial studies were performed prior to assessing 
the range of exponential product accumulation for each primer 
pair and so can not be considered quantitative in any way.
The gene transcript levels of both Topoisomerase II (Figs. 
3.5.1.7 - 3.5.1.10) and its a subunit (Figs. 3.5.1.11 -
3.5.1.14) were assessed throughout the PCR exponential phase of
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product accumulation in DLKP and its drug resistant variants 
DLKPA, DLKP/VP-3 and DLKP/VP-8 . However, as with similar studies 
performed to assess the relative differences in MDR 1 mRNA 
levels, because the samples from each cell line were run out on 
separate gels and the densitometry readings from the resulting 
bands could not be directly compared, amplification of the 
Topoisomerase Ila region in each of the four cDNA stocks from
each cell line was repeated at 25 cycles. The products of 
amplification of each extract were then ran together on a single 
gel (Fig. 3.5.1.16) and were analysed together by densitometry 
(Table 3.5.1.16.1). This allowed a direct comparison be made 
between the Topoisomerase Ila levels in each of these cell
lines.
From the RT-PCR analysis of Topoisomerase Ila mRNA, it 
appears that the levels of this gene transcript are reduced in 
the drug resistant variants - DLKPA, DLKP/VP-3 and DLKP/VP-8, by 
comparison to the sensitive parent cell line. However, the 
reductions in band intensities resulting (when analysed by 
densitometry) were very small and were not obvious, when 
analysed visually.
The levels of Topoisomerase II enzyme studied, using a 
polyclonal antibody, which detects a nuclear protein of 170-180 
kDa, were reduced in the DLKP MDR variants, DLKPA and DLKP/VP-3, 
when compared to the levels in the sensitive cell line. DLKP/VP- 
8 cells, however, apparently possessed slightly elevated levels 
of this protein. From results obtained using this polyclonal 
antibody, it cannot be established, however, whether it is the 
Topoisomerase Ila or Topoisomerase 11(3 subunit which is affected 
in this way. When the Topoisomerase Ila levels of this enzyme 
were analysed independently (using a specific monoclonal 
antibody) , reduced levels were observed in each of the MDR 
variants compared to DLKP. This suggests that the increase in 
Topoisomerase II observed in the DLKP/VP- 8 nuclear extracts is 
indicative of alterations in the Topoisomerase U p  subunit. This
may also explain the more significant changes in Topoisomerase
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Ila levels in the other cell lines, which were not so obvious 
when studying Topoisomerase II, as a whole.
By densitometry (Table 3.7.2.1) and visual analysis of the 
Topoisomerase Ila Western blot, the greatest reductions in gene
transcript levels were observed in the adriamycin selected MDR 
cell line, DLKPA, (when compared to the VP-16 selected cell 
lines) although its fold-resistance profile is slightly less 
than that of DLKP/VP- 8 (Table 4.1). In the case of the VP-16 
selected cell lines, the levels of Topoisomerase Ila mRNA seemed
to correlate with the resistance profiles of these cell lines 
i.e. the more resistant cell line, DLKP/VP-8, apparently possess 
lower levels of this gene transcript than the less resistant 
line, DLKP/VP-3.
From these studies of Topoisomerase Ila it appears that
this enzyme may be of importance in the development of MDR in 
variants of DLKP. Although the Topoisomerase Ila protein levels
were found to correlate well with the resistance profiles of the 
cell lines, this was not observed at the mRNA level. This 
suggests that regulation of this enzyme may be at the 
translational, rather than the transcriptional level.
When comparing the two most resistant cell lines, although 
both DLKPA and DLKPA/VP- 8 exhibited similar levels of resistance 
to adriamycin, vincristine and VP-16, DLKPA possessed the lowest 
levels of Topoisomerase Ila, while DLKP/VP- 8 had the highest
levels of p-glycoprotein. This suggests that although both 
mechanisms of resistance are of significance in both the 
adriamycin and VP-16 selected cell lines, alterations in 
Topoisomerase Ila may be a dominant mechanism in the adriamycin- 
selected cells and p-glycoprotein, in the VP-16 cell lines. This 
is based on the assumption that the results from p-glycoprotein 
analysis are real, and not a consequence of protein degradation, 
prior to Western analysis. However, the fact that the membrane 
preparations for p-glycoprotein analysis by Western blotting 
were prepared together, during the exponential growth phase of 
each of the six cell line, that the isolation was performed in
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the presence of a proteolytic inhibitor (PMSF), that the 
lyophilised samples were stored at - 8 0 °C until required and 
were all quantified simultaneously against a common standard 
curve, suggests that if protein degradation occurred, it would 
probably be equally destructive for all cell lines.
4.10 Analysis of MDR-related Gene Transcripts
in Clinical Specimens
Cell culture systems, because of their extensive 
availability and immortality, are useful models for analysis of 
MDR in which the direct role of a particular mechanism in 
determination of drug resistance can be evaluated (for review 
see Clynes et al., 1993). Although many important studies can be 
performed on cultured cells e.g. establishing how subpopulations 
of cells exist in a heterogenous population of cells, etc., it 
is obviously of great importance for all analysis to be 
performed on clinical biopsies. This is to ensure that results 
obtained from studies on cultured cells and on whole tumours 
correspond, if they are to contribute in any way to the design 
of chemotherapeutic stratagies, acting as a predictor of 
response before therapy or an indicator of acquired resistance 
during therapy.
The extraction of un-degraded template RNA from tissues is 
particularly difficult because of its labile nature and the 
presence of active RNase enzymes in the tissue itself (Jackson 
et al., 1991). Although many of the RNA studies reported to date 
involve using cultured cells, successful extraction and analysis 
of RNA from tumour biopsies has been reported (Horikoshi et al., 
1992; Kan-Mitchell, 1993; Vergier et al., 1993). In these
situations, the tissue fragments obtained at surgery were frozen 
in liquid nitrogen within 60 seconds to 30 minutes of their 
removal, to prevent RNA degradation.
In this study, the possibility of extracting intact RNA 
from normal and tumour biopsies kept for up to four hours (1.5 -
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4.0 hours) after surgery was assessed. As illustrated in Figs. 
3.9.1.1 - 3.9.1.4, successful extraction of RNA, reverse
transcription of this RNA into cDNA, and amplification of the 
desired regions of MDR 1, MDR 3, MRP, GST jz, Topoisomerase I, 
Topoisomerase II, Topoisomerase Ila, Topoisomerase lip and (3- 
actin were achieved in 8/ 8 normal and tumour lung biopsies 
studied. Amplification of the CYPIAl region did not occur. 
However, this was frequently found to be the case when studying 
cultured cells. Differences in transcript levels, between normal 
and tumour tissues, of a number of genes were observed in this 
study, the most significant effects being on MDR 1 mRNA levels. 
Because 30 cycles of PCR amplification were performed when 
analysing each of the transcripts, this analysis cannot be 
considered quantitative. However, these preliminary studies 
indicate that in situations where it is not possible to 
immediately start processing biopsies after their removal, 
studies on a broad range of MDR-related RNAs can be successfully 
performed. This may help broaden the range of material in which 
gene transcripts can be studied.
The ability to predictably recover sufficient undegraded 
RNA from paraffin-embedded tissue to act as a template for RT- 
PCR analysis has broad implications for cancer research, because 
of the almost unlimited amounts of material available for 
retrospective analysis.
In this thesis, a technique was developed which enabled RNA 
to be extracted from formalin-fixed paraffin-embedded breast and 
ovarian tissues in 24 hours (see Section 3.9.2) and subsequently 
used to study a range of MDR-related gene products. Initial 
attempts to amplify cDNA formed on these RNA templates, using 
oligo (dT) primers, resulted in the successful amplification of 
only one message, namely p-actin, the endogenous control. A
number of, apparently, "non-specific" products also resulted. 
Using a combination of oligo (dT) and random primers, however, 
resulted in amplification of most of the gene transcripts under 
analysis in many of the specimens studied (Fig. 3.9.4 - 3.9.6).
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The reason for the success of this combination, in these 
circumstances, unlike oligo (dT) alone, may be as follows: 
Reverse transcription of RNA extracted from cultured cells and 
normal and tumour lung biopsies was performed successfully using 
oligo (dT) primers which bind to the poly (A) + tail of mRNA. 
This mRNA, however, was extracted under ideal conditions and 
stored at -80 °C, until required for analysis. With 
polyadenylated mRNAs, however, removal of the poly (A)+ tail 
appears to be an early stage in mRNA degradation. Therefore, in 
at least some of the paraffin-embedded specimens, which had been 
stored for between 2 and 10 years, degradation of the poly (A)+ 
tail may have occurred. Lack of this tail, or nicks in the mRNA 
in the 3' region would prevent reverse transcription occurring. 
Random primers, as suggested by their name, bind randomly to the 
mRNA templates. Although full-length cDNAs (which may be 
obtained with oligo dT primers under ideal conditions) do not 
result using random primers, their application is obviously 
necessary for "sub-optimal" studies. Recent reports of 
procedures for RNA isolation, from paraffin-embedded tissues, 
for RT-PCR analysis have been published (Mies, 1994; Foss et 
al., 1994). Studies of estrogen receptor mRNA in seven human 
breast cancers, which had been stored for 1-3 years, were 
reported by Mies (1994). The procedure involved using a 
commercial available solution, RNAzol, which contained 
guanidinium thiocyanate, phenol and an unspecified lysis agent. 
Foss et al. (1994) studied the effects of fixation and fixation 
time on amplification of two "house-keeping" gene transcripts, 
GAPDH and HPRT, extracted from paraffin-embedded mouse spleen 
tissue. Most successful amplification was achieved after fixing 
in "Omnifix II" with no amplification after formalin fixation. 
However, no such application of these techniques to the study of 
an extensive range of gene products, as described in this 
thesis, has been documented.
Although further work may be required to optimise the 
procedures developed in this thesis for RNA extraction for 
formalin-fixed paraffin-embedded tissues, these preliminary 
studies of both "fresh" and paraffin-embedded tumours indicate
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the potential to study RNA levels of an unlimited number of 
genes, in an unlimited number of clinical specimens.
4.11 Quantitative RT-PCR
RT-PCR is an extremely sensitive method for mRNA analysis, 
and for a number of reasons may be favoured over the more 
conventional methods of RNA analysis including Northern 
blotting, RNase protection, slot blotting, in situ 
hybridisation, etc. Because of the sensitivity and relative 
simplicity of this technique, it can be used in many 
circumstances, including analysis of gene expression in cultured 
cells and especially in clinical biopsies where tissue amounts 
are very limited. This method has now been developed for 
retrospective studies of paraffin-embedded tissues, increasing 
its worth as a medical research tool many fold. RT-PCR may also 
be very important in virological diagnosis (Goswami et al., 
1994) e.g. viruses that do not grow easily in culture or when 
results are required more quickly than the time required for 
cell culture or electron microscopy. Such techniques also have 
potential for automation, which is important from a diagnostics 
point of view. Because of its extreme sensitivity, RT-PCR shows 
great potential for development as a quantitative method. 
However, obtaining quantitative information with this technique 
can be difficult, due primarily to the fact that there are two 
sequential enzymatic steps involved i.e. the synthesis of cDNA 
on the mRNA template by reverse transcriptase enzyme and the 
polymerase chain reaction catalysed by a DNA polymerase enzyme. 
Although PCR and RT-PCR have recently been developed to a 
quantitative level for the analysis of expression of specific 
genes (pioneered by Wang et al., 1989b), as detailed in Section
1.4, conflicting ideas seem to exist as to what extent this 
quantitative analysis can be achieved.
Basically, these are two types of quantitative PCR/RT-PCR, 
both of which were examined in the work described in this 
thesis. These include a semi-quantitative method where relative 
differences in gene expression can be compared and which, 
theoretically, offers a basis on which to obtain absolute data.
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The method of choice depends on the information required and the 
time and effort available for developing the technique. For many 
purposes, for example to establish whether a drug causes 
amplification of levels of a particular mRNA in tissues from a 
patient, after certain periods of treatment, relative ratios 
between gene expression in tumour samples are as useful as 
absolute values and are more easily obtained experimentally. 
Because of this, many more samples may be studied in a given 
time period. The potential use of RT-PCR is not without 
problems, however, and there are conflicting opinions as to 
whether or not this application of PCR technology can provide a 
reliable and reproducible measure of gene expression (Phillips 
et al., 1993). In this thesis, attempts were made to develop the 
RT-PCR analysis of MDR-related gene expression to a semi- 
quantitative and quantitative level.
Quantitation of mRNA levels or of changes in mRNA levels 
can be problematic, due to the exponential nature of PCR, where 
small variations in amplification efficiency can lead to 
dramatic changes in product levels. This has the effect of 
obscuring differences in levels of the target mRNA. In addition 
due to the consumption of the reaction components and generation 
of inhibitors, the amounts of product generated plateaus during 
later stages of the reaction (Cottrez et al., 1994). Therefore, 
two of the most fundamental requirements for any form of 
quantitative PCR or RT-PCR are that (a) internal controls are 
used in all reactions to act as standards with which each 
specific amplified product can be normalised and so compared 
from sample to sample, and (b) all analysis be performed during 
the PCR exponential phase of product accumulation, as PCR 
product accumulation is proportional to that of the starting 
target DNA only as long as the product accumulation remains 
exponential (Singer-Sam et al., 1990).
The choice of internal control is very important. This 
must be expressed at a constant level in all cell types studied. 
This control product must differ in size from the target 
amplified product so that they can be easily distinguished from
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each other, yet it must be close enough in size so that they 
amplify with similar efficiencies. As previously discussed 
(Section 4.2), in this study of MDR-related genes, p-actin was
chosen as an internal control for use throughout this thesis 
(with few exceptions), as its expression was found to be 
constant in both the drug sensitive and MDR cells analysed.
The exponential range of product accumulation can be 
determined in two ways i.e. either performing the PCR for a 
fixed number of cycles on serial dilutions of cDNA, or by 
performing the reaction with a varying number of cycles on a
fixed quantity of cDNA, both of which produce similar results
(Murphy et al. , 1990). In this study, the latter method was
favoured as it requires less input RNA and so more repeats of
the analysis can be performed to determine its reproducibility. 
The exponential phase for each primer pair was estimated from 
plots of PCR cycle number versus product yield (as determined by 
densitometry) . This is the range of PCR cycles from which 
initial exponential product accumulation is observed, to the 
point at which continued cycles do not produce significantly 
increased product yields. As this involved a visual estimation 
of the resulting plots, mid-range cycle numbers were considered 
suitable for routine studies, to ensure that they were within 
the exponential phase.
The PCR exponential phase was found to vary from one primer 
pair to another and from one cell type to another (as detailed 
in Section 3.4), although no significant differences in this 
range was observed between each sensitive cell line and its 
respective MDR variant. Because the ranges of exponential 
accumulation for each primer pair overlapped when evaluated for 
RNA from different cell types, a mid-range cycle number which 
was common to all cell types was considered ideal (as summarised 
in Table 3.4.3). The cycle ranges for which product accumulation 
appeared to be exponential were similar in experiments performed 
with batches of RNA extracted from different stocks of each cell 
line and between batches of cDNA formed on these mRNA templates 
(Table 3.4.1 and 3.4.2). This supported the use of these
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particular cycle numbers of PCR amplification in subsequent 
quantitative experiments.
Many genes considered as endogenous controls are expressed 
at higher levels than most messages under study and so reach a 
plateau more quickly, so that a false appearance of comparable 
loading may occur. When co-amplifying the target and reference 
gene (i.e. endogenous control) in the same tube, the exponential 
amplification range of both must coincide for the quantitation 
to be valid. Murphy et al. (1990) reported studies where the 
internal control (P2-microglobulin) had entered the plateau
phase even before the target mRNA was detectable. To overcome 
this, independent amplification of the target and control, with 
which it was to be normalised, were performed in separate tubes 
within their respective exponential ranges. This was not 
considered ideal in this study, however, for a number of 
reasons. Firstly, it is generally considered necessary for the 
standard and target to be co-amplified in the same tube, in 
order to overcome poor reproducibility of the PCR step 
(Horikoshi et al., 1992 ). (Variability in the yield of PCR 
products have been reported to be as much as six-fold among 
duplicate amplifications (Gilliland et al., 1990a)). Secondly, 
using densitometry analysis, in this study, it was found that 
although the relative ratios were comparable from one gel to 
another, the actual densitometry data could not be directly 
compared. Unless the target and control were run on the same 
gel, the target could not be normalised by the control. In this 
study, therefore, the exponential and plateau ranges for p-actin
(the endogenous control) were also evaluated. As indicated in 
Figs. 3.1.10.1 & 3.1.10.2, Table 3.4.1 & 3.4.2, the exponential 
range of product accumulation with these primers is between 
approximately 16 - 27 cycles. As this range includes the
proposed "optimum" cycle numbers for amplification with each of 
the other primer pairs, this also supports the suitability of p-
actin as control in these studies.
310
4 . 1 1 . 1  S e m i - Q u a n t i t a t i v e  R T -P C R
Using (3-actin as endogenous control and the proposed 
"optimum" cycle numbers, attempts were made to develop this 
study to a semi-quantitative level for the analysis of MDR 1 
(Figs. 3.5.1.1 - 3.5.1.6), Topoisomerase II (Figs. 3.5.1.7 - 
3.5.1.10) and Topoisomerase Ila (Figs. 3.5.1.11 - 3.5.1.14) gene
transcript levels, as these were the most significant 
differences observed (in preliminary experiments) between the 
sensitive and drug resistant cell lines. As a linear 
relationship between the quantity of mRNA and the final PCR 
product requires both efficient cDNA formation and PCR product 
accumulation, studies were initially performed to establish if 
both the RT and PCR reactions were 100 % efficient. This
involved forming cDNA copies from RNA at a range of 
concentrations, from each cell line to be analysed; amplifying 
the resulting cDNA by PCR; and analysing the results visually 
and by densitometry. With few exceptions, the densitometry 
results implied that a linear relationship existed between the 
band intensities representing product and the initial RNA 
concentrations. However, this data was not indicative of a 
directly proportional relationship. Similar results were 
produced from each repeat of the experiment. These results 
suggested that either (or both of) the RT and PCR reactions 
might be less than 100 % efficient. To further investigate this, 
MDR 1 mRNA levels in a range of RNA concentrations, and a range 
of resulting cDNA amounts, were analysed by RT-PCR (Fig. 3.5.3.1 
- 3.5.3.8). RNA and CDNA derived from cells previously shown to 
contain relatively low (DLKPA-2B) and high (DLKPA-5F) levels of 
MDR 1 mRNA were analysed in this way. These cell lines were 
chosen to establish if, in the case of DLKPA-5F where the mRNA 
levels under study were relatively high, possibly the RT and/or 
PCR reactions were saturated with excess substrate. However, the 
results from this study, as with the previous studies, showed 
that a non-proportional relationship existed between the 
densitometry analysis of the product and the initial RNA and 
cDNA concentrations. This was found even for DLKPA-2B, where the
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levels of MDR 1 mRNA were relatively low and also for DLKPA-5F, 
when a range of lower concentrations of RNA were evaluated.
From visual analysis of the photographs resulting from both 
these studies, however, it was seemed that in many cases, 
although the densitometry data suggested otherwise, the 
intensities of the bands seemed to indicate proportionality with 
both the starting RNA and starting cDNA concentrations (e.g. 
Fig. 3.5.3.1(i)), particularly at low RNA and cDNA 
concentrations, suggesting that both the RT and PCR reactions 
were efficient. This observation was further supported by 
evaluating the sensitivity and linearity of the densitometer 
with known DNA concentrations (Fig. 3.5.2.2 & Fig. 3.5.2.3) (as 
previously discussed) and realising that the resulting data did 
not correlate proportionally with the corresponding DNA 
concentrations.
Overall from these results it can be concluded that 
although this method (of mRNA and cDNA dilutions) is suitable 
and necessary for semi-quantitative analysis, a more accurate 
means, than densitometry (as performed here), of quantifying the 
products is necessary. In many cases throughout this study, 
visual analysis was apparently more accurate than densitometry 
analysis (at low RNA concentrations a two-fold difference in 
intensity could often be detected). Obviously by visual analysis 
there is the possibility of bias unless all analyses are done as 
a blind-study. Furthermore, the precision of visual analysis is, 
of course, not great enough for absolute quantitative PCR/RT- 
PCR. HPLC may be more suitable for this analysis. It must, 
however, be realised that the number of samples that could be 
analysed in a given time period would be very much reduced if 
using HPLC instead of gel electrophoresis and densitometry 
analysis.
312
4 . 1 1 . 2  A b s o l u t e  Q u a n t i t a t i v e  R T -P C R
Quantitation of mRNA by RT-PCR is performed using an 
exogenous RNA or DNA standard of known concentration in the RT 
or PCR reactions, respectively. With both RNA and DNA exogenous 
controls, a dilution series of either the control or target are 
made and are titrated against a constant amount of the other 
component. When the PCR products resulting from the control and 
target are equal, the amount of mRNA in the original sample is 
assumed to equal the amount of template added.
The differences between these two types of controls is as 
follows: In these systems, the exogenous RNA control is added 
with the target gene mRNA template in the RT reaction and so 
they are simultaneously reverse transcribed. The products of 
this exogenous control and target mRNA then compete for primers 
in the PCR reaction. Exogenous DNA controls, in contrast, are 
added after the RT reaction, with the resulting cDNA for 
competitive amplification by PCR. In both methods, the target 
and control standards are co-amplified with the same primers and 
the target mRNA is quantified in its cDNA form from a known 
amount of the standard (Babu et al., 1993).
Exogenous RNA controls, theoretically, are more useful and 
have frequently been favoured over DNA controls (Wang et al., 
1989b; Futscher et al., 1993) because they control for 
variations in both the efficiency of the RT and PCR reactions. 
However, they also have certain disadvantages, including the 
fact that secondary structure formations may cause inefficiency 
of RT reactions. Because of the possibility of secondary 
structure formations the control and target must be as close as 
possible in size and structure so that comparisons can be made. 
Furthermore, RNA controls are more laborious than DNA controls 
to form.
It has been suggested that these problems may be overcome 
by using a DNA control and taking into account the RT reaction 
efficiency (Babu et al., 1993). In this study, therefore, a DNA
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control was used for the quantitative analysis of MDR 1 mRNA in 
DLKPA-2B and DLKPA-5F cells. DNA controls compete for 
amplification with the target cDNA primers during the PCR 
reaction. However, as described in Section 1.4.2.1 (Fig. 6 and 
Fig. 7) the intervening sequence may be homologous to that of 
the target cDNA or slightly longer or shorter as a result of an 
intron insertion or deletion or an internal region. 
Alternatively, the intervening sequence may be non-homologous to 
that of the target (Section 1.4.2.1, Fig. 8). In this study the 
latter form of control was used (constructed by Dr. Carmel 
Daly). This control was amplified by the same primers as the 
endogenous MDR 1 mRNA product and so competed with it for 
amplification.
In the original attempts of this analysis, the 
concentrations of exogenous controls used were too high and so 
did not correlate with any of the corresponding DLKPA-5F bands 
(Fig. 3.6.1). DLKPA-5F MDR 1 mRNA levels could not be quantified 
with this range of exogenous control concentrations. A lower 
concentration range of exogenous control was, therefore, 
titrated against a constant amount of cDNA formed on a 1.0 nq/jul 
RNA template (initial total RNA concentration) from DLKPA-2B 
cells and on a 0.25 ¡ig/pil RNA template from DLKPA-5F cells (Fig.
3.6.2). From this analysis, the concentrations of MDR 1 mRNA 
levels in the DLKPA-5F cell line seems to be approximately 8 
times that in the DLKPA-2B cells. Similar results were obtained 
by both visual and densitometry analysis in this case. By semi- 
quantitative analysis, this difference had been estimated as 
approximately 2 - 3-fold. Although there seems to be a conflict 
between the results obtained using semi-quamtitative and 
quantitative methods, it must be considered that the semi- 
quantitative studies on DLKPA-5F were performed prior to the 
range finding experiments. Greater differences in MDR 1 mRNA 
levels in DLKPA-2B and DLKPA-5F are probably obscured by this. 
The semi-quantitative and quantitative techniques are probably 
more in agreement than suggested by these results.
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Although use of this exogenous control has proven quite 
successful in these studies, bands resulting from endogenous MDR 
1 were relatively weak and so not very easily correlated with 
those of the exogenous control, by visual analysis. This may be 
a reflection of the size difference between the exogenous 
control (331 bp) and the endogenous MDR 1 cDNA region amplified 
(157 bp), rather than a difference in gene transcript copy 
number i.e. less ethidium bromide may intercalate with the MDR 1 
product and so its intensity would seem less. (This obviously 
would also be a problem if endogenous controls were used in 
semi-quantitative studies which differed greatly in size from 
the target product). It may be easier for comparisons to be made 
if controls (either endogenous or exogenous) were close in size 
to the target that they quantified.
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4 . 1 2  S u m m a r y  a n d  C o n c l u s i o n s
1 . This thesis investigated mechanisms of multiple drug 
resistance in a range of human tumour cell types. This involved 
analysis by RT-PCR (Reverse Transcriptase-polymerase Chain 
Reaction) of gene expression at the mRNA level in both 
clinically derived lung and breast tumour specimens, and MDR 
variants of cell lines derived from human tumours. 
Investigations on both adriamycin- and VP-16-selected variants 
of DLKP (a human squamous cell carcinoma line) were performed. 
Homogenous subpopulations with varying drug resistance profiles, 
previously cloned from a heterogenous cell population (the 
adriamycin-selected MDR variant of DLKP), were also studied. 
Qualitative analysis was also performed on other adriamycin- 
selected MDR variants of cell lines including OAW42 (an ovarian 
carcinoma), HEp-2 (an epidermoid carcinoma of the larynx) and 
SKMES-1 (a human squamous cell carcinoma).
2 . A list of criteria for PCR primer design was prepared 
and primers for RT-PCR analysis of MDR-related genes were 
selected for MDR 3, MRP, GST a, GST re, CYPIA1, Topoisomerase I, 
Topoisomerase II, Topoisomerase Ila and Topoisomerase lip. 
Primers for p-actin amplification were also selected. Care was 
taken (by sequence search analysis in the EMBL data base) to 
ensure that none of the ten pairs of primers selected in this 
thesis amplified any "non-specific" cDNA regions. Others primers 
pairs previously reported in the literature, including those for 
amplification of MDR 1, P2-microglobulin, GAPDH and Esterase D
were also evaluated. Before applying to routine analysis, each 
set of primers was tested to ensure that it produced a single 
band of the correct size. The identity of the product was 
further verified by restricting with an endonuclease enzyme, the 
recognition site of which was previously identified as being in 
the amplified region.
3 . An endogenous control which would act as a "common 
denominator" by which all target genes from normal, tumour (drug 
sensitive) and MDR cells could be normalised, was selected. A
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number of so-called ubiquitously expressed genes were considered 
for this role, including p-actin, (32-microglobulin, GAPDH and 
Esterase D. p-actin was favoured as control because its gene 
transcript levels were found to be consistent between sensitive 
tumour cells and MDR cells. The region amplified, when studying 
P-actin was slightly larger than that of any of the target
genes. Therefore, it was clearly distinguished, after gel 
electrophoresis, from the target gene products. Furthermore, 
because of its slightly larger size, the p-actin product may be
considered to be a relatively good marker for RNA degradation as 
its size may increase its probability of degradation.
4. Although slight alterations in P2-microglobulin 
(decreased) and GAPDH (increased) mRNA levels (assessed by RT- 
PCR) were observed in MDR cells, the most significant effects 
were seen for Esterase D mRNA (increased), which was therefore 
considered inappropriate as a control.
5. Using this range of primers for amplifying MDR-related 
gene products, with p-actin as a control, it was found that
after 30 cycles of amplification (qualitative RT-PCR), the most 
significant general effects in MDR cell lines were over­
expression of the MDR 1 gene and apparent reduced expression of 
Topoisomerase Ila mRNA. The importance of working within the
exponential range was obvious from many of these results.
6 . To develop this technique to a semi-quantitative 
level, the range of exponential product accumulation, when 
amplifying with each primer pair, was assessed in four cell 
lines (two sensitive cell lines and their sensitive resistant 
variants) to act as representatives for subsequent studies. The 
exponential ranges were found to be similar in sensitive and MDR 
cells. Although the range varied slightly in the cell lines from 
different origins and when amplifying with different primers, a 
significant overlap in their respective ranges was found to 
exist. The ranges of exponential accumulation were found to be 
the same in duplicate cDNA stocks formed on RNA templates 
extracted from two or three independent stocks of each cell
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line. A mid-range cycle number (which varied from one primer 
pair to another) was selected as suitable for use in the 
subsequent semi-quantitative and quantitative studies.
7 . Semi-quantitative analysis of MDR 1 gene expression 
was performed on the adriamycin-selected variants of DLKP, 
namely, DLKPA and its cloned variants DLKPA-2B, DLKPA-6B and 
DLKPA-5F; and the VP-16 selected cell lines, DLKP/VP-3 and 
DLKP/VP-8 . Similar analysis of Topoisomerase II and 
Topoisomerase Hot transcript levels in DLKP, DLKPA, DLKP/VP-3
and DLKP/VP - 8 were conducted. A range of three initial 
concentrations of RNA were studied in each cell line. These 
studies were performed on duplicate stocks of cDNA formed on two 
independent RNA extractions. Analysis of the results by 
densitometry alone was found to be unreliable i.e. although 
increased readings resulted with increased band intensities, 
this relationship was not proportional to the band intensities 
(or the starting RNA concentrations). With few exceptions, a 
two-fold difference in band intensities was detected by visual 
analysis in any given cell line, within the exponential phase of 
product accumulation. Obviously from visual analysis it could 
not be proven that the differences were, in fact, precisely two­
fold. However, it could confidently be said that, in the 
majority of cases, if two-fold serial dilutions of RNA were 
analysed, the rank order of their concentrations could be 
determined. Beyond the PCR exponential phase, obviously no such 
claims could be made.
This observation was generally found to be very consistent 
on repeat analysis from any given RNA extract. The 
reproducibility of results from one RNA extract to another was 
also generally good. In a few cases, however, both (3-actin and
the target gene products were apparently less in one extract, 
compared to the other. This was possibly due to partial RNA 
degradation. In a few cases where such an observation was made, 
however, inconsistent printing of the negative was found to be 
responsible. This was realised by the fact that the molecular 
weight markers also appeared faint on the photographs.
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Because of the obvious limitations of the densitometry 
analysis, it was not possible to confidently compare results 
from one gel to another. One concentration of RNA from each 
batch of all cell line included in this analysis, were therefore 
studied simultaneously. These semi-quantitative results 
suggested that the levels of MDR 1 expression in the DLKP MDR 
variants were in the following rank order: DLKPA > DLKPA-5F > 
DLKP/VP-3 > DLKP/VP - 8 > DLKPA-6B > DLKPA-2B, although the
differences in densitometry readings between DLKP/VP-3 and DLKP- 
VP - 8 were quite small. The greatest differences between the cell 
lines expressing highest (DLKPA) and lowest (DLKPA-2B) levels of 
this gene transcript was 1.6-fold. By visual analysis, the MDR 1 
transcript levels were apparently as follows: DLKPA = DLKPA-5F = 
DLKP/VP-3 = DLKP/VP- 8 > DLKPA-6B > DLKPA-2B, estimated to be 
between a 2-3 fold difference between the cell lines expressing 
highest and lowest levels. This relationship was more obviously 
detected in the analysis on the second extract of each cell line 
where the resulting bands were, in general, printed more 
faintly. No overall differences in Topoisomerase Ila mRNA levels
were noted between DLKP, DLKPA, DLKP/VP-3 and DLKP-VP- 8 by 
visual analysis, although slightly reduced levels of expression 
were apparent in the in the MDR variants by densitometry 
analysis. Generally, relatively bright bands were more difficult 
to analyse visually than weaker bands. This emphasised the 
importance of performing densitometry analysis on negatives, as 
inconsistent printing (identified by the molecular weight marker 
intensities) may apparently bias the results.
8 . Further semi-quantitative studies using a range of RNA 
concentrations and cDNA dilutions from the DLKPA clones 
expressing the lowest levels (DLKPA-2B) and the greatest levels 
(DLKPA-5F) of the MDR 1 gene were performed. Differences could 
be detected (i) between the RNA concentrations, and (ii) between 
cDNA amounts for DLKPA-2B. When different concentrations of RNA 
and cDNA were analysed, fold increases with RNA concentrations 
could only be confidently detected in the lowest concentrations 
of cDNA. At higher concentrations differences were seen, but not
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proportionally. This may be indicative of saturation of the 
ethidium bromide detection method. A range of lower 
concentrations of RNA extracted from DLKPA-5F cells were, 
therefore, analysed in this way. The bands produced, although of 
slightly greater intensity, were similar to those of DLKPA-2B 
_l  .  e .  visually detecLable increases in band in Lens i Lies, more or 
less in proportion to both the RNA and cDNA concentrations. Two 
very significant conclusions can be made from this: (i) if such 
a procedure is to be used to study expression of a gene in a 
number of cell lines, an initial range-finding experiment should 
be performed, for each cell line, to determine the range of 
serial RNA and cDNA dilutions over which PCR amplification is 
linear for each target species; (ii) since bands of proportional 
intensities were produced with both RNA and cDNA concentrations 
within the ranges determined by (i), it can be assumed that at 
this level both the RT and PCR reactions are of a constant 
levels of efficient between samples.
9. For quantitative analysis, using known concentrations 
of an exogenous competitor, it was assumed that a DNA control, 
rather than an RNA control (which is generally believed to be 
more problematic due to the labile nature of RNA, possibility of 
secondary structure formations, more laborious preparation 
technique etc.), is sufficient. By visual analysis of the 
quantitative studies, the levels of MDR 1 mRNA in DLKPA-5F cells 
was found to be slightly less than eight-fold greater than in 
DLKPA-2B cells (and slightly more than eight-fold when analysed 
by densitometry) . There may be a number of reasons for the 
varying fold-differences detected by quantitative analysis 
(approximately 8-fold) and semi-quantitative analysis (2-3 fold) 
between DLKPA-2B and DLKPA-5F, including the inaccuracy of 
visual detection. The most likely reason is, however, that these 
semi-quantitative analyses were performed on a common RNA 
template concentration for each cell line, prior to observing 
that range-finding experiments should initially be performed for 
all cell lines.
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10. A direct correlation between mRNA levels and protein 
levels (detected by Western blotting) was generally not observed 
with either the MDR 1 or Topoisomerase Ila gene products. In the
case of the MDR 1 gene, lower levels of p-glycoprotein were 
apparent in DLKPA and DLKPA-5F, although compared to DLKPA-2B 
and DLKPA-6B, these cells express greater levels of MDR 1 mRNA 
and their levels of resistance are greater. This suggests that 
p-glycoprotein may be a less significant mechanism of MDR in 
DLKPA and DLKPA-5F than in DLKPA-2B and DLKPA-6B cells. 
Alternatively this result may be due to altered protein 
degradation in the different clones during extraction. In the 
VP-16-selected cell lines, over-expression of both MDR 1 mRNA 
and p-glycoprotein were detected.
Although possibly slight reductions in Topoisomerase Ila 
mRNA levels may occur with resistance in both the adriamycin- or 
VP-16-selected cell lines; much more significant reductions in 
Topoisomerase Ila protein levels were found, which seemed to
correlate with drug resistance levels. This suggests that this 
gene is involved in the MDR phenomenon in these resistant 
variants and that it may be translationally, rather than 
transcriptionally controlled.
11. Induction of MDR 1 mRNA expression was observed after
short-term exposure of OAW42 cells to adriamycin. (This analysis
was performed using multiple primers on porated whole cells ("in 
situ"), rather than extracted RNA). Induction was associated 
with physical signs of stress in the cells, and was proportional 
to the drug concentration to which the cells were exposed. 
Although similar signs of stress were apparent after exposing 
DLKP cells to these concentrations of adriamycin for the same 
time period, no changes in MDR 1 transcript levels were 
observed. This supports the physiological role of p-glycoprotein 
as a cell protector and may be of clinical relevance.
12. An MDR 1-specific ribozyme was transfected into DLKPA- 
5F cells (and DLKP-4 cells, as a control) to evaluate its
potential to reduce or reverse MDR. This ribozyme was
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successfully transfected and transcribed, but no significant 
effects on MDR 1 mRNA or resistance to adriamycin, vincristine 
or VP-16 were observed. This may be due to the fact that the 
expressed ribozyme is not locating and cleaving it's substrate 
(the MDR 1 transcripts). Alternatively, it may be due to the 
fact that because MDR 1 mRNA is very highly over-expressed in 
DLKPA-5F cells, a small, but significant reduction in its levels 
may not be easily detected.
13. Successful analysis of a number of MDR-related gene 
transcript levels were performed on normal and tumour lung 
biopsies, which had been removed at surgery for up to 4 hours 
before extracting RNA. Although this analysis was only 
qualitative, it shows potential for extensive studies of gene 
transcripts in clinical material previously not considered 
suitable.
14. A method was developed by which RNA could be extracted 
from paraffin-embedded tissues, which would allow retrospective 
studies be performed on an extensive range of archival tissue. 
Preliminary attempts at this resulted in amplification of only 
one gene product, namely p-actin (and the production of non­
specific bands). As this was probably indicative of degraded 
RNA, a combination of different primers were included in the RT 
reaction. Oligo (dT) primers (which bind to the poly (A)+ tail), 
when used alone resulted in reverse transcription of only f3-
actin. This suggests that many of the RNAs under analysis were 
partially degraded. This was supported by the fact that random 
primers, when used independently only resulted in p-actin
amplification and the production of "non-specific" bands. 
However, using a 1 : 1 ratio of oligo (dT) : random primers, 
successful amplification of cDNA, representing many of the genes 
under study, was observed. Results from this study prove that 
successful analysis of mRNA from tissues embedded in paraffin 
for at least ten years, can be achieved.
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Overall, the aims (as described in Section 1.6) were 
fulfilled in so far as RT-PCR was proven to be a suitable 
technique for analysis of MDR-related gene expression at the RNA 
level. Suitable primers for the study of a number of such gene 
transcripts were selected and an appropriate endogenous control 
for these studies was also chosen. Methods were developed to 
allow quantitative analysis of specific mRNAs, but a number of 
limitations and potential problems were identified.
Techniques were developed which enabled RNA, suitable for 
RT-PCR analysis, be extracted from tissue biopsies which had 
been removed at surgery for up to 4 hours. RNA was also 
extracted from tissues embedded in paraffin for up to 10 years.
A ribozyme was successfully transfected into MDR cells 
which seemed to slightly reverse the MDR phenomenon in some, but 
not in all, transfectants.
Results from Western blot analysis, taken in conjunction 
with RT-PCR analysis, suggest that translational control, rather 
than transcriptional control, may be important in determining 
multiple drug resistance in some of the cell lines studied in 
this thesis.
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4 . 1 3  F u t u r e  W or k  a r i s i n g  f r o m  t h i s  T h e s i s
Overall, from the results of this research, it seems that 
RT-PCR is a necessary technique for studies of mRNAs from a 
range of origins. By comparison to results published from other 
methods of mRNA analysis, including Northern blotting, it seems 
that, in many cases, due to its sensitivity, specificity and 
potential as a quantitative method, RT-PCR is a more superior 
technique. Because of its sensitivity, mRNA levels in clinical 
specimens, which could not have been detected by other methods 
available, can now be analysed using RT-PCR. The realisation 
that this technique can be applied to studies of many gene 
transcripts from very small amounts of tissue embedded in 
paraffin for a decade, adds a new dimension to MDR studies (and 
mRNA studies, in general), which frequently are performed on 
cultured cells. Furthermore, using this technique, qualitative, 
semi-quantitative and absolute quantitative details may be 
obtained, depending on the information required.
From these studies, however, it is also apparent that RT- 
PCR as a quantitative method is not completely without problems. 
During the course of this work, a number of important 
observations were made which help to define the capabilities and 
limitations of this technique. The results from this thesis also 
give rise to a number of potential areas of further study.
From studies using the exogenous competitive control, it 
seems that the accuracy of results comparing products detected 
by intercalation of ethidium bromide may possibly be dependent 
on size differences of the products and not just on their copy 
number. It would, therefore, be interesting to evaluate other 
detection methods e.g. incorporation of fluorescent dNTP's 
during PCR amplification, and compare them with results obtained 
using ethidium bromide. Smaller exogenous controls (closer to 
the size of the endogenous target cDNA) could be constructed to 
establish if size differences is, in fact, a problem.
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Semi-quantitative and absolute quantitative analyses of 
endogenous MDR 1 gene transcripts were performed in this study. 
It may be interesting to develop exogenous controls for the 
analysis of a number of other gene products, in a similar way.
In many cases throughout this research, it was apparent 
that visual analysis was more accurate than densitometry 
analysis. Alternative methods of quantitation e.g. HPLC could 
therefore be evaluated.
Using the method which has been developed for RNA 
extraction from paraffin-embedded tissues, extensive 
retrospective studies of paired normal and tumour biopsies from 
a number of organ types could be performed. The results could be 
correlated with histological studies and the patients medical 
records.
It may be interesting to study the effects of the MDR 1 
ribozyme in MDR cell lines expressing low levels of MDR 1 mRNA, 
to establish if a more significant effect would result than that 
observed in DLKPA-5F cells.
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